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vThis volume of the Proceedings of the College on
Drug Dependence, 1993 is dedicated to the memory
of Drs. William R. Martin and Daniel X. Freedman,
two distinguished scientists whose outstanding
contributions to drug abuse research, treatment, and
public policy are recognized nationally and internationally.
Their dedication over many years to the College on Problems of
Drug Dependence deserves particular acknowledgement.
We will sorely  miss them.
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IN MEMORIAM: WILLIAM ROBERT MARTIN, M.D.
1921-1993
On May 27, Dr. William R. Martin died in a tractor accident at his home in Midway,
Kentucky.
It is fitting that we pay tribute to Bill at the CPDD, as this is an organization with which he
was closely affiliated for more than 30 years. He presented frequently at these meetings,
served on the Board of Directors, received the Nathan B. Eddy Award, and was a Charter
Fellow of the College.
Dr. Martin is probably best known to this audience from his years at the Addiction Research
Center (ARC) in Lexington, Kentucky and then at the Universitv of Kentucky. Bill was
born in ‘Aberdeen. South Dakota, 72 years ago. After earning his undergraduate degree at
the University of Chicago, he earned his M. D. and M. S. in Pharmacology at the University
of Illinois. An internship at the Cook County Hospital and a faculty position at Illinois in
Pharmacology preceded his arrival at the ARC in 1957 as a staff scientist.  He became
Director of ARC, taking over from Harris Isbell in July of 1963 (coincidentally on the day 1
arrived as a young medical officer fresh out of internship).
Don Jasinski joined the ARC staff two years later. Don and I were but two of the many
students and young scientists who were privileged to have Bill Martin as their primary
mentor. Bill retired from the Public Health Service (PHS) and the ARC in 1977 and went
across town to become the Chairman of Pharmacology at the University of Kentucky
Medical Center, a position he held until 1990. Never one to stop working, he then became a
Research Professor in the Department of Anesthesiology, where he continued his research in
close collaboration with Dr. Jewell Sloan, his student and colleague for more than 35 years.
Bill Martin’s work in substance abuse is well known to this audience, from his work in
multiple opioid receptors (begun in the 60s), to studies in sedative hypnotics, stimulants and
hallucinogens, to his more recent work on nicotine receptors. His work and interests
spanned a broad range from fundamental preclinical research to experimental clinical
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studies, to research  in treatment  modalities, to concerns  with drug abuse in the broadest
social, medical and geo-political contexts. Bill’s ideas and writings have helped to shape the
directions of our field for the past two decades and will likely remain influential for several
more. The ideas he proposed and the body of work he produced is an important legacy.
Over the 20 years Bill spent at the ARC and 15 more at the University of Kentucky, several
generations of young scientists, graduate. students and medical students came under the
influence of his teachings. We learned much from him - not only substantive knowledge in
pharmacology and substance abuse, but also principles of intellectual integrity and a
commitment to the continued striving for excellence and the search for new knowledge.
We, his students and colleagues, am his second legacy, perhaps in some ways even more
enduring and far reaching than his first, as we pass his lessons on to further generations of
students and young colleagues.
Although we tend to key on Bill Martin, the Scientist, let us also pause a moment to
remember Bill Martin, the Man. Bill was a true gentleman and egalitarian. I spent more
than ten years as his EEO Officer at the ARC and learned well the depth of his feelings for
fairness and equality. He was also a deeply caring and compassionate man.
We send our heartfelt condolences to Bill’s wife, Catherine, and his children, Kathy, David
and Douglas. And we thank Bill for the lessons he taught us, for the ideals and principles he
helped us shape into our own systems of values, for his mentorship and for his friendship.
We will miss him.
Charles W. Gorodetzky
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IN MEMORIAM: DANIEL X. FREEDMAN, M.D.
1921 - 1993
Daniel X. Freedman, the Louis Block Professor Emeritus of Psychiatry at the University
of Chicago, and since 1983, the Judson Braun Professor of Psychiatry and Pharmacology
at UCLA, died in his sleep at his home in Los Angeles on June 2, 1993, at the age of 71,
He is survived by his wife, Mary.
The contributions of Danny, as he was known to his friends, to the development of a
scientific foundation for the practice of psychiatry arc inestimable. Trained as a
physician, psychiatrist, psychoanalyst, and pharmacologist, he had an extremely
productive and influential career as a scientist,  teacher,  writer, editor, policymaker and
practitioner.
Danny received his undergraduate degree from Harvard University and then went to Yale
where he completed medical school and a residency in psychiatry. He joined the faculty
at Yale in 1956 and remained there until 1966. During that period Danny began the
pursuit of his life long goal of understanding the neurochemical basis of the actions of
LSD and other hallucinogenic drugs. In addition, working with colleagues and students,
Danny found that environmental stress could alter the levels and effects of the brain
neurotransmitters  serotonin and norepinephrine. Further, he discovered  the presence of
high levels of serotonin in the pineal gland of the brain and that severely retarded and
autistic children had abnormally high levels of brain serotonin. Perhaps even more
important than Danny’s own research was his establishment of an NIMH training
program in which basic biological scientists and clinicians worked side by side to solve
the mysteries of the biological basis of mental disorders. During the period at Yale,
Danny became a leader in the revolution to demonstrate that a scientific base for the
applications of psychiatry was possible.
In 1966, Danny became the chairman of the Department of Psychiatry at the University
of Chicago where he continued his activities as a researcher, teacher, editor of the
Archives of  General Psychiatry, mentor to his residents and junior staff and a major force
in shaping policy issues in the area of mental health at both the state and national level.
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He kept the airlines in business shuttling back and forth from Chicago to Washington to
serve on innumerable government committees. When he wasn’t in Washington, he was
in constant phone contact with policymakers, dispensing his sage advice in his own
inimitable style. At the University of Chicago, Danny also built one of the most unique
and respected departments of psychiatry by continuing to foster the interaction of basic
research scientists with clinicians. It was during this period of time that I was recruited
by Danny to join the Department of Psychiatry. For 15 years I had the delightful
opportunity to work with Danny and observe his interactions with students and
colleagues. His energy and enthusiasm for brain and behavioral research were boundless
and infectious. Coupled with his sensitivity and concern for the victims of mental and
addictive disorders, he was an exemplary role model and teacher for all of us.
Danny was also a very romantic person which was obvious to all that saw him with his
wife Mary. His romantic sense was brought home to me personally when my youngest
daughter was born and came home from the hospital. We received a package from the
local florist and laughed at what we believed was their mistake when we saw that it was a
corsage. The message however set us straight. It said: “To Alyson-I wanted to be the
first man in your life to send you flowers-Love, Danny Freedman”.
While I served as the Director of NIDA, I was always comforted by the fact that when I
was really in a quandary I could call Danny Freedman night or day and spend as long as
necessary to get his advice, solace and support I know that he served this same function
for innumerable people. We will all miss him terribly, but take heart in the fact that his
influence, through his writings and the students and colleagues who were fortunate
enough to learn from him, will remain.
Charles R. Schuster
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ANY MAN’S DEATH: PRESIDENTIAL ADDRESS
T. J. Crowley
I am honored to have been associated with the Board of Directors of the
College on Problems of Drug Dependence since 1988, and to have served as
President of CPDD during the last year, as it became a membership society. I
feel honored because it is the members of this College who have taught me
what I know. It is now nearly a third of a century since I finished medical school,
and in my professional lifetime the field has moved incredibly. Unfortunately, as
our knowledge grew so did our frustrations, and I want to talk about both.
First let me remind you of a dozen of those advances. This is a personal list;
others will make other lists, but these are the changes that have affected my
work. A good benchmark of where a field stands is what it teaches its students.
As a junior medical student I was assigned as a psychiatry text Noyes and Kolb
(1958). In it we were told that “drug addiction is usually symptomatic of a
personality disorder”. Addicts were described in these terms: emotionally
immature, hostile, aggressive, seeking relief from inner tension, with immature
drives for immediate goals, and frankly neurotic with anxiety and obsessive
compulsive symptoms. It was stated that relapse is “actually but a
rationalization of their emotional defects”. We were told that the patient “usually
has a resistance to gaining insight into the real causes of his addiction”, as
though the authors of the book were quite sure of such causes. “The moral
deterioration in the cocaine addict is even greater than in the morphine
habitue”, they said. And after this intensely negative description of addiction,
we were told that therapists “will not be critical or judging”.
Behind such pseudo-scientific jargon was a blaming and reviling of addicted
persons, and while we may now laugh at such material, an entire generation of
American physicians left medical school believing that that stuff summed up the
addictions. It is amazing that any of us came to work in this field.
But since then ...
1)  Scientists in our field have laid to rest much of that psychologizing with
concrete evidence that animals self-administer most of the same drugs that
people take.
2)  Members of this organization have used learning theory to make sense out
of the complex behaviors of drug dependent persons.
3 )  Our members have shown that dependence on alcohol and nicotine are
problems of drug dependence, and those are propositions with profound public
health impact.
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4)  Scientists here with us today have demonstrated that definable receptors,
transmitters, and pathways mediate in central nervous system the process of
drug reinforcement.
5)  Our colleagues have proved a genetic vulnerability to certain kinds of drug
dependence, and have organized data strongly suggesting a genetic influence
in most drug dependence.
6)  Epidemiologists belonging to CPDD have shown that substance abuse and
dependence diagnoses comprise 3 of the 4 most prevalent psychiatric
disorders in the U.S. general population.
7 )  Those same investigators have demonstrated that other psychiatric
disorders, especially Antisocial Personality Disorder, very frequently have
associated substance abuse or dependence.
8)  Sadly, we now have recognized that nearly one-fourth of the 2 million U.S.
deaths each year are premature deaths due to drug abuse or dependence
(Figure 1).
FIGURE 1. Estimated Annual Mortality, Drug and Related Problems (about
1990). Tobacco estimates from Shultz (1991). Alcohol estimates from Schultz
et al (1990). Other-drug estimates: (all US deaths from US Vital Statistics) X
[deaths involving various drugs in all DAWN jurisdictions (DAWN 1990) / all
deaths in all DAWN jurisdictions (US Vital Statistics)]. AIDS, Homicide from US
Vital Statistics. “Alc + Drug”, alcohol in combination with another drug; “Her -
Morph”, heroin or morphine.
9 )  Giants in the history of CPDD proved that agonist and antagonist drugs
could be cornerstones of successful treatments for opioid dependence.
10)  We have learned that contingency management, the arrangement of
6
rewards and punishments, powerfully could suppress drug use.
11) Fellows of CPDD found that psychotherapy combined with methadone
notably improves outcome in treatment.
12)  And our members have demonstrated efficacy of HIV prevention activities
among addicts.
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And so, in my professional lifetime our field has stopped simply blaming and
despising addicts. We have applied the best biological, clinical, and social
science techniques to these problems. We have made extraordinary advances
in understanding etiology. Our research has illuminated social policy and
focused prevention, has improved therapies, and it has made people’s lives
better.
But sometimes the frustrations are so great that it is hard to keep going. Let me
add a baker’s dozen of those frustrations.
It is draining for us to deal with lawmakers who seem unable to understand
public health problems. Some years ago I and some colleagues testified on
funding for substance treatment programs to the Colorado legislature. When
we were done a member of that legislative committee pounded on the table and
said to us, “We have been funding these alcoholism programs for 10 years, and
you guys still haven’t solved this problem!”
It is draining for us to deal with hospital administrators and other clinicians who
ignore the mortality data, who ignore what really is killing our fellow citizens,
and who make it clear that they do not want addicts defiling their Temples of
Health. Emphysema patients are dying of nicotine addiction, and just last year
our federally-funded Clinical Research Center disapproved a study in their
Ambulatory Care Area of rapid smoking therapy for emphysema patients. That
therapy, which involves having addicts rapidly smoke a number of cigarettes,
was rejected, the Center reviewers said, because we now have a non-smoking
hospital!
It is draining for us to deal with university administrators who do not want any
bad press generated from the support of drug-related animal research.
It is draining for us to deal with hostile Animal Research Committees. Ours once
reviewed an application of mine and concluded that developing drug self-
administration in animals “may be considered inhumane”, while literally millions
of our fellow citizens, all humans, are addicted to crack, heroin, alcohol,
nicotine, and numerous other drugs.
It drains us to fend off animal-rightists’ insults. These people think they indict us
when they taunt us about a willingness to kill monkeys to save junkies. And
they tell our fellow Americans that BIGGEST LIE, that nothing useful has come
from animal research in our field, when in fact the discovery of self-
administration of drugs among animals produced a sea-change in the field, and
when nearly all of our understanding of the CNS basis of drug abuse has come
from animal research. They ignore the nearly half-million drug-related deaths
annually, instead writing letters to local newspapers -- as they have about me --
decrying “the horrors of the lab”. And this was despite the fact that my
colleagues and I ran a huge, beautiful outdoor monkey-park, where the animals
had trees, grass, and lovely views.
It is draining for us to deal with university officials who appoint, as they did in
Colorado, an animal rights activist to our Institutional Animal Care and Use
Committee, saying “Now we can work with them”. That guy then voted against
every protocol presented to the committee. Moreover, he collected those
protocols and later published many of them in an animal-rights journal.
It drains us constantly to be on guard against break-ins and sabotage by animal
terrorists.
About half mile from where my monkey lab stood, my colleagues and I have a
residential treatment program for deeply troubled, drug-dependent adolescents.
American society could afford to send squadrons of veterinarians frequently to
inspect that gorgeous monkey facility to assure that we never mistreated a
monkey. But society apparently could not afford enough child protection
workers to intervene in the squalid neglect, the violent physical abuse, and the
revolting sexual abuse that characterize the history of almost every youth
admitted to our treatment program, and it drains us to have such priorities
forced on our field.
It drains us to deal with loonies of assorted stripes who ignore the clear
empirical data and still tell us, most recently on 60 Minutes national television,
that methadone maintenance treatment is either ineffective or immoral.
It is draining for us to work with fellow professionals who believe that drug
abuse is just too dirty to be a subject of science. When the cocaine epidemic
began we knew almost nothing about cocaine use, and I sent a grant
application to the National Institute on Drug Abuse asking to go into the
community to watch people use cocaine, an ethnographic study. But my own
Human Subjects Committee refused approval saying that such work was
inappropriate for a University Professor. I eventually withdrew the application
after a pediatrician on that committee said, “You want to study drug abuse.
Well, I study child abuse, but I don’t go into people’s homes to watch them beat
up their kids!”
Tens of thousands of Americans now use cocaine in back-alleys every day. It is
draining for us to deal with well-intended but misguided people who say (safety
questions) that it is morally unconscionable to study this scourge by
observing the cocaine use of a few of those people in our laboratories.
It is draining for us to deal with a despising public, represented by that woman
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who sat next to me on an airplane last year. She asked what I do, and perhaps
unwisely, I told her. She listened for a moment or two and then said, almost
sneering, “You try to treat people who act like that?”.
And yes, the patients whom we study and treat drain us. They often do not
accept or respond to the best treatments that we can offer. They sometimes
continue to take terrible risks with their lives. They frequently seem to care less
about themselves than we care about them. Some commit suicide; some
commit homicide.
So we who would understand drug-taking are ringed about by the friends of
darkness. On the one hand are those who say that we cannot go to the places
where addicts use drugs, for that is beneath us. On the other hand are those
who would not permit us to examine drug taking by humans in our hospitals and
laboratories. Out ahead are the animal-rights crazies, who revile us for studying
drug use in animals. And always, always behind us are the sounds of
thousands, and thousands, and thousands of dying people.
So why do we continue? We are all smart people who could make more money
in real estate.
One reason that we continue is that we know of the suffering caused by these
disorders, and we are committed to make some difference.
And I think there also is a shared experience which keeps us going. It is the
intense support we give each other in this meeting, as we do our best to
address the great public health problem of our time. Oh sure, we fight and
argue and disagree about the data, but even in that we support each other in a
joint search for a truth that may make people’s lives better.
I think that what keeps us all going was summed up almost 400 years ago by
the clergyman and poet, John Donne. You know the lines; you may know the
story. Donne had officiated for many years at funerals, and then fell ill himself.
But from his rectory sick bed he still could hear the funeral bells. We see
Figure 1 when reading what he wrote then ...
Any Mans death diminishes me, because I am involved in
Mankinde; and therefore never send to know for whom the
bell tolls; It tolls for thee.
Friends, colleagues, there is a simple moral to this lament. We can use CPDD
to support one another. If you think that you qualify for membership in this
organization, but you haven’t yet joined, do. In this field, as in no other, we
desperately need each other’s support. And thank you for making me your
President this year.
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DRUG ABUSE RESEARCH ACCOMPLISHMENTS AND
OPPORTUNITIES: A REPORT FROM THE NATIONAL
PERSPECTIVE
Richard A. Millstein
I am very pleased to be here with you again this year to share in the exhilaration that
characterizes this important meeting and to share the exciting and fruitful efforts in
which we have been engaged.
At this time last year, I spoke to you about the imminent reorganization which would
bring NIDA, as well as the National Institute of Mental Health, and the National
Institute on Alcohol Abuse and Alcoholism, within the organizational fold of the
National Institutes of Health (NIH).
The mechanics of this reorganization are now well behind us; and while the challenges
of the process of integration into the NIH system have not been easy, this move has
conferred an important gain on our Institute and on our field: the colocation of science
on the disease of drug addiction with the rest of this nation’s premier biomedical and
behavioral research enterprise at the NIH. By placement of NIDA alongside the other
NIH Institutes, Congress affirmed the status of drug abuse as a disease which should
command the same degree of compassion and scientific dedication--and funding--as
any other disease. NIDA has moved forward and is, I believe, stronger and more
resilient than ever, and better equipped to accomplish our central mission of
supporting scientific research of the highest excellence. I feel a genuine and growing
sense of optimism with regard to NIDA’s future and for the future of drug abuse
research.
In keeping with this promising opportunity, at last year’s meeting I spoke to you on
the State-of-the-Institute in relation to a “Focus on the Future: A Steadfast
Commitment to Research.” Today, with the experience of 12 months of nearly
continuous change, I come before you not only to reaffirm that commitment but also
to convey to you what I see as critical to our ability to ensure this commitment.
NIDA and the research community we represent can and will capitalize on the
unprecedented and unparalleled scientific opportunities presented by dint of your work,
and the excellence of the science will be matched with the funding it should command
to optimally fulfill the promise, only if we--all of us--find ways to enlighten the
American public--and here I include prevention and treatment practitioners,
foundations, the media, and policy-makers--on the value and the far-reaching benefits
of research on drug abuse--now, in this coming year, not “by the year 2000.” For
without the necessary resources, these opportunities to significantly further our mission
to improve the public health, no matter how vital, will remain unrealized.
NIDA-funded research has consistently shown that, like many other diseases, drug
addiction is preventable, measurable, and treatable. And, as with research into other
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diseases, long-term, stable funding in the addiction sciences can--as it has in the past--
yield improvements in the quality of life for millions of affected individuals; decrease
health care costs; and help the Nation fight serious communicable diseases such as
AIDS and tuberculosis. But we have to tell that story.
And unlike other health Institutes whose areas of research receive substantial research
support from the private sector, NIDA is, in essence, nearly the sole provider of our
Nation’s drug abuse research--supporting 88% of that conducted in our country. This
means that when the Congressional Budget Office recommended, just 3 or 4 months
ago, that scientists funded by NIH can find other means of support--for a five-year so-
called “savings” to the Nation of 1.7 billion dollars--we must conclude that they have
not been well enough informed about the nigh absence of alternative funding sources
for drug abuse researchers and of the value of the work in which we engage. It also
means that when budget appropriations for NIDA reach a stalemate, so does drug
abuse research. And this against a backdrop of substantial declines in the past few
years already. Just from 1990 to 1993, as but one measure, the number of competing
RO1 grants supported by NIDA has suffered a 15% decrease, from 267 in 1990 to an
estimated 224 this year. We have to tell that story as well.
Now some promising news.
In the past few months many national figures have been suggesting that the President
and the Office of National Drug Control Policy review the allotment of Federal drug
abuse control expenditures. Today, over 60% of the Federal budget authority for drug
abuse is directed to supply reduction; less than 33% to prevention and treatment
activities; and only about 4% to drug abuse research--this, despite the fact that
research provides essential information about the causes of drug addiction while
assessing new prevention strategies and treatments for its consequences. Reallocation
of just 1% of the 13 billion dollar Federal drug abuse expenditure--130 million
dollars--into the research budget of NlDA would allow for the development of
advances that are critical to the provision of long range solutions to the multitude of
drug abuse problems this Nation daily confronts--and would not increase the nation’s
budget deficit.
NIDA, under legislative authority, has developed a bypass budget request of more than
$500 million, which would allow the enhancement of research that promises to have a
major impact on the health problems of today by increasing the 4% now dedicated to
research to 5% through reallocation of existing funding. This is the recommendation
made by CPDD in its testimony before the House Appropriations Subcommittee last
February, and by other groups and individuals as well.
Further, it is not the research community alone that is promoting additional funding
without affecting the deficit. Just last month, Senators Tom Harkin and Mark
Hatfield, Chairman and ranking minority member, respectively, of the Senate’s HHS
Appropriations Subcommittee, proposed a medical research trust fund based on a 5
dollar per month set-aside from every family’s health insurance premium. Based on
an expectation of 100 million policies, this amounts to $6 billion each year. Under
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their proposal these funds would be allocated to NIH institutes based on each
institute’s percentage of the total NIH appropriation.
In addition, beyond the one percent reallocation proposal and the medical research
trust fund proposal, we are aware of an increase in consensus and petition letters
written to Congress in support of increased NIH funding.
So the proposals are out there. But--how will they fare?
To be optimally persuasive in terms of fiscal impact, the enormous contributions that
research conducted and supported by NIDA has made in many areas must be conveyed
in a meaningful and effective manner to the American public. Admittedly, this is not
an easy task. We often lose sight of the fact that the scientific terminology and the
technically complex ideas that are commonplace in our working environments often
have no measurable impact on those for whom they are essentially unfamiliar. There
is an art to the type of translation these concepts require which we must all strive to
master. Enlightening the public about the very positive outcomes of investing in drug
abuse research, particularly about its “real world” applicability to prevention and
treatment programs, is truly an investment in the future of drug abuse research. It is
up to those of us who are most knowledgeable to create a clearer understanding of
how long-term activities in a laboratory can improve the quality of life on a personal
and individual basis--for a child, a brother or sister trying repeatedly to get off
cocaine, or for the coworker whose excessive absenteeism places an undue workload
on other staff and financial burden on the company. The sense of excitement that
each of us at this meeting has about the findings and the promise of research in drug
abuse is what we must effectively impart to others.
Although perhaps one of the most difficult areas to communicate effectively, NIDA’s
basic research program has generated some recent developments that give us cause to
raise the public’s level of enthusiasm. These findings are important because they
represent outstanding science that is literally pushing the frontiers of basic research,
especially in the cellular and molecular neurosciences. And they will likely bear great
fruit in revealing the biological bases of drug addiction--and also in the broader
biomedical sciences--and thus have potential for further enhancing treatment of drug
abuse.
For example, NIDA grantee Dr. Christopher Evans and his colleagues at UCLA
reported on the cloning of the delta opioid receptor gene in the December 18, 1992
issue of Science. The same issue reported also on the work of Dr. Brigitte Kieffer at
l’Ecole Superieure de Biotechnologie in Strasbourg, France on the molecular
characterization of a delta opioid receptor by expression cloning. As you know,
investigators discovered endogenous opioid peptides roughly 15 years ago. In the
laboratory, however, these compounds have remained ligands in search of receptors--
receptors which at times seemed grail-like as researchers pursued the quest for their
genes. Now, the cloning of the first opioid receptor gene has opened the way for
discovering others, and for conducting more rigorous studies on their role in
fundamental cellular processes, such as neuronal control and, perhaps, even
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development. This work, in turn, offers promise for enhancing our understanding of
the biological mechanisms associated with addiction and withdrawal, pain and
analgesia, and other processes of the nervous system--ultimately, for developing better
medications to treat addiction, pain, and other disorders. Drs. Evans and Kieffer will
be reviewing their research at a symposium today.
As another example, Drs. William Devane and Raphael Mechoulam reported that in
their NIDA-supported work at the Hebrew University of Jerusalem they found a
compound which they call “anandamide” (a Sanskrit word meaning “eternal bliss”) that
behaves like an endogenous ligand to the cannabinoid receptor. This compound is
derived from arachidonic acid--a fatty acid component of cell membranes. This
research is almost a mirror image of the opiate research, which has focused on the
search for the receptors of known endogenous ligands; the cannabinoid studies have
centered on the pursuit of endogenous ligands for a receptor cloned just 2 years ago.
This work is significant for several reasons. It offers promise of studies on an entirely
new neurochemical system and, ultimately, perhaps even insights into the processes
associated with learning, memory, mood, and perception. Medically, it also opens new
avenues in the search for analgesics, antihypertensives, anti-nausea drugs, and
medications for treating glaucoma. This work will be discussed in a symposium
tomorrow.
And yet another development relates to nitric oxide--featured as “Molecule of the
Year” for 1992 by Science magazine. Nitric oxide received this honor because of the
burgeoning numbers of studies in 1992 implicating the simple--or is it not so simple?--
gas in a host of biological processes ranging from digestion to blood pressure
regulation. Among the most intriguing of its roles to emerge has been its possible
function as a novel neurotransmitter. NIDA is pleased to have supported--through the
laboratory of Dr. Solomon Snyder at Johns Hopkins University--much of the original
work which has spurred studies of nitric oxide’s role in the nervous system.
Dr. Snyder and his colleagues isolated and characterized nitric oxide synthase, the
enzyme responsible for making nitric oxide in the body, and studied its distribution in
the brain. From their work came postulates of nitric oxide’s role as a novel
neurotransmitter which performs its actions through diffusion rather than packaging
and release in traditional synaptic vesicles. Dr. Snyder has postulated that nitric oxide
may be but one member of a family of novel neurotransmitters; he and his colleagues
have presented evidence suggesting that carbon monoxide may also function as a
neurotransmitter.
NIDA is very excited to be playing a significant role in discoveries concerning nitric
oxide, because a picture is emerging which reveals that this molecule has a much
larger role in basic biological mechanisms than any of us might have imagined even a
very short time ago. For example, in their studies on neurotoxicity, Dr. Snyder and
his colleagues already have implicated nitric oxide as a possible mediator of some of
the toxic phenomena associated with the HIV-1 virus.
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In other NIDA-funded work, Dr. Gavril Pasternak and his colleagues at the Memorial
Sloan-Kettering Cancer Center and Cornell University Medical College have some
very intriguing findings suggesting that morphine tolerance in mice can be blocked by
an inhibitor of nitric oxide synthase.
Of course, since I spoke with you last year, there have been, in addition to these
developments from NIDA’s basic research program, many, many significant findings
in drug abuse research across the spectrum of basic and clinical science. I will not, as
I did last year, present a comprehensive overview. But as just a sampling:
• While at the Montefiore Methadone Maintenance Treatment Program in the
Bronx, NIDA grantee Dr. Peter Selwyn demonstrated that prophylactic
treatment for active tuberculosis is effective with drug abusers attending a
methadone treatment program. Injecting drug users who are coinfected with
HIV and the tubercle bacillus are at high risk for developing active TB. Dr.
Selwyn found a significantly decreased rate of development of active TB
among those patients who received and complied with the recommended 12-
month TB treatment regimen.
• NIDA grantee Dr. Thomas McLellan at the University of Pennsylvania has
shown that the treatment success rate of methadone maintained patients is
greatly enhanced with the addition of medical services, social work assistance,
family therapy, and employment counseling and job training. Improvement has
been seen in terms of decreased cocaine and alcohol use, psychological
problems, and crime rates, and increased employment.
• And at Emory University, Dr. Claire Coles’ recently-completed study of fetal
growth and neonatal behavior relative to prenatal exposure to cocaine and
alcohol reported no evidence of dysmorphia or physiological withdrawal in a
sample of full-term neonates. This study suggests that many of the problems
seen in cocaine-exposed infants may be due to cocaine’s ability to cause
premature birth, or to the effects of other drugs used in addition to cocaine.
PRIORITY PLANNING
So we have the scientific opportunities. We may have the opportunity to compete for
additional funding to support them. We are recommitted to do even more to educate
and enlighten others and to infect them with our passion and enthusiasm. And now
the mode of transmission.
As I described to you last year, NIDA staff have been engaged in the development of
S-year research plans in 7 areas: neuroscience, medications development,
nonpharmacologic treatment, AIDS, maternal and fetal effects of drugs of abuse,
epidemiology and prevention, and research training and career development. Through
the development of these NIDA 5-year plans so many of you have been so
instrumental in shaping we now will be able to convey not only to drug abuse
researchers, but also to practitioners, to Congress, and to the lay public our current and
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future research priorities, founded on scientific promise and public health need, and
our vision for the future. These plans provide convincing documentation that drug
abuse not only is a serious and costly health problem in its own right, but one that
impacts heavily as well on such medical and social problems as HIV infection and
AIDS, hepatitis, tuberculosis, violence, the productivity of our workforce, and the
educational abilities of our children--whether born to an addicted mother, raised in an
environment permeated by parental drug abuse, or taking drugs while attending school.
They are reflective of our belief that, if these health and social problems and their
high associated economic and human costs are to be reduced, we must address the
prevalence of drug abuse and its consequences--through research. They respond to our
legislative mandate, the scientific opportunities available, and the urgent need for drug
abuse research.
INITIATIVES FOR FY 1994
Now that I have presented this optimistic scenario, let me temper it--but just a bit. If
there was a pre-eminent theme to my talk at Keystone last year it was “let a hundred
flowers--research flowers--bloom”. Today I am saying that if, despite fiscal
stringencies, we are to do well in the competition for dollars, we must emphasize but
2 or 3 major initiatives, and emphasize these consistently and repeatedly. This does
not gainsay the need for growth in other areas--but is strategically necessary. So this
morning I would like to share with you a few particularly promising initiatives in drug
abuse research which we have under way or are about to launch in the coming year.
Through these initiatives NIDA hopes to capitalize on recent technological advances
and treatment research methodology to the benefit of urgent public health need. They
include:
• a new initiative to translate the basic neuroscience accomplishments and bring
them into the clinic;
• a continuing priority on medications development for drug addiction and
dependence, with a focus on medications for cocaine abuse and on medications
that do not cross the placenta; and
• a second new initiative, to validate behavioral and psychotherapies for drug
abuse and drug addiction.
Clinical Neuroscience of Drug Addiction
The first new initiative relates to human neuroscience. NIDA-funded research using
animal models has clearly demonstrated that drug addiction directly involves neuronal
circuits which mediate the pharmacological and psychological consequences of drug
abuse. This evidence comes at a time when emerging brain imaging technologies
permit the visualization of the structure and activity of the brain during the
administration of drugs of abuse, as well as the interaction of drugs, drug abuse
medications, and behavioral therapies in the living brain.
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These developments point to a compelling opportunity for NIDA to expand its
neuroscience program in the area of human studies. Expanded research will lead to
answers to the most central and baffling problems of addiction, such as why drug-
induced euphoria occurs; how environmental variables and cues, learning, and memory
interact in the addiction process; what biological and behavioral mechanisms are
responsible for craving, abstinence, tolerance, and dependence; and why it is so
difficult to break the addiction cycle.
In fiscal year 1994, NIDA plans to expand its neuroscience program in the area of
human studies with the Clinical Neuroscience Initiative. The Initiative will develop,
integrate, and validate non-invasive technologies for use in drug abuse diagnosis and
treatment. As part of this approach, investigators will measure neuroanatomical,
chemical, and physiological parameters associated with drug use during the various
stages of addictive disorders--including craving, tolerance and dependence, withdrawal,
abstinence, and relapse.
For various drugs and use patterns, studies will focus on identifying neuronal systems
associated with reinforcement and brain reward, the biochemical mechanisms through
which they function, and the effects of drugs upon these systems. In addition, this
Initiative will assess the full range of brain development and maturation, including
possible relationships between early or chronic drug use and brain function in later life
and the onset of subsequent neurological disorders. Particular emphasis will be placed
on studies assessing the prenatal and perinatal effects of in utero drug exposure
through a variety of cognitive function and behavioral tests. NIDA is proposing to
support regional multidisciplinary neuroscience research facilities which would have as
their focal point state-of-the-art neuroimaging facilities. The research at these centers
would include both animal and human studies, with the emphases on prevention and
treatment. In addition, the imaging facility would be used in this clinical setting to
evaluate the efficacy of various treatment modalities, including medications and
behavioral approaches. The clinical neuroscience centers would be developed in sites
that would allow us to attract trained scientists and clinicians from other related
disciplines, such as psychiatry, neurology, cognitive neurobiology, and computational
neuroscience--experts who might not otherwise consider drug abuse research as a
career. Perhaps most importantly, we propose that each site have contained within it a
state-of-the-art drug treatment facility, to provide care for patients in addition to
conducting research.
Medications Development for Drug Addiction and Dependence
As for medications development, a continuing priority, as you know, of the thousands
of medications approved for marketing in this country, only two have been approved
for drug abuse indications: methadone, available for a quarter of a century, and
naltrexone, approved for marketing in 1984. A third medication, LAAM (levo alpha
acetyl methadol) was reviewed just last week by the FDA’s Drug Abuse Advisory
Committee, and, I am delighted to report, received unanimous approval. This
recommendation now goes to an FDA Review Group for action.
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Rapid approval is anticipated for LAAM’s formal New Drug Application (NDA) to be
filed next week, and after the 3 to 4 months for required regulatory changes to occur
and for the pharmaceutical manufacturer to launch the product for clinical treatment of
opiate dependence, a third medication will be available--our programs’s first tangible
success in terms of a newly marketed pharmaceutical for a drug abuse indication.
LAAM is not intended to replace methadone; rather, its use is intended to provide the
treatment community with more options and improved treatment matching for patients.
We hope that this will help us progress from serving 100,000 individuals in need of
treatment for opiate dependence to 200,000.
We expect to follow the availability of this third medication with buprenorphine and
clonidine within the next 18 to 24 months. NIDA is now conducting a 12-site, 720-
subject double-blind clinical trial to study the effectiveness of buprenorphine at various
doses (1, 4, 8, and 16 milligrams) and plans to develop buprenorphine as well as a
buprenorphine-plus-antagonist  medication to lessen the risk of diversion.
LAAM, buprenorphine, and clonidine all, of course, are treatments for opiate
dependence. With the recent isolation and cloning of the cocaine receptor, along with
the availability of new brain imaging technologies, it is now promising to develop
antagonist medications for cocaine. Such medications are critical because of the truly
completely overpowering nature of drug craving and the effects of drugs of abuse on
the brain and alteration of behavior. Medications that reduce this craving will also
allow nonpharmacological treatments to strengthen or reinforce the decision-making
processes of the brain.
Teams of structural and molecular biologists are now prepared to modify the amino
acid sequence of the receptor protein to alter the binding of cocaine. The newly
synthesized candidate medications will then be administered and brain imaging
technologies used to visualize the effects of the medications on brain structure and
function. Our increased understanding of the interrelationship between the brain and
behavior will allow us to modulate and influence various systems and receptor proteins
that can prevent the profound effects of drugs of abuse.
Building on the successes of the medications development program and fundamental
research on the mechanisms of action of drugs of abuse, another priority that can now
be explored is the development of medications that do not cross the placenta or are not
active in the fetus, so that drug dependent and addicted pregnant women can receive
drug treatment without major influence on the developing fetus.
Behavioral Therapies
Our ultimate goal is to successfully merge the best pharmacotherapies and the best
behavioral therapies into comprehensive, integrated treatment programs for various
types of addiction. That brings me to our second new initiative in 1994, which relates
to the behavioral and psychotherapies.
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Drug addiction is a complex disease with strong, indeed critical, behavioral and
psychosocial determinants, and such factors must be addressed in the treatment of the
drug abusing patient. Behavioral therapies, including a range of psychosocial
interventions, are the most frequently administered treatments for drug addiction, and
they remain the only available treatment approaches for many drugs of abuse.
Behavioral interventions also serve as adjuncts to pharmacological treatments,
addressing concomitant interpersonal and environmental problems and facilitating
medications compliance. But while considerable progress has been made over the past
decade in developing promising behavioral therapies, treatment retention and relapse
too often remain problematic.
Systematic research on psychotherapy and behavior therapy for drug addicts is in its
early stages. Although many forms of therapy exist, most were not developed or
tested specifically for drug abusers. There exists no counterpart for the behavioral and
psychotherapies of the FDA role in approving pharmacotherapies for the treatment of
drug abuse disorders. NIDA therefore plans to support a Behavioral Therapies
Initiative to apply the same rigorous testing processes to behavioral therapies.
This Initiative will build on the knowledge gained from basic behavioral studies to
identify, formulate, and systematically test promising existing psychotherapeutic,
behavioral, and counseling interventions, as well as to develop and test new
therapeutic modalities. Particular effort will be made to develop protocols for
matching specific types of patients to particular therapies and to develop new
counseling strategies for treating comorbid drug abusers. The Behavioral Therapies
Initiative includes four phases:
• Phase I involves identifying promising research findings relevant to drug abuse
treatment, generating and formulating new psychobehavioral therapies,
operationally defining the therapies in manuals, and pilot testing and modifying
the therapies.
• Phase II continues NIDA’s program of small-scale efficacy testing of promising
therapies and undertakes the replication, at other sites, of studies with positive
results.
• Phase III consists of large-scale testing of therapies that have been shown to be
efficacious in more than one controlled clinical trial. This involves rigorously
controlled, centrally coordinated, multi-site clinical trials of promising therapies
in community-based treatment programs,
• In Phase IV, results of the efficacy studies will be evaluated by panels of
experts, and where substantial evidence for efficacy is demonstrated, the
therapy will be packaged in a way that practitioners can utilize it most
effectively. Also, through our research dissemination and technology transfer
programs, NIDA will develop videotapes, curricula, and other means for
translating the results of the research into clinical practice.
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DEVELOPMENT OF DRUG ABUSE RESEARCHERS
There is so much I cannot in any one presentation talk about. I have only touched on
our AIDS program and our expanded research on drug users and tuberculosis. I have
barely noted the increasing sophistication of our prevention research in achieving and
sustaining behavioral change. And there is so much more. Nonetheless, and despite
time strictures, I must address NIDA’s long-range planning to ensure an adequate
supply of “intellectual capital”--well-trained biomedical and behavioral researchers
critical to the long-term success of addiction research--the sine qua non for a strong
research program to flourish. NIDA’s current training and career efforts are aimed
toward increasing the pool of students interested in drug abuse research; providing
adequate resources to support the training of those individuals who choose to pursue
careers in this field; increasing access to research support and training for special
populations and research scientists; and improving the retention of trained
investigators, especially clinical investigators.
In 1992, we supported 275 full-time training fellowships for pre- and postdoctoral
study; 73 investigators were awarded individual fellowships and 202 were supported
through institutional training grants. But the cadre of drug abuse researchers is aging;
of persons submitting competing research grant applications, those between age 46-50
are increasing while those age 3.5 and below are on the decline. If we do not
intervene now, this trend will severely impede progress and advances towards our
understanding of addiction, and thus towards better drug abuse prevention and
treatment.
We have just in the past few weeks been saddened by the loss of two virtual giants in
the field of drug abuse.
• In May, Dr. William R. Martin died at his home in Kentucky. Dr. Martin
spent more than 40 years in neuropsychopharmacology, and served as Director
of NIDA’s Addiction Research Center from 1963-1976. His work focused on
the addictive nature of narcotic analgesics, and led to the development of new
analgesics which have greatly increased the safety of treatment for chronic
pain. His prescience was sometimes uncanny, evidenced by the redundancy
model of drug tolerance, multiple opiate receptors, and the critical interaction
between drug dependence, psychopathology, and criminal behavior. At the
time of his death, he was an anesthesiology professor at the University of
Kentucky College of Medicine, where he also conducted research on drug
addiction.
• And on June 2, Dr. Daniel X. Freedman passed away in Los Angeles. A
pioneer in psychopharmacology, in the 1950s Dr. Freedman demonstrated the
link between hallucinogens and serotonin. He was the first to identify elevated
serotonin levels in the blood of autistic patients, thus establishing a biological
basis for the condition; and was among the first researchers to describe how
stress affects the brain and how the brain plays a role in allergy symptoms.
Dr. Freedman had been a past president of the American Psychiatric
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Association and, since 1970, had been editor of the American Medical
Association’s Archives of General Psychiatry.
These outstanding individuals will be sorely missed by those of us who knew and
worked with them and comprehend the extraordinary contributions they made during
their lifetimes and that will continue to have lasting benefit in the years to come.
They led by the examples of their industry, insight, and perspective, and by their role
as mentor to so many drug abuse researchers. Their deaths make us keenly aware of
the necessity to foster the kind of training that produced such superlative researchers,
and to which they were so committed.
In fiscal year 1994, NIDA plans to initiate a comprehensive Clinical Research Training
Program which will expose students at the undergraduate level to research, involve
students at the graduate and post-graduate level in clinical drug abuse research, train
clinicians in drug abuse research methods, and attract preventive medicine residents
into clinical research involving substance abusers. This will help train individuals who
can directly translate NIDA’s research advances in neuroscience, pharmacotherapy,
and behavioral sciences into more effective prevention and treatment strategies.
As with clinical research, epidemiology is a shortage area. Training opportunities in
descriptive and analytical epidemiology and methodology development and
improvement will be expanded for fellows pursuing research in the epidemiology of
illicit drugs and nonmedical use of licit drugs.
Further, to fill the demand for expertise in the complex area of medications
development, NIDA plans to establish a Career Development Initiative that involves
trainees with both private industry and the FDA. This linkage will provide individuals
with highly specific, intensive, and comprehensive research and regulatory experience
that will maximize their effectiveness and productivity following the training period.
WOMEN AND MINORITIES  IN DRUG ABUSE RESEARCH
In addition, NIDA will continue its support of mechanisms to promote the recruitment
and retention of women and minorities to drug abuse research. For example, NIDA’s
Special Populations Program, designed to help minorities participate in NIDA’s
research activities, includes implementing training to increase the number of ethnic
minority drug abuse researchers, and promoting support of more ethnic minority drug
abuse research.
We also need to learn more about the subpopulations that comprise our research
community and to recruit more researchers in this area. Last summer, NIDA
convened a meeting of ethnic minority researchers to recommend a research and
training agenda for the Institute. The Special Populations Program has also sponsored
meetings with groups such as National Asian Pacific American Families Against
Substance Abuse, and with representatives including presidents of Historically Black
Colleges and Universities, the National Medical Association, colleges and schools of
clinical pharmacy, and meetings around African American Issues involving Morehouse
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School of Medicine, Drew Medical School. Hopefully, this will lead to enhanced
participation in NIDA’s research and training programs, increased membership on
IRGs, and greater employment of minorities within NIDA.
TECHNOLOGY TRANSFER
Finally, we come to technology transfer. Continuing and improving the research
process of discovery and the subsequent application of findings to practice provides
our country’s best opportunity for continuing to reduce the demand for illicit drugs
and to reduce the burden of HIV infection and AIDS. NIDA’s Technology Transfer
Program provides such a mechanism for enabling researchers to transmit their study
findings to prevention and treatment practitioners, and for practitioners and program
directors to transmit to researchers their clinical knowledge, wisdom, judgments, and
needs. These insights will serve to define and improve new research proposals as they
are developed and will help to keep our research relevant to the practitioner
community.
I hope many of you already are aware of NIDA’s Second National Conference on
Research and Practice - An Alliance for the 2lst Century, to be held at the
Washington, D.C. Renaissance Hotel, July 14-17. This is our second drug abuse
technology transfer conference designed to familiarize drug abuse practitioners from
communities nationwide with promising, research-based approaches that are needed to
address local drug problems. The conference is expected to draw 1,500 drug abuse
prevention and treatment specialists. It will showcase outcomes of NIDA-supported
research on the treatment and prevention of drug abuse and drug abuse-related HIV
infection and AIDS, with a special emphasis on cost-beneficial techniques and
procedures ready for application in the drug abuse field. Nationally recognized experts
in research--many of whom are at this meeting--as well as frontline treatment and
prevention practitioners, will share their knowledge and experience in plenary sessions,
research awareness seminars, issues forums, and intensive skills-building workshops. I
hope many of you will be able to attend and interrelate with other researchers and
prevention and treatment practitioners in this forum to capitalize on the many new and
exciting opportunities for innovative and vital research in drug abuse and to expedite
the transfer and application of research findings to clinical practice.
In closing, I would like to reiterate what a pleasure it is for me to be with you at this
annual meeting. I welcome the chance to talk with many of you individually about
your work, our programs, and our shared commitment. We at NIDA are enormously
grateful to the CPDD and its members for the ardent support you have given us
through the years, and, in particular, for your continued support and assistance during
this time of promise but uncertainty. Your suggestions on how to improve the
visibility of drug abuse research to Congress and the American public are most
welcome, and I invite you to work together with us at NIDA in mastering this
essential skill. I look forward to the challenges we will face together in the coming
year and to the many exciting prospects and opportunities that lie ahead.
AFFILIATION: National Institute on Drug Abuse, Rockville, MD 20857
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LINKING RESEARCH AND SERVICE DELIVERY: THE UNIQUE
MISSION OF THE SUBSTANCE ABUSE AND MENTAL HEALTH
SERVICES ADMINISTRATION
•
Mary A. Jansen
I want to thank you for inviting the Substance Abuse and Mental Health Services
Administration to participate in this year’s College on Problems of Drug Dependence. I
bring greetings from Dr. Elaine Johnson who is our Acting Administrator and who has
participated in these meetings in the past. She very much wanted to be here with you today
but unfortunately she was called away on other business at the last moment. She asked me
to convey her best wishes to you.
As you may know, the Substance Abuse and Mental Health Services Administration
(SAMHSA) was established by Congress in October 1992 to provide Federal leadership for
the prevention and treatment of addictive and mental disorders. It is the newest member of
the Public Health Service and the primary Federal agency responsible for enhancing access
to high quality alcohol, drug abuse, and mental health services for those who need them.
Congress established SAMHA to: (and I quote from the Conference Report) “... fully
develop the Federal government’s ability to target effectively substance abuse and mental
health services to the people most in need, and to translate research in these areas more
effectively and more rapidly into the general health care system”
(Committee of Conference, 1992, p. 127).
This legislation is historic in that, for the first time, Congress has recognized the relationship
between the Nation’s health and the provision of services to those with alcohol, drug abuse,
and mental disorders. Indeed, there are few, if any disorders that impact upon America’s
health and societal well-being as do these.
Consider these sobering statistics which most of you already know all too well:
• 10 percent of adult Americans are alcoholics. Thirty percent of high school
seniors abuse alcohol heavily.
•
•
•
40 percent of deaths in highway accidents are alcohol related.
33 percent of all HIV/AIDS cases are associated with injection of drugs, including
90 percent of HIV-infected infants and 71 percent of HIV-infected women.
Cocaine  mentions in emergency rooms increased by 25 percent from 1990 to
1991. Heroin mentions also have been on the rise.
14 percent of high school seniors smoke marijuana regularly.
An estimated 40 percent of hospital admissions are associated with alcohol,
tobacco, and/or illicit drugs.
•
•
• Over half of all incarcerated adults have alcohol and other drug problems.
Nearly 25 percent of Americans have their health destroyed by cigarette smoking.
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• The most recently published estimates of the cost of drug abuse to our society are
from 1988 and these indicate that when we include costs for treatment, accidents,
illness, death and the related costs for law enforcement and victimization, the figure
stands at $58.3 billion. We have extrapolated from these data and used the Medical
Price Index as a corollary to estimate the societal costs of drug abuse in 1992. The
figure we have come up with is $194.6 billion. Also, consider that these figures do
not include any costs related to “crack” cocaine.
SAMHSA’s mandate is to provide Federal leadership for the prevention and treatment of
addictive and mental disorders. Stated simply, SAMHSA’s mission is to:
Reduce the incidence and prevalence of addictive and mental disorders.•
Thus, SAMHSA’s unique national leadership responsibility is to:
•
Test prevention and treatment approaches and policies to determine which are
effective and which are not;
• Disseminate timely, accurate, objective information about effective prevention and
treatment practices; and
• Provide targeted expenditures to initiate innovative or specialized ADM prevention
and treatment programs that address populations in need of them.
To accomplish this mission, SAMHSA has developed a strategic framework for setting
important priorities to ensure that prevention and treatment services are effective. The
framework focuses on realizing SAMHSA’s overarching mission by targeting four key
principles: access, quality, empowerment, and data systems.
• Access refers to increasing the ability of individuals in need of ADM prevention and
treatment services to obtain those services.
• Quality refers to improving the degree to which services provided to those in need
are properly matched to their needs, are technically correct, and achieve a beneficial
impact.
• Empowerment refers to expanding the ability of individuals, families and
communities to actively participate in addressing factors that cause or sustain ADM
disorders.
• Data Systems involves monitoring progress with objective data and improving
effectiveness through services evaluations in order to answer the perennial question:
“What works?’
SAMHSA consists of three Centers that administer the prevention and treatment services
programs of the agency: the Center for Substance Abuse Prevention (CSAP), the Center for
Substance Abuse Treatment (CSAT), and the Center for Mental Health Services (CMHS).
The Programs of each Center are summarized on this slide. As you can see, we are
attempting to reduce the problems of drug dependence through a variety of demonstration
programs and through the Block Grant to each state.
A word about SAMHSA’s work in relation to health care reform seems in order at this point.
Although we are all anxiously awaiting the Administration’s proposal, it seems almost
certain that substance abuse prevention and treatment services will be included in some way.
If our field is to be credible and taken seriously, we must be able to identify the most
effective and cost beneficial services. In order to do this, we have undertaken an array of
scientific activities designed to provide answers to some of the most pressing questions.
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I would like to outline for you the various kinds of scientific endeavors which arc underway
within SAMHSA as we attempt to fulfill our Congressional mandate and answer these
questions to identify the most effective practices in prevention and treatment service
delivery.
First, each of our individual grant projects is required to conduct both a process and an
outcome evaluation to determine the effects of the intervention delivered.
Second, each of the overall grant programs is conducting an evaluation of the projects
funded within the program in order to determine the worth and impact of the program as a
whole.
Third, each of our Centers is conducting a national evaluation designed to cull out the
consistent findings from prevention and treatment service programs. Once completed, these
findings will be synthesized into a coherent picture of what works, for whom, and under
what circumstances.
These national evaluation efforts are exciting for us because these will be the first systematic
attempts to provide a comprehensive picture of what is working. And AOD abuse
prevention and treatment am emerging as robust fields that are beginning to generate
measurable success.
Fourth. CSAP is planning to fund a National Center for Advancement of Prevention. A
primary goal of the Center will be to develop standardized methodologies and
instrumentation for the conduct of prevention intervention evaluations. The Center will also
be charged with conducting secondary analyses, and where possible, meta analyses, on
results obtained from primary evaluation efforts.
Fifth, CSAT’s National Treatment Improvement Evaluation Survey NTIES) is a multi-
year, multi-site evaluation of patient and program outcomes designed to assess the
effectiveness of enhancements to standard treatment programs funded by CSAT’s
discretionary grants. This look at additive effects of such things as child care for women
who need it to remain in treatment, and transportation for those who could not otherwise
reach treatment sites, will afford us the opportunity to assess the costs and benefits of
providing such ancillary services. In this analysis, the staffing patterns are also being looked
at as a variable which may impact on treatment outcome. This study will conduct long-term
follow-up on each cohort to assess the extent to which treatment effects are sustained in out
years.
Sixth, both CSAP and CSAT are developing standards upon which to guide the field. Some
of the areas targeted by this effort are depicted on this slide for prevention. These include
developing criteria for culturally sensitive programs, developing needs assessment criteria,
and identifying the elements of comprehensive prevention programs.
The topics under development within the treatment effort are outlined on this slide. These
include improving treatment of drug exposed infants, screening for infectious diseases
among substance abusers, and the development of simple screening instruments for AOD
outreach.
I said earlier that a primary responsibility of SAMHSA programs is to generate knowledge
about effective services and practices. As you may know, an Office of Applied Studies was
created when SAMHSA came into being. This office is a part of the immediate Office of
the Adminstrator and is responsible for carrying out the major surveys we conduct,
identifying needed areas for services research, and overseeing the program evaluations
carried out by the Agency.
In addition to the major national surveys conducted by OAS such as the National Household
Survey, we arc hoping to continue the good work begun by NlDA on the Drug Services
2 5
Research Survey. This effort, which will be called the Services Research Outcomes Study
(SROS) in Phase III, has given us good data on access, quality, capacity, financing and
reimbursement, and has produced preliminary analyses of cost effectiveness. Some of the
benefits of the SROS are that the Phase III data will be nationally representative, at the
individual level, modality specific, longitudinal in nature, and linkable across programs,
treatments, clients and outcomes. We are very excited about this effort and are hoping to be
able to fund Phase III beginning in FY 94.
Another aspect of our Congressional mandate is to work jointly with NIDA and NIAAA
around their services research program. We are in the process of developing an Interagency
Agreement with the Institutes which will facilitate the identification of needed studies and
hasten the feedback of results which can be disseminated to the field. Some beginning
questions we hope to have answers to in the near future include:
• Which prevention models are most useful in building resiliency in populations at
highest risk? And what are the critical components of these models in terms of their
contribution to the overall effect?
• Which treatment models work best and under what conditions do the effects vary?
In what combination do treatments need to be delivered to have maximal impact?
• Which financing and reimbursement systems encourage appropriate use of effective
service interventions where a cost benefit ceiling becomes apparent?
• What changes or additions need to be made to existing diagnostic and procedure
nomenclature and coding systems to facilitate enhanced information collection,
research and service delivery?
But obtaining the answers to critical questions such as these is only the first step in fulfilling
our responsibilities to the field. The next step is to transfer new knowledge to those who are
developing interventions. This knowledge transfer function is one which SAMHSA takes
very seriously, and we need your help if we are to be successful in our efforts to disseminate
timely new knowledge. We must work together with the Institutes and all of you to achieve
our joint goal of reducing our nation’s dependence on drugs.
Last year at this meeting, Dr. Elaine Johnson issued a challenge to you to help us as we
build this new agency into one which will truly serve all those affected by substance abuse
disorders. I want to renew that challenge and tell you that I believe that if we work together
we can indeed reduce the tragic loss of life and productivity due to substance abuse
disorders. I hope we can count on you to help us with this task.
Thank you.
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INTRODUCTION OF NATHAN B. EDDY AWARD RECIPIENT
L. B. Cottler
It is a great privilege for me to introduce Dr. Lee Robins, my mentor and friend, as this
year’s recipient of the Nathan B. Eddy Award.
This award, which commemorates the legacy of Nathan Eddy since his death in 1973, is
meant to be an acknowledgement of excellence in research relevant to drug abuse. A
wonderful description of Nathan Eddy was incorporated into the lecture by the first Eddy
awardee. Dr. Seevers. He was described as “a plain man of indomitable will, untiring zeal,
and undeviating faith in the goal he sought.” If these are qualities the Selection Committee
uses, those who know Lee can see why the Committee chose her.
In the 50’s, while changing diapers and cooking meals for her family of four boys, Lee was
working on her Ph.D. thesis. In describing life as a working mom to a Radciffe-Harvard
alumnae magazine reporter, she tells the story of having her mother-in-law watch her sick
children so she could defend her dissertation and remembering how her mother-in-law
eventually offered to pay her to stay home and take care of her grandchildren. Thank
goodness Lee said, “No.”
Although Lee would have you believe that her academic achievements have mostly fallen
into her lap, those of us who know her well, recognize that this is not true. On the other
hand, when opportunities have fallen into her lap, she has known how to “sew a silk purse
from a sow’s ear.” Her first contribution to the field of social psvchiatric epidemiologv, and
eventually to the drug abuse field, is a good example of this. Lee was a junior faculty
member in the Department of Psychiatry at Washington University School of Medicine
when a psvchiatrist friend asked her if she were interested in the medical records of one of
the first child guidance clinics in the U. S. which were stored in an unused city hospital
room and about to be burned. She heard these records crying out for her and agreed to take
them. The records were used to follow up 524 children who had been treated for behavior
problems. This was the first longitudinal studv of disorders among children and the best
account to date of the natural history of childhood behavior problems. The classic text
entitled “Deviant Children Grown Up”, described the 30 year follow-up study. Achieving a
95 percent response rate, Lee found early antisocial behavior to be the strongest predictor of
later adult behavior-even stronger than social class, economic status or family background.
This finding has had implications for recent work in the field with studies looking at
precursors of substance abuse and dependence and the relationship between ASP and high
risk HIV behaviors.
In this study, and in those that would follow, Lee pioneered new approaches in research
methodology, which have been revolutionary in the fields of social psychiatry. It was in this
first study that she started to use lay interviewers to collect detailed histories from
respondents. She found that non-clinicians were capable of eliciting information from
respondents that clinicians often found difficult, such as information on sexual behaviors,
child abuse, illicit drug use and criminal activities.
The child guidance study was followed by another study on the problems of African
American school children, which in turn, led to her next project, which was commissioned
by the White House Special Action Office for Drug Abuse Prevention. There were concerns
about a large number of returning Vietnam Veterans who had been addicted to narcotics
while in Vietnam. The study was funded by the Department of Defense, Departments of
Justice, and Labor, the Veterans Administration and the National Institute of Mental Health.
The first wave of face-to-face interviews was conducted in 1972, a year after the soldiers
had returned home. Three years later, a  NIDA- funded follow-up was conducted on 93
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percent of the men. Among the major findings were that the rate of opiate addiction
dropped from 20 percent in Vietnam to one percent one year after Vietnam, and less than 10
percent of those addicted in Vietnam became re-addicted to opiates in the three years after
returning home. This study helped clarify the natural history of heroin addiction, and
demonstrated quite clearly the influence of “triggers” and “environmental cues” on drug-
using behavior.
In the larger field of psychiatric epidemiology, which of course includes substance use
disorders, Lee’s contributions has had a profound global impact. In the olden days,
psychiatrists themselves went out into the community and surveyed people about their
problems.
This was obviously expensive and could lead to information bias since clinicians often have.
their own biases about what line of questioning should be followed and what characteristics
are most important to them. Thus, not all persons are asked the same set of questions--for
example, little old ladies are not asked about alcohol, or deviant behaviors and virtually no
one had the nerve to ask about sexual behaviors.
However, the Department of Psychiatry at WUMS, changed all of this with its pioneering
work by developing criteria for all major mental disorders--including substance use
disorders. Eli Robins, Lee’s husband, who was Head of the Department from 1963-1975,
brought psychiatry out of the dark ages with a new approach in psychiatry with the help of
Lee. Along with this diagnostic manual of criteria, which was the forerunner to the DSM
manual, an-interview was developed so that clinicans could begin to ask patients about their
behaviors in a consistent way. With Lee’s help, a formal interview was written, and written
in such a way so that even non-clinicians could ask the questions!
Because of this pioneering work, the NIMH asked Lee to consider applying for a grant to
develop an instrument which would be suitable for a major epidemiologic survey in the
United States. This effort eventually became the NIMH ECA project and the instrument
became the Diagnostic Interview Schedule. Lee was one of five PIs on the ECA study--the
largest collaborative effort to document mental disorders in North America.
Now the DIS has been translated into over 30 languages. Due to the success of this
approach, the WHO asked Lee to spearhead the development of another interview based on
the ICD-10 criteria--one that could be applicable for use in many cultures. This instrument
is the CIDI and already has several offspring such as the clinician assessment tool, the
SCAN, the substance abuse module, and screening and computer versions. With the advent
of these instruments, there is an opportunity for cross-cultural and cross-national
comparisons in rates of mental disorder that has been unprecedented.
Every decade, Lee has had a major study--all have made major contributions to the field of
social science, psychiatry and substance abuse. I have worked with Lee for almost 13 years.
Her high standards might intimidate people who don’t know her very well. But she fosters
independence by demanding clear thinking, clear writing and creativity. Let me give you
my personal experience. The best advice Lee ever gave me was received very poorly on my
part at first. It was the week before Christmas and we were meeting over my third revision
to my dissertation proposal. I was very frustrated when she told me the specific aims on my
proposal were still not clear enough. She told me that I would never make it in research if I
couldn’t write a clear proposal. Boy, was she right!
Recently, I have observed a change in Lee’s activities. She has shifted her focus from
conducting her own studies to mentoring other’s work. She has been a consultant to many
people in this audience, including Institute Directors; thus, her recent contributions are
having an even broader impact in the field as she creates the state-of-the-art
Like all “big shots”, Lee has held important positions and offices. She was the first woman
and social scientist on the Board of Directors of CPDD. She has been honored with many
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awards, including the Paul Hoch Award, the NIDA Pacesetter Award, the Sutherland
Award, and the Rema Lapouse Award. In addition, Lee is an honorary fellow of the Royal
Societv of Psvchiatrists and the American Societv of Psvchiatrists. She has been a prolific
writer-authoring  15 books, authoring or co-authoring 237 papers. Recently, Washington
University named her University Professor--which means that she is an official treasure to
the entire University.
What Lee has done for us in the field of drug and psychiatric epidemiology and social
science, has been to give us a way to communicate with one another more precisely--
forever. Although in the future we might revise her interview questions slightly by updating
them to fit the times, her method will never be outdated. She has elevated the task of
writing questions, asking questions and devising methods for conducting studies to a precise
science. Those of us who have collaborated with her on instrument development are
impressed with her perspicaciousness. Her line tooth comb is the finest I have ever seen.
In addition to her numerous academic achievements, Lee promotes a warm family
atmosphere at work, is a fantastic cook, especially of her native New Orleans cuisine, a great
seamstress of her grandchildren’s Halloween costumes, a fun traveling companion and a
whiz at the New York Times crossword puzzles.
The fields of social science and psychiatric epidemiology are celebrated today as Lee Robins
is awarded the Nathan B. Eddv Award. The women in the audience can be proud, too; she is
the second female recipient of this award but the first to receive it solo. On behalf of the
College on Problems of Drug Dependence, I am happy to help present the Nathan B. Eddy
Award to Dr. Lee Robins.
AFFILIATION:
Washington School of Medicine
St. Louis, Missouri
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THE NATHAN B. EDDY LECTURE: CHALLENGING
CONVENTIONAL WISDOM ABOUT DRUG ABUSE
L. N. Robins
It is a tremendous honor to be the Eddy awardee. I have held in awe both Dr.
Eddy’s name and the dedication of the Committee on Problems of Drug Dependence
(CPDD) to the research areas he initiated since I joined the Committee in 1972. I
have also been more than awed by the people who have received this honor before
me. This award has recognized those who gave us new insights into the working of
the brain, cracked the secrets of the effects of chemicals on the nervous system,
demonstrated that animals of many species can detect the rewards of drug use, feel
the pain of withdrawal, and develop conditioned responses to drugs. These findings
in turn have made it possible to predict how human beings will respond to new drugs
to which no man has yet been exposed.
As I looked over the achievements listed by previous awardees, I wondered how the
work of an epidemiologist could compare with these. I was not just afflicted with
personal modesty. I once served on an ill-fated Medical School committee created to
select an epidemiologist as head of a department of population medicine. Instead of
choosing a leader, we witnessed the destruction of the department by a distinguished
bench scientist who said, “Why hire an epidemiologist; he’ll never get a Nobel
prize.” Probably none of us ever will, but for me the Eddy award is its closest
relative, and I am thrilled to be its recipient.
When I asked myself what my work in the epidemiology of substance use and abuse
has accomplished, I decided that probably its importance was in challenging the
conventional wisdom with findings that have stood the test of replication across
diverse populations studied in different ways and in different eras. I wish I could
claim that these findings had then been reflected in public policy, but changing public
views requires more than scientific evidence.
Still, the public view is not exactly as it was at the time I began working on
substance abuse almost 30 years ago, early in the history of the drug epidemic that is
still with us. At that time, everyone “knew” that marijuana was a stepping stone to
hard drugs, that heroin was the most dangerous drug of all, that exposure to it rapidly
and inevitably led to addiction, with characteristic craving that required engaging in
violent crime to satisfy its demands, and that addiction was virtually permanent
without long-term, preferably residential, treatment. This “information” came almost
exclusively from studying people in treatment, because everyone also “knew” that
you couldn’t interview non-patients about illegal behaviors because they would lie.
I became involved in studying substance abuse as a by-product of following
antisocial children into adulthood. Fist I studied the adult lives of child guidance
clinic patients seen in the 1920s and compared them with a control group selected
from school records and matched for neighborhood, race, and IQ. Drug abuse was
one of the outcomes I looked at, but it was rare in that cohort. Based on personal
interviews and the collection of many records (arrests, welfare, psychiatric care, etc.),
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we found excess alcoholism, crime, poor work histories, and marital breakup among
the patients referred for antisocial behavior. We also found that both ex-patients and
controls were quite frank in interview, as revealed by agreement of their statements
with what we found in records they did not know we had.
A STUDY OF YOUNG BLACK URBAN MEN
To validate the results, I repeated the study in a small sample of black St. Louis-born
schoolboys born 20 years later. These men reached adolescence shortly after World
War II, when drugs had entered the black ghettos but had not yet reached the white
middle class. I studied their outcomes in their early thirties. They reached that age
in the mid-1960s. by which time the country was frantic about the impact of drugs on
the young. We interviewed them and again collected a great variety of records for
them -- police, psychiatric, school, military. We found the men to be extremely
honest. Only one man for whom we found a record of a drug-related arrest failed to
tell us in interview that he had used illicit drugs.
Half of these young men reported having used marijuana, and 10% said they had
been addicted to heroin. Their drug use typically began with marijuana at about age
15. Most used no other drugs, but if they did go on, they progressed first to
barbiturates, then to amphetamines, and finally to heroin.
Popular stereotypes about who would use and what the outcome would be did not
hold. The users were not the dregs of society. In fact, they came from the slightly
more affluent families and had slightly higher IQs than the non-users. They obtained
their drugs from friends, not from an evil pusher in the schoolyard. They did more
often have a history of antisocial behavior before they began drug use. Also they
often did poorly in school, despite their good IQs, and eventually dropped out
(Robins and Murphy, 1967).
Their drug use fit the model of an infectious disease epidemic rather well. Those at
risk had friends who were users. Social isolates and those so deviant that they never
entered high school were protected against drug use.
The most surprising finding was that almost all the men who said they had been
addicted to heroin were free of heroin use throughout the year of interview, although
very few had had any treatment (Figure 1).
The other big surprise was that virtually the only men still using marijuana at age 31-
33 were those using heroin (Figure 2). Although drug use had begun with marijuana,
the progression was not a stepping stone pattern. Rather it was a pattern of accretion,
with the addition of new drugs preserving the drug used previously.
These results were surprising, but they were based on a small sample from a single
birth cohort born in one city. Were the findings true elsewhere? My chance to find
out was provided by Dr. Jerome Jaffe.
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Figure 1
Figure 2
CURRENT USE OF NON-NARCOTIC DRUGS:
HEROIN ADDICTS VS. OTHER DRUG USERS
VIETNAM VETERANS
In June 1971, at President Nixon’s request, Jerome Jaffe went to Vietnam and
established a urine screening program, which required that any man due to leave
Vietnam be tested and have a “clean” urine before boarding the airplane. Urine
initially positive by the FRAT test was to be re-tested with gas chromatography. If
the test was again positive, the man was to be sent to detoxification for about a week,
and his urine re-tested before he was allowed to leave the country. As soon as Dr.
Jaffe returned from Vietnam, he invited me to design a study to estimate the size of
the problem both in Vietnam and after return. To do so, I selected 900 men who, in
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September of 1971, when they returned from Vietnam, had been Army enlistees. We
enriched the number of heroin users in the sample by choosing approximately half
this sample from among those for whom the Surgeon General’s office had a record
showing a positive urine test at departure. Military records were then checked to
verify departure dates. From Selective Service records, we drew a sample of draft-
eligible civilians who did not serve but matched the veterans with respect to age,
region lived in, and education at the time the veterans entered service.
We had a remarkably high interview completion rate, 96% when the veterans had
been back 8-12 months. Our completion rate for a second interview at 3 years after
their departure from Vietnam was 94% for the men previously interviewed, and the
same rate for the control sample.
We also had access to all the record information we needed from the military and the
Veterans Administration. And we collected urines at the end of each interview.
These checks on what the men told us showed impressive honesty: 97% of those
whose military record showed narcotics use told us about their use while in service,
and tests of urine samples collected at the end of the interview showed no higher
rates positive for current use than did their self-reports given before they knew they
would be asked for a urine sample.
Narcotic use in Vietnam
The findings were remarkable. We estimated that almost half (45%) of Army
enlisted men in Vietnam in 1970-71 had tried narcotics; 34% tried heroin and 38%
tried opium. While fewer used heroin or opium than alcohol or marijuana (Figure 3).
narcotics were used at a truly astounding rate. These figures reflect the fact that
narcotics were cheap and pure, so pure that there was no need to inject them, a
method which would have repelled many soldiers. Instead heroin could be mixed
with tobacco and smoked. That opium was used so widely was a particular surprise;
the press had reported only on heroin use.
Physical dependence was common. Twenty percent claimed to have felt strung out
or addicted to narcotics, almost half of those who used narcotics at all. While 20%
of a general population being dependent was a truly amazing figure, it is still notable
that half of those who used did not become dependent.
Almost 11% of these Army enlisted men’s urines had tested positive at departure.
This meant that half of the men who reported being dependent in Vietnam had
stopped their use at least 3 or 4 days prior to their scheduled departure. We asked
men detected as positive why they had not quit, and found that it was not always
craving for the drug or fear of withdrawal that explained their positive urine. Some
had received their departure orders less than the 3 days ahead needed for their urines
to clear; others were ignorant about the chemistry involved, and knowing they were
to be tested for heroin, switched to opium, and of course tested positive. Thus more
than half could have stopped their narcotic use on their own, without help in
detoxifying, had they had the information they needed.
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Figure 3
SUBSTANCE USE IN VIETNAM
SUBSTANCES
The orderly pattern, describable as a Guttman scale, in which no one uses an illicit
drug without also using the legal drugs alcohol and tobacco, and no one uses a “hard”
illicit drug without also using a “softer” illicit drug (Kandel and Faust, 1975), was
turned topsy-turvy in Vietnam. While for these very same men both before and after
Vietnam, heavy alcohol use was almost a prerequisite for narcotic use, in Vietnam,
narcotics and alcohol were inversely correlated (Figure 4). This may have been a
result of military rules against selling alcohol to soldiers under age 21; for the
average enlisted man, who arrived in Vietnam at age 19, heroin was more available
than alcohol. The pattern was also reversed for amphetamines. Before service,
amphetamines were often used by men who used no opiates, but the reverse was not
true. In Vietnam, amphetamines were essentially used only by users of narcotics.
(Remember we did not study Marines, whose Green Beret divisions received
amphetamines as part of their military issue kit.) These pattern reversals show that a
drug’s position in the sequence has more to do with its availability and cost than
either with its intrinsic qualities such as addiction liability, or with popular beliefs
about its dangerousness.
What about the impact of the childhood behavior problems that had predicted drug
use so effectively in my study of young black men? One might have expected that
the much greater availability of drugs in Vietnam and the stresses of serving in a war
would dwarf the link with childhood deviance. But they did not. The relationship
between early behavior problems and drug use held in Vietnam. We counted
occurrence and severity of 5 pre-service behaviors: fighting, truanting, drunkenness,
arrest, and school expulsion. Each was scored as not present, present mildly, or
present at a serious level. Both a larger number and greater seriousness of these
behaviors increased the risk of using narcotics in Vietnam (Figure 5).
34
Figure 4
IN VIETNAM, NARCOTIC USE AND DRINKING
WERE INVERSELY RELATED
Figure 5
BEHAVIOR BEFORE VIETNAM AND
NARCOTIC USE IN VIETNAM
A history of pre-service drug exposure was also important. We counted with how
many of 4 drug categories men were familiar before Vietnam -- marijuana,
barbiturates, amphetamines, and opiates (usually codeine). All of those who had tried
all 4 types before Vietnam used narcotics in Vietnam. The fewer drug categories with
which men were familiar at arrival, the less the likelihood of trying narcotics in
Vietnam. Nevertheless, one out of every 4 men who came to Vietnam with no drug
experience whatsoever tried narcotics while there.
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Use and addiction after return
In the first year after return, only 5% of those who had been addicted in Vietnam
were addicted. The rate for men with urines positive at the time of departure was
almost equally low. This finding was totally unlike the outcomes of young men
treated at the Federal Narcotics Hospital in Lexington. When those young men were
followed 6 months later, two-thirds were found already to be re-addicted (Stephens
and Cottrell, 1972). The likelihood of any use, heavy use, and addiction for veterans
was the mirror image of that for treated civilians. Nor was this good result transient.
When we followed veterans at 3 years, only 12% of those addicted in Vietnam had
been addicted at any time in the 3 years since return, and for those re-addicted, the
addiction had usually been very brief. Their claim not to be still addicted was
validated by finding few of them to have positive urines at either the first or the
second follow-up interview.
It was not treatment that explained this remarkable rate of recovery. Only a third of
the men addicted in Vietnam received even simple detoxification while in service,
and only a tiny percentage of Vietnam enlisted men went to the Veterans
Administration for drug abuse treatment after release from Service -- 4% of those
who used narcotics in Vietnam, 6% of those who were positive at departure, and 14%
of those positive at departure who continued to use after return. Yet, veterans who
did enter treatment had relapse rates as high as the young civilian men in
Lexington -- two-thirds had relapsed by the time we interviewed them (Figure 6).
Relapse often occurred the very day they left the hospital.
Nor did recovery require abstention. Nearly half the men addicted in Vietnam tried
narcotics again after return, but only 6% got re-addicted (Figure 7). Some were
spared by using only narcotics other than heroin; some by not injecting, some by
using only occasionally. But even regular heroin users became re-addicted in only
half the cases.
We found few simple heroin addicts among the men who did become re-addicted on
return from Vietnam. They also used a great variety of other drugs. More than 80%
used amphetamines, more than 70% used barbiturates, and almost all used marijuana,
and many had multiple dependencies. When heroin addicts were asked what their
“main” drug was, more than half named alcohol or marijuana rather than heroin
(Figure 8).
Nor did heroin seem uniquely associated with adverse social outcomes. Use of
heroin on return was associated with more crime, unemployment, illegal employment,
divorce or separation, violence, transiency, and credit problems than use of
barbiturates or amphetamines, but not if we held constant pre-service behavior
problems and the number of other types of drugs used (Figure 9). Indeed, the variety
of drugs used was a better predictor of adverse consequences than which drugs were
u s e d .
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Figure 6
RELAPSE TO DRUG USE FOLLOWING
VA IN-PATIENT TREATMENT
Figure 7
RISK OF READDICTION DEPENDING ON
DEGREE OF EXPOSURE
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Figure 8
THE “MAIN” DRUG WHEN HEROIN AND OTHER
SUBSTANCE USED AFTER RETURN FROM VIETNAM
Figure 9
POST-VN DRUGS AND SOCIAL PROBLEMS,
CONTROLS FOR NUMBER OF DRUGS AND
PRESERVICE PREDICTORS
3 8
These then were the major conclusions: availability of a drug, rather than its
chemical action or social consequences, appeared to determine its place in the
hierarchy of popularity. When men moved to narcotics, they did not abandon the
legal or illicit drugs they had used previously, but merely added narcotics to their
repertoire. The most important determinants of narcotics use in Vietnam and after
were pre-service behavior problems and drug experience. Narcotic addiction in
Vietnam occurred in only about half those who used narcotics, and could be
terminated voluntarily by most who became addicted. Re-addiction after return from
Vietnam was rare and brief. Veterans re-addicted and entering treatment had as high
a relapse rate as civilians. Heroin’s adverse effects were no greater than those of
amphetamines or barbiturates when juvenile behavior and concomitant use of other
drugs was taken into account.
Reactions to the findings
The Department of Defense (DoD) was pleased with the study’s findings, because
they showed that Vietnam veterans had not been consigned to a life of unrelenting
dependence on drugs, The press and the research community were more skeptical.
They resisted giving up the beliefs that heroin was a uniquely dangerous drug, to
which a user because addicted very quickly, and addiction to which was virtually
incurable. They maintained these beliefs by offering 3 interpretations of our findings:
1)
2)
The results were false, perhaps tailored to exonerate the DoD.
Addiction in Vietnam was explained by the extraordinary setting -- the misery
of war that made addiction a “normal” reaction; so the relatively benign
outcome of addiction in Vietnam was irrelevant to addiction in the U.S.
3) The drop in frequency of addiction on return was caused by a change in
setting. In the US. these men would not know where to get heroin, and the
settings in which they lived and worked would not be associated in their
minds with use or withdrawal symptoms, and therefore would not serve as
stimuli to relapse. Thus again, the study findings were irrelevant to addiction
beginning in the U.S.
I will argue that each of these views fails to fit the facts.
1) The idea of a whitewash by the DOD was extensively investigated by a New
York Times reporter who had recently returned from that newspaper’s Saigon
office. During the 2 months’ preparation of his article, he went over the study
in great detail, often calling me to challenge what he took to be discrepancies
between statements in my report. I spent a lot of time teaching him how to
read graphs and tables, When the article finally appeared, it barely mentioned
the Vietnam study. To get only one line in the two-page story that had been
intended as an expose showed that the reporter could not support suspicions of
a DoD whitewash.
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The argument that addiction in Vietnam was a response to war stress, and
therefore remitted on exit from the Vietnam war theatre, is still frequently
cited as though it were self-evident, because it sounds so plausible. Yet this
argument does not fit the facts. Heroin was so readily available in Vietnam
that more than 80% were offered it. Those who became addicted had
typically begun use early in their Vietnam tour, before they were exposed to
combat. One man told us he was offered heroin as he got off the plane at
arrival by a man who wanted to swap it for a clean urine so he could get onto
that same plane to go home.
Veterans who saw active combat were more likely than others to use
narcotics, but not once their pre-service histories were controlled for. Those
with the pre-service antisocial behavior and drug experimentation that
predicted drug use also saw more combat, presumably because their lack of
school success and troubles with the law meant that they acquired none of the
skills that kept cooks, typists, and construction workers behind the lines.
When we asked men why they used heroin, they did not tell us that they were
trying to overcome fear or stress. Rather, they said it was enjoyable and
made life in service bearable (Table 1).
3) The argument that men addicted in Vietnam would not relapse after return
because they would not be re-exposed in the U.S. to the stimuli which had
become associated with their drug use and withdrawal symptoms in Vietnam
makes sense for those who did not become re-addicted in the U.S. However,
it fails to account for the high rate of recovery while still in Vietnam. Nor
does it explain why the periods of re-addiction for the minority who became
re-addicted after return were so brief, since they remained in the setting in
which the re-addiction occurred.
Table 1
WHY MEN USED NARCOTICS IN VIETNAM
REASON VOLUNTEERED P E R C E N T
TO FEEL HIGH 4 0
TOLERATE ARMY REGULATIONS 1 3
RELIEVE BOREDOM 9
RELIEVE DEPRESSION 9
RELIEVE FEAR 8
PASS TIME 5
BE ONE OF THE GROUP 3
The findings of the Vietnam study cannot be dismissed by these claims of whitewash,
extraordinary wartime stress, or change in setting. Yet mysteries remain. While we
have powerful predictors of who would use drugs in Vietnam, and who would return
to drugs when they got back to the States, none of our predictors told us anything
about which of the veterans addicted in Vietnam who returned to heroin after return
would get re-addicted (Table 2).
Nor can we be sure how generalizable these findings are. They are difficult to
replicate in a sample of the population because heroin use is so rare -- only
1% have ever used it according to the Epidemiologic Catchment Area study (ECA) --
that studying heroin addiction in the general population is not practical.
Table  2
VARIABLES THAT FAILED TO PREDICT READDICTION
AMONG VETERAN ADDICTS WHO RETURNED TO NARCOTICS
BEHAVIOR PROBLEMS BEFORE SERVICE
PARENTS' SUBSTANCE ABUSE, ARREST, PSYCHIATRIC CARE
SUBSTANCE USE IN VIETNAM (TYPES, DURATION, INJECTION)
I Q
DRAFTEE OR VOLUNTEER
COMBAT
MILITARY DISCIPLINE PROBLEMS
DEMOGRAPHIC CHARACTERISTICS
THE ECA
In the 1980s. I was the principal investigator for one of 5 ECA sites. Heroin users
were not many, even in this sample of 20,000. However, we were able to learn a
little from that study. Unlike interviews in other ECA sites, the St. Louis interviews
asked whether those who had ever met criteria for each type of substance abuse had
experienced problems with it in the year before interview. We found that only 20%
of those ever abusing opiates had had any symptom in the last year, a rate slightly
lower than that for other drug types. This is a confirmation that heroin addiction is
not interminable, and indeed tends to last no longer than addiction to other drugs.
We also showed that heroin users, like abusers of all drugs except cannabis, usually
abused a variety of drugs. We found virtually no one dependent only on narcotics,
confirming the polydrug use of the Vietnam veterans.
Yet heroin continues to be regarded as a unique drug. We see the impact of these
beliefs when we look at treatment experience. In the St. Louis ECA site, the average
rate of receiving treatment in a special drug treatment facility in the 6 months before
interview was 16% if there had been symptoms of drug abuse in the last year. If
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symptoms were related to heroin, the treatment rate doubled, to 35%, more than 3
times the rate for abusers of any other drug (Figure 10). There are special treatment
slots for heroin users because of public concern about it and because a unique
treatment, methadone maintenance, is available to treat it.
Figure 10
TREATMENT THIS YEAR: HEROIN VS. OTHER
ILLICIT DRUGS
ECA SAMPLE WITH DRUG PROBLEM THIS YEAR
In all ECA sites the importance of childhood conduct problems as a predictor of
substance abuse was confirmed (Robins and McEvoy, 1990). To overcome the
problem of the rarity of heroin abuse, we divided the sample according to the number
of categories of substances with which problems had been experienced: alcohol,
marijuana, opiates or cocaine, and all other illicit drugs. If there were problems with
substances in 3 or 4 of these categories, sample members were considered to have
serious substance abuse problems; if in only 1 or 2, they were considered to have
mild problems. The more childhood behavior problems (e.g., lying, stealing, truancy,
fighting, vandalism), the greater the likelihood of both severe substance abuse
problems and any substance abuse problems (Table 3).
The ECA also allowed us to learn more about how conduct problems affected
substance abuse. Conduct problems lowered the age at which substance use began.
As the number of conduct problems increased, the age first drunk dropped from 17
years to 12; the age at first use of an illicit drug dropped from 21 years to 15. And
the earlier use began, the more likely was the user to develop problems (Robins and
Przybeck, 1985). But reducing age at first use was only part of the explanation for
the impact of conduct problems on substance abuse. Even among those with a
“normal” age of onset (i.e., ages 15 to 19). a history of prior conduct problems was
associated with increased risk of problems (Figure 11). Development of substance
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Table 3
RANGE OF CONDUCT PROBLEMS BEFORE 15
AND SUBSTANCE ABUSE PROBLEMS AMONG USERS
Figure 11
CONDUCT DISORDER AND SUBSTANCE ABUSE
CONTROLLING ON AGE OF FIRST USE
abuse problems appears particularly enhanced when there is both early exposure and -
a history of prior behavior problems. Nonetheless, substance abuse is not just a part
of conduct disorder, A substantial minority of substance abusers have no history of
prior conduct problems, although they often develop a later history that looks much
like that predicted by early conduct difficulties.
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LINKING EPIDEMIOLOGY TO LABORATORY SCIENCE
It seems to me that the important message that comes out of these epidemiological
studies of substance abuse is that there is enormous variation in how human beings
respond to potentially addictive substances. Some of these differences appear to be
the effects of prior experiences, both with other substances and with other behaviors
that seem to affect later drug responses. Yet there are clearly limits to how much of
this diversity epidemiologic research can explain. Can laboratory researchers make
use of epidemiologic observations and design studies that can explain individual
variation, as they have previously endeavored to explain variation across drugs and
across species?
For example, we wonder why age of first substance use makes such a difference in
outcome. Is it because the brain does not complete its maturation until late
adolescence and these substances do permanent damage only to immature brains?
Age of exposure appears to interact with prior conduct problems. Could one model
this combination in the laboratory by comparing long-term effects of drug exposure
in aggressive, immature animals to effects in older aggressive animals and immature
non-aggressive ones?
Human beings who use heroin or cocaine have typically used other types of drugs
earlier, and continue to use them along with the heroin or cocaine. Can laboratory
studies examine the transfer of experience across drug types, and the effects of
concurrent use of multiple drug types? Laboratory studies would allow studying the
interactions among drugs without the confounders of adverse social consequences that
so confuse the picture for human beings.
When I first sat on the Committee on Problems of Drug Dependence in the early
1970s some social scientists were claiming that the euphoric effects of drugs require
that the user expect them. Animal experiments have since convinced all but the
diehards among us that the rewards of drug taking depend on biological action in the
brain as well as on socialization by the peer group. I hope that the time is
approaching when social scientists can return the favor by providing insights that will
be as useful to laboratory science as laboratory science has been to social science.
Discovering biological mechanisms that explain the diversity of human reactions to
drugs has obvious potential for selecting those in need of preventive strategies, and
may suggest treatments to increase resistance to drug effects. Epidemiologists have
found no social variables that predict the transition from heavy use to addiction. Nor
do we understand why almost all drug use wanes and disappears in middle age.
Perhaps these transitions are almost entirely biologically determined. Perhaps noting
where epidemiology has not shed light on mechanisms of abuse and dependence will
suggest critical laboratory experiments that will further understanding how biology
affects drug behavior.
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OPIOID RECEPTORS: MOLECULAR AND STRUCTURAL
STUDIES
E. J. Simon
INTRODUCTION
This was a very exciting symposium, in which we heard the first oral presentations on the
successful cloning of an opioid receptor, the receptor from NG108-15 cells. This was
achieved simultaneously by the laboratories of Drs. C. Evans and B. Kieffer, both of
whom presented their results. Probes from the receptor cDNA were subsequently used to
screen for other types of opioid receptors. By now all three major types, µ , and , have
been cloned and sequenced. Drs. L. Yu and G. Uhl, who simultaneously cloned the µ
receptor were added as discussants in the last minute. Dr. T. Reisine whose laboratory was
successful in the cloning of a receptor was not available.
New data on the reconstitution and characterization of a highly purified uI receptor were
presented by Dr. J. Hiller and novel studies on second messenger pathways of opioid recep-
tors were reported by Drs. P. Law and S. Childers. A brief summary of each talk follows.
PROGRESS IN THE CLONING AND SEQUENCING OF THE cDNA OF THE DELTA
OPIOID RECEPTOR FROM NG108-15 CELLS.
Christopher J. Evans, UCLA, Los Angeles, CA.
Our strategy for cloning of a delta opioid receptor from NG108-15 cells was as follows: a
random-primed cDNA expression library was constructed in the expression vector CDM8
using mRNA isolated from NG108-15 cells. COS cells were transfected with the library
and receptor expressing cells identified by screening COS cell lawns with the opioid pep-
tide ligand DALA2DLeu5-enkephalin radiolabeled with 125I at the N-terminal tyrosine.
Positive cells were detected by autoradiography and plasmids isolated from these cells were
amplified in bacteria then transfected into COS cells. Following three rounds of screening
a pure clone, DOR-1, was identified and fully characterized.
The receptor protein is 372 amino acid in length. There are two consensus N-linked glyco-
sylation sites close to the N-terminus and a third consensus glycosylation site is present at
residue 352, though this site resides in the C-terminal domain of the protein which is
predicted to be intracellular. The sequence of DOR-1 contains many consensus protein
kinase C as well as cAMP or cGMP dependent kinase sites. Interestingly, there is a cluster
of kinase sites in the third intracellular loop, which, by analogy to other G-protein-cou-
pled receptors, may be critical for interaction with G-proteins. It is anticipated that
phosphorylation of the receptor will be involved in the adaptive responses to continued
exposure to agonists as has been elegantly demonstrated for the ß-adrenergic receptor. By
analogy with other receptors Cys³³³ is postulated to be a potential palmitoylation site.
Of particular note are aspartate residues at positions 95 (conserved in all somatostatin
receptors) and 128 in the second and third proposed membrane spanning regions. Equival-
ent aspartic residues in the ß-adrenergic receptor are implicated in ligand binding. For
binding of both peptides and alkaloids to opioid receptors there is an absolute requirement
for a positive charge and it appears likely that Asp 128 in the third membrane spanning
region of DOR-1 could serve as the counterion for opioid binding.
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Homology comparisons with other G-protein coupled receptors have revealed high homolo-
gy with receptors for somatostatin, angiotensin, 118 and n-formyl peptide. The high homol-
ogy of DOR-l with somatostatin receptors is of particular interest. Presently there are
four isoforms of somatostatin receptors that have been identified and DOR-1 has highest
homology with isoform 1. In addition to binding to a variety of somatostatin receptors,
somatostatin binds to mu opioid receptors, albeit with low affinity. Analogs of somatosta-
tin with high affinity for mu receptors have recently been synthesized and demonstrated to
be opioid antagonists. As is the case for opioid receptors, stimulation of somatostatin recep-
tors results in inhibition of neurotransmitter release by inhibiting Ca2+ currents and in-
creasing K+ conductance.
Localization of delta receptor mRNA was studied by in situ hybridization. Similar hybridi-
zation patterns were observed in both mouse and rat brains, although more intense labeling
was detected in the mouse brain sections, consistent with the murine origin of DOR-1.
The most striking feature of the neuroanatomical distribution of DOR-1 mRNA is the
intense labeling in the olfactory bulb, predominantly localized to the external plexiform
layer. Additional hybridization signals in olfactory structures were found in the olfactory
tubercle and anterior olfactory area. Diffuse labeling is present throughout the cortex and
basal ganglia, the caudate putamen, hybridizing more intensely in lateral than medial
regions. Other limbic areas such as amygdala, hypothalamus and hippocampus also show
hybridization. In the brainstem the pontine and interpeduncular nucleus show strong label-
ing and more diffuse and less intense hybridization is observed in the substantia gelatinosa
of the cervical spinal chord. No detectable hybridization is present in the thalamic nuclei
and mouse cerebellum, although there is some labeling of deep cerebellar nuclei in the rat.
These observations parallel the distribution of delta opioid binding as determined by recep-
tor autoradiography with exception of the rat cerebellum and the strong hybridization in
the pontine nucleus. All the labeling could be competed by the incorporation of a 50x
excess of unlabeled probe in the hybridization mixture.
Finally we report on DOR-1 mRNA in mouse brain and NG1OB-I5 cells. Preliminary
analysis of the multiple transcripts in NGl08-I5 cells indicate that the two smaller bands
(2.2 and 2.5KB) appear to result from alternative polyadenylation sites. Mouse brain has
only two major transcripts at about 8.5 and 10KB. With regard to regulation of DOR-1
transcripts, little change in DOR-1 mRNA levels is revealed after treatment with DADLE
or etorphine. However, treatment of the cells with forskolin and IBMX caused a dramatic
down regulation of DOR-1 mRNA levels.
THE MOLECULAR CHARACTERIZATION OF THE DELTA OPIOID RECEPTOR BY
EXPRESSION CLONING
Brigitte L. Kieffer, Ecole Superieure de Biotechnologie, Strasbourg, France
Opioid receptors are membrane proteins which mediate the analgesic effect of opium-
derived alkaloids. Progress in the design of potent analgesics, devoid of severe side-effects,
was strongly limited by the lack of knowledge of the primary amino acid sequence and the
secondary and tertiary structure of the receptors.
In order to achieve the molecular cloning of one of these receptors, we constructed a
random-primed expression cDNA library from NGl08-15 cells. These cells are known to
express opioid receptors which are exclusively of the delta type. Pools of plasmid DNA
were transfected into COS sells which were screened for the ability to bind tritiated Tyr-
dAla-Gly-Phe-Leu-Thr (DTLET). A cDNA was isolated which encodes a membrane pro-
tein with all the structural characteristics of a G-protein coupled receptor. Analysis of the
deduced protein sequence indicates that this receptor is most probably entirely embedded
in the membrane. Its amino acid sequence is highly homologous to that of the somatostatin
receptors with which it shares an interesting feature: the presence in the same receptor of
both the short cytoplasmic loop typical of peptide-binding G-protein-coupled receptors
and the conserved Asp residue in the third transmembrane domain, characteristic of recep-
tors that bind amine neurotransmitters, such as catecholamines and acetylcholine.
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When expressed in COS cells, the receptor exhibits pharmacological properties typical of a
delta opioid receptor: high affinity binding sites for DTLET (Kd=1.4nM)), stereoselectivity
and a highly selective pharmacological profile, characteristic of delta receptors. The cloned
receptor transiently expressed in COS cells is negatively coupled to adenylyl cyclase, i.e.,
intracellular cAMP accumulation is decreased by opioids in a concentration-dependent
manner. These data indicate that the cDNA we have isolated encodes the delta opioid
receptor present in NG108-15 cells. Northern analysis studies show that this receptor is
also expressed in mouse tissues. The major transcript is 8.5kb in size and is found in
brain. It is also weakly present in heart but not detectable in kidney, lung, liver or spleen.
The availability of this cDNA should allow the isolation of clones encoding other opioid
receptor types and subtypes. The characterization of all members of the opioid receptor
family will ultimately lead to a better understanding of their involvement in nociception
and analgesia.
RECENT STUDIES ON THE STRUCTURE AND RECONSTITUTION OF PURIFIED
MU OPIOID RECEPTORS
Jacob M. Hiller, New York University Medical Center, New York, NY.
An opioid binding protein (OBP), purified to homogeneity from bovine striatal membranes,
has been reconstituted into liposomes. For most experiments the necessary lipids and G-
proteins were provided by a CHAPS extract of bovine striatum. This extract was prepared
in such a way that it was devoid of opioid binding activity. The liposomes were produced
by precipitation of a mixture of OBP and CHAPS extract with polyethylene glycol 6000
and resuspension in buffer containing calcium but devoid of sodium. While soluble OBP
binds opioid antagonists with high affinity it binds opioid agonists with low affinity,
characteristic of a receptor uncoupled from G-protein. However, reconstituted OPB bound
the mu opioid agonist, [³H]DAGO, saturably and with high affinity, equivalent to that seen
in membrane-bound mu-opioid receptors (1.5 nM). Competition binding studies against
the universal opioid ligand [³H]bremazocine with mu, delta and kappa agonist ligands
demonstrated the high mu selectivity of the reconstituted OBP. Stereoselectivity of binding
was shown by the inability of (+) naloxone to compete gainst 3H-DAGO, while (-) nalox-
one competes with a Kj of 2nM. We have also found that completely inhibits
[³H]DAGO binding to the reconstituted OBP, confirming the successful coupling between
receptor and G-protein. The stimulation of low Km-GTPase by DAGO has also been
demonstrated. In preliminary experiments, carried out in liposomes made by PEG precipi-
tation and resuspension of a mixture of OBP, bovine brain phospholipids (Sigma) and
purified G-protein, Gj or Goa, (courtesy of Drs. J. Hildebrand, J. Dinkus and M. Wilcox),
high affinity [3H]DAGO binding was restored.
Peptide fragments of OBP, generated by chemical cleavage, have been microsequenced and
polyclonal antibodies against synthesized segments of the peptides, conjugated to thyro-
globulin, have been produced in rabbits. Antibody 165, which recognizes the unique amino
acid sequence, IRNLRQDRSKYY, was used in an immunohistochemical study in rat brain.
The distribution of immunoreactive perikarya and neuronal processes in various regions of
the brain and spinal cord correlate well with mu-ligand binding distribution as revealed by
autoradiographic techniques.
ANALYSIS OF DELTA OPIOID RECEPTOR FUNCTIONS
P.Y. Law amd H.H. Loh, University of Minnesota Medical Center, Minneapolis, MN.
In neuroblastoma x glioma NGl08-15 cells, activation of delta-opioid receptors results in
multiple cellular responses. Delta-opioid agonists lower the intracellular cAMP level by
inhibiting adenylyl acyclase activity and stimulating phosphodiesterase activity. They regu-
late intracellular calcium levels by regulating voltage-dependent calcium channels and by
controlling phospholipase C activity, and thereby IP3 level. This coupling to multiple
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effectors could be due to the presence of multiple delta-opioid receptors in NG108-15
cells, the ability of a homogeneous population of delta-opioid receptors to interact with
multiple G-proteins, or the presence of one or more subtypes of delta opioid receptors able
to interact with a single G-protein, which is able to regulate multiple effectors. It is the
purpose of current studies to distinguish the above possibilities. We examined the identity
of G-proteins which interact with delta-opioid receptors in NG108-15 cells, By taking
advantage of the ability of agonists to promote GDP dissociation and GTP association to
of GTP, [32P]GTPazidoanalide, we were able to demonstrate DADLE-concentration-
the G -subunit of heterotrimeric G-proteins, and using the photoaffinity labeling analogue
dependent radioactive labeling of proteins with molecular mass 39-41 kDa. By separating
these proteins by urea-SDS-PAGE and identification of the proteins by Western analysis
with G -subunit specific antibodies, we demonstrated that DADLE promoted [32P]GTPa-
zidoanilide  labeling of Gi , both isoforms of Goa and the isoform, of Gi3a found in
NG108-15. Furthermore, similar concentrations of DADLE were required to promote the
association and hence labeling of the G -subunits by GTPazidoanilide. One possibility was
that multiple delta-opioid receptor subtypes are being expressed at a high level in NG108-
15 cells. We therefore stably transfected Chinese hamster ovary cells (CHO) with a recently
cloned delta-opioid receptor cDNA (courtesy C. Evans). Different levels of receptor ex-
pression were obtained in several clones of CHO. Although the amount of [32]GTPazidoa-
nilide incorporation by G -subunits was dependent on receptor concentration, DADLE
promoted [32P]GTPazidoanilide labeling of G , G o a  and G in all three clones of
delta-opioid receptor transfected CHO cells tested. The ability of delta-opioid receptors to
couple to other G-proteins was demonstrated further when in vitro transcribed delta-
opioid receptor mRNA was co-injected into Xenopus oocytes with CFTR, a chloride
channel which can be activated by elevated intracellular CAMP levels. Instead of the pre-
dicted lowering of intracellular CAMP, application of DADLE to oocytes injected with
delta receptor and CFTR mRNA’s resulted in an increase in Cl-current, indicative of an
elevation of intracellular cAMP level, which could be blocked by naloxone. A similar
increase in Cl-current was observed when isoproterenol was applied to oocytes which had
been injected with ß-adrenergic receptor and CFTR mRNAs. It is postulated,that in
Xenopus oocytes, which do not express G delta-opioid receptors regulate intracellular
cAMP levels by coupling to G How delta-opioid receptors regulate different effector
systems when they are able to couple to multiple G-proteins remains unsolved.
SIGNAL TRANSDUCTION MECHANISMS FOR OPIOID RECEPTORS
Steven R. Childers, Department of Physiology & Pharmacology, Bowman Gray School of
Medicine, Winston-Salem, NC.
The recent cloning of the delta opioid receptor by Evans et al. and Kieffer et al. have
confirmed the G-protein-coupled nature of this receptor. The deduced structure contains
seven transmembrane segments and other features which place it in the G-protein super-
family of receptors. Such a structure was predicted some years ago from the finding that
the three major types of opioid receptors (mu, delta and kappa) all produced responses
typical of receptors which belong to the G -coupled family. These responses can be
detected throughout the signal transduction pathway, including the following components:
1. Receptor. Guanine nucleotides inhibit the binding of most agonists to receptor sites by
increasing their dissociation rates. In this way, the high affinity state of opioid receptors
for agonists is eliminated by GTP and sodium. The recent development of agonists which
are insensitive to this effect dramatically increases their potencies under conditions where
high affinity agonist binding is normally lost.
2. G-protein. Significant progress has recently been made in determining the identity of
specific G-proteins coupled to opioid receptors. These G-proteins include several subtypes
of Gi and Go. The precise G-protein coupled to different opioid receptors may depend on
the cell type. Moreover, opioid agonists stimulate low Km GTPase present on the alpha
subunit of the G-protein. This activity is a measure of agonist efficacy, as well as a
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mechanism for inactivating G-protein. Methods which decrease GTPase activity (such as
treatment at low pH) thus increase agonist efficacy.
3. Effectors. All opioid receptor types inhibit adenylyl cyclase. They are also coupled to
ion channels, particularly to the closing of Ca2+ and the opening of K+ channels. The
mechanism of receptor action in most cases involves direct coupling of the receptor to the
channels through the G-protein without an intervening diffusible second messenger system.
However, other mechanisms may occur in other cell types, and other effectors may be
identified in the future.
4. Post-effector events. Opioid-inhibition of adenylyl cyclase results in the inhibition of
the phosphorylation of several proteins. Major opioid-inhibited phosphoproteins in brain
are synapsins I and II, which are vesicular proteins that play a role in mediating neuro-
transmitter release. Reduction in synapsin phosphorylation is consistent with the actions of
opioid agonists in inhibiting neurotransmitter release. Inhibition of intracellular cAMP also
plays an important role in regulating several genomic events. For example, the proenkepha-
lin gene contains a cAMP-responsive element which is stimulated by cyclic AMP-
dependent protein kinase. Opioid agonists reduce proenkephalin mRNA synthesis by reduc-
ing cAMP levels, thus providing a potential negative feedback system for regulation of
opioid peptide levels.
5. Regulation of signal transduction systems during opioid tolerance and dependence. Two
different mechanisms are relevant to the role of signal transduction pathways in the devel-
opment of opioid tolerance and dependence. The first event involves desensitization of
receptor-effector coupling, followed by receptor downregulation. These events occur in
cell culture, and are mediated by processes typical of other Gi/o-coupled receptors.
However, in brain, desensitization of opioid-inhibited adenylyl cyclase does not commonly
occur during chronic agonist treatment. In this tissue, a second process occurs which
involves compensatory changes in signal transduction systems. In this process, activities
which were inhibited by acute opioid action become stimulated during chronic agonist
treatment. Thus, basal levels of adenylyl cyclase, activity of cyclic AMP-dependent pro-
tein kinase, and phosphorylation of synapsin are all increased during chronic morphine
treatment. These changes occur in the direction opposite to those observed after acute
morphine administration, and may contribute to the overall phonemena of tolerance and
dependence.
THE CLONING OF THE MU OPIOID RECEPTOR
George Uhl, NIDA Addiction Research Center, Baltimore, MD
Lei Yu, Indiana University School of Medicine, Indianapolis, IN.
When the chairpersons learned that the mu receptor had also been cloned, Drs. George Uhl
and Lei Yu were added to the program as discussants. In brief, both laboratories made use
of cDNA probes derived from the nucleotide sequence of the recently cloned delta recep-
tor cDNA. In one case (Uhl), PCR was used with single stranded cDNA from whole rat
brain as the primer to obtain a 700 base pair insert. Rat brain cDNA libraries were
screened at low stringency. In both laboratories a clone was obtained which had a high
degree of sequence homology with the cDNA of the murine delta receptor. The amino acid
sequence exhibited the structural features of a G-protein coupled receptor. When transfec-
ted into COS cells, the cDNA conferred on these cells a binding site with the pharmacolog-
ical characteristics of a mu opioid receptor. Yu and coworkers found that DAGO decreased
the accumulation of cAMP and this decrease was reversed by naloxonazine, supporting the
functional coupling of the mu receptor to G-protein. Uhl and coworkers found high levels
of a 10.5 kB mRNA in thalamic neurons which hybridizes with the cDNA from their mu
receptor clone.
Summarized by Eric J.Simon, New York Univ. Med. Ctr., New York, NY
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THE TERATOGENICITY OF THE DRUGS OF ABUSE: A
SYMPOSIUM
L. P. Finnegan, A. P. Streissguth, G. Koren, D. Neuspiel and K. Kaltenbach
A great deal of concern has been expressed over the last several decades concerning the
effects of licit and illicit drugs upon pregnancy, the fetus, the newborn and child. Numerous
research studies have undertaken the difficult task of determining the effects of alcohol,
cocaine, and opiates from a physiological and developmental standpoint. Many issues have
been clearlv defined with regard to the effects of alcohol on pregnancv. the fetus. and the
newborn and its relationship to long-term development. Fetal Alcohol Syndrome  has been
described as well as Fetal Alcohol Effects. Long-term studies involving infants prenatally
exposed to alcohol have been on-going over the last decade.
With regard to cocaine, despite a growing number of studies that have investigated the
reproductive effects of maternal cocaine use, a homogeneous pattern of fetal effects has not
been established, and, there is little consensus on the adverse effects of the drug. Although,
considerable concern has been expressed about the high rate of cocaine use among pregnant
women; a rush to judgement about the extent and permanency of specific effects of
intrauterine cocaine exposure has occurred. Many predictions with regard to cocaine have
been promulgated by the scientific and lay communities in spite of the lack of supportive
scientific evidence. Many have been concerned about the potential severity and universality
of cocaine effects, but premature conclusions may be potentially harmful to children.
Infants have been exposed to opiates for centuries and it has only been in the last two
decades that researchers have generated a number of studies evaluating the short and long-
term effects. The neonatal abstinence syndrome has been defined and recommendations for
treatment have been published. However, studies on long-term effects are limited and also,
as in the research of cocaine effects confounded by a host of variables seen in pregnant
opiate-dependent mothers. This symposium presented evaluations of the current literature
with regard to longitudinal outcomes of children exposed to alcohol, structural defects and
behavioral outcomes of infants exposed to cocaine, and the long-term effects of opiate
exposure in utero.
ALCOHOL: LONGITUDINAL OUTCOMES
The Seattle Longitudinal Prospective Study on Alcohol and Pregnancy involves around 500
children who have been examined at various points in time, including day 1 and 2 of life, 8
and 18 months, 4, 7, and 14 years, with data from classroom teachers obtained at 7 and 11
years. Follow-up of the cohort has been maintained at around 82 percent of the original
cohort, with no systematic loss of high-risk subjects. Mothers were primarily white, middle
class, well-educated married women at fairly low risk for adverse pregnancy outcome. All
were in prenatal care by the fifth month of pregnancy, when they were interviewed
regarding drinking habits and other potential covariates. Approximately 80 percent were
drinking during pregnancy, with the same proportion drinking prior to pregnancy.
A recent longitudinal analysis of the data for the first seven years of life involves analysis by
the Partial Least Squares, a relatively new multivariate statistical method combining themes
from factor analysis, multiple regression and non-linear scaling. Our principal findings are
as follows: (1) Effects of prenatal alcohol exposure am manifest at all ages from birth to
seven years; they arc manifest on a variety of behavioral measures; and they do not attenuate
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with time. (2) Among the most salient sequelae of exposure. are neonatal habituation to
light, time in error from the Wisconsin Motor Steadiness Battery at age four, standardized
WISC-R and WRAT-R arithmetic subtests at age seven years. and academic adjustment as
rated by the second grade teacher. (3) For most of the outcomes, binge drinking has more
serious consequences than the same amount of steady drinking, and drinking early in
pregnancy has more serious consequences than the same reported pattern of drinking in mid-
pregnancy. (4) There is no statistical evidence for a “risk-free” threshold level of prenatal
drinking. (5) These alcohol effects cannot be “explained away” by any of 150 covariates we
considered; including  Parents’ education. prenatal  nutrition,  and prenatal exposure to
nicotine. (6) Profiles of alcohol-related Scholastic and neurobehavioral deficit strikingly
independent of the usual covariates are manifest by the second grade in school. These show
promise for the characterization of individual children as fetal-alcohol-affected based on
neurobehavioral criteria.
Data from classroom teachers when the children were 11 years old revealed prenatal
alcohol-related difficulties with classroom behavior, academic performance (particularly
arithmetic), and information processing. At 14 years of age, continued effects of prenatal
alcohol on laboratory measures of attention and memory were observed, as well as problems
with phonological processing and numerical reasoning.
COCAINE: STRUCTURAL DEFECTS
Over the past decade, a large number of studies addressed the association between in utero
cocaine exposure and malformation rates. Invariably, these studies have compared rates of
malformation in cocaine-exposed vs. cocaine-unexposed babies. There are serious
methodological issues with these studies. Firstly. exposure is often verified by maternal
history, which is less than 50 percent sensitive; urine tests become negative within a few
days due to the short elimination half-life of the drug. Secondly, mothers who use cocaine
have clustering of other risk factors, including alcohol and cigarette consumption, poor
prenatal care, sexually transmitted diseases, poor nutrition and low SES. Therefore,
association of the fetal adverse effects does not prove causation.
In meta-analysis of all published papers, we have revealed that for most end points, positive
studies are balanced by negative studies. When cocaine-exposed children are compared to
middle-class women and their children, the former suffer from many more adverse effects.
However, when they are compared to babies exposed to other drugs of abuse but no cocaine,
most adverse effects are nullified.
In summary, while cocaine does not appear to be a major human teratogen, we hypothesize
that polymorphic metabolism and placental transfer may expose some babies to its potent
pharmacological effects.
COCAINE: BEHAVIORAL OUTCOMES
The behavioral effects of intrauterine cocaine exposure on the infant and child are
controversial, with various studies reporting conflicting results. Inconsistent findings may
emerge from various methodological problems in this research, including sampling,
exposure measurement, cohort retention and selection of dependent variables. The problem
of confounding is of particular concern. To be a confounder, a variable must be: a) a risk
factor for the study outcome, regardless of cocaine exposure status; b) associated with
cocaine exposure; and c) not be an intermediate factor in the causal pathway between
cocaine exposure and outcome. In the presence of a strong confounder and weak or non-
existent primary exposure effect, misclassification of confounding may lead to biased
results.
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Extant studies of cocaine effects on infant and child behavior have not consistently or
accurately assessed confounding effects. For example, tobacco smoke exposure has been
considered in most of these studies, its measurements have been limited, with potential for
misclassification and undercontrol for smoking effects. Many other confounders have been
inadequately controlled in these investigations. The effects of undercontrol for confounding
may lead to greater positive bias (falsely reporting adverse outcomes from cocaine exposure)
than the negative bias resulting from misclassification of cocaine users as non-users.
These methodologic problems may lead to biased magnified estimates of the risk of cocaine
exposure. This may have clinical and policy consequences, including unnecessary
termination of pregnancy, labeling and reduced expectations for cocaine exposed children,
and decreased attention to social programs directed toward other sources of behavioral risk.
Attention to improved methodology in future research can result in a clearer view of the true
risks of cocaine exposure to the behavior and development of infants and children.
OPIATE EXPOSURE
An overview of existing research on prenatal opiate exposure, identifying limitations of past
work and offering suggestions for future research paradigms was presented. A critique of
current research investigating the effects of prenatal cocaine exposure leaves one with a
sense of deja vu. Opiate research in the late 70s and early 80s typically used a bi-variate
approach with little or no attention to multiple confounding factors. While the signs and
symptoms of neonatal abstinence were well documented, findings among studies were often
diverse as women differed on whether or not they were maintained on methadone; daily
methadone dose; length of methadone maintenance during pregnancy; and amount of
prenatal care. Additionally, poly-drug abuse including alcohol and nicotine use was rarely
taken into account. By the mid-80s most investigators recognized that not only biological
but social and environmental risk factors must be considered and began to call for a multi-
factorial approach to investigate  perinatal and developmental outcomes associated with
prenatal opiate exposure. Unfortunately, as research strategies evolved toward a multi-
variate approach, funding interest in the effects of opiates (i.e., methadone) began to wane
and the cocaine epidemic produced a wave of investigators naive in the field of maternal
addiction and prenatal drug exposure. Returning to the critique of research investigating the
effects of prenatal cocaine exposure suggests that we have come full circle. Investigators
are again beginning to call for a multi-factorial approach. Aside from issues concerning the
strategies to control for confounding effects, the need to address prenatal drug exposure
within a multi-risk model in order to identify the effects of cumulative risks concomitant to
maternal substance abuse is most relevant to the accomplishment of this research.
In summary, research studies on prenatal exposure to alcohol, cocaine, and opiates have
defined a number of structural and behavioral effects upon the fetus and newborn. It is
clear, from a pharmacological basis and animal research, that many of these effects are
biologically plausible through direct or indirect mechanisms. However, the research to date
has not clearly defined specific independent effects, such as in the case of cocaine in human
infants. In reviewing previous studies on long-term effects (to school age), except in the
case of alcohol, few studies have been reported with regard to opiate exposure, and no
studies have evaluated infants exposed to cocaine. Research in the area of prenatal exposure
to licit and illicit drugs is of key public health importance. Moreover, researchers and
funding agencies must work diligently to advance the research from the methodological
weaknesses of the past and to define the risk and nature of structural as well as behavioral
outcomes. While defining these effects, researchers, clinicians, and those involved in public
policy should clearly develop intervention services for both mothers and children and to
advocate for improved health care and drug treatment services for those women who are
dependent upon alcohol, cocaine, or opiates.
53
REFERENCES:
Carmichael Olson, H., Sampson, P. D., Barr, H., Streissguth, A. P., and Bookstein, F. L.
Prenatal exposure to alcohol and school problems in late childhood/ A longitudinal
prospective study. Development and Psychopathology 4, 341-359, 1992
Carmichael Olson, H.. Streissguth, A. P., Bookstein, F. L., Barr, H. M. Sampson, P. D.
Hutchings. D. E. Prenatal opioid exposure and the problem of causal inference. In:
Current Research on the Consequences of Maternal Drug Use. T. M. Prinkert (Ed) 6-
19. National Institute. on Drug Abuse Series (DHHS Publication No. ADM 85-1400),
Washington, D. C.. U. S. Government Printing Office, 1985
Kaltenbach, K. and Finnegan, L. P. Prenatal opiate exposure: physical, neurobehavioral
and developmental effects. In: Devel opment of the Central nervous System:
Effects of Alcohol and Opiates, M. Miller (Ed) pp. 37-46, Wiley-Liss, Inc., 1992
Koren, G.. Shear, H., Graham, K. and Einarson, T. Bias against the null hypothesis: The
reproductive hazards of cocaine. Lancet. 1440-1442, 1989
Lutiger, B., Graham, K., Einarson, T., and Koren, G. Relationship between gestational
cocaine use and pregnancy outcome: A meta-analysis. Teratology 44: 405-414,
Marcus, J., Hans, S., and Jeremy, R. J. A longitudinal study of offspring born to methadone
maintained women. III. Effects of multiple risk factors on development at 4, 8, and
12 months. In: American Journal of Drug and Alcohol Abuse. 10 (2), pp 195-207,
1984
Mayes, L. C., Granger, R. H., Bernstein, M. H.. Zuckerman, B. The problem of prenatal
cocaine exposure, a rush to judgement. JAMA, Vo1267, No. 3, January 15,1992
Neuspiel, D. R., Hamel, S. C. Cocaine and infant behavior. J. Devel Behav Pediatrics.
12: 55-64, 1991
Streissguth, A. P., Sampson, P. D., Barr, H. M., Bookstein, F. L., Carmichael Olson, H.
Effects of prenatal alcohol vs tobacco on children: Contributions from the Seattle
longitudinal prospective study and implications for public policy. In: Needleman,
Herbert, L. and Bellinger, David (eds). Prenatal Exposure to Pollutants. Johns
Hopkins University 1993 (in press)
Streissguth, A. P., Bookstein, F. L., Sampson, P. D., and Barr, H. M. The Enduring effects
of prenatal exposure on child development: Birth through seven years.
University of Michigan Press. 1993 (in press)
AUTHOR
Loretta P. Finnegan
AFFILIATION
National Institute on Drug Abuse, National Institutes of Health, Rockville, Maryland
54
CANNABINOID RECEPTORS: PHARMACOLOGY, SECOND
MESSENGER SYSTEMS AND ENDOGENOUS LIGANDS
B. R. Martin, S. Childers, A. Howlett, R. Mechoulam and R. Pertwee
Research during the past few years has dramatically expanded our knowledge of the actions of
cannabinoids in the brain. Prior to this time, it seemed that one could invoke an argument for
almost any neurochemical system as a cannabinoid substrate. We now know that there are
specific cannabinoid receptors discretely located throughout the brain which are G-protein
coupled. An endogenous substance has been isolated from brain which binds to this receptor
and produces cannabinoid effects. The purpose of this symposium was to summarize these
latest discoveries.
C A N N A B I N O I D  T O L E R A N C E  S T U D I E S  W I T H  T H E  M O U S E  V A S
DEFERENS
One of the primary goals of Dr. Pertwec’s laboratory is to explore the suitability of the mouse
isolated vas deferens as a model with which to study the basis of cannabinoid tolerance. The
experiments described here were directed at establishing whether in vivo pretreatment with
tetrahydrocannabinol (THC) can induce tolerance to the inhibitory effects of psychotropic
cannabimimetic agents on electrically-evoked contractions of the mouse isolated vas deferens.
Previous experiments in this laboratory had shown that tolerance to THC-induced
hypothermia can develop rapidly in mice and it was therefore decided to determine whether a
THC pretreatment producing such tolerance would also induce cannabinoid tolerance in the
vas deferens. Apart from THC, the drugs used in this investigation were CP-55,940, WIN
55,212-2 and the putative endogenous cannabinoid, anandamide. These drugs bind avidly to
cannabinoid binding sites, possess cannabimimetic pharmacological properties, and yet have
markedly different chemical structures both from each other and from THC.
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Male MFl mice were injected i.p. once daily for two days with either THC (20 mg/kg) or
Tween 80 (40 mg/kg ). The hypothermic effects of THC, CP-55,940, WIN 55.212-2 and
anandamide were measured 24 h after the second i.p. injection of THC or Tween by noting
the maximum decrease in rectal temperature produced by each compound. Unless stated
otherwise, these compounds were injected intravenously (n=6). In other experiments, mice
were killed 24 h after the second pretreatment with THC or Tween 80 and their vasa deferentia
removed and placed in an organ bath in order to determine the effects of the cannabinoids on
electrically evoked contractions. THC (1.0 mg/kg, i.v.) was significantly less hypothermic in
THC-pretreated mice (0.19 ± 0.13 °C; means ± s.e.) than in Tween-pretreated mice (2.77 ±
0.43 °C; P < 0.001). Similarly, THC (10 nM) inhibited the twitch response to a lesser extent
(P < 0.001) in vasa deferentia obtained from THC-pretreated mice (5.4 ± 5.1%; n=8) than in
tissues obtained from Tween-pretreated animals (42.4 ± 5.5%; n=8). The inhibitory effects of
CP-55,940 (0.316 nM), WIN 55.212-2 (3.16 nM) and anandamide (100 nM) on the twitch
response were also significantly less (P < 0.05) in tissue from THC-pretreated mice (13.6 ±
3.8%. 23.2 ± 4.9% and 27.4 ± 4.7%. respectively; n=5 to 8) than in tissue from animals
pretreated with Tween (40.2 ± 4.9%, 77.16 ± 4.4%. and 49.5 ± 8.9%, respectively; n=6 to
8). Results from other experiments indicated that the degree of tolerance produced, both to the
hypothermic effect of THC and to its inhibitory effect on the vas deferens, was directly related
to the size of the pretreatment dose of THC and to the number of ptetreatments given (data not
shown). Additional experiments were carried out to establish whether the in vivo pretreatment
with THC that had been found to render the vas deferens tolerant to CP-55,940, WIN 55,212-
and anandamide would also induce tolerance to the hypothermic effect of these drugs. It was
found that CP-55,940 (0.05 mg/kg) and WIN-55,212-2 (0.2 mg/kg) were indeed significantly
less hypothermic (P < 0.001) in THC-pretreated mice (0.05 ± 0.20 °C and 0.08 ± 0.13 °C
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respectively) than in animals that had been pretreated with Tween (2.07 ± 0.31 C and 2.16 ±
0.31 °C respectively) whereas anandamide (10 mg/kg) was no less hypothermic in THC-
pretreated mice (1.32 ± 0.22 C) than in Tween-pretreated animals (1.47 ± 0.07 °C; P >
0.05). Hypothermic responses of THC-pretreated and Tween-pretreated mice to anandamide
(20 mg/kg, i.p.) were also found not to differ significantly from each other (2.54 ± 0.27 °C
and 2.22 ± 0.22 °C respectively; n=5).
These results confirm that cannabinoid tolerance can be rapid in onset and provide further
evidence for the hypothesis that is mainly pharmacodynamic in nature. Our finding that in
vivo pretreatment with THC can induce tolerance both to its own inhibitory effect on the
mouse isolated vas deferens and to that of other cannabimimetic agents suggests that this
preparation would be suitable as an experimental model for investigating the mechanisms
responsible for cannabinoid tolerance.
C A N N A B I N O I D  R E C E P T O R - M E D I A T E D  G - P R O T E I N  C O U P L E D
ACTIVITIES IN CEREBELLUM AND HIPPOCAMPUS
The discovery that -THC and other cannabinoids bind to G-protein-coupled receptors
(Howlett, 1985) is a discovery with profound implications for the molecular and cellular
mechanisms of these drugs in brain. The cannabinoid receptor is a member of the  Gi/o family
of receptors, containing a single protein subunit with seven transmembrane segments
(Matsuda et al., 1990). Cannabinoid  agonists  inhibit  adenylyl cyclase through pertussis toxin-
sensitive G-proteins, and they act directly through G-proteins to close calcium channels
(Mackie and Hille, 1992). The research presented by Dr. Childers describes the properties of
cannabinoid receptors in brain membranes and cerebellar granule cells, explores the
relationship between cannabinoid receptors and other G-protein-coupled receptors, and
characterizes the possible role of cannabinoid inhibition of adenylyl cyclase in regulating
voltage-dependent potassium channels.
Using potent ligands such as CP-55,940 and WIN 55,212-2, which are 10-100 times more
potent than THC in binding to cannabinoid receptors, Pacheco et al., 1991 showed that
cannabinoid agonists inhibited adenylyl cyclase in brain membranes to a significant extent.
The cerebellum contained the highest level of cannabinoid-inhibited  adenylyl cyclase and also
displayed a high level of cannabinoid-stimulated GTPase, which is a direct measure of
receptor-coupled G-protein function. Cannabinoid agonists stimulated GTPase in cerebellar
membranes by 80-100%, which is the highest level of receptor-stimulated GTPase. activity
reported in brain membranes. Such a high level of receptor-coupled G-protein function
reflects the relatively high levels of cannabinoid receptors present in brain.
Since cannabinoid-inhibited adenylyl cyclase was absent in mutant mice where cerebellar
granule cells were specifically absent (Pacheco et al., 1993), Childers  hypothesized  that these
receptors existed primarily on granule cells in the cerebellum. In cultured granule cells,
cannabinoid agonists inhibited cAMP levels with the same pharmacological specificity as in
receptor binding studies, with analogs like CP-55,940 and WIN 55212-2 being most potent,
and THC being only moderately potent These agonists also inhibited glutamate release from
granule cells, thus showing that cannabinoid receptors are probably pre-synpatic in these cells.
Other Gi/o linked receptors, including GABAB receptors, also exist in cerebellar granule cells.
When cannabinoid and GABAB receptor function was assayed simultaneously in these cells,
agonists for both receptors demonstrated non-additivity in inhibition of cAMP levels.
However, cannabinoid and GABAB agonists were additive in stimulating GTPase in cerebellar
membranes. These results demonstrate the phenomenon of receptor convergence. In this
case, GABAB and cannabinoid appear to share common adenylyl cyclase catalytic units
although they do not share common G-proteins. Such convergence shows how agonists
acting at different receptors can provide similar effects in certain types of cell systems.
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One important unanswered question involves the role of cannabinoid inhibition of adenylyl
cyclase in regulating neuronal function. Although cannabinoid receptors are coupled to
calcium channels, their mechanism apparently involves direct coupling of the receptor to
calcium channels via G-proteins, without any diffusible second messenger system. Recent
data from Dr. Deadwyler’s laboratory have shown that cannabinoid receptors are coupled to
another type of ion channel: the voltage-dependent potassium A channel. In cultured
hippocampal cells, cannabinoid agonist increased potassium A current (Deadwyler et al., in
press) by shifting the voltage-dependent inactivation and activation curves. This effect was
mediated through G-proteins, since it was blocked by pertussis toxin and mimicked by GTP-
S. The actions of cannabinoid agonists on this current were blocked by addition of 8-Br-
cAMP, but were still evident in the presence of forskolin. These results are consistent with
the ides that cannabinoid effects on potassium A current are mediated by inhibition of adenylyl
cyclase. In this concept, cAMP stimulates protein kinase A to increase phosphorylation of the
potassium A channel. The phosphorylated channel would be inactivated, so that decrease in
phosphorylation by cannabinoid-inhibited adenylyl cyclase would increase potassium
conductance through this channel. These results confirm the importance of this second
messenger system in mediating effects of cannabinoid receptors in neurons.
Because cannabinoid receptors are members of the G-protein-coupled superfamily of
receptors, it is probable that endogenous ligands exist in brain for these receptors. One such
ligand, anandamide (an ethanolamine amide of arachidonic acid), has already been reported
(Devane et al., 1992). Childer’s laboratory has also been active in isolating endogenous
cannabinoids from brain extracts. One compound has been isolated from acid extracts of
bovine brain. This compound is relatively polar in nature, is relatively small in size (MW
between 100 and 500) and is apparently non-peptide in nature. Although its structure is not
yet known, its chemical and chromatographic behavior clearly demonstrates that this
compound is different from anandamide. In addition, this compound is relatively specific for
cannabinoid receptors, since it displaces the binding of two chemically unrelated cannabinoid
radioligands, [³H]WIN-55212-2 and [³H]CP-55,940, to rat cerebellar membranes, and it has
no effect on the binding of radioligands to four other G-protein-linked receptors. Future
studies will demonstrate whether this compound is structurally related to anandamide or other
putative endogenous cannabinoids.
CANNABINOID RECEPTOR BINDING ACTIVITY OF
NEUROMODULATOR-LIKE LIGANDS
The identification and characterization of the cannabinoid receptor has recently been
accomplished, and the conserved localization within the CNS, its presence on neurons, and its
coupling to G-proteins are properties typical of a receptor for neuromodulators (Howlett et al.,
1990). Cogent arguments for a natural agonist for the cannabinoid receptor in the CNS have
been posited ((Howlett et al., 1992)). Among these include the argument that all G protein-
coupled receptors studied to date require association with a ligand for activation. Although
ligands which bind to a large number of neuromodulator receptors have been screened for
their ability to bind to the cannabinoid receptor, no obvious neuromodulator competes
effectively for binding to the cannabinoid receptor at concentrations at which it would be
expected to bind to its identified receptor (Bidaut-Russell et al., 1990; Howlett et al., 1992;
Kuster, 1993).
Following the premise that an endogenous cannabinoid receptor ligand should have the
properties of a neuromodulator being stored in intracellular vesicles, the ability of increased
intracellular Ca2+ to stimulate release from rat brain slice (250 X 250 µm) was examined in
Howlett’s laboratory. The displacement of [³H]CP-55940 binding to cannabinoid receptors in
rat synaptosomal membranes was the primary assay. The Ca2+ ionophore, A23187, released
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cannabinoid receptor binding activity in the presence but not in the absence of Ca2+ in the
media (Evans et al., 1992). The effect of A23187 was maximal at 1.2 µM, consistent with
vesicular release. It was necessary to increase. the concentration of extracellular free Ca²+ to >
60 nM in order to evoke release. The released cannabinoid receptor binding activity displaced
[³H]CP-55940 in a concentration-dependent manner.
The endogenous cannabinoid receptor binding activity also could be released in response to a
depolarizing stimulus (75 mM   K+) in the presence of extracellular Ca2+ (Evans, et al.,
submitted). K+-evoked release was not observed in the absence of extracellular Ca2+ and was
reduced by over 50% in the presence of either of the specific L and N calcium channel
blockers, verapamil and -conotoxin, respectively. The efflux of cannabinoid receptor
binding activity is greatest within 5 to 10 min of stimulation and receptor binding activity was
enhanced by the presence of cocktail of peptidase inhibitors. However, these agents were not
effective if a 10-min release period were examined. Examination of the contribution of
individual inhibitors revealed a specificity for captopril and thiorphan, inhibitors that act on
angiotensin converting enzyme and enkephalinase. These data are consistent with vesicle-
mediated release from neuronal terminals. It can be speculated that the factor(s) responsible
for competing for [³H]CP-55940 binding may include peptide that are vulnerable to
common enzymes responsible for the degradation of a number of neuropeptides in the CNS
and other tissues. The specificity of the released factor(s) for the cannabinoid receptor was
corroborated by the ability to compete with the aminoalkylindole radioligand [³H]WIN-55212
for binding to this receptor.
The properties of the released cannabinoid receptor binding activity are consistent with its
being a relatively small neuropeptide. The released material retains cannabinoid receptor
binding activity after boiling and treatment at acid pH. It is able to pass through filters having
nominal molecular weight cut-offs of 1000 Da (Evans et al., 1992). The possibility that the
responsible factor(s) may be a small peptide is supported by the augmentation of ligand
binding activity by inclusion of peptidase inhibitors in the brain slice release preparation
(Evans et al., submitted). Thus, Howlett proposed that the cannabinoid receptor agonist in the
brain is a small peptide that is stored in vesicles within nerve terminals such that release can be.
evoked by depolarization in a Ca2+- dependent manner.
IDENTIFICATION OF ENDOGENOUS CANNABINOID LIGANDS
The approach taken by Mechoulam’s laboratory towards the isolation of the endogenous
cannabinoid in the brain was based on the assumption that it is a lipid soluble compound. The
SAR’s in the cannabinoid series indicate that increases in liposolubility, at least up to a certain
point, lead to increases in cannabimimetic activity. On this somewhat tenuous basis they
assumed that the endogenous cannabinoid ligands were lipids. However, in view of the
identification of peptides as modulators of a long list of receptors (including the opiate
receptor) the decision to put most of their effort on the lipid soluble fractions was essentially
intuitive.
Porcine brains were extracted with solvents appropriate for lipid constituents, namely
chloroform-methanol. Several separation routes were investigated. One of them was direct
silica gel chromatography of the extract. Numerous problems were encountered. The lipid
content of the brain is very high; the extracts presumably contained only minuscule amounts of
active material in a complex mixture of various types of lipids which on chromatography
possibly served as co-elutants and the active compound therefore was dispersed throughout
the chromatographic fractions. By repeated chromatography on silica gel (normal phase and
later reverse phase), Mechoulam and his colleagues were able gradually to concentrate the
active fractions. A problem which became obvious only towards the end of the endless
purifications was the lability of the product: Seldom were they able to elute from the column
the amount of active material deposited on it.
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The activity was monitored by the ability of fractions to displace a radiolabeled probe,
[3H]HU-243, in a centrifugation-based ligand binding assay. However, HU-243, like many
cannabinoids. binds to the siliconized polypropylene microfuge tubes in which the assay was
conducted. This 3-way equilibrium of the probe among the synaptosomal receptors, the
solution and the microfuge tube was a major obstacle in the interpretation of the binding
values. Ultimately a fraction was isolated which gave one spot on TLC and eluted mainly as
one peak on gas chromatography. This constituent inhibited the specific binding of [3H]HU-
243 in a manner typical of competitive ligands with a Ki value of 52±1.8 nM. As mentioned
above Pertwee and his collaborators have found that THC inhibits the twitch response of
isolated murine vas deferens. Anandamide also elicited a concentration-dependent inhibition
of the twitch response.
The laborious isolation procedures described above led to several hundred micrograms of
purified material. The isolation of very small amounts of a natural constituent from a
complicated mixture inevitably poses problems for the structural elucidation, due to the
presence of minor impurities associated with the isolation process. Anandamide, as ultimately
isolated, contained traces of materials that originated from the plastic labware as well as traces
of solvents, tightly bound to the viscous anandamide.
The structure of anandamide was deduced from mass spectrometric (MS) and nuclear
magnetic resonance (NMR) measurements. The initial measurements  were by high-resolution
MS which suggested the elemental composition C22H37NO2 (m/z 347.2762). that indicates
the presence of five double bonds (or rings). The first indication of the structure was the
observation that NMR peaks. presumably of double bond protons. were coupled with peaks
which were assumed to be signals of doubly allylic protons. Such protons, their couplings
and the ratio of vinylic to doubly allylic protons, are typically observed in all-cis, non-
conjugated polyunsaturated fatty acids.. At this point Mechoulam and his group assumed that
they had a N-derivative of such a fatty acid. Further NMR and MS spectra led to the
assumption that anandamide is the ethanolamide of a C-20 fatty acid with four unconjugatcd
double bonds, presumably arachidonic acid. This assumption was proved by a simple
synthesis.
Shortly after the initial publication on anandamide they published the first report on its in vivo
pharmacological activity. The cannabinoids produce a unique syndrome of behavioral effects
in animals: at low doses a mixture of depressant and stimulatory effects is observed, while at
higher doses central depression predominates. Anandamide exhibited the same profile. At a
low dose it caused significant stimulation in the open field. At higher doses, anandamide
produced significant depression in the open field, catalepsy, hypothermia and analgesia. In
collaboration with Z. Vogel and Y. Barg of the Weizmann Institute they have shown that like
THC, anandamide inhibits forskolin-stimulated adenylyl cyclase in N18TG2  cells. The same
effect was observed with transfected cells but not with non-transfected cells.
Recently they were able to isolate two additional active ethanolamides (EA’s) of fatty acids:
the EA’s of homo- -linolenic acid and of 7,10,13,16-docosatetraenic acid. Their level of
binding to the receptor is very close to that of anandamide. The presence of several fatty acid
ethanolamides indicates that the brain produces a familv of endogenous cannabinoid ligands
rather than a single mediator of activity. This parallels the situation with prostaglandins,
leukotrienes and enkephalins. The exact biological profile may yet reveal subtle differences in
the activity of individual members of this new biochemical family.
PHARMACOLOGICAL PROFILE OF ANANDAMIDE
The preliminary reports on the pharmacological properties of anandamide indicate that it
produces effects similar to those of THC (Fride and Mechoulam, 1993). Mattin and his
colleagues have also examined anandamide’s effects in mice. Anandamide was administered
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i.v. to male ICR mice in order to evaluate its effects on spontaneous activity (5-15 min), tail-
flick response (20), rectal temperature (60) and immobility (90) at the times indicated in
parenthesis. Anandamide produced a dose responsive inhibition of spontaneous activity with
an ED50 of 24.9 mg/kg. Anandamide also produced antinociception in a dose related manner
with an ED50 of 13.9 mg/kg. On the other hand, it produced less than 10% immobility and
less than a 1 °C decrease in rectal temperature at doses up to 60 mg/kg. A few deaths were
obtained at the 60 mg/kg intravenous dose. Gross observation of the animals suggested that
anandamide had an onset and duration of action which was more rapid than that of -THC.
A time course study revealed that maximal antinociception and hypoactivity occurred within 15
min. of an i.v. injection of 60 mg/kg. The greatest immobility (40%) was measured at 5 mm
and dissipated within 1 hr. The pattern of hypothermia was somewhat different in that the
greatest decrease (=2 °C) was found at 15 min which gradually returned to baseline levels
between 1 and 2 hr. Reexamination of the e results indicate that anandamide is capable of
producing effects similar to those of -THC in mice despite being at least 15 times less potent
than -THC and having a shorter duration of action.
Dr. Welch has also evaluated anandamide for  antinociceptive effects following intrathecal (i.t.)
administration. The peak effect in the tail-flick procedure (ED50 =77 µg/mouse) occurred 3
min following injection. The ED50 for -THC (i.t.) is 45 µg/mouse. Anandamide was
approximately 10 times less potent than -THC in the PPQ test. The ED50's were 3 and 30
µg/mouse for -THC and anandamide, respectively. No blockade of anandamide (200
µg/mouse) was observed following pretreatment with naloxone (20 µg/mouse, i.t. or 10
mg/kg, s.c.), nor-BNI (70 ug/mouse, i.t.), ICI 174,864 (20 µg/mouse, i.t.), 8-chloro-c-AMP
(10 ug/mouse, i.t.), forskolin (10 ug/mouse, i.t.), or apamin (10 ng/mouse, i.t.). The
antinociceptive effects of anandamide were totally blocked by pretreatment of the mice for 7
days with 0.5 µg/mouse pertussis toxin administered i.t. Anandamide produces
antinociception following i.t. administration which differ in potency and profile of action from
the antinociceptive effects produced by -THC.
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INNOVATIVE APPROACHES TO DRUG ABUSE TREATMENT
J. V. Brady
The presentations by the six participants in this symposium focused on a range of research
and demonstration initiatives to enhance treatment in patients who, for the most part, were
involved with multiple drugs of abuse including both heroin and cocaine. Karst Besteman
opened the proceedings with a report on a study to define the differential impact of two
levels of treatment services on a randomly assigned patient population which mirrors the
demographics of those individuals treated in the local publicly funded drug abuse treatment
system of Washington, D.C. Two clinics with defined service differences and different
levels of resources are involved in the study focusing upon treatment outcome,
effectiveness, and cost-benefit/effectiveness. The general design of the studies provides
for randomized patient selection by a NIDA grantee research group (KOBA Associates)
operating in conjunction with the central intake system of the District of Columbia
(Alcohol and Drug Abuse Services Administration). Both process and outcome (in-
treatment and post-treatment progress) evaluations are as well provided by an independent
NIDA grantee research evaluation group (Research Triangle Institute) responsible for both
the design and administration of evaluation instruments, methods, and procedures. Over
400 patients have been enrolled in the two clinics which differ primarily in their counselor
to patient ratios and the level of ancillary services provided (vocational guidance, wellness
support. psychiatric intervention). A focus on physical status has produced a number of
frequently diagnosed conditions with medical referrals approximating a rate of 10% of the
active patients each month. The expected rates of HIV, TB, and other chronic conditions
are consistent with the population the two clinics serve. Methadone maintenance with
intensive counseling intervention characterizes the major treatment modality in both clinics
with comparisons based upon patient attrition through drop out and non-compliance. Early
findings confirm that drug use among patients in both clinics has decreased dramatically
with 70% and 50% of the patients in each clinic respectively, providing drug-free urine test
analyses.
Extending the theme of clinical issues in drug abuse treatment, David Novick addressed
the topic of long-term methadone maintenance citing the lack of published studies on
patients with five or more years of treatment. The presentation focused on three important
issues regarding the clinical status of such patients: 1) physiological normalization, 2)
medical safety, and 3) treatment modification. In the first instance, a comprehensive
medical evaluation study was performed on a randomly selected sample of methadone
patients admitted to treatment between 1965 and 1968 who remained in treatment for 11 to
18 years (median 14.4 years). Based upon previous findings by Kreek and colleagues
suggesting that neuroendocrine (ACTH. cortisol, and beta-endorphin) and immunologic
(natural killer activity, lymphocyte subsets, and immunoglobulin levels) parameters
become normalized during long-term methadone maintenance in former heroin abusers, the
patients in the study sample were compared to an untreated control group of 56 long-term
heroin abusers. The findings confirmed that with regard to medical diagnoses,
symptomatic complaints, physical examination results, and laboratory test outcomes there
was little difference between the long-term methadone patients and the untreated heroin
abusers. Moreover, from the perspective of medical safety, the results showed that
successful long-term methadone patients who are employed, have completed the
counseling process, and are no longer using illicit drugs or alcohol can be effectively
treated in a physician’s office rather than in a licensed drug abuse treatment clinic. A
follow-up study of such methadone maintenance in the context of general medical practice
has shown high retention rates up to nine years with few management problems in a
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carefully selected group of patients. These studies have also provided the basis for
developing new treatment modification programs for other groups of long-term methadone
maintenance patients based upon the application of laboratory, clinical, and evaluation
research findings that confirm the safe and effective use of such extended pharmacological
interventions.
Despite the demonstrated success of long-term methadone maintenance treatment in highly
selected groups of heroin abusers, reported one-year retention rates of patients admitted to
methadone maintenance programs in general vary widely from 34% to 89%. The
variations in retention can be presumed to arise as a result of variations in patient, program,
and other situational factors with several reports suggesting that required treatment fees
impair retention on methadone maintenance. James Maddux described the results of a
prospective study designed to evaluate the effects of such treatment fees on retention in a
methadone maintenance treatment program. One hundred and fifty-two (152) illicit opioid
abusers were admitted to the treatment  program and randomly assigned to a fee or no-fee
condition, even though virtually all the patients expressed a desire to enter the study
because of the possibility of free treatment. The patients in the fee group were required to
pay $2.50 per day during the course of treatment while the patients in the-no-fee group paid
nothing. All patients were followed for one year with interviews obtained from all but two
of the patients who had died. The results showed clearly that the no-fee group had
significantly greater retention rates than the fee group. The one year retention rate for the
patients required to pay the $2.50 daily fee was only 34% compared to 54% for the patients
in the no-fee group. There were however, no significant differences between the degree of
improvement in those patients who remained in treatment for the one year period
regardless of whether they were in the fee or no-fee group. As measured by urine test
results and subject-reported intravenous drug use, crime and incarceration, only small, non-
statistically-significant differences between the two groups were found. The patients in the
no-fee group did however, report significantly more days of productive activity than the
patients in the fee-paying group. The age of the patients was the only one of 21
personal/demographic variables that was significantly related in a positive direction to
retention rate. A measure of the maximum methadone dose level during treatment was
also positively correlated with retention rate while the number of interviews per month
with a caseworker was found to be inversely related to retention rate. It seemed likely
however, that both the increased number of caseworker interviews and the decreased
retention rate may have been a function of the severity of a third factor, the problems for
which the patients sought treatment.
Among the many general health status problems that substance abuse treatment programs
are increasingly called upon to address, the need to provide services for patients who are
infected with the human immunodeficiency virus (HIV) is perhaps the most serious.
Steven Batki described an innovative substance abuse treatment approach integrating
medical and psychiatric service for such HIV-infected drug abusing patients. The common
finding of psychiatric co-morbidity was confirmed in a series of 84 HIV-infected
intravenous drug abusers in methadone maintenance treatment for more than six weeks at
the San Francisco General Hospital Substance Abuse Services, 65% of whom required
psychiatric consultation. Those requiring psychiatric consultation were found to have
higher rates of continued drug abuse and lower rates of zidovudine (AZT) use, though
daily on-site dispensing did significantly improve AZT adherence. A prospective study of
75 HIV-infected drug abusing patients at the San Francisco General Hospital did show that
methadone maintenance treatment was associated with significant reductions in drug use
even in this compromised patient population. Poor outcomes after 12 months in
methadone maintenance treatment were however predicted by cocaine use at intake and
confirmation was provided that cocaine abuse is more treatment-resistant  than opiate abuse
in HIV-infected methadone maintenance patients. On the other hand, a controlled trial of
fluoxetine for cocaine dependence in HIV-infected intravenous drug abusers at the San
Francisco General Hospital was able to demonstrate that such an intervention was both safe
and at least to some extent, effective in reducing cocaine use as well as depression in this
patient population. The results of these several studies confirm that treatment for HIV-
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infected intravenous drug abusers should integrate psychiatric, HIV-medical, and substance
abuse related services and that additional research can be expected to yield safer and more
effective substance abuse  treatments for such patients.
Among the most important factors that determine the effectiveness of drug abuse treatment
programs in general and methadone maintenance treatment in particular are the
accessibility of essential services and the length of time that patients are maintained in
contact with those services. Joseph Brady described a demonstration research project that
has as its objective the development, maintenance, and evaluation of an innovative mobile
heath service delivery system approach to the enhancement of drug abuse treatment. The
focus of the project has been upon the identification and recruitment of intravenous drug
abusers into a treatment program that provides health education, outreach, and clinical
support to targeted inner city communities in Baltimore, Maryland with a high prevalence
of substance abuse and other poor health status indicators. Two mobile units, each
consisting of a medication dispensing van and a house trailer modified to serve as a
counseling and general clinical services unit, provide the treatment. One unit visits
multiple locations in west Baltimore each day and the second unit remains stationary for
the entire day in a demographically comparable area in east Baltimore. Over 500
intravenous opioid abusers have applied for admission to the program during its first year
of operation and some 200 patients have been actively enrolled in treatment with a
gratifying low drop-out rate approximating less than 15%. Both process and outcome
evaluations completed to date confirm the savings in time and money reflected in the
patient self-reported comparisons between their previous drug abuse treatment programs
and the mobile health service drug abuse treatment program. Urine sample measures have
also shown a marked decrease in drug use during treatment compared to pretreatment and
intake drug use levels. Self-reported levels of legitimate employment have increased from
less. than 20% at intake to over 35% during the first 6-month course of treatment and
comparisons with other fixed site drug abuse treatment programs in the city of Baltimore
suggest a range of differential process and outcome effects. The results of this comparative
analysis show that the mobile health service had a higher percentage of patients reporting
daily drug use on admission; fewer previous drug abuse treatment admissions; and an
average length of stay in the mobile health service treatment program was greater than for
fixed-site programs.
In a discussion of these several presentations, John Ball called particular attention to the
innovative aspects of both the methodological and substantive contributions described and
emphasized the need for continuing research evaluations to expand the data base upon
which the safety and efficacy of improved drug abuse treatment must depend.
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THE ROLE OF EXCITATORY AMINO ACIDS IN THE
ACTIONS OF ABUSED DRUGS
J. F. McGinty
The participants in this symposium discussed the interactions between dopamine and
excitatory amino acids (EAA) in the CNS pathways affected by abused drugs. Many of the
actions of alcohol, opiates, and psychostimulants are mediated by EAA receptor
stimulation. The focus of this svmposium. however. was entirelv on nsvchostimulants
because of the explosion of research during the last four years which has demonstrated that
N-methyl-D-aspartic acid (NMDA) and non-NMDA EAA receptor antagonists block the
motor stimulating, neurotoxic, and rewarding actions of cocaine and the amphetamines.
The subjects covered by the speakers included (1) identification of the CNS sites in which
locally infused EAA receptor antagonists exert anti-stimulant actions, (2) the ability of
dopamine agonists to release glutamate, (3) the ability of competitive and non-competitve
NMDA antagonists to block the dopaminergic neurotoxic actions of methamphetamine, (4)
blockade of cocaine- and methamphetamine-induced  increases in striatal neurotensin and
dynorphin expression, and (5) a theoretical framework in which to interpret dopamine-
glutamate interactions based on proposed tonic and phasic dopamine release in the striatum.
The functional organization of the neurochemical/anatomica1 circuitry important in
stimulant-induced reward and motor behaviors was reviewed by McGinty and Kalivas.
The dorsal striatum receives dopaminergic input from the substantia nigra pars compacta
and glutamaternic input from widespread areas of the cerebral cortex. Its GABAergic
outputs are to-the globus pallidus’and substantia nigra with striatopallidal outputs
containing enkephalin and striatonigral outputs containing dynorphin and tachykinins. The
dopamine/EAA innervation of the ventral striatum is organized in a similar manner.
Besides the dense dopaminergic projection to the nucleus accumbens (NAc) from the
ventral tegmental area (VTA), glutamatergic input arises from three major sources: the
prefrontal cortex, amygdala, and hippocampal formation. Output from the nucleus
accumbens includes GABAergic projections to the ventral pallidum and VTA. These
projections also contain neuropeptides, including the opioid peptides, enkephalin and
dynorphin, as well as tachykinins. The VTA also sends dopaminergic input to the
prefrontal cortex which, in return, sends a glutamatergic projection back to the VTA.
Therefore, there are two major CNS sites in which dopamine/EAA interactions may
mediate, the response to psychostimulants: the NAc and the VTA.
Psychostimulant-induced dopamine uptake blockade and increased release into the
synapses of the dorsal and ventral striatum stimulate dopamine receptors of all types.
However, most is known about the consequences of Dl and D2 receptor stimulation. Dl
receptor stimulation leads to increased immediate early and dynorphan gene expression in
the striatonigral pathway whereas increased D2 receptor activity has little, if any, effect on
enkephalin gene expression in the striatopallidal pathway. These changes in gene
expression are attenuated by NMDA receptor antagonists. Although the involvement of
EAAs in the acute effects of stimulants is controversial, strong evidence exists that
behavioral sensitization to repeated administration of stimulants is mediated by
glutamatergic systems. Preliminary evidence indicates that increased glutamate release as
well as upregulation of EAA receptors may be involved.
Karler (1989) initially reported that amphetamine and cocaine-induced behavioral
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sensitization could be blocked by prior administration of the non-competitive NMDA
receptor antagonist, MK-801 (dizocilpine maleate). Further research by Karler’s group
(Karler 1991) and others has begun to discriminate between the role of NMDA and non-
NMDA receptors in the induction and expression of stimulant-induced sensitization. To
date, the effects of psychostimulants which have been inhibited by EAA receptor
antagonists include (1) behavioral sensitization (locomotor activity and stereotypies), (2)
convulsions, (3) dopaminergic neurotoxicity, (4) neuropeptide alterations, and, most
recently, (5) rewarding  properties of cocaine and amphetamine.
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Peter Kalivas reviewed the current thought on the circuitry and neurochemical mechanisms
involved in behavioral sensitization (Kalivas 1991; 1993). He presented recent data that
MK801 infused into the VTA or amygdala, but not into NAc, blocks cocaine-induced
sensitization (Alesdorf and Kalivas in press). In addition, he discussed evidence indicating
that repeated cocaine exposure results in a blunting of the response of mesocortical DA to a
cocaine challenge dose seven days later. These data may indicate that the inhibitory tone of
mesocortical dopamine on glutamate release is diminished with resultant disinhibition of the
prefrontal cortical EAA influence on VTA. Finally, Kalivas’ preliminary data indicates that
administration of a full Dl agonist into VTA causes an increase in extracellular glutamate as
detected by microdialysis. Thus, a portion of Dl receptors may reside on prefrontal
cortical glutamatergic endings in the VTA in addition to their presence on NAc-VTA
terminals.
Pat Sonsalla discussed the role of NMDA receptors in dopaminergic  neuronal degeneration
in methamphetamine-treated mice. Sonsalla and colleagues (1989; 1991) have
demonstrated that competitive and non-competitive NMDA receptor antagonists block
methamphetamine-induced neurotoxicity. However, Sonsalla’s group did not observe any
effect of MK801 on methamphetamine-induced  dopamine  release in contrast to the data of
Weihmuller and colleagues (1991). In addition, Sonsalla discussed possible reasons why
dopamine terminals in the caudate are selectively vulnerable to methamphetamine-induced
degenera t ion .  F ina l ly ,  Sonsa l la  cont ras ted  the  ro le  of  NMDA receptors  in
methamphetamine-induced toxicity with that in MPTP- and MPP+-induced toxicity.
Although Turski and colleagues (1991) had reported successful blockade of MPP+ effects
by MK-801, Sonsalla’s data indicate that this form of dopaminergic toxicity is less
sensitive to NMDA receptor blockade (Sonsalla and Nicklas 1992).
Glen Hanson reviewed data generated in his lab that methamphetamine and cocaine cause
D1- mediated increases in dorsal and ventral striatal neurotensin and dynorphin which are
blocked by MK801 (Johnson et al., 1990; Singh et al., 1991). He focused his attention on
stimulant-induced  neurotensin changes, which  are particularly  robust in the medial caudate
and NAc and the fundus striata, because there is evidence that neurotensin administration is
functionally antagonistic to the actions of psychostimulants (Nemeroff et al., 1985).
Conversely, subconvulsive stimulation of NMDA receptors or blockade of D2 receptors
increases neurotensin-immunoreactivity  in the striatum. His data indicate that NMDA
receptors are necessary for D1, but not D2, receptor stimulation of these peptide systems
in limbic and motor striatum and substantia nigra, changes that may contribute to the
actions of psychostimulants.
Tony Grace provided evidence for EAA/dopamine interactions in the NAc and introduced a
theoretical framework (Grace 1991) in which to interpret such interactions in response to
psychostimulants. He introduced evidence that D2 receptor agonists attenuate EPSP’s in
the NAc evoked by stimulation of glutamatergic inputs in vitro and that multiple stimulation
of these afferents; which augments glutamate release, causes an increase in D2-mediated
attenuation of these EPSPs. Furthermore, Grace proposed that tonic dopamine release,
which is locally regulated by D2 and NMDA receptor activity at the presynaptic dopamine
terminal, and phasic, or action potential-dependent, dopamine release are affected
differentially by acute, chronic, and withdrawal phases of psychostimulant administration.
The full proceedings of this symposium will be published together in an upcoming issue of
Drug and Alcohol Dependence.
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TOLERANCE AND SENSITIZATION TO OPIOIDS AND COCAINE
J. U. Adams, S. Izenwasser, T. H. Kramer, C. W. Stevens, P. J. Tiseo and
E. M. Unterwald
An important and fascinating feature of addictive processes is the alteration in drug
sensitivity which often occurs with repetitive use of the drug. Opioids and cocaine are
especially notable in this regard. The effects of chronic administration of opioids or cocaine
are manifested in biochemical changes, alteration in the shape and position of drug dose-
response curves in animals, and changes in the magnitude of effects of drugs administered to
humans for purposes therapeutic or otherwise. In this Young Investigator’s Symposium,
researchers integrate findings from a variety of perspectives on the pharmacology of opioids
and cocaine.
TOLERANCE TO OPIOIDS
The Relationship Between Opioid Tolerance and Dependence
Jill U. Adams
The dissociation of tolerance and dependence is often reported. Many factors can influence
the degree of tolerance and dependence observed and may account for apparent separation
of the two processes. The purpose of this presentation is to review some of these factors.
First, the experimental methods used to measure tolerance arc quite different than those
typically used to measure dependence. For example, tolerance  to morphine-induced
analgesia is often compared to a naloxone-induced syndrome of gross behavioral signs
indicative of withdrawal. Even when a single. baseline is used to measure both effects, there
are fundamental differences in the actual changes being measured. For instance, tolerance is
a decreased sensitivity to an agonist-induced effect whereas dependence is the presence of
an antagonist-induced effect where before there was none. Moreover, tolerance requires the
presence of the agonist to be measured, whereas dependence requires its absence (the
principle of uncertainty, Collier, 1984). These fundamental differences may make definitive
association or dissociation of tolerance and dependence difficult to experimentally
demonstrate Second, depending on the sensitivity of the assays, the magnitude of tolerance
and dependence may differ and this may account for one effect persisting in the apparent
absence of the other.
Third, the contribution of non-pharmacodynamic factors, namely behavioral conditioning,
may alter the expression of tolerance and dependence. The role of behavioral conditioning
in opioid tolerance has been elegantly characterized by Siegel (1983). It can be argued that
even differential interactions with behavioral influences might indicate differences in
mechanism. For example, different signs of withdrawal can be differentially modified by
environmental stimuli. Monkeys have been conditioned to emit some but not all signs
normally associated with opioid withdrawal upon presentation of a cue previously paired
with nalorphine injections (Goldberg & Schuster, 1970). Regardless of behavioral factors,
tolerance to different effects of opioids develop at different rates. There is the classic
example of analgesic tolerance occurring in the absence of tolerance to the inhibition of
gastrointestinal transit. Thus, it would appear that tolerance (or dependence) is dissociable
from itself. In light of this, how relevant arc conclusions of dissociation of tolerance from
dependence?
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In conclusion, while opioid tolerance and physical dependence may be dissociable several
factors may be taken into account to evaluate the relevance of such a result. The great
majority of data regarding the relationship between tolerance and dependence suggest that,
in general, the two processes are closely related.
TOLERANCE TO OPIOIDS IN AN AMPHIBIAN MODEL
C. W. Stevens
Opioid administration produces a profound and long-lasting analgesia in humans and in a
variety of pain models using other mammalian species. However, opioid analgesia is not
limited to mammals as analgesic or antinociceptive effects have been observed after
morphine administration in lower vertebrate and invertebrate animal models (Kavaliers
1988, Steve 1992). With regard to the amphibian model, we have developed a behavioral
assay for opioid action based on the application of diluted acetic acid to the frog hindlimb,
called the acetic acid test. Results using the acetic acid test demonstrate that amphibians
exhibit long-lasting and dose-dependent analgesia following systemic administration of
morphine (Pezalla 1983; Pezalla and Stevens 1984; Benyhe and Wollemann 1988; Benyhe
et al, 1989; Stevens and Pezalla 1989), levorphanol (Pezalla and Stevens 1984). and
oxymorphazone (Benyhe et al., 1989). Additionally, direct administration of opioids to the
frog spinal cord by intraspinal injection produces a potent and dose-dependent analgesia as
shown following administration of morphine and other alkaloids (Stevens and Pezalla 1983,
Stevens and Pezalla 1984. Stevens and Pezalla 1989. Stevens 1991a). met-enkephalin. beta-
endorphin, and dynorphin (Stevens et al., 1987) and highly selective opioid agonists
(Stevens 1991b). Finally, amphibians appear to possess a well developed endogenous
opioid system, replete with high concentrations of opioid binding sites and endogenous
opioid peptides (Stevens 1988). While the above suggest that the mechanisms of opioid
action in amphibians may be similar to that observe humans and other mammalian
species, there has not been a systematic examination of opioid tolerance in the amphibian
model.
Daily bolus injection of about an ED85 dose of morphine (100 nmol/g.s.c.) or saline (10
µl/g) for one week resulted in a significant analgesia for three days in the morphine group,
which fell to levels indistinguishable from the saline-treated controls on days 4 through 7. In
separate experiments, animals were treated identically with morphine or saline but were not
tested daily for pain thresholds. In these animals, administration of a range of morphine
doses on day 8 yielded dose-response curves significantly shifted rightward by a factor of
3.3 in the morphine-treated group compared to the saline-injected controls. These studies
are the first to show the time course of tolerance development and the magnitude of
morphine tolerance in a non-mammalian vertebrate species. Finally, the ability of
amphibians to withstand a wide range of ambient temperature, may allow for unique studies
for the rate of opioid tolerance under unique experimental conditions.
CLINICAL TOLERANCE TO OPIOIDS
Paul J. Tiseo
The experimental literature on tolerance, consisting primarily of animal studies and studies
with human addicts, is replete with reports demonstrating the progressive loss of effect in
the face of steady dosing which results in the need for continual dose escalation to maintain
a desired effect. The expected result of such a process in a patient with chronic pain would
be a continuous escalation of opioid dosing and an inability to maintain an adequate
analgesic effect. Fortunately, long term evaluation of the opioid requirements of cancer
patients demonstrates that this process rarely occurs in the clinical setting.
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The limited data from clinicaI studies suggest that the phenomena produced in experimental
models can occur to some degree in patients. It is evident, however, that the complexity of
human pain and its effects on the CNS demands caution in extrapolating the findings from
these studies to the clinical situation. In order to address the extent to which patients
chronically receiving opioids increase their opioid  requirements over time, a number of
survey studies have been undertaken to assess the patterns of drug use in patients with
cancer pain (for review, see Foley 1993). From these studies, three patterns of drug use
emerge which are in contrast to the phenomenology of tolerance as described in the animal
and human addict literature and suggest the presence of factors other than tolerance playing
a role in this setting. The three patterns are: 1) stable dosing which extends for prolonged
periods of time (weeks to months) during which analgesia is maintained in the absence of
dose escalation; 2) rapidly escalating opioid doses, where the need for dose escalation can be
attributed not simply to tolerance, but to the progression of disease and increasing pain; and
3) the marked reduction of opioid dosing following effective relief of pain by anti-cancer
therapies or anesthetic or neurosurgical procedures. Of critical importance in this latter
group however, is the observation that failure to reduce the opioid dose following the
attenuation of pain will result in the onset of a spectrum of symptoms normally associated
with opioid toxicity (i.e., sedation, myoclonus, respiratory depression), demonstrating that in
the sudden absence of pain these patients no longer exhibit tolerance to the adverse. effects
of their opioid.
It is speculated here that although these patients can tolerate high doses of opioids, they are
not tolerant to all opioid effects in the same pharmacological sense that experimental
models are following chronic exposure to the drug. It is hypothesized then that it is not
tolerance alone, but the “driving force” of pain itself (i.e., nociceptive transmission through
the brainstem; increased sympathetic drive) which allows these patients to have near normal
autonomic function (i.e., respiration, alertness) in the presence of high doses of opioids. In
addition, we would postulate that the presence of pain either prevents or rapidly reverses the
cellular changes ( i.e., receptor-effector  uncoupling) which are suggested to take place in
experimental studies in which chronic pain is not present and in which there is a need for
continued dose escalation to achieve an effect. One could speculate that this is simply a
physiological adaptation which allows cells to remain functional in the face of a persistent
nociceptive stimulus. As such, the patient continues to be opioid sensitive, and this is
clearly demonstrated by the onset of opioid toxicity in those patients whose pain is abruptly
removed and whose opioid dose is not reduced.
SENSITIZATION AND TOLERANCE TO COCAINE
Sari Izenwaser and Ellen M. Unterwald
Cocaine is a psychomotor stimulant that inhibits the reuptake of dopamine into presynaptic
dopaminergic neurons. thus increasing synaptic dopamine concentrations. Acute injection
of cocaine produces an increase in locomotor activity which becomes progressively greater
upon repeated drug administration. Although there have been many studies aimed at
determining the neurochemical bases underlying this sensitization or enhanced behavioral
response to repeated cocaine, definitive results have not been obtained. Changes in stores of
neurotransmitter do not appear to be important, as tissue levels of dopamine in the striatum
and nucleus accumbens are not changed after acute or chronic cocaine administration. The
effects of cocaine on dopamine receptor densities have been equivocal with reports of
increases, decreases, or no change in D1 and D2 receptor number.
Cocaine and several other psychomotor  stimulants in vitro inhibit reuptake of
[3H]dopamine into  presynaptic terminals. Repeated daily cocaine injections (15 mg./kg ip
once daily for three days) produce behavioral sensitization. result in a persistent decrease in
[3H]dopamine uptake in vitro, and increase the potency for cocaine inhibition of uptake in
rat nucleus accumbens, but not in the caudate putamen (Izenwasser and Cox 1990). In vivo
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microdialysis studies have shown that an acute injection of cocaine increases extracellular
dopamine. This increase is augmented seven days after withdrawal from a repeated dosing
regimen (e.g., Akimoto et al., 1989) but attenuated following a shorter withdrawal period of
24-48 hours (Hurd et al., 1989; Segal and Kuczenski 1992).
Under certain conditions, tolerance rather than sensitization develops to behavioral and
neurochemical effects of cocaine. Continuous cocaine administration via osmotic
minipumps produces tolerance to the locomotor-stimulating effects of cocaine (Reith et al.,
1987; unpublished data from Izenwasser and Cox 1992a). In addition, tolerance to the
effects of cocaine on operant behavior has been observed. Acute administration of cocaine
produces dose-related decreases in response rates in animals on an FR 30 schedule of food
reinforcement. Repeated daily cocaine administration produces tolerance to this effect, as
evidenced by a shift to the right of the dose-effect (Katz et al., 1993).
Cocaine administration also affects the endogenous opioid system. Dynorphn peptides
(Sivam 1989) and prodvnorphin mRNA (Spangler et al., 1993: Hurd et al., 1992) are
elevated following repeated cocaine exposure.Chronic “binge” cocaine administration
(three injections/day at one-hour intervals for 14 day) produces behavioral sensitization and
causes upregulation of mu and kappa, but not delta, opioid receptors primarily in brain
regions rich in dopamine terminals (Unterwald et al, 1992). Alterations in [3H]
naloxone binding have been reported following continuous infusion of cocaine (Hammer
1989). Similar to some of the effects on behavior and dopamine uptake. different treatment
regimens produce differential effects on opioid receptor function. Chronic “binge” cocaine
results in a loss of delta opioid inhibition of adenylyl cyclase activity in both the caudate
putamen and nucleus accumbens,with no change in the regulation of this second messenger
by mu opioid ligands (Unterwald et al., 1993). In contrast, chronic infusion of cocaine
produces an increase in mu opioid inhibition of adenyl cyclase activity in the nucleus
accumbens, but not in caudate putamen, and has no effect on delta opioid receptor function
(Izenwasser and Cox 1992b).
Thus, chronic administration of cocaine has profound effects on a number of nuerochemical
systems. The biological bases, underlying sensitization or tolerance to cocaine is not yet
fully understood. There are, however, a number of factors that influence the development of
sensitization and tolerance and include drug dose, dosing regimen, length of treatment, time
since the last treatment, and the behavioral measure. A better understanding of the effects of
different treatment regimens that lead to sensitization of tolerance to cocaine, and the
neurochemical changes associated with these effects, should aid in the identification of
factors that may be important in the development of treatments for cocaine addiction.
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OVERVIEW: ANTISOCIAL PERSONALITY AND
TREATMENT RESPONSE IN SUBSTANCE ABUSERS
A.I. Alterman
There is a long-standing belief that substance abusers with a diagnosis of antisocial
personality disorder (APD) do not benefit from treatment. A review of the relevant studies
indicates, however, that APDs do benefit from treatment, although to a lesser degree than
patients with no additional psychiatric disorders (Alterman and Cacciola 1991). The APD
diagnosis is not a uniquely negative prognostic indicator. Patients with diagnoses of major
depressive disorder as well as those with an additional substance diagnosis benefit less from
treatment. A number of studies have shown that APD is a heterogeneous categorization and
that there may be subtypes of APD patients with a differential treatment response. It is
therefore encouraging that a number of studies are now being conducted to further delineate
and clarify the implications of the APD diagnosis in substance abusers. The following
papers describe a number of approaches concerned with issues related to APD and its
relation to treatment response.
HISTORY OF ANTISOCIAL BEHAVIOR AND TREATMENT OUTCOME IN
WOMEN
L. Cottler, W. M. Compton, III and G. A. Asmus
Childhood conduct disorder has been shown to lead to adult antisocial behavior (AAB) and
antisocial behavior may predict treatment outcome among substance users. This paper
discusses the subtypes of antisocial behaviors and their effects on HIV risk behavior after
one year of follow-up. The data came from two studies of the seroprevalence and
serconversion among current and former drug users and partners of current users. Both
studies had a 12 month follow-up in the protocol. Of the 1080 persons interviewed, there
were 262 women; 21% met criteria for Antisocial Personality disorder (APD); 41% met
adult criteria only, but not childhood; 36% met neither threshold; and 3% reported
childhood only.
Recency of injection drug use and high risk sexual behaviors (such as 10 or more partners,
not always using condoms, having a partner who injected drugs, etc.) was evaluated among
women with and without adult antisocial behavior (n=162 vs. n=100). Women with AAB,
compared to those without, were more likelv to report IDU 133% vs. 13%). but were more
likely to change this behavior over 12 months; equally likely to report high risk sexual
behaviors, but not more likely to change this behavior (82% vs. 78% recalcitrant); were
more likely to use cocaine (86% vs. 53%); and more likely to receive drug treatment (74%
vs. 41%). Older white women with AAB and a history of both depression and drug abuse
treatment were more likely to be injection drug users at the 12-month follow-up. High risk
sexual behaviors at the 12 months follow-up were predicted by AAB only.
Further analyses are needed to evaluate among women the association between AAB and
recalcitrant behaviors. However, it appears that women are more likely to change their drug
using behaviors than their high risk sexual behaviors.
74
POST-TREATMENT OUTCOME IN CONDUCT-DISORDERED BOYS
T. Crowley
Youths with Conduct Disorder comprise a sizable proportion of patients with adolescent
drug problems. Descriptions of these patients’ drug use have been limited, and there have
been no reports of the outcome of drug treatment of these patients. We here describe a
cohort of such patients admitted to long-term residential care, including information on
follow-up of these patients.
Subjects and Methods. Patients were referred by criminal justice and social service agencies
throughout Colorado for long term residential care at Synergy, a program of our service.
Patients referred to Synergy share these characteristics: serious substance involvement,
considerable antisocial behavior, major family turmoil, frequent failures in previous
treatments, frequent placements in group homes or detention,  not psychotic, and not
considered imminently dangerous despite histories of violence, fire-setting, or past suicide
attempts.
Synergy is an unlocked, non-hospital residential treatment program offering 6-12 months
duration with extensive aftercare available. It operates as a modified Therapeutic
Community relying on intensive confrontational groups, individual and family counseling
by state certified drug abuse counselors, vocational and recreational activities, and an on-
site school.
Assessments included the Diagnostic Interview Schedule for Children (DISC) on about Day
3, the Composite International Diagnostic Instrument - Substance Abuse Module (CIDI-
SAM) on about Day 2, the Comprehensive Addiction Severity Index - Adolescents (CASI-
A) on about Day 5, the Carroll Self-Rating Scale for Depression, and a modified Aggression
Rating Scale on about Day 25. Follow-up interviews using the CASI, Carroll, and DISC
were done at 6 and 12 months with all patients who could be tracked and agreed to be paid
follow-up participants.
Results. Eighty-five percent of the youths were either White Anglo or Hispanic, and their
mean age was 16.2 years. All were male. All patents had clinical diagnoses of Conduct
Disorder. All also had Drug Dependence diagnoses by DSM-III-R criteria. The group was
highly aggressive on a standardized aggression scale. The prevalence of dependence
exceeded 60% for marijuana, for alcohol. and for tobacco, which were the three drugs of
highest prevalence in this group.
At one year follow-up the youths reported a sizable drop in the 6 month prevalence rate of
Conduct Disorder symptom behaviors, in number of drugs used, and in the days of use of
various drugs. The youths reported fewer drug problems at follow-up. There were
significant reductions in self rated depression at follow-up, and there was a marked
reduction in the prevalence of Major Depressive Disorder at follow-up. There was a striking
and highly significant increase in the proportion of youths who had graduated from high
school or obtained GED’s at one year follow-up. The number who had recently been in jail
or detention had fallen dramatically, whereas the proportion living in group homes or
therapeutic situations had risen significantly.
There was an average, marked improvement in the clinical status of youths one year after
admission to a treatment program. Without a control group it is not possible to ascribe the
improvement to the treatment, but it is important to recognize that improvement can occur
in violent, conduct disordered, drug dependent youths.
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TREATMENT OUTCOMES ASSOCIATED WITH ANTISOCIAL PERSONALITY
AND OTHER PERSONALITY DISORDERS.
R. Brooner
Antisocial Personality Disorder (APD) in opioid abusers has been associated with poor
treatment prognosis and increased risk of HIV infection (Woody et al. 1985: Brooner et al..
1992). These findings have stimulated interest in both the diagnosis of APD and in possible
subtypes of the syndrome. For example, APD opioid abusers who met criteria for other
personality diagnoses also scored higher on measures of neuroticism and psychiatric distress
compared to patients who met criteria for APD only (Rousar et al., in press). The present
study examined the relation between personality disorder comorbidity in APD opioid
abusers and treatment outcome. A total of 344 opioid abusers categorized diagnostically into
one of four groups: 1) no personalitv diagnosis - NONE; 2) APD only - Pure; 3) APD plus
other personality diagnoses - mixed: and 4) personality diagnosis other than APD - Other.
Diagnoses of personality disorder were made using the Structured Clinical Interview for
DSM-III-R. Personality traits were assessed using NEO Personality Inventory (NEO-PI)
and psychiatric distress was measured using the SCL-90R.
The majoritv of patients were categorized in the None group (N= 231), followed by 54 Pure
APD, 21 Mixed’APD, and 38 Other personality disordered patients. The Mixed APD group
had a higher Neuroticism domain score compared to both the Pure APD and the Non-Axis II
groups (p<.01), and significantly higher scores on 5 of the 6 facets of Neuroticism
compared to both the Pure APD and the None groups (e.g., Anxiety, Hostility, Depression,
Self-Consciousness, and Vulnerability). The Mixed group also reported significantly higher
state levels of distress on each of the SCL-90 subscales compared to the Pure and None
groups. No significant differences on these measures were found between the Mixed and the
Other group. This data indicate that Axis II comorbidity among APD opioid abusers is
associated with higher levels of emotional distress and instability.
The impact of chronic, pervasive dysphoria reported by Mixed APD patients and treatment
outcome was examined by comparing their intake and 7-month Addiction Severity Index
(ASI) composite scores (CSs), treatment survival rate, and percent of urine specimens
positive for illicit drugs to Pure APD patients and those in the remaining two groups. There
was a modest trend for greater treatment retention for Mixed APD group compared to
patients in the Pure APD group and the Other Groups (63% vs. 52% and 50%. respectively).
The Mixed groups also had significantly higher intake AS1 CSs on the medical and alcohol
scales compared to the three remaining groups, and a significantlv higher psvchiatric CS
than the Pure group (.15 vs. 05). AIthough the Mixed group had lower medical and alcohol
CSs at month 7 compared to intake these differences were not statistically significant. In
contrast, both the Pure APD and the None groups reported significantly lower drug CSs at
month 7 versus intake. Urine results for opiods and cocaine revealed an interesting  picture.
The Mixed group had the lowest rate of opioids positive urines (10%). with the Pure, Other
and None groups having very similar positive rates (28%, 25%, 25%, receptively); this
difference was not significantly significant. The Pure APD had a significantly higher percent
of cocaine positive urines compared to the None Group (32% vs. 20%. respectively): the
Mixed group had the lowest rate (19%) though this difference was not significantly
significant. Finally, there was a modest trend for the Mixed group to have a lower overall
positive urine  rate (i.e., opioids, cocaine, sedatives combined) compared to the Pure APD
group (33% vs. 58%).
In summary, a subset of APD patients were found (i.e., Mixed) that were significantly more
prone to dysphoria than Pure APD patients, with significantly higher intake ASI medical.
alcohol and psychiatric severity scores. The Mixed-APD’s had a slightly higher rate of
treatment survival and the lower rates of opioid, cocaine and combined urine positives.
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THE PSYCHOPATHY CHECKLIST AS A PREDICTOR OF NEGATIVE
TREATMENT OUTCOME
A. I. Alterman, J. S. Cacciola and M. J. Rutherford
Introduction. In an ongoing study we are comparing the reliability and predictive validity of
the APD diagnosis and the psvchopathy diagnosis derived from administration of the
revised Psychopathy Checklist ( PCL-R; Hare 1991). There is some indication in the
literature that the PCL-R determination may yield a more severe antisocial subtype than
APD (Alterman and Cacciola 1991).
Subjects and Method. The subjects were new intakes into methadone maintenance (MM)
treatment. All were males. The number of subjects at baseline was 18 1, that at one month
was 178, then was 159 at 6 month follow-up and 67 at 24 month follow-up. The PCL-R and
an APD interview were administered at 0,1, 6, and 24 months as well as the ASI.
Results. The test-retest reliability (different interviewers at each timepoint) of the APD
diagnosis for baseline vs. one month, baseline vs. 6 months and baseline vs. 2 years was
0.39. That for the psychopathy diagnosis (baseline PCL-R score of 25 or more) was 0.72 for
the same time points. Thus, the psychopathy diagnosis was more reliable than the APD
diagnosis. APD subjects (n=47) had significantly poorer baseline ASI composite scores than
non-APD (n=134) subjects in the legal and family/social areas. Psychopathic (PSYCHOP-
n=39) subjects had significantly poorer scores in the legal, drug, and employment areas than
non-psvchopathic  subjects (non-PSYCHOP-n=143). AU groups showed significant
improvements in the ASI at six and 24 month follow-ups except for the medical and
employment areas. APD and PSYCHOP subjects improved as much as non-APD and non-
PSYCHOP subjects. No differences were found for up to seven months of treatment  urines
for the APD vs. non-APD group. There was a tendency for the urines of PSYCHOP subjects
to be dirtier than those of non-PSYCHOP subjects (barbiturates: 11.8% vs. 2.2%; p<.08).
PSYCHOP subjects also had a higher proportion of dirty cocaine urines than non-’ ’
PSYCHOP subjects (75.5% vs. 60.2%). but this difference was not statistically different.
PSYCHOP subjects were significantly more likely than non-PSYCHOP subjects (47.1% vs.
21.5%; p<.004) to drop out of treatment. Differences in treatment retention were not found
for APD/non-APD subjects (33.3% vs. 25.7% dropout; ns).
Conclusions. The findings indicate that both antisocial and non-antisocial MM patients
benefit from treatment. There is limited evidence that psychopathic patients represented a
more severe form of antisocial subgroup than those qualifying for an APD diagnosis.
DISCUSSION
G. E. Woody
Antisocial personality disorder (APD) is a very serious problem among persons with
substance use disorders. It is the one pre-existing disorder that has consistently been shown
to serve as a risk factor for the development of substance use disorders. It is associated with
an increased risk for HIV infection and an increased death rate, often attributable to violence
or accidents. Most studies have found that persons with APD do not do as well in treatment 
as those without the disorder. However, many studies also show that APD is a
heterogeneous category. Some indicate that there is a “treatment responsive” subgroup.
Dr. Cottler’s study is one of the first that examines the relationship between adult antisocial
behavior, drug use, and behaviors that increase the risk for HIV infection among women.
She finds that women with AAB use more drugs than women without it. Over a period of
12 months she finds that those with AAB decrease injecting drug use but that they are less
likely to decrease cocaine use than those without AAB. In contrast to the improvements in
drug use and its associated risky behavior, she finds no significant decrease in risky sexual
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behavior. She also finds that major depression is associated with better outcome. These
data are very consistent with other studies which have shown that risky behavior associated
with drug use is more amenable to change than risky sexual behavior, that persons with
APD am less responsive to treatment, and that patients with both depression and APD have
a better response to treatment than those with APD alone.
Dr. Crowley’s data are very interesting and unique. The level of social problems displayed
by his group of adolescents is stunning. The data offers an insight into a large group of very
disordered children who ate in great need of help. These adolescents are obviously at very
high risk for the later development of APD. The data presented indicate that large numbers
of these children may respond to treatment, though the intensive therapy provided is often
not available elsewhere. Additional work in this area, especially controlled studies of
treatment outcome, strike me as very important. If left unattended, these adolescents are
very likely to cause very serious problems for themselves and others as they become older.
Dr. Brooner’s study adds a new dimension by suggesting that not only APD, but Axis II
disorders in general are associated with a poorer response to treatment. Dr. Brooner’s
findings are definitely worth pursuing in other studies and with other populations; they
probably apply to other disorders as well.
Dr. Alterman’s study indicates that those with APD have more severe drug problems than
those without APD, and that they improve with treatment. In this regard, his data are
similar to those found in most other studies. His data differ, however, in finding that
persons with APD improve at the same rate as those without the disorder. Most studies
have found slower rates of improvement among persons with APD than those without it. It
is uncertain why his data differ from that of others in this regard; perhaps his subjects
represent more of the “treatment responsive” subgroup than other studies, perhaps earlier
samples were unrepresentative of the overall program, or perhaps our treatment program is
doing a better job with these patients than we did in the past !
In summary, these studies address a range of important issues surrounding APD and raise a
number of interesting questions. How does APD influence outcome compared with other
Axis II disorders? are adolescents with conduct disorders responsive to therapy and if so,
what kind and for how long? how can we best treat persons with APD, especially in
reducing their risk for HIV infection? These and other questions am important areas that
should be addressed by future clinical studies.
Arthur I. Alterman, John Cacciola and Megan Rutherford
University of Pennsylvania, Philadelphia, PA
Robert Brooner, Johns Hopkins University, Baltimore, MD
Thomas Crowley, University of Colorado, Denver, CO
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REFERENCES
Furnished upon request of senior author.
78
CARDIOVASCULAR EFFECTS OF COCAINE: UNDERLYING
MECHANISMS
C. W. Schindler
High levels of cocaine-related emergency room admissions led to a renewed interest in
the cardiovascular effects of cocaine in the late 1980’s. As a result, a great deal has been
learned about cocaine’s effects on the cardiovascular system in recent years. The purpose
of this symposium was to bring together researchers with a broad range of views on the
mechanisms underlying the cardiovascular effects of cocaine. The work presented
includes both animal and human research. Despite an overall decline in the abuse of
cocaine in recent years, the continued high levels of emergency room admissions citing
cocaine use gives added importance to the study of cocaine’s cardiovascular effects.
OVERVIEW OF COCAINE’S CARDIOVASCULAR EFFECTS IN ANIMALS
R. D. Wilkerson
Hypertension, sinus tachycardia and elevated circulating levels of catecholamines are sine
qua non of the acute actions of cocaine in humans. Both the pressor effect and the sinus
tachycardia associated with cocaine administration appear to be catccholamine-mediated,
since pretreatment with appropriate adrenergic antagonists has been shown to inhibit both
actions. In addition to these global cardiovascular actions, cocaine has also been shown
to affect the coronary circulation in humans. Although much has been written about
cocaine-induced large epicardial coronary artery vasospasm and myocardial infarction,
vasospasm has not been observed in patients who received cocaine during coronary
arteriography. Indeed, only a modest reduction in the diameter of large coronary arteries
was observed, without any evidence of mycocardial ischemia.
Animal models employed to study the cardiovascular actions of cocaine should, at a
minimum, exhibit the three cardinal actions of cocaine described above for humans. To
date, those actions of cocaine have been demonstrated in a number of species, including
rats, dogs, rabbits and subhuman primates, but a requirement is that the animal be studied
in the conscious, fully awake state. Numerous studies have shown that anesthesia or
sedation significantly blunts all of the above described actions of cocaine. Indeed, when
cocaine has been administered to anesthetized animals, a common finding has been a de-
crease, rather than an increase, in blood pressure, presumably a manifestation of the
vasodilator effects mediated by the local anesthetic action of cocaine, which is not
masked by increased adrenergic activity in this preparation.
In animal models which exhibit cocaine-induced cardiovascular responses similar to
those observed in humans, the mechanism(s) of action of cocaine is still unclear. Some
effects of cocaine, such as myocardial depression, are, undoubtedly, the result of the local
anesthetic actions, but many questions surround the adrenergic actions of cocaine.
Although there appears to be general agreement that circulating catecholamines are ele-
vated by cocaine in conscious animal models, it is not clear whether this is merely the re-
sult of inhibition of peripheral neuronal monoamine uptake, or whether peripheral sym-
pathetic tone is elevated by a central action of cocaine. If peripheral sympathetic tone is
elevated, the relative roles of sympathetic neuronal stimulation and adrenal medullary
catecholamine release are also unclear at this time. In this latter regard, recent studies,
even in conscious animals, have demonstrated that the activity of specific sympathetic
neurons innervating the heart and some regional vascular beds is inhibited after cocaine
administration. To date, there has been no explanation for this apparent paradox; that is,
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increased adrenergic activity, as evidenced by hypertension, tachycardia and increased
circulating catecholamines, occurs in association with decreased peripheral sympathetic
nerve activity.
PERIPHERAL MECHANISM’S IN COCAINE’S CARDIOVASCULAR
EFFECTS
R. A. Gillis with F. E Kuhn, H. K. Erzouki and Y. M. Hernandez
Cocaine administration is associated with a number of cardiovascular changes including
increases in arterial blood pressure (BP), heart rate (HR), rate-pressure product and
coronary vasoconstriction. These changes are due to a cocaine-induced augmentation of
sympathetic nervous system function. Currently, augmentation of sympathetic nervous
system function produced by cocaine is thought to be due primarily to stimulation of
sympathetic centers in the brain (central effect) and to inhibition of catecholamine uptake
into post-ganglionic sympathetic nerve terminals (peripheral effect). It is our thesis that a
peripheral effect can explain most of the sympathomimetic effects of the drug on the
cardiovascular system. Evidence that cocaine-induced changes in cardiovascular
function, particularly those that peak within 1 to 5 minutes after an i.v. bolus injection of
the drug, are due to a peripheral effect is as follows: (1) the time course of action and
dosage range of cocaine to potentiate neurally-released and injected norepinephrine (NE)
on the heart follows that which increases BP, HR. rate-pressure product and coronary
vasoconstriction; (2) cocaine given in i.v. doses that increase BP has no significant effect
on spontaneously occurring cardiac sympathetic nerve activity; and (3) cocaine
methiodide, a quaternary derivative of cocaine which is not able to cross the blood-brain
barrier, given in equimolar doses to cocaine, produces quantitatively and qualitatively
similar cardiovascular responses to cocaine. Cocaine methiodide has been shown to act
peripherally to inhibit the uptake of NE into post-ganglionic sympathetic nerve terminals.
Further evidence for a lack of central excitatory effect of cocaine on sympathetic centers
are the findings that: (1) cocaine given into the cerebroventricles in doses that would
reach the brain when given systemically in recreational doses has very little effect on BP
and HR; (2) cocaine administered directly into the blood supply of the hindbrain produces
no increase in BP, HR or sympathetic nerve activity; instead, decreases in BP and
sympathetic nerve activity occur.
Two additional points about cocaine’s actions on the peripheral sympathetic nervous
system are that: (1) tachyphylaxis develops towards cocaine’s potentiating effect on the
heart, and (2) cocaine given in doses of 2 to 4 mg/kg i.v. can act at sympathetic ganglia to
reduce post-ganglionic sympathetic nerve activity. Tachyphylaxis appears to be mediated
in part by the interaction of synaptic accumulated NE on presynaptic alpha-2
adrenoceptors on post-ganglionic cardiac sympathetic nerves, while reduction of sympa-
thetic ganglionic transmission appears to be mediated in part by the interaction of synap-
tic accumulated NE on ganglionic alpha-2 adrenoceptors. Based on our results we con-
clude that the mechanism for cocaine’s sympathomimetic effect on cardiovascular func-
tion is unrelated to any excitatory effect of the drug on CNS centers, but is due primarily
to the ability of the drug to inhibit uptake of catecholamines into post-ganglionic
sympathetic nerve terminals.
PHARMACOLOGICAL MECHANISMS IN COCAINE’S CARDIOVASCULAR
EFFECTS
C. W. Schindler
Cocaine has a diverse pharmacology. For example, cocaine produces potent blockade of
the uptake of dopamine, norepinephrine and serotonin as well as local anesthetic effects.
Our laboratory is interested in how this diverse pharmacology contributes to cocaine’s
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cardiovascular effects. In conscious squirrel monkeys, we have tested a variety of com-
pounds as cocaine pretreatments. The squirrel monkey is a reliable model for cocaine’s
cardiovascular effects in that it mimics the human response to cocaine. Moderate to high
doses of cocaine produce a sustained pressor effect and tachycardia. Both the non-
selective -adrenergic antagonist phentolamine and the selective -1 antagonist prazosin
completely block this pressor effect of cocaine. In contrast, the non-selective ß-adren-
ergic antagonist propranolol and the ß-1 selective antagonist atenolol completely block
the tachycardia produced by cocaine. These results indicate the importance of -1 and ß-
1 adrenergic mechanisms in mediating the pressor and tachycardiac effects of cocaine
respectively. While propranolol was effective as an antagonist of cocaine’s tachycardiac
effect, it simultaneously enhanced cocaine’s pressor effect, thus making its utility as a
treatment agent questionable. We found little support for a role of dopaminergic mecha-
nisms in the hemodynamic effects of cocaine. Neither the dopamine D1 selective
antagonist SCH 23390 nor the D2 selective antagonist haloperidol attenuated the pressor
effects of cocaine and only haloperidol slightly attenuated the tachycardia following co-
caine. We have also tested a variety of calcium channel antagonists In general, the
calcium channel antagonists were able to only attenuate the cocaine-induced pressor re-
sponse.
Toxicity to cocaine is often observed hours following its administration, pointing to a
potential role of the cocaine metabolites. In an anesthetized rat preparation where the lo-
cal anesthetic effects predominate, high doses of cocaine produce a depressor effect,
bradycardia and QRS widening. Cocaethylene, a metabolite produced with co-adminis-
tration of cocaine and ethanol,produced comparable effects. Unlike cocaine, norcocaine
tended to increase blood pressure at higher doses while simultaneously widening QRS.
The major cocaine metabolites benzolyecgonine and ecgonine methyl ester did not pro-
duce QRS widening, but did produce clear pressor effects. These results indicate that the
cardiovascular effects of cocaine arc not necessarily mimicked by its metabolites and
therefore these differing effects of the metabolites  should be considered when evaluating
cocaine’s cardiovascular toxicity.
CARDIOVASCULAR EFFECTS OF COCAINE IN HUMANS
R. W. Foltin and M. W. Fischman
Studies in which experienced cocaine users receive cocaine under controlled laboratory
conditions are an excellent source of data on the cardiovascular effects of cocaine.
Studies with intranasal, intravenous. and smoked cocaine all show that under conditions
simulating cocaine “bingeing,” in which subjects are allowed to take cocaine repeatedly,
heart rate (HR) generally returns to near baseline levels despite gradually increasing
cocaine blood levels. In contrast, blood pressure (BP) has been shown to gradually
increase when the dosing was i.n. and the time between injections approximately 35
minutes, although with the other routes of administration it generally mirrored the HR ef-
fect. The effects of repeated doses of smoked or i.v. cocaine were directly compared in
10 research volunteers who received the same smoked or i.v. cocaine dose twice with a
14 min interval between doses. When smoked and i.v. cocaine administration resulted in
similar venous plasma levels, similar cardiovascular effects were observed, with minimal
differences as a function of route of administration. The repeated-dose data suggest the
rapid development of acute (i.e., with session) tolerance to cocaine.
Cocaine is often self-administered in close temporal proximity to ethanol, marijuana or
heroin. An unexpected cardiovascular interaction was observed in nine subjects who
inhaled cocaine and drank ethanol-containing beverages. This combination resulted in
HR increases that were significantly larger than observed with either drug alone, but
produced similar or lower BP increases than that produced by cocaine alone. A single
i.v. dose of either cocaine or morphine sulfate alone produced dose-dependent increases
in peak HR and BP, but there were few instances in which the cardiovascular effects of
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combinations of cocaine and morphine were significantly greater than those produced by
cocaine alone. When i.v. cocaine was combined with smoked marijuana in seven male
volunteers, combinations of cocaine and marijuana increased HR above levels seen with
either drug alone. Increases in BP following combinations of cocaine and marijuana were
equivalent to those produced by cocaine alone. These studies indicate that it is impossible
to predict the cardiovascular effects of drug combinations based on the effects of either
drug alone. HR was often increased substantially by drug combinations, while the effects
of a drug combination on BP were often equal to that of one drug alone. Likewise, the
interaction of potential treatment drugs with cocaine should be assessed under controlled
settings prior to large scale treatment studies. When six research subjects were allowed
to self-administer i.v. saline or cocaine (8, 16, or 32 mg) before and during a period of
maintenance on desipramine there was a significant increase in baseline HR and BP
during desipramine maintenance. Cocaine administration engendered increases in HR
and BP above the desipramine-elevated baselines, suggesting that cocaine self-
administration may have the potential for greater cardiovascular effects when patients are
maintained on desipramine. Clearly, drug interactions can have unexpected
cardiovascular effects, and laboratory studies provide a controlled setting for
understanding and researching these interactions. Such data are necessary for the safe
introduction of new pharmacotherapies for substance abuse treatment.
EFFECTS OF COCAINE ON VAGAL TONE IN HUMANS
D. B. Newlin
This research was conducted within the broad framework of our research looking for
commonalities in the cardiovascular response pattern of drugs of abuse in humans.
Based on empirical results with various abused substances, we hypothesized that acute
cocaine would produce a distinct cardiovascular pattern consisting of tachycardia with a
reduction of cardiac vagal tone. Vagal tone index is a noninvasive measure of
parasympathetic inhibitory influences on the heart. It is derived using time series
analysis from sequential R-wave to R-wave intervals of the ECG; it quantifies respiratory
sinus arrhythmia, or heart rate variability at approximately 0.30 Hz. When tachycardia is
associated with reduction in vagal tone, it implies that the increased heart rate is due to
withdrawal of vagal chronotropic inhibition rather than due to active sympathetic
activation. We have observed this characteristic pattern, to varying degrees, with a broad
range  of  d i f fe ren t  d rugs  of  abuse ,  inc lud ing  mar i juana .  n ico t ine .  a lcohol .
methylphenidate, morphine: pentobarbitol and diazepam. These drugs are dramatically
different pharmacologically, but are common in producing: 1) self-administration; 2)
positive place-preference conditioning; 3) low dose locomotor activation effects; 4)
reductions in cortical glucose utilization in neuroradiological studies in humans; 5)
generally positive subjective effects; and 6) vagally-mediated tachycardia. We have been
able to rule out this cardiovascular pattern with several nonabused or aversive drugs,
including naloxone in opiate-dependent individuals, flumazenil (a benzodiazepine
antagonist), and mCPP (a serotonergic drug that is generally dysphoric).
Cocaine (IV., 20 mg and 40 mg) and placebo (saline) were administered on separate days
to 14 male residential volunteers with histories of cocaine abuse. Cocaine produced dose-
dependent increases in heart rate. This effect was precisely mirrored by robust decreases
in vagal tone index, as well as decreases in a lower frequency (approx. 0.10 Hz) heart rate
rhythm associated with blood pressure homeostasis. Injection of saline (i.e., cocaine
cues) produced an initial 14 bpm increase in heart rate that had no significant vagal
component. Vagal tone index and the lower frequency rhythm decreased approximately
2 to 2.5 log units in response to 40 mg cocaine, with a trough 9 to 14 minutes after I.V.
administration. Therefore, cocaine led to a pronounced decrease in heart rate variability.
The results indicate that cocaine-induced tachycardia has a strong parasympathetic
component and appear to contradict the common assumption that tachycardia from
cocaine is due primarily to sympathetic activation. It is consistent with the view that at
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low to moderate doses in humans, cocaine increases heart rate due to withdrawal of vagal
inhibition. Evidence indicates that vagal inhibition normally suppresses cardiac
arrhythmias, and that profound release of vagal restraint can be arrhythmiagenic.
Moreover, our results indicate that this effect is conditionable in the sense that cocaine
placebo given to experienced users produced robust, but short-term, placebo and antici-
patory responses in the same direction as the drug itself. The central neuroanatomical
and neurochemical substrates that control this common cardiovascular pattern are not
known.
DISCUSSION
H. R. Levin
The majority of cocaine-related emergency room visits and associated hospitalizations are
due to cocaine’s cardiovascular effects. Thus, a clear understanding of the physiologic
mechanisms of these effects are necessary to develop specific treatments. In the papers
presented above, the effects of cocaine on the peripheral and central nervous systems
have been described. A functional understanding of these systems and their effects on
autonomic tone are necessary in order to appreciate the clinical significance of these
findings. For example, a lethal complication of cocaine use, sudden cardiac death (SCD),
is a mutifactorial event that may be precipitated by cardiovascular, neurological and/or
hematologic events. Though a sustained arrhythmia is probably the final event leading to
SCD, these arrhythmias are caused by the combination of an abnormal substrate (i.e.,
myocardium) and a trigger (i.e., a premature ventricular contraction {PVC}).
Abnormalities in autonomic tone can produce PVCs. In addition, changes in autonomic
tone can alter the electrical properties of the myocardium, allowing a PVC to initiate a
sustained arrhythmia. The cardiovascular effects described in the previous papers may
lead to ischemia, myocardial infarction and fibrosis. These factors can also adversely
alter the electrical properties of the myocardium, predisposing it to SCD. However,
factors other than those previously mentioned may play a role in producing SCD.
Although cocaine transiently decreases ventricular contractility, the prolonged decrease in
ejection fraction from cocaine-induced peripheral vasoconstriction may result in vital
organ hypoperfusion. Further, unwitnessed deaths assumed to be caused by SCD may in
fact be the result of cocaine-induced seizures or malignant hyperthermia. Finally, cocaine
may alter platelet aggregation increasing the risk of coronary thrombosis.
While an understanding of the cardiovascular effects of cocaine are important, there arc
other important health problems associated with drug abuse such as AIDS, hepatitis and
endocarditis which necessitate new treatment modalities. Similar to any other drug or
device development, human research is needed to show the efficacy of a new treatment.
Certainly, administration of cocaine to subjects carries a risk of adverse cardiac events.
However, the doses used in human studies are well below average street doses and the
trials are performed under controlled conditions that, if necessary, would allow prompt
treatment of any adverse event. In addition, it should be noted that the cardiovascular
changes noted during human studies are less than those observed during a clinical exer-
cise stress test or with normal exercise. Thus, while human research may carry some risk,
these trials may allow the development of treatments not only for the cardiovascular
effects of cocaine, but the problem of cocaine addiction as well.
AFFILIATIONS:
NIDA Addiction Research Center, Baltimore, MD, Medical College of Ohio, Toledo,
OH, Georgetown University, Washington, DC, Columbia University, New York, NY
Columbia-Presbyterian Medical Center, New York, NY
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FORUM ON DRUG RESEARCH WITH POLICY IMPLICATIONS
B. A. Rouse and J. H. Autry, III.
As part of the process by which science in general and drug research in particular
can inform policy decisions, this Forum presented drug research of current policy
significance, highlighted the importance of policy relevant research, and encouraged
researchers to look for policy relevance in any research they undertake. The related
policy issues discussed include drug detection, health policy approaches to drug
abusers with infectious and/or contagious diseases (e.g., partner notification),
criminal justice system approaches to drug abusers, and the assessment of the quality
of care. Dr. Herb Kleber discussed the policy implications of the research presented
and provided a wider perspective from which researchers in general can play a role
in policy development.
The first presentation was on “Analytical Challenges in the Chemical Diagnosis
of Drug Exposure Using Urine, Blood, Saliva and Hair” by Donna M. Bush and
Edward J. Cone. Mandatory Guidelines for Federal Workplace Drug Testing
Programs were issued on April 11, 1988. These implemented the National
Laboratory Certification Program and became known as the “gold standard” for
workplace drug testing. These Guidelines specified urine as the testing specimen
and prescribed testing procedures for drugs of abuse, using two independent
chemical tests: immunoassay and gas chromatography/mass spectrometry.
Because, in essence, drug test results are now evidentiary in nature and the
consequences of a positive drug test in the workplace may include adverse personnel
action, the accuracy and reliability of drug testing procedures must be paramount.
This presentation examined the current state of knowledge concerning the
pharmacological profile of drug actions and analytic studies of the testing process
in urine, blood, saliva and hair. Each specimen is unique with its own properties
which must be understood; each specimen tells us something new and different.
Blood is the specimen where pharmacokinetics of a drug can be measured. E.g.,
kinetics following cocaine smoking or IV administration are similar and reflect even
absorption and elimination compared to nasal inhalation which shows uneven
absorption characteristics. Blood may be useful in looking at performance
impairment since blood reflects the amount of drug in the brain more closely that
other specimens. Studies are needed to examine the relationships among drug
administration route, blood concentrations, and performance impairment as well as
studies of blood levels and pharmacokinetics. As far as research on saliva is
concerned, not only is there a lack of data on levels of drug in saliva and effects on
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behavioral performance, but saliva drug concentrations have been found to correlate
poorly with plasma concentrations and pharmacological drug effects.
Although hair analysis appears to be an attractive alternative to urine drug testing
because it may provide a long term window for drug detection, this is an area of
new science with few controlled clinical studies. Observations of drug using
populations show large concentrations of cocaine deposited in hair from cocaine
ingestion, small to moderate amounts of cocaine from passive exposure, but only
small concentrations of heroin from ingestion. The amount of drug deposited and/or
detected may be affected by recency of drug use, hair color, chemical treatments,
environmental contamination, and varying rates of hair growth on different parts of
the body. Commercially available urine drug test kits have not been approved by the
FDA for use with hair specimens.
In summary, analytical considerations (e.g., accuracy, precision, sensitivity,
specificity, quality control, and interpretability of results) are well established for
ur ine  as  the  spec imen,  less  wel l  es tab l i shed  for  b lood,  and  are  in  bas ic
developmental stages for saliva and hair. The scientific basis of drug testing
specimens, rather than expediency, must be carefully considered in policy decisions
and applications.
“HIV Transmission Models as Epidemiologic Tools for Evaluating the
Consequences of Partner Notification Programs” by Sally Blower, Ph.D.,
University of California, Berkeley, CA was presented next. Notification of sex
partners of HIV+ persons identified through counseling and testing programs has
been conducted in some states to curtail the HIV epidemic. Mandatory notification
programs to be implemented by state health departments throughout the country has
been proposed. Research into the effects of partner notification, however, is scant.
Unknown are the degree notified individuals are likely to reduce their risk behavior,
the degree HIV seroconversion in HIV discordant partnerships is prevented, and the
adverse consequences of partner notification programs (PNP). E.g., an HIV+
woman tested as part of her prenatal care may be required to inform her injection
drug using partner which may result in violence toward the woman or dissolution
of the relationship. It is also possible that there may be strong community reactions
to mandatory PNP resulting in avoidance of contacts with health institutions.
This presentation discussed  how models of the transmission dynamics of HIV could
be used to evaluate PNP as an epidemic intervention strategy. HIV epidemics are
complex non-linear systems characterized by specific transmission processes,
multiple linked risk groups with different risk levels of acquiring HIV, interaction
between population and individual level processes, risk behavior changes with both
direct and indirect effects, and extremely long and variable incubation time.
Three different approaches for modeling PNP were discussed: scenario analyses,
basic reproductive rate calculations, and sensitivity analysis. Results from a
simulation model of the HIV epidemic for New York City were presented. This
subgroup transmission model included HIV transmission probabilities for sexual and
needle-sharing exposure with stranger or buddy as well as the population mixing
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patterns which result in HIV exposure contacts. It took into account a bridge
population (non-injecting heterosexual partners of IDU), infection states (susceptible,
HIV seropositive, AIDS), differential non-AIDS mortality rates, and gender
differences in injecting and sexual behavior. Findings included the following: The
degree of sexual mixing that occurs between injecting drug users and non injectors
is critical in determining the future number of AIDS cases in women and pediatric
AIDS in NYC. Prediction precision in the future number of AIDS cases for NYC
was low; but that imprecision was due to the estimation uncertainty of only a few
biological-behavioral parameters. These key variables were the heterosexual
transmission efficiencies per partnership (i.e., the average probability that a
susceptible individual will acquire HIV during a heterosexual partnership given that
the partner is infected), the adult incubation time, and the vertical transmission
efficiency.
In summary, currently, the only way that HIV epidemics may be controlled is by
risk behavior reduction. To evaluate the significance of behavioral changes, it is not
sufficient to know only the type, magnitude, and timing of the behavioral change.
The seroprevalence level at which the behavior change occurs and the prevailing
mixing patterns of the various at-risk groups are also important. Partner notification
programs have been suggested as a potential epidemic control measure. Before such
programs become public policy it is necessary to assess their potential efficacy,
ethical issues, and acceptability to target communities. Policy decisions should take
into account the potential for varied impact on population subgroups; mathematical
models are useful to preview these impacts.
Next was “Outcomes of an Experimental Intervention Directed to Drug Abusing
Parolees” by David Nurco, T.E. Hanlon, R.W. Bateman, T.W. Kinlock, and E.
Toledano, University of Maryland School of Medicine and Friends Medical Science
Research Center, Baltimore, MD. An experimental intervention designed to reduce
drug use and crime by male and female parolees with a history of narcotics or
cocaine use was presented. The experimental project offered intensive social
support, case management with social services job bank, client advocacy and weekly
urinalysis for 12 months post-prison release. The two control conditions were
weekly urinalysis at the project site and routine parole supervision (agent visits and
random urinalysis). Parole record reviews indicated that the experimental group had
the lowest number of arrest warrants, rearrests, and reincarcerations 6 months post-
release; the next lowest was among the control group with weekly urinalysis. The
most predictive variables of counselor-rated lack of treatment success were being
male, other family members involved in crime, and younger age at first crime.
The importance and difficulty in correctly identifying drug abusers within the
correctional system and of matching these clients to treatment were addressed.
Newly available instruments to help include the Drug Offenders Profile and Referral
Assessment (DOPERS) which provides more specific information on the relationship
of drug involvement to criminality, the Offender Profile Index which serves as a
preliminary triage function, and the “heuristic” approach to drug abuse classification
and treatment planning used at Patuxent in Maryland to guide drug abuse
intervention efforts.
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Based on this research, the following were recommended: continuity between
rehabilitative efforts in correctional settings and treatment efforts in the community;
drug testing prior to a client’s release from custody because some inmates have
access to drugs while incarcerated; escorting parolees to their treatment clinic rather
than relying on their own initiative in making the necessary clinical contact;
consistency in disciplinary actions for infractions occurring under parole conditions;
periodic transmittal of treatment progress information (e.g., treatment compliance,
accomplishment of treatment goals, and evaluation of personal and community
adjustment) from treatment programs to parole officers to be considered in
determining the parole status of individuals at any given point in time; and, finally,
the use of a progressive series of intermediate sanctions to work on reducing
deviance through more intensive clinical efforts and the aggressive use of significant
others and available community resources.
The final presentation was “National Study of Drug Treatment Quality Standards
and Assessment” by Beatrice A. Rouse, Ph.D., SAMHSA and Richard W.
Scalenghe, JCAHO. The current emphasis on cost-effectiveness and cost
containment in health care reform indicates the importance of determining,
measuring, and monitoring the quality of care given. Two studies were presented
which were conducted to determine the formal mechanisms in the current delivery
system used to promote drug abuse treatment quality improvement. Study #1 was
a descriptive national study of the licensing and credentialing standards and
requirements for drug abuse counselors and programs as of 1991. Data were
extracted from the latest available legislation and state regulations. The majority of
states (39 plus the District of Columbia) had voluntary certification requirements for
drug abuse/chemical dependency counselors. While States with mandatory
certification were more likely to require drug abuse education or training and those
with voluntary certification were more likely to accept relevant experience, the
differences were not statistically significant. Ten states had drug abuse specific
requirements for noncounselor drug treatment practitioners. Twenty states accepted
JCAHO or CARF accreditation as full or partial compliance for state licensing or
certification. Several additional states also accepted such accreditation for meeting
State insurance requirements.
Study #2 was an indepth case study of formal quality assessment programs in
selected drug abuse treatment programs from a variety of modalities, settings, and
funding sources. Philosophical differences were noted between the two current
major approaches to setting, evaluating, and monitoring standards of care: Quality
Assurance is a more problem oriented approach focussing on identifying and
monitoring sentinel indicators such as suicide, violence, disappearance of
medications, etc. and comparing performance against some set of standards. In
contrast, Continuous Quality Improvement is more system-oriented with the
emphasis on aggregate data such as mean time to relapse, attrition rates, etc.
Proponents feel that this latter perspective moves the standards and quality of care
constantly upward rather than focussing on some minimum, static standard which
eventually tends to become the goal. The standards, assessment and improvement
procedures, and staff involvement were described for 5 exemplary programs. In
addition, examples of the different quality assessment approaches, data elements,
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and data sources were presented for discharge planning and for examining cases that
left against program advice.
In summary, the State system for setting treatment standards consisted of a
combination of standards, guidelines, policies, laws, and regulations. Also, States
differed in the level of specificity of their requirements. Often, the most effective
control mechanisms imposed by the States were those directly related to funding
decisions. In regard to formal quality assessment mechanisms by individual
programs, no clear trend emerged as to their design or implementation. Equally
successful programs varied vastly in their approaches. In general, treatment was
monitored in a systematic way with reasonable criteria. Both setting and evaluating
appropriate drug treatment quality and continuous improvement in care given also
requires attention to the organizational structure under which treatment is provided
as well as to the process and outcome of care. Designated quality assurance and
improvement programs are only part of the effort to improve treatment for substance
abuse. Other aspects include developing patient placement criteria and clinical
guidelines; targeting services for special needs (e.g., pregnancy); matching the
treatment to the patients; and formally implementing relapse prevention and after
care services.
The discussant was Dr. Herbert D. Kleber who shared some of his experiences with
data needs for policy decisions while Deputy Director for Demand Reduction at the
Office of National Drug Control Policy. He indicated that we still need timely and
accurate research on such epidemiologic issues as how many people need what kinds
of treatment, how many users get addicted, and how to reliably and validly measure
drug use and addiction. Treatment issues included the natural history of people
who enter the treatment system, patient/treatment matching, and the critical factors
predictive of successful treatment outcome. Dr. Kleber indicated that the public
expectations for successful substance abuse treatment included decreased use of
medical services, elimination of criminal activities, employment, reduced family
disruption, and the maintenance of abstinence from drug use. Research needs
regarding prevention included protective factors from drug abuse, effective
prevention for different segments of the adolescent population, and how to do
prevention in the declining phase of an epidemic. Finally, he outlined some needed
policy changes which included better targeted preventive efforts which emphasized
protective factors as well as risk factors, focus on community efforts, the use of
t rea tment  as  an  a l te rna t ive  to  p r i son ,  expanded  t rea tment  capac i ty ,  and
comprehensive substance abuse care to include coexisting conditions such as HIV
and TB.
Taken as a whole, the studies presented show the importance of research and its
application to policy. Research not only can but should inform policy and contribute
to better policy formulation. The application of research to policy development is
an important part of the continuum of basic, preclinical, clinical, and applied
research.
AFFILIATION:
Substance Abuse and Mental Health Services Administration, Rockville, MD
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DRUGS OF ABUSE AND IMMUNOSUPPRESSION
M. J. Kreek, T. Eisenstein, H. Friedman, P. Peterson, L. Soderberg and L. S. Brown
OPIATES AND THE IMMUNE SYSTEM
T. K. Eisenstein, T. J. Rogers. J. L. Bussiere, M. Rojhavin, I. Szabo, J. J. Meissler, S.
M. Belkowski, E. B. Geller and M. W. Adler
The central question which our research addresses is whether opioids can act as
immunomodulators. Our studies have shown that opioids are immunosuppressive when
given in vivo or in vitro. Our published work demonstrates that the µ and agonists inhibit
the in vitro secondary response to sheep red blood cells (SRBCs) of murine splenocytes.
Suppression by morphine is blocked by pretreatment with naloxone, and that caused by the
agonist, II-50,488H. is blocked by norbinaltorphimine (nor-BNI). New data show that the
agonists, DPDPE and D-Ala2,Glu4 -deltorphin, am also suppressive in this assay. Use of
selective 1 and 2 antagonists showed that both DPDPE and deltorphin were inhibited by
cys-4-deltorphin, but not by DALCE, supporting a role for 2but not 1, receptors in
immunosuppresssion.
In another type of experimental paradigm, groups of mice were implanted with a 75-mg
morphine pellet, with a naltrexone pellet, or with both types of pellets. Sham-operated or
normal animals served as controls. Morphine treatment inhibited the primary in vitro
plaque-forming cell response to the SRBCs in all mouse strains tested, and simultaneous
implantation of a naltrexone pellet blocked suppression in mice of the C3H lineage.
Addition of normal macrophages to morphine-suppressed cultures restored responses.
Addition of recombinant interleukin-1 (IL-1), IL-6 or interferon- also restored responses in
a dose-dependent fashion, whereas IL-2. IL-4, and IL-5 were not effective in reversing
suppress ion .  Morphine  pe l le t - implanted  mice  had  reduced sp leen  s izes .  The
immunosuppression was evident whether the number of antibody forming cells was
calculated on a per spleen basis or per 10-7 cells. The immunosuppression may have
resulted either from a relative decrease in the numbers of macrophages following morphine
administration, or from decreased functional capacity of individual macrophages.
Experiments were carried out to test the capacity of normal or morphine-treated murine
resident peritoneal cells to phagocytize the yeast, Candida albicans When morphine was
administered in vivo by pellet implantation, periotoneal exudate cells showed approximately
a 40 percent reduction in Phagocytic Index (number of yeasts per macrophage based on
microscopic examination of 200 to 400 cells), at a particle to macrophage ratio of 10: 1, and
a 30 min period of phagocytosis. Phagocytosis was not depressed in mice receiving
morphine and naltrexone pellets. Addition of morphine in vitro resulted in 40 percent
depression of phagocytosis at 10-8M. The effect of 10-6M morphine was blocked by
naltrexone (10-8 M) and CTAP (10-6 M). but not by nor-BNI or naltrindole. indicating the
action of the agonist was through a µ receptor. It was also found that DAMGO, U50 and
DPDPE added to spleen cells in vitro depressed phagocytic function, and the action of
these drugs was blocked by CTAP, nor-BNI. and naltrindole, respectively, in a dose-
dependent fashion. These results support the conclusion that activation of µ, o r opioid
receptors decreases macrophage function. Additional support for this conclusion comes
from studies on the macrophage cell line, P388Dl. U50 was found to inhibit LPS-triggered
secretion of IL-1 as assessed by bioassay and by Northern blotting, and the inhibition was
blocked by nor-BNI. In summary, immunosuppression can occur via µ, o r opioid
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receptors, as demonstrated when receptor-selective agonists and antagonists are
administered in vivo or in vitro. Macrophages appear to be a prime target of opioid
activity. (Temple University, Philadelphia, PA).
MARIJUANA AND ITS PSYCHOACTIVE COMPONENTS AS
IMMUNOMODULATORS
H. Friedman
Marijuana and/or its psychoactive component, i.e., tetrahydrocannabinol (THC), is known
to affect the immune response system. Detailed studies have shown that chronic exposure of
mice or rats to marijuana or its active components suppresses antibody formation, cellular
immunity and/or lymphocyte blastogenesis. The marked immunosuppression has been
attributed to direct THC effects. Studies in this laboratory have shown that antibody
formation in vitro by mouse lymphoid cells are suppressed when spleens are obtained from
animals injected with THC or metabolic products of this drug, such as 11-OH-THC. We
have also found that these components of marijuana affect metabolism of lymphoid cells
including protein kinase C activity, arachidonic acid metabolism, as well as calcium
metabolism. Recently, we have also shown that cytokines, important as molecular signals
by which cells communicate, are markedly affected by cannabinoids. For example,
interferon production is suppressed, as well as production of IL-2 and TG cells activated to
produce cytokines by a variety of stimulators. However, we have also found that THC,
rather than being suppressive, enhances the production of pro-inflammatory cytokines and
this appears related to increased susceptibility of cannabinoid-treated individuals to
opportunistic micro-organisms. It has been shown that THC results in heightened
susceptibility of mice to infection with a bacterium such as Listeria or to a virus-like herpes
virus. Recently, we found that mice treated with THC have altered susceptibility to
infection by Legionella pneumophila, an opportunistic intracellular bacterium which infects
primarily macrophages. THC induced marked alterations in susceptibility of macrophages
in vitro to these bacteria. Furthermore, mice infected with sublethal numbers of Legionella
did not develop immunity to a secondary challenge infection with larger numbers of the
bacteria. as occurs in non-treated animals. Furthermore, we found that mice infected with
sublethal numbers of Legionella develop an acute death syndrome, similar to toxic shock
death, when treated one day before and one day after infection with THC. Serum samples
from such THC-treated animals showed increased levels of the acute phase cytokines, TNF
and IL-6, which have been related to toxic shock death. Treatment of the mice with a single
injection of a monoclonal antibody to TNF or IL-6. or a mixture of both. one hr prior to the
second THC injection resulted in complete inhibition of the toxic shock-like’ death. A
marked fluctuation in blood granulocytes levels also occurred after THC injection,
supporting the likelihood that the acute phase cytokine production was related to THC
induced toxic shock-like death after sublethal infection with Legionella. Thus, results
obtained in this laboratory have shown a relationship between the detrimental effects of
THC on the immune response and heightened susceptibility to microbial infection and this
appears to be mediated by the effects of the drug on cytokine production.
(University of Southern Florida, Tampa, FL)
M O R P H I N E  A N D  C O C A I N E :  M O D U L A T O R S  O F  I M M U N E  S Y S T E M
COMMUNICATION
P. Peterson, T. Molitor and C. Chao
The mechanisms of opiate- and cocaine-induced immunomodulation involve both indiect
effects (via central nervous system [CNS]- neuroendocrine pathways) and direct actions on
cells of the immune system. While considerable understanding exists regarding the effects
of these drugs on communication signals within the CNS ( i.e., neurotransmitters), little is
known of the influence of opiates or cocaine on cytokines, the messenger molecules of the
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immune system ( i.e.,“immunotransmitters”). Studies in our laboratories suggest that
modulation of cytokine production may explain a number of the actions of morphine and
cocaine on immune cells. The concept of morphine and cocaine as modulators of cytokine
production arose from studies of the effects of these drugs both on human peripheral blood
mononuclear cells (PBMC) in culture and on the pathogenesis of swine herpes virus (SHV)-
1 infection in morphine-dependent pigs. Of relevance to the hypothesis that drugs of abuse
act as cofactors in AIDS, we found that morphine and cocaine amplified the replication of
HIV-I in PBMC cultures stimulated with cytomegalovirus. Increased production of two
cytokines, transforming growth factor-ß and tumor necrosis factor (TNF) , by morphine- or
cocaine exposed PBMC played in a central role in this in vitro phenomenon. On the other
hand, morphine was found to markedly suppress the production of another cytokine,
interleukin-1, by porcine alveolar macrophages in both an in vitro culture system and in
vivo. This morphine-induced effect could explain, in part, the increased pathogenesis of
SHV-1 pneumonia in morphine-dependent pigs. Interestingly, morphine-dependent pigs had
a decreased severity of SHV-1 induced CNS disease. The latter observation contributed to
our current interest in the immunomodulatory effects of morphine within the brain. Because
the brain is a key target organ for morphine and cocaine as well as for neurotropic viruses.
such as HIV-l and SHV-1, we have initiated studies of the immunomodulatory effect of
morphine or microglia and astrocytes. These glial cells am known to serve many immune
functions within the brain. Using primary murine microglial cell cultures, we determined
that morphine potentiates the production of TNF- by these macrophages. In an in vitro
model of HIV-l infection of the human brain, we have found that morphine amplifies the
expression of HIV-l via a mechanism involving increased glial cell production of TNF-
These findings suggest that in addition to altering neurotransmission within the CNS,
opioids may also function as modulators of immune cell communication within the brain
(Hennepin County Medical Center, Minneapolis, MN)
IMMUNOTOXICITY OF NITRITE INHALANTS
L. Soderberg
Amyl, butyl and isobutyl nitrite are representative of a group of nitrite inhalants commonly
called “poppers.” These inhalants have been very popular among male homosexuals and to
a lesser extent among adolescents. Inhalation of these compounds causes vasodilation,
producing a “high”, and also causes relaxation of smooth muscles, facilitating anal sex.
Epidemiological studies have reported that, independent of other risk factors, heavy abuse of
nitrite inhalants is a risk factor for HIV seropositivity and for Kaposi’s sarcoma among
AIDS patients. While it has been suggested that nitrite inhalant abuse is simply a marker of
risky behavior, nitrites could facilitate infectious disease or tumor growth by depressing
immune responses. Inhalation exposure of mice to isobutyl nitrite impairs both antibody
and cell-mediated immune responses. Antibody production is particularly important in
controlling extracellular bacterial infections. Exposure of C57B1/6 mice to 900 ppm
isobutyl nitrite for 45 min/day for 14 days resulted in reductions of T-dependent antibody
induction of up to 70 percent. Cell-mediated immunity is important for protection from viral
infections and from growth of tumor cells. Two distinct cell-mediated immune mechanisms
were impaired by exposure to the inhalant. Cytotoxic T cell and macrophage mediated
tumoricidal activities were reduced by 36 percent and 59 percent, respectively, following
immunotoxic exposure. Natural killer cell mediated cytotoxicity, on the other hand, was not
affected. While the immunotoxicity seemed to preferentially affect T cell-dependent
functions, the apparent targets of toxic activity were accessory cells, presumably
macrophages. T-independent antibody responses and B cell mitogenic responses were not
altered by the exposure, suggesting that B cells were not directly affected. In unseparated
spleen cell cultures, T cell responses to allogeneic and mitogenic stimulation were inhibited.
However, exposure to the inhalant did not affect T cell production of IL-2 or T cell
expression of CD25, the IL-2 receptor beta chain. Purified T cells from exposed mice
responded normally to mitogenic stimulation when untreated accessory cells were used,
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suggesting that T cell functions were affected directly. Moreover, the ability of accessory
cells from exposed mice to support the proliferation of control T cells was reduced by half.
(University of Arkansas, Little Rock, AR)
CD4 DIFFERENCES BETWEEN HIV-INFECTED IDUs AND NON-IDUs
L. S. Brown
The use of the CD4 cell count in AIDS has provided an opportunity to discuss the merits and
drawbacks of surrogate markers in general and the CD4 marker in particular. In research,
reliable markers allow the development of useful information about the natural history of a
disease and provide a means to assess the utility (safety and efficacy) of potential therapeutic
interventions to modify the natural history of a disease. In medical care, surrogate markers
provide an important clinical tool for diagnosis, assessing the efficacy for therapeutic
interventions and determining the appropriate timing for prophylactic and therapeutic
options. There are generally accepted criteria for surrogate markers. The surrogate should
be biologically plausible and its presence/absence should be different among persons with
and without the disease in question. The surrogate marker should correlate with important
clinical disease progression events or endpoints. Useful surrogate markers show greater
improvement in persons with treated disorders than untreated persons. In many natural
history studies, injecting drug users (IDUs) experience a different range of opportunistic
infections than other HIV infected populations, yet survival rates are similar. Many of these
studies reveal higher CD4 count levels among IDUs as compared to other HIV infected
populations. There are many reasons why the application of these markers in HIV disease
may differ among various subpopulations. Reasons include diurnal mechanisms that affect
CD4 distribution, age, viral load or replicating status of the virus, and concurrent
immunomodulating disorders or therapies. Other factors include different measurement
techniques or differences in the utilization of the measurement techniques. These findings
suggest the need for two types of investigations to determine if clinically important
differences in CD4 cell counts exist among subpopulations at risk for HIV infection: 1)
comparative studies of CD4 cell count distribution among various non-HIV infected
subpopulations; and 2) comparative studies of the CD4 levels when important clinical events
first occur among various HIV infected populations. In both types of studies, there is a need
to include IDUs, especially given the increasing impact of drug use among AIDS cases in
the United States. (Addiction Research and Treatment Corporation, Brooklyn, New York
and Department of Medicine, Harlem Hospital and the College of Physicians and Surgeons,
Columbia University, New York, New York)
DISCUSSANT
M. J. Kreek
As discussed by the symposum participants, opiates, marijuana, cocaine, nitrite inhalants,
and also alcohol may all significantly affect the immune system. Some of these agents may
act as immune modulators; others may frankly disrupt the immune system. Of particular
interest are the opiate effects on immune function, since such findings related to opiate
effects first suggested that the endogenous opioids, the enkephalins, dynorphins, and
endorphins, may play a role in the normal physiological modulation of immune function,
and in addition. may impact upon immune function in an atypical way in the setting of
pathological states. A great deal of research evidence has been forthcoming to document
such effects of the endogenous opioid system on specific indices of immune function. It is
provocative to suggest that other endogenous ligands which bind to the recently defined
marijuana receptors may also serve as immune modulators. In all studies of the effects of
drugs of abuse and also potential treatment agents on immune function, it is critical to
consider first what constitutes these effects, that is. which cellular or humoral components of
the immune system is affected, and, if more than one component is affected, what may be
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the impact on the integrated immune system. Secondly, the question of whether any
observed immune effects are direct effects, that is, the drug acting directly on cellular or
humeral components, or indirect effects, for instance, by the drug altering endocrine and
neuroendocrine function, must be addressed.
Finally, it has been well documented that there are profound species differences, both with
respect to the effects of drugs of abuse on immune function, and on other systems, which
may in turn alter immune function. Therefore, although many extraordinarily exciting
findings may be made in whole animal models, as well as various in vitro systems,
ultimately, the question of whether or not similar changes are observed in human drug
abusers must be addressed. In man, normalization of neuroendocrine function occurs during
steady dose, steady state methadone maintenance treatment of former heroin addicts. The
normalization of immune function in a long-term methadone maintained patient may in fact
be due to normalization of neuroendocrine function as seen in that setting. (The Rockefeller
University, New York, New York)
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HALLUCINOGENIC AGENTS: DRUGS OF ABUSE AS
NEUROCHEMICAL TOOLS
F. I. Carroll, R. A. Glennon, M. R Johnson, M. Teitler and D. M. Zimmerman
The purpose of this mini-symposium was to popularize the notion that drugs of abuse can
serve as valid research tools to investigate various neurochemical mechanisms and may
also act as templates for the design of novel therapeutically useful agents. Classical
hallucinogens, for example, are becoming widely used to investigate serotonin receptors
and to identify novel 5-HT2 antagonists. A series of N-substituted trans-3,4-dimethyl-4-
(3-hydroxyphenyl)piperidines have proven to be useful in the development of novel
opioid antagonists and in the characterization of antagonist pharmacophores for the
opioid receptors. Several classical and nonclassical cannabinoids were used to
characterize the cannabinoid receptor and are continuing to be used to further understand
mechanism of action of this class of compounds. Similarly, cocaine analogs are serving
as biochemical probes to study the mechanism of action of psychostimulants. Some of
the mom recent discoveries are summarized in the following sections.
CLASSICAL HALLUCINOGENS
Hallucinogenic agents are one of the oldest known classes of drugs, and the ready avail-
ability of these agents constitutes a significant and long-standing abuse problem. Lately,
there has been a resurgence of interest in the use of classical hallucinogens and
structurally-related designer drugs. Classical hallucinogens fall into two broad
categories:  (1) phenalkylamines such as the phenethylamine mescaline and the
phenylisopropylamines, DOM, DOB, and DOI; and (2) indolealkylamines such as the
N,N-dialkyltryptamine, DMT, the ergoline. (+)-LSD, and the ß-carboline harmaline.
Although serotonin (5-HT) had been implicated as playing a role in the mechanism of
action of these agents since its discovery in the late 1940s. it was not until 40 years later
that evidence was provided for the involvement of 5-HT2 receptors (Glennon et al.,
1993). However, with the subsequent discovery of 5-HT1C receptors (Pazos et al., 1984)
came the finding that classical hallucinogens possess affinity for both 5-HT2 (now
5-HT2A) and 5-HTlC (now 5-HT2C) receptors, and that hallucinogenic potency was
significantly correlated with receptor affinity in both cases (reviewed; Glennon 1993).
[3H](+)-LSD was one of the early nonselective radioligands used to label 5-HT receptors.
[3H]DOB and [125I]DOI are significantly more selective than [3H](+)LSD and display
high affinity for 5-HT1C/5-HT2 receptors. Unlike the standard 5-HTlC/5-HT2
antagonist radioligand [3H]ketanserin, the two radiolabeled phenylisopropylamine
hallucinogens appear to label the agonist high-affinity state of 5-HT2 receptors (Lyon et
al., 1987). With the recent cloning of more than a dozen different subpopulations of
5-HT receptors, phenylisopropylamine hallucinogens (which typically are more selective
than the indolealkylamine hallucinogens) are being employed to aid in the classification
of these receptors. These radioligands are also being used in autoradiographic mapping
of certain 5-HT receptors (e.g., Appel et al., 1990).
Phenylisopropylamine hallucinogens exert stimulus control of behavior and can serve as
effective training drugs in drug discrimination studies involving rats. Using DOM as a
training drug, there is a significant correlation (r > 0.9) between stimulus generalization
ED50 values and (1) human hallucinogenic potencies and (2) 5-HT2 receptor affinities for
a large number of classical hallucinogens. Hallucinogen-trained animals are also being
used to identify novel .5-HT1C/5-HT2 antagonists (which likely possess antidepressant,
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neuroleptic, anxiolytic, and cardiovascular activity) and to investigate the stimulus prop-
erties of novel designer drugs.
USE OF TRANS-3,4-DIMETHYL-4-ARYLPIPERDINES AS SELECTIVE
OPIOID ANTAGONISTS AND THERAPEUTIC AGENTS
N-Substituted-trans-3,4-dimethyl-4-(3-hydroxyphenyl)-piperidines represent a unique
series of pure opioid antagonists (Zimmerman et al., 1978). Prior to their discovery,
opioid antagonists were generally N-allyl or N-methylcyclopropyl analogs of morphine
and other multicyclic morphine-like agonists. The opioid antagonist activity in these 4-
arylpiperidines is most importantly a consequence of 3-alkyl substitution of the piperidine
ring. Earlier structure activity relationship studies had shown that affinities for opioid
receptors depended largely on the nitrogen substituent. Further SAR studies within this
series have now been pursued for the development of selective opioid antagonists as
pharmacological probes and therapeutic agents. Alterations of the N-substituent led to
the discovery of LY255582, an opioid antagonist with marked appetite suppressant
properties (Shaw et al., 1991). and recently to LY246736, a peripherally selective mu
receptor antagonist with good activity following oral administration. These SAR studies
also led to the discovery of many highly potent opioid receptor antagonists with only
limited receptor selectivity. Importantly, no N-substituted derivative possessed
detectable opioid agonist activity. Thus, this work confirms the pure opioid antagonist
nature of the trans-3,4-dimethyl-4-arylpiperidine nucleus, and also suggests that
additional SAR studies within this series could lead to the discovery of highly selective
opioid receptor antagonists.
CANNABINOIDS
Consroe and Sandyk have written that the second modem era of cannabinoid research
began in 1987 when Howlett and her colleagues at St. Louis University Medical School
and Pfizer announced the discovery of the; cannabinoid receptor in rat brain. The
foundation for the neurochemical tools they employed was laid in 1974 by Everette May
and his group at the NIH who made the discovery that 9ß-hydroxyhexahydrocannabinol
(HHC) was equipotent to morphine in the hot plate test. This was the first evidence that
analgesia was a structurally dissociable feature of the cannabinoid molecule.
Johnson and Milne at Pfizer made a remarkable structural observation (“The
Prostaglandin Overlap Hypothesis”) linking the key structural features of HCC to the
blockade of a prostaglandin E sensitive adenylate cyclase proposed in Collier’s
Hypothesis for the mechanism of action of morphine. Guided by this structural
hypothesis, Johnson, Melvin, and their coworkers at Pfizer synthesized hundreds of
“classical” tricyclics (e.g., levonantralol) and “non-classical” bicyclic structures (e.g., CP-
55,940 and CP-55,244) over the next eight years. This work culminated in the medicinal
chemical conceptualization of the cannabinoid receptor, “The findings of exceptional
potency in the microgram/kilogram range, retained spectra of activity despite extremes of
structural elaboration and simplification, regio-, stereo-, and enantiospecificity of action
and indirect effects on multiple biochemical systems mandate a novel site of action
involving a distinct neurotransmitter system.”
The neurochemical tools and ligands developed by the Pfizer group were used by Howlett
to elucidate a biochemical model of cannabinoid action by demonstrating that the
N18TG2 neuroblastoma cell in culture provided a suitable model system for the study of
cannabinoids at the cellular level. She showed that the inhibition of adenylate cyclase by
both the classical and non-classical cannabinoids was (1) cell-type specific; (2) rapid and
reversible; (3) mediated by Gi; (4) dose-dependent in nM range; (5) stereoselective; (6)
NOT due to adrenergic. muscarinic, or opioid receptors; and (7) correlated with
biological activity. Having established a biochemical correlate for the cannabinoid
receptor, Howlett used the new neurochemical tool [3H]-CP-55,940 and the same ligands
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to demonstrate CP-55,940 receptor binding that was of high affinity (Ki = 68 pM).
enantioselective, with rapid (<45 min) and reversible kinetics. Receptor binding
correlated with functional models of analgesia (r > 0.9) and inhibition of adenylate
cyclase (r > 0.9). Herkenham and coworkers extended the work of Howlett to a slice
assay and were able to provide a complete neuroanatomical picture of cannabinoid
receptor binding across species (rat/monkey/human). These neuroanatomical
distributions. in turn, allowed Linda Matsuda in Brownstein’s lab at the NIH to realize
they had cloned the receptor (rat). More recently, the human receptor has been cloned.
Currently, Kenner Rice and his group at NIDDK are preparing affinity ligands of CP-
55,244 and WIN-55,212 to be used in searching for receptor subtypes, isolating and
purifying drug receptors, studying physiological functions of drug receptors, producing
antibodies of drugs, and producing anti-idiotypic antibodies to purify receptors and
identify gene products.
These and other neurochemical tools will be necessary to further understand the role of
the cannabinoid receptor and various mechanisms of action in order to answer the
therapeutically relevant question, “Can we separate the traditional activities of
cannabinoids (i.e., specific agonists)?” To do this, we must find if there are
physiologically relevant receptor subtypes. The availability of binding assays and
affinity ligands from the three structurally distinct types of cannabinoid ligands (classic,
e.g., HU-210; non-classic, e.g., 55,940 and 55,244; alkylamino indole, e.g., WIN-55,212)
provides a good starting point for this search. The major neurochemical tool still lacking
is a functional cannabinoid antagonist which would provide mechanistic insight as well
as having potential therapeutic (e.g., Parkinsonism) properties. At least three chemically
distinct endogenous substances have been isolated (Mechoulam, Howlett, Childers). Full
structural and functional characterization of all three of these may provide insight into the
largely theoretical issue-Why does man have a receptor in his brain for psychoactive
plant extracts? as well as providing new chemical templates for the design of selective
cannabinoid therapeutants.
COCAINE: A STRUCTURE ACTIVITY RELATIONSHIP STUDY
Cocaine has several sites of action in the central nervous system; however, it is the site
associated with the dopamine transporter that has been implicated in the reinforcing
properties of cocaine (Kuhar et al., 1991; Ritz et al., 1987).
To obtain information relating the structural features of cocaine which lead to potent and
selective binding at the cocaine site on the dopamine transporter, we examined the effects
of variations of 2-carbomethoxy, 3-benzoyloxy, and N-methyl substituents as well as the
stereochemistry of the system of cocaine on binding affinity at the dopamine transporter.
First of all, the cocaine binding site at the dopamine transporter was found to be stereo-
selective (Carroll et al., 1991b).
Removal of the N-methyl group of cocaine to give norcocaine resulted in only a small
reduction in affinity. In contrast, the addition of a second N-methyl group to cocaine to
give cocaine methiodide as well as the acetylation of norcocaine to give N-nor-N-acetyl-
cocaine (RTI-54) yielded compounds with very low or no affinity for the transporter.
N-Nor-N-benzyl cocaine (RTI-36) was about 6-times less potent than cocaine (Abraham
et al., 1992).
The most potent compounds in binding and behavioral studies repotted before our studies
began were 3ß-phenyltropan-2ß-carboxylic acid methyl ester (WIN-35,065-2) and 3ß-(p-
fluorophenyl)tropan-2ßcarboxylic acid methyl ester (WIN-35,428). the so-called “WIN
compounds,” reported by Clarke and coworkers (Clarke et al., 1973) In order to further
develop the pharmacophore model for the cocaine binding site, we synthesized ten new
4’-substituted phenyl analogs of WIN 35,065-2. We found that the p-chloro (RTI-31).
p-bromo (RTI-51). p-iodo (RTI-55), and p-methyl (RTI-32) analogs were 13- to 20-times
more potent than WIN 35,065-2. The log (1/IC50) values for the WIN 35.065-2 analogs
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were correlated with the structural features using Comparative Molecular Field Analysis
(CoMFA) (Carroll et al., 1991a). The CoMFA model developed was used in predicting
new structures to be investigated. For example, the 3',4'-dichloro (RTI-111) and 3'-
methyl-4'-chloro analogs (RTI-112) were predicted to be potent analogs and were found
to be 29- and 28-times more potent than WIN 35,065-2 (Carroll et al., 1992).
We have shown that the presence of a 2ß-substituent contributed substantially to the
binding affinity of cocaine analogues at the dopamine transporter (Lewin et al., 1992).
Replacement of the 2ß-carbomethoxy group of cocaine by a hydrogen to give
ß-tropacocaine, or epimerization to give pseudococaine. results in a 50- to 200-fold loss
in potency. Replacement of the 2ß-carbomethoxy group with a 2ß-hydroxymethyl group
t o give (R)-3ß-(benzoyloxy)-2ß-hydroxymethyl-8-methyl-8-azabicyclo[3.2.l]octane
resulted in a 5.6-fold loss in potency which could be partially restored (2.7) by
acetylation to give 2ß-acetoxymethyl analog. Based on these results, we suggested a
pharmacophore model in which the 2ß substituent enhances affinity to the binding site by
an electrostatic interaction, probably serving as a hydrogen bond acceptor. In agreement
with this possibility, we had noted that replacement of the carbomethoxy methyl group in
3ß-(substituted phenyl)tropan-2ß-carboxylic acids methyl esters by an isopropyl and
phenyl group had only small effects on the affinity at the DA transporter, but caused large
increases in the affinity for the NE and 5-HT transporter suggesting a highly specific
interaction at the 2ß-position (Carroll et al., 1992). In addition, we showed that the 2B-
(1,2,4-oxadiazole) bioisosteres of the above compounds have binding potencies similar to
their parent esters and that 3B-(4’-chlorophenyl)-2B-[3'-(4"-methoxyphenyl)-1',2',4'-
oxadiazole-5-yl] tropane (RTI-141) which possesses an electron donating methoxy group
is more potent than analogues RTI-143 and RTI-144 which contain electron withdrawing
4”-chloro and 4”-bromo groups, respectively, also suggesting an electrostatic contribution
in the region of the 2ß-substituent (Carroll et al., 1993).
In an unpublished study of 3ß-(4’-chlorophenyl)tropan-2ß-carboxylic amides, we have
found that tert-amides such as the dimethyl amide RTI-129 were more potent at the DA
site than primary and secondary amides, RTI-118 and RTI-106. respectively. Similarly,
the cocaine N,N-dimethyl tert-amide RTI-160 is more potent than the N-methyl
secondary and prima cocaine amides, RTI-66 and RTI-128. respectively. 3ß-(4’-
Chlorophenyl)tropan-2ß-pyrrolidine carboxamide (RTI- 147) is both potent and selective
for the DA site and will be a useful biochemical probe for studying this site. We have
also shown that affinity for the DA site is increased by adding an oxygen atom to RTI-
129 and RTI-160 to give 3ß -(4'-chlorophenyl)tropan-2ß-(N-methyl-N-
methoxy)carboxamide (RTI-183) and (R)-3ß-(benzoyloxy)tropan-2ß(N-methyl-N-
methoxy)carboxamide (RTI- 192). respectively. suggesting again that electrostatic
interaction is important to the interaction of 2ß-substituents with the DA site. It is clear
from these studies (Carroll et al., 1992; Lewin et al., 1992) that 2ß-substituents pos-
sessing increased potential for electrostatic interaction can lead to increased affinity for
the DA site. However, unpublished results from our laboratory as well as results reported
by others (Kozikowski et al., 1992) suggest that this may not be a necessary requirement
for high affinity for the DA site. These apparent differences could be explained if
different ligands are binding at different sites or at the same site with different types of
interactions with the DA transporter protein. Alternately. the DA transporter protein
could be changing to adapt to different ligand types. Regardless of the reason, the high
affinity observed for cocaine analogues possessing grossly different 2ß substituents raises
the possibility that some of the pharmacological properties of the two types of analogues
may be different. Additional studies are underway to gain information that will help
explain the relationship between structural features at the 2ß-position, their interaction
with the DA transporter protein, and their in vivo properties.
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BEHAVIORAL, PHARMACOLOGIC AND NEUROBIOLOGIC
VARIABLES IMPORTANT TO THE ANALYSIS OF DRUG SELF-
ADMINISTRATION: IMPLICATIONS FOR THE DISCOVERY OF
POTENTIAL PHARMACOTHERAPIES
INTERRELATIONSHIPS BETWEEN DRUG SELF-ADMINISTRATION AND
DRUG DISCRIMINATION
N. A. Ator
Drug self-administration procedures are used to study the reinforcing functions of
psychoactive drugs ( i.e., whether a particular drug will maintain rates of responding greater
than the drug vehicle alone). Those drugs that are reliably self-administered by laboratory
animals typically have been those abused by humans and/or that have a profile of subjective
effects similar to abused drugs. In drug discrimination procedures, drugs are established as
discriminative stimuli ( i.e., a subject is trained to make one response if a particular drug
dose has been administered and to make a different response if it has not), and the range of
other drugs that will occasion the same response as the training drug can be studied.
Because investigations have tended to presume that the effect that makes it possible to train
a drug discrimination with a psychoactive drug is equivalent to the subjective effect of that
drug, there has been the tacit or explicit assumption that information about the
discriminative stimulus effect of a drug will yield information about its reinforcing efficacy
and, by extension, abuse liability. For certain classes of drugs, sufficient data exist to
compare the ability of a wide range of related compounds to maintain self-administration
with their ability to substitute for a highly abused training drug in a drug discrimination
procedure. For example, barbiturates are drugs with established abuse liability that also
maintain self-administration in non-human primates. A wide range of CNS depressants that
readily substitute for pentobarbital in drug discrimination studies with monkeys do also
maintain self-administration. However, exceptions to this relationship emphasize that this is
merely correlational and that similarities in discriminative stimulus effects of two drugs
under one procedure may not be a function of the same variables that determine reinforcing
efficacy.
Recently studies in baboons have investigated directly relationships between the
discriminative and reinforcing effects of drugs. In one study, there was a disjunction
between generalization to a particular dose of a training drug (midazolam) and self-
administration of that dose by the same baboon in experimental sessions immediately
following the drug discrimination. Furthermore, a drug (pentobarbital) that did not occasion
midazolam-appropriate responding in drug discrimination, did maintain self-administration
at a level comparable to that maintained by midazolam. These results point out the
limitations of extrapolating drug reinforcement information from drug discrimination results
and emphasize the role of the training drug in determining whether or not closely related
drugs will substitute.
Another important area of investigation is whether a history of self-administering a drug
may increase the probability of detecting subtle effects of that (or related) drugs.
Conversely, it is possible that having been explicitly trained to discriminate a drug may
increase the probability of self-administering that (or related) drugs. A history of drug
discrimination training with midazolam apparently increased the probability of midazolam
self-administration in baboons. Furthermore, recent data showed that sensitivity to the
discriminative-stimulus effects of midazolam could be modulated differentially by
behavioral experience with self-administered and response-independent midazolam.
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CONTEXTUAL DETERMINANTS OF DRUG SELF-ADMINISTRATION IN
MONKEYS.
Jack Bergman
Self-administration procedures in laboratory animals have been useful in the preclinical
assessment of abuse liability and in evaluating therapeutic strategies for drug dependence.
Although it is widely recognized that both pharmacological and contextual factors contribute
to the effects of drugs in self-administration procedures, drug abuse research in laboratory
animals has been directed primarily at evaluating pharmacological modification of drug-
maintained behavior. From a practical viewpoint, however, pharmacological interventions
are likely to serve only as adjuncts in long-term programs to treat drug dependence.
The present remarks are intended to review some of the available information describing
contextual determinants of drug self-administration in monkeys. The role of schedule of
availability in studies of drug self-administration in monkeys and non-pharmacological
reduction of drug-maintained behavior will be discussed. With regard to schedules of
availability, data illustrate that different patterns and rates of self-administration can be
maintained under different schedule conditions and that the slope and position of dose-effect
functions may be qualitatively different when self-administered drugs are studied under
different schedules.
With regard to the reduction of drug self-administration, several studies have evaluated the
effects of suppressing drug-maintained behavior in monkeys by noxious stimuli such as
response-contingent electric shock. These studies indicate that such procedures are most
effective only under restricted conditions, raising questions of practical application. Studies
in monkeys employing programmed options that may be incompatible with drug self-
administration also have proven successful in reducing drug intake. Such strategies may
have wider therapeutic application and deserve further investigation.
COCAINE AND HEROIN SELF-ADMINISTRATION: BEHAVIORAL AND
PHARMACOLOGIC VARIABLES AND THEIR IMPLICATIONS FOR THE
DISCOVERY OF POTENTIAL PHARMACOTHERAPIES
S. I. Dworkin
A discussion of the importance of considering behavioral and pharmacologic variables in
interpreting data obtained from self-administration studies will be presented. Some of the
factors that will be addressed include the drug (differences between cocaine and heroin),
dose, drug access and behavioral specificity of observed effects. Additionally, data obtained
from studies evaluating the effects of a novel tropane analogue 2ß-propanol-3ß-(4-toluyl)-
tropane (PTT) will be used to illustrate the importance of these variables. PTT, which is 20
times mom potent than cocaine in displacing     [ 125 ]  RTI-55 binding, was evaluated for its
effects of cocaine self-administration. Doses of the compound (10-90 µg/inf) maintained
responding when substituted acutely for cocaine (0.33 mg/inf in rats responding under a
fixed-ration 10 schedule of reinforcement. Moreover, a moderate dose of PTT (30 µg/inf
was also able to engender and maintain self-administration in naive rats. The IP
administration of PTT (1 or 3 mg/kg) resulted in a significant attentuation of cocaine self-
administration. However, only the larger dose suppressed responding maintained by either
heroin or food. The results from these-studies sug
gest that several different behavioral procedures should be used in the assessment of
potential pharmacotherapies.
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BEHAVIORAL, PHARMACOLOGIC AND NEUROBIOLOGIC MEASURES OF
COCAINE REINFORCEMENT AND ‘CRAVING’ USING A MULTIPLE
SCHEDULE IN THE RAT
G. F. Koob
Operant measures of drug reinforcement have long been used to measure the reinforcing
properties of drugs of abuse. In primates, multiple schedules have been useful in
characterizing not only the acute reinforcing actions of drugs but also in measuring of the
reinforcing properties of stimuli associated with drug reinforcement. In the present series of
studies a multiple schedule has been employed in the rat that is sensitive to pharmacologic,
neurobiologic and behavioral manipulations. Male Wistar rats were trained to lever press
for food and subsequently implanted with intravenous jugular catheters and trained in daily
2-hour sessions on a fixed-ratio multiple schedule alternating every 30 min for food and
intravenous cocaine, in that order. Pairing of a light or tone with food or cocaine produced
reliable lever pressing for this discriminative stimulus in daily 5 min pre-sessions prior to
the start of the multiple schedule and priming with either cocaine or food selectively
increased responding for the appropriate discriminative stimulus. Responding could be
reinstated after extinction by presentation of the cocaine paired cue. Systemic
administration of dopamine D-1 antagonists at low doses selectively decreased cocaine self-
administration, and neurotoxin selective lesions of nucleus accumbens dopamine terminals
also reduced responding for cocaine but failed to alter food responding. These results
suggest that a food/drug multiple schedule in the rat may prove to be a valuable method for
evaluatiing the neurobiological bases of the reinforcing actions of cocaine and the ability of
cocaine to impart reinforcing properties to previously neutral stimuli (“craving”).
EFFECTS OF POTENTIAL PHARMACOTHERAPIES ON BEHAVIOR
MAINTAINED BY COCAINE OR BY ALFENTANIL
Gail Winger
Rhesus monkeys are given the opportunity to self-administer cocaine, or the opioid
alfentanil: the drugs are delivered intravenously as a consequence of responses on an
available lever in The animal’s home cage. The schedule of drug delivery is FR 30 to 45”.
There are two daily sessions and each 130 min session consists of four components. Each
component is as much as 25 min in duration and is followed by a 10 min time out period.
The dose of drug (either cocaine or alfentanil) available during each component is different,
and is controlled by the duration of the remotely-operated infusion pump: Thus, a dose-
response function is obtained in each session, and pretreatment-induced changes in ED50
can be observed during the course of a single session.
Two strategies are used in searching for drugs that have potential use in the treatment of
drug abuse: One is to identify an antagonist of the self-administered drug; the other is to
find an agonist that suppresses self-administration of the drug. A sufficiently large dose of
any drug will suppress drug-taking behavior, so an additional criterion for the second
strategy is that the agonist suppress self-administration of one drug, either cocaine or
alfentanil, in smaller doses than those required to suppress self-administration of the other
drug. Thus, we are searching for an agonist-induced, drug-selective suppression of drug
self-administration.
In the opioid system, drugs have been identified for both strategies. Thus, the opioid system
can give us examples of what we are looking for in the more recalcitrant cocaine system.
Quadazocine, the mu-selective opioid antagonist, when administered prior to a session in
which various doses of alfentanil are available, produces a dose-dependent increase in the
dose of alfentanil necessary to maintain high rates of responding. We am aware that opioid
agonists have not been well-accepted in the treatment of opioid abuse, but theoretically, they
should be quite successful, if motivation is high and compliance with medication-taking can
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be assured. There are long-acting, opioid irreversible antagonists available. One of these,
clocinnamox, is also able to increase the ED50 for alfentanil.
The agonist strategy, where compliance with medication administration is more likely to
occur, has been demonstrated most clearly in the opioid class with buprenorphine. In our
paradigm, very small doses of buprenorphine suppress alfentanil self-administration. Much
larger doses are required to modify cocaine self-administration; doses that suppress cocaine
self-administration; do not modify food-maintained behavior in a separate paradigm. This
suggests that buprenorphine might be effective in treatment of opioid abuse with little
problem of side effects. The more widely used methadone is also able to modify alfentanil-
maintained responding. at doses that do not modify cocaine-maintained responding. A drug
that is thought to have some buprenorphine-like properties, in that it has agonist and
antagonist effects, and the antagonist effects are long-lasting, is NIH 10420, It, like
buprenorphine, acts as a reinforcer. But when given-prior to sessions of alfentanil
availability, it acts like an antagonist, rather than like an agonist. This is a remarkably
curious outcome.
When we concentrate on trying to modify cocaine-reinforced behavior in a selective fashion,
there is considerably more difficulty. The drugs that seem most reasonable to evaluate as
antagonists are drugs that act on the D1 and/or the D2 receptor systems. There is some
tendency for these drugs to produce increases in cocaine’s ED50 ( i.e.,
look like antagonists), but this appears to be due to some extent to the ability of cocaine to
antagonize the rate-decreasing effects of these drugs. This is evident by the fact that smaller
doses than those necessary to modify cocaine self-administration are necessary to modify
alfentanil self-administration. Furthermore, doses of these drugs that produce-a suppression
of drug self-administration also produce marked changes in the general behavior of the
subjects. It is unlikely that these drugs will be satisfactory in a treatment regimen.
Other drugs with potential cocaine antagonist effects are the atypical neuroleptics,
amperozide and clozapine. These. drugs have some interaction with the dopamine system,
but have a great deal more interaction with the serotonin system. Specifically, they are
thought to have a large component of 5-HT2 antagonist action The interaction of these
drugs with cocaine is quite different from that of the classic D1 and D2 antagonists.
Clozapine produced similar effects at similar doses in animals self-administering cocaine
and animals self-administering alfentanil. In each of the three alfentanil subjects, the
smallest dose of clozapine produced increases in the maximum rate of alfentanil self-
administration. Amperozide produced a somewhat different profile of action. It is the only
drug we have evaluated that suppress cocaine-maintained responding at smaller doses than
those necessary to suppress alfentanil-maintained responding. The dose differential was not
great, but sufficiently unusual to rate notice.
We have done a little work with potential agonist interactions with cocaine self-
administration. In this work, we did not use alfentanil as a control, but compared the ability
of cocaine and GBR 12909 to modify cocaine self-administration. GBR 12909 was found to
have reinforcing effects that appeared to be somewhat less than those of cocaine in that
lower rates of responding were maintained by GBR 12909. The two drugs were virtually
identical in their remarkable small and short-lived ability to suppress cocaine self-
administration. In our hands, GBR 12909 did not appear to have use in treatment of cocaine
abuse.
AFFILIATIONS:
Johns Hopkins University, Baltimore, MD
Harvard Medical School, New England Primate Research Center, Southborough, MA
Wake Forest University, Bowman Gray School of Medicine. Winston Salem. NC.
Scripps Clinic and Research Foundation, La Jolla, CA
University of Michigan, Ann Arbor, MI
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DEPENDENCE STUDIES OF NEW COMPOUNDS IN THE
RHESUS MONKEY, RAT AND MOUSE (1993)
M.D. Aceto, E.R. Bowman, L.S. Harris and E.L. May
All compounds, except nor binaltorphimine.HCl (nor BNI), dynorphin (1-13).
dynorphin (2-17), naltrexone.HCl, (-)-nicotine, tartrate Pro-Leu-Gly-Amide (MIF), (-)-
quadazocine·HCl, and morphine·SO4 were supplied by Dr. Arthur Jacobson, Laboratory
of Medicinal Chemistry, NIDDK, NIH. The identities of all the compounds, except
those indicated above, were. unknown to us when they were originally submitted. These
studies were conducted under the auspices of the Drug Evaluation Committee of the
College on Problems of Drug Dependence.
Dependence-Liability Studies in Rhesus Monkeys
Substitution-for-Morphine (SDS) Test. Male and female rhesus monkeys (M. mulatta)
weighing 2.5-7.5 kg were used, and they received 3 mg/kg, s.c., of morphine SO4 every
6 h. All the animals had received morphine for at least 3 months and were maximally
dependent on morphine (Seevers and Deneau 1963). A minimal 2-week recuperation
period was allowed between tests. At least 3 monkeys/dose were used. The assay
(Aceto and co-workers, 1977 and 1978) was initiated by a subcutaneous injection of the
test drug or control substances (morphine and vehicle) into animals in a group that had
not received morphine for 14-15 h and showed definite signs of withdrawal. Each
animal was randomly chosen to receive one of the following treatments: a) a dose of the
compound under investigation; b) morphine control, 3.0 mg/kg; and c) vehicle control, 1
ml/kg. The animals were scored for suppression of withdrawal signs during a 2.5-h
observation period. The observer was “blind” regarding the choice of treatments. At the
end of the study, the data were grouped according to dose and drug. The mean
cumulative score + SEM was calculated and the data illustrated in figure form.
Precipitated-Withdrawal (PPT-W) Test. This evaluation was done under the same
conditions as described above, except that the animals were administered a test compound
2-3 h after the last dose of morphine. These animals were not in withdrawal.
Naloxone ·HCl (0.05 mg/kg, s.c.) served as the positive control.
Primary-Physical-Dependence (PPD) Study. Drug-naive monkeys were medicated with
drug, using escalating dose regimens, periodically challenged with naloxone or placed in
abrupt withdrawal. They were observed for overt behavioral signs during drug
administration and when they were challenged with antagonist or abruptly withdrawn
from the drug.
Rat-Infusion Studies
The continuous-infusion method was reported by Teiger (1974) and certain modifications
are indicated as follows. Rats were anesthetized after which each was fitted with a
specially prepared cannula which was passed subcutaneously from the nape of the neck
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to the lateral side of the lower abdomen and then inserted into the peritoneal cavity. The
cannula was anchored at both ends with silk sutures and attached to a flow-through
swivel mechanism which allowed the animal to move about in the cage and eat and drink
normally. The swivel was connected to a syringe which was attached to a syringe pump.
The animals received 7-10 ml of solution every 24 h. Occasionally, when deemed
necessary, as with cocaine, infusions were given via the right jugular vein.
Substitution-for-Morphine (SM) Test. The rats received morphine·SO4 (50 mg/kg/24 h
on the first day, 100 mg/kg/24 h on the second day, and 200 mg/kg/24 h from days 3-6).
Then, a test drug was substituted for 2 days. The morphine controls received an infusion
of water. The animals were observed for changes in body weight and for behavioral-
withdrawal signs for 0.5 h at 6, 24, 48, 72 and/or 96 h after stopping the infusion of
morphine.
Primary-Physical-Dependence (PPD) Study. The rats received test compound, as
specified above, for 6 days and then, were placed in abrupt withdrawal and observed for
overt behavioral signs.
Mouse-Antinociception Tests
Male mice, weighing 20-30 g, were used. All drugs were dissolved in distilled water or
in the vehicle indicated and injected subcutaneously (s.c.). At least three doses were
tested, and 6-10 animals per dose were used. When applicable, ED50’s were. calculated
by using computerized probit analysis.
Tail-Flick (TF) and (TF vs M) Assays. The procedure and modifications were described
(D‘Amour and Smith, 1941 and Dewey et al., 1970 and 1971) in the literature. Briefly,
the mouse’s tail was placed in a groove which contained a slit under which was located a
photoelectric cell. When the heat source of noxious stimulus was turned on, the heat
focused on the tail, and the animal responded by flicking its tail out of the groove. Thus,
light passed through the slit and activated the photocell which, in turn, stopped the
recording timer. The heat source was adjusted to produce tail flick of 2-4 s under control
conditions. Mice were injected with drug or vehicle and tested 20 m later. In the assay
for antagonism of the antinociceptive effect, the potential antagonists were administered
10 m before the agonist, and evaluation occured 20 m later.
Phenylquinone Abdominal-Stretching (PPQ) Assay. The procedure was reported
previously (Pearl and Harris, 1966). The mice were injected with test drugs and 10 m
later received 2.0 mg/kg  ip of a freshly prepared paraphenylquinone (PPQ) solution. The
mice were then placed in cages in groups of two each. Ten minutes after the PPQ
injection, the total number of stretches per group were counted over a l-m period. A
stretch was characterized by an elongation of the mouse’s body, development of tension
in the abdominal muscles, and extension of the forelimbs. The antinociceptive response.
was expressed as the percent inhibition of the PPQ-induced stretching response.
Hot-Plate (HP) Assay. The method was also reported previously (Eddy and Leimbach,
1953 and Atwell and Jacobson, 1978). The hot plate was held at 55°C. Mice were
placed on the hot plate and activity was scored if the animal jumped or licked its paws
after a delay of 5 s or more, but no more than 30 s beyond the control time. Table 2
contains a summary of all the new data generated this year on compounds that had not
previously been tested.
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Calculation of Apparent pA2 Using the tail-flick assay, the apparent pA2 and 95%
confidence limits were calculated using Schild and constrained plots as described in
Tallarida and Murray (Manual of Pharmacologic Calculations with Computer Programs,
2nd ed., Springer Verlag, N.Y., 1987).
Table 1
Comparitive DAtea(ED50, mg/kg s.c.) [95% C.L.] of selected standards in 4 Mouse
Agonist-Antagonists Tests
Drug Tail Flick Tail Flick Phenylquinone Hot-Plate
Antagonist
Pentazocine 15%at 10.0 1 8 1.7 - - - -
(12-26) (1.0-2.5)
Cyclazocine 17% at 1.0a 0.03 0.01 - - - -
(0.020-0.78) (0.005-0.03)
Nalorphine·HCI None at 10.0 2.6 0.6 - - - -
(0.7-10.0) (0.03-1.44)
Naloxone·HCI None at10.0 0.04 No Activity - - - -
(0.01-0.09)
Naltrexone·HCI None at 10.0 0.007 No Activity - - - -
(.002-0.02)
Morphine·SO b 0 . 7 b 0 .4 b 3 .1 b
(0.4-1.5) Inactive (0.2-0.8) (1.5-6.4)
Codeine·PO4 - - - Inactive - - - 6.4
(0.39-16.8) (0.39-16.8)
Meperidine·HCI - - - Inactive - - - 4.6
(1.8-11.7)
aMice were ataxic at 3.0 and 10.0 mg/kg but there was no further increase in reaction 
time
bICR-Harlan-Sprague-Dawley Inc.
Briefly, mice were pretreated with vehicle or various doses of antagonist followed 10 min
later by an injection of agonist. The mice were tested 30 min after receiving the
antagonist. Dose-response lines for antinociception were plotted using at least 4 doses of
each opioid agonist in the presence of vehicle or one of the selected doses of antagonist.
ED50s were estimated according to the method of Litchfield and Wilcoxon (J.
Pharmacol. Exp. Ther., 96, 399, 1949). Each dose ratio (x) was calculated by dividing
the ED50 of the opioid in the presence of a given dose of antagonist by that of the agonist
alone. Log (x-1 ) was plotted against the negative logarithm of the molar dose of the
antagonist. At least 3 logs (x-1) were plotted. The pA2 values for the antagonist were
calculated from the point of intersection of the regression line with the abscissa.
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Table 2
Summary of New Hot-Plate Data on Previously Untested Compounds
NIH Compound NAME ED50 or % Activity (mg/kg)*
- - - 0.5 (0.2 - 1.5)
- - - 38% at 10 and 30
- - - Inactive
- - - Inactive
- - - Inactive
- - - Inactive
- - - Inactive
Inactive
Inactive
Inactive
Inactive
- - - Inactive
- - - Inactive
Inactive
Inactive
- - - 13% at 1.0; 30% at
Inactive
3.4 (1.7 - 6.8)
- - - 13% at 30.0
- - - 3.7 (1.6 - 9.1)
Inactive
Inactive
- - - 0.3 (0.1 - 0.8)
- - - 1.3 (0.6 - 3.2)
- - - 1.2 (0.6 - 2.5)
Inactive
- - - 0.3 (0.1 - 0.7)
- - - Inactive
- - - Inactive
Inactive
Caffeine
Boldine
Flumazenil
(+)-Etorphine
10602
10604
10605
10606
10607
10612
10613
10614
10616
10617
10618
10619
10620
10621
10623
10626
10627
10629
10630
10631
10633
10634
10635
10636
10642
10644
10647
10648
10649
(+)-Thevionone
(+)-Propylthevinol     oxalate
(+)-N-n-Hexyl-normetazocine
(-)-N-n-Hexyl-normetazocine
(-)-Thevinone
(+Decarbannoylphysovenine
(-)-Bromoeseroline
(-)-N-Benzylnometazocine
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Table 2 Summary of Hot-Plate Data (continued)
NIH Compound NAME ED50 or % Activity (mg/kg)*
10650 - - -
10651 - - -
10652 NorLAAM
10653 (-)- -N-Acetyl-N-N-dinormethadol
10654 (-)- -N-Acetyl-N-N-normethadol
10655 (-)- -N-Acetyl-N-N-dinormethadol
10656 Naloxone benzoylhydrazone (BOZO)
10657 - - -
10658 - - -
10659 - - -
10660 - - -
10661 - - -
10662 - - -
10663 Nalmefene-3ß-D-glucuronide
10665 Etonitazene
Inactive
13% at 30.0
0.4 (0.2 - 1.0)
Inactive
Inactive
Inactive
Inactive
Inactive
6.9 (2.5 - 19.6)
Inactive
Inactive
Inactive
0 .8  (0 .3  -  2 . 3 )
Inactive
0.003 (0.001 -
0.009)
25% at 10.0
1.5 (0.8 - 2.9)
- - - 13% at 30.0
- - - Tested
1.1 (0.4 - 3.4)
- - - 11.5 (4.4 - 30.2)
2.4 (1.1 - 5.1)
- - - 13% at 30.0
- - - 11.5 (4.4 - 30.2)
LAAM 6.7 (3.5 - 12.8)
- - - Inactive
- - - 25% at 30.0
25% at 30.0
- - - 0.3 (0.1 - 0.9)
- - - 13% at 30.0
10666 -(±)-N-Normetazocine
10667(7410) -(±)-Metazocine
10670
10672
10673 -(±)-N-Heptyl-N-Normetazocine
10674
10675 -(-)-N-Heptyl-N-Normetazocine
10677
10678
10679
10680
10681
10682 Benzoylecgonine
10683
10684
*Inactive = Inactive at 1, 10 and 30 mg/kg
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SUMMARY OF NEW DATA
Compound
NIH Common Name
Chemical Name MOUSE
or Generic Class TF  TF  vs  M PPQ HP
RAT
SM/PPD
MONKEY
S D S PPt-W PPD
9733
9752
9930
10303 Special
d
10588
10661
10662
10665
10678
10688
10697
10698
10707
10711
10714
10715
10716
10718
10720
10735
10740
10741
10742
10743
10744
10745
10748
10750
10751
10752
(-)-Nicotine-di-/-tartrate
(-)-Quadazocine
Naltrexone
Dynorphin (1-13)
nor-Binaltorphamine
Morphine-6-glucuronide
Codeine-6-glucuronide
Etonitazene
Pyridyl-3-pyrrolidine
6,7-Benzomorphan
14-Hydroxydihydromorphone
Peptide
Bis-naltrexone
Morphine-6-glucuronide
Codeine-6-glucuronide
Benzimidazole
4-Phenylbutenylamine
Piperidine-4-methanol
(-)-6,7-Benzomorphan
(+)-6,7-Benzomorphan
3-Aminopiperidine
3,7-Diazobicyclononanone
3,7-Diazobicyclononanone
3,7-Diazobicyclononanone
3,7-Diazobicyclononanone
1-Phenethylpiperidine-4-amide
1-Phenethylpiperidine-4-amide
(+)-3-Hydroxymorphinan
1-Phenethylpiperidine-4-amide
1-Phenethylpiperidine-4-amide
l-Phenethylpiperidine-4-amide
1-Phenethylpiperidine-4-amide
1-Phenethylpiperidine-4-amide
1-Phenethylpiperidine-4-amide
(+)-3-Hydroxymorphinan
(+)-6,7-Benzomorphan
(+)-6.7-Benzomorphan
(+)-6,7-Benzomorphan
+ a , b
+ b , c
+ b
+c
+
+
+ b , e
+
+
+
+ e , g
+h
+
+ h
+h
+
+h
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+b,e
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+f
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+
+
+
+
Compound
NIH
Chemical Name MOUSE RAT MONKEY
Compount Name or Generic Class TF TF vs M PPO HP SM/PPD SDS PPt-W PPD 
10753 + + + + +
10754 + + + + +
10755 + + + + +
10756 + h + + + +
10757
+h + + + +
10759 + + + + +
10760 + + + + +
10761 +
h + + + +
10762 +
h + + + +
10763 +
h
+ + + +
10765 + + + + +
10766 + + + + +
10768 + + + + +
10769 + + + + +
10770 + + + +
10771 + + + +
10772 + + + + +
10778 + + + +
10779 + + ++ +
10780 + + + +
1078 1 + + + +
10783 +
h + + +
10799 +
10800
Morphine Sulfate
Ethylnarceine
Narceine
Dynorphin (2- 17)
MIF
Morphine
1-Phenylpiperidine-4-amide
1-Phenylpiperidine-4-amide
N-1-Hydroxyindanyl-piperidine
N-Tetrahydronaphthylpiperidine-
4-amide
Phenylethylamine
Phenylethylamine
1-Phenethylpiperidine-4-amide
1-Thienylethylpiperidine-4-amide
1-Thienylethylpiperidine-4-amide
1-Benzylpiperidine-4-amide
Piperidine
(-)-6,7-Benzomorphan
(+)-6,7-Benzomorphan
(-)-3-Hydroxymorphinan
(-)-3-Hydroxymorphinan
(+)-6,7-Benzomorphan
5-Phenylmorphan
5-Phenylmorphan
(-)-3-Hydroxymorphinan
(-)-3-Hydroxymorphinan
1-Phenethylpiperidine-4-amide
Peptide
Peptide + i +i
pA2 determination vs NIH 10672 and morphine. 
dSpecial - Behavioral effects in morphine-tolerant and morphine-non-tolerant rhesus monkeys
(see table 1 of text) especial - Naloxone AD50 vs ED80 in TF and PPQ. fPreliminary - SDS in one monkey. Special - Naloxone AD50 vs ED80
of morphine in TF. hSpecial - Nlaoxone AD50 vs ED80 in T. iSpecial - MIF effects on tolerance to and dependence on morphine.
SUMMARY OF NEW DATA (cont)
aSpecial - Nicotine antagonism of morphine-induced   antinociception. bSpecial - pA2 naloxone antagonism of nicotine antinociception. cspecial -
NIH 9733 (-), (S)-Nicotine di-1-tartrate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 5.2 (2.7 - 10.0)a,b
2) TF vs. M - 0.6 (0.03 - 15.0)a,b
3) PPQ - 1.3 (0.5 - 3.2)a,b
4) HP - 2.2 (1.6 - 3.0)a,b
a  Reported previously (NIDA Monog.
34, 1981)
 bdoses expressed as salt
MONKEY DATA  reported previously, op cit.
A .
B .
(SDS)
In the dose range of 0.03 - 0.75 (mg/kg, salt), nicotine did not substitute for
morphine.
(PPt-W)
In the dose range of 0.06 - 0.96 (mg/kg, salt) some withdrawal signs noted, but data
were confounded by unusual vehicle controls.
SPECIAL STUDY
The results of recent studies in humans suggested that nicotine not only reinforced
smoking behavior because it released beta endorphin, but also negatively reinforced
smoking behavior in response to nicotine withdrawal associated with low plasma
concentrations. In our laboratory, we established over a decade ago that nicotine had
opioid properties (op cit). Accordingly, we decided to characterize these properties
further.
The results of the Nicotine-Morphine (NIC-MOR) antagonism studies are illustrated in
the fig. Complex dose interactions involving both Nic and Mor were evident. Versus
either the Mor MPE 50 or 80 similar biphasic responses were evident. The effect was
much more robust when lower doses of Nic or Mor were involved. Nevertheless, Nic
blocked the Mor MPE 50 in the remarkably low-dose range of 0.003 to 0.03 mg/kg. The
descending portion of the biphasic curve probably reflects the emergence of Nic
antinociception. These data did not suggest a competitive interaction rather, they indicated
physiological antagonism.
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NIH  9733  (-),(S)-Nicotine  di-1-tartrate (cont.)
NICOTINE VERSUS MORPHINE
The results of studies involving Naloxone-Nicotine (Nal-Nic) are shown in the fig. The
data involving Nic alone and in combination with increasing doses of Nal are graphically
displayed in the inset along with the Schild plot and slope function. The value of the
slope function (-0.46) confirms that this interaction is not competitive. The apparent pA2
was 5.3.
NALOXONE / NICOTINE APPARENT   pA2  (Schild)
1 1 1
NIH 9733 (-),(S)-Nicotine di-1-tartrate (cont.)
Summary
Nicotine produced antinociception in mice which was antagonized noncompetitively by
naloxone. In addition, at significantly lower doses (2-3 orders of magnitude), nicotine
antagonized morphine-induced antinociception. We tentatively propose that these
opiatergic and anti-opiatergic properties may play a role in promoting and maintaining
smoking behavior in man.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
NIH 9752 (-)-Quadazocine, Win 44441-3
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF Inactive at 1.0, 10.0 and 30.0
2) TF vs M - 0.06 (0.01 - 0.39)
Time Course - 78% at 1 hr; 71% at 3
hr, 31% at 10% and 0% at 30 hr
3) PPQ - 44% at 0.001; 27% at 0.01;
33% at 0.1; 65% at 1.0 and 47% at
30.0
4) HP- No dose response
5) N - Inactive to 100.0
Reported previously. NIDA Res. Mong.
34, 1981.
MONKEY DATA - Reported previously - op cit.
A . (SDS) Did not substitute for morphine, exacerbated withdrawal, and long duration
of action.
B. (PPt-Withdrawal) Precipitated withdrawal and very long duration of action.
Apparent pA2 Determination: NIH 9752/morphine and NIH 9752/NIH 10672 in TF test.
Despite reports from this and other laboratories indicating that (-)-quadazocine was a
potent mu antagonist of long duration (Aceto, et al, NIDA Res. Monog. 34, 1981, some
investigators still describe this compound as a selective kappa antagonist. To resolve this
issue, apparent pA2s  were calculated vs. morphine, a mu agonist and NIH 10672 or [5R-
)]-N-[7-(1-pyrrolidinyl)]-1-oxaspiro[4,5][dec-8-yl]-4-benzofuranacetamide·-
HCl a purported potent and selective kappa agonist. For additional biological data on
NIH 10672 consult (Aceto, et al., NIDA Res. Monog. 119, 1992).
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NIH 9752 (-)-Quadazocine, Win 44441-3 (cont.)
WIN 44441-3 (NIH 9752) VERSUS MORPHINE IN TAIL-FLICK
Apparent PA2-Schild (30 MIN)
As shown in the appropriate fig., an apparent pA2 of 6.8 (6.71 - 6.97) and a slope of -0.9
were calculated for (-)-quadazocine versus morphine. Approximately the same values
were calculated for naloxone vs morphine. The results indicate that (-)-quadazocine acts
competitively on mu receptors. In sharp contrast, the apparent pA2 of 6.16 (6.13 - 6.19)
and slope of -1.7 for (-)-quadazocine vs NIH 10672 suggests that (-)-quadazocine has
less affinity for kappa receptors than for mu and that the interaction is not competitive.
1 1 3
NlH 9752 (-)-Quadazocine, Win 44441-3 (cont.)
WIN 44441-3 (NIH 9752) VERSUS NIH 10672 IN TAIL-FLICK
Apparent pA2-Schild
Summary
(-)-Quadazocine  is a competitive antagonist on mu receptors. It’s action on kappa
receptors is noncompetitive.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
NIH 9930 Naltrexone·HCl
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0 and 30.0
2 ) TF vs M - 0.001 (0.0004 - 0.004)
3 ) PPQ - Inactive at 1.0, 10.0 and 30.0
4 ) HP - 10% at 20,40% at 50.0
Reported previously - NIDA Res.
Monog. 43, 1983.
MONKEY DATA - Reported previously - op cit.
A. (SDS) Exacerbated withdrawal at 0.0625 mg/kg
1 1 4
NIH 9930 Naltrexone•HCl (cont.)
B . (PPt-W) Precipitated withdrawal. Potency approximately 10x naloxone
Apparent PA2 determination: naltrexone/morphine in TF test
Studies in this laboratory indicated that naltrexone was 10x as active as naloxone and
approximately equipotent to nalmefene. The objective of the present study was to
determine if the same relationships could be shown using pA2s. As shown in the fig,
naltrexone’s pA2 is 7.71. The wide confidence limits reflect the fact that only 3 dose
ratios were plotted. The pA2 calculated for naloxone was 7.2 and that for nalmefene was
8.0 (Aceto, et al, NIDA Res. Monog., 132, 1993). Thus, naltrexone’s affinity for the mu
receptor is approximately equal to that of nalmefene and is 5 x more than that of naloxone.
NALTREXONE VERSUS MORPHINE IN TAIL FLICK
Apparent pA2 (Schild)
Summary
There is a rank-order correlation between pA2s or affinity constants and potencies for
naloxone, naltrexone and nalmefene. Naltrexone’s affinity for the mu receptor is
approximately equal to that of nalmefene.
1 1 5
NIH 10303 Dynorphin (1-13) (porcine) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-
Lys-Leu-Lys
aNot tested
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) T F a -
2) TF vs. Ma-
3 ) PPQ a-
4 ) H P a -
MONKEY DATA
SDS
Special Study: Effects of Dynorphin (1-13) on Morphine-Tolerant and Non-Tolerant
Monkeys
As shown in the accompanying table, morphine-dependent monkeys displayed fewer
overt behavioral signs than monkeys that had not received morphine for varying periods
when challenged with dynorphin (1-13). Dynorphin acted promptly and its overt actions
had dissipated in approximately 30 m.
Comment:
Morphine-dependent monkeys appeared to be much less susceptible than non-tolerant
animals to the effects of dynorphin (1-13).
1 1 6
Table 1. Scored Overt Behavioral Effects of Dynorphin (1-13) on Morphine-Tolerant and Non-Tolerant Rhesus Monkeys
Morphine-Dependent Non-Tolerant
Dose mg/kg i.v. in sterile saline 30 10 30
Sex M M F F F
Monkey ID Number 1197 1233 1013 3 0 1 0 b  1 0 8 3 c  1 1 9 5 a  4 0 7 d  1 1 9 1 d  1 1 4 3 a
Fell off Perch
Drowsiness
Slowing
Ataxia
Body Sag
Jaw Sag
Lying Down
Ptosis
Respiration Labored and/or Slow
Subdued or Tamed
Genital Touching
Restlessness
Retching
Vomiting
Piloerection
Irritability
Red Face
Scratching
aHad not received any drugs for at least a year; bHad not received morphine for at least 6 months; Wad not received morphine for at least
3 months; previously drug naive.
Monkeys 1143, 1195,1197, and 1233 received batch #030475, Peninsula Labs, Belmont, CA.
Monkeys 3010, 1083,1191, and 407 received batch #021697, Peninsula Labs, Belmont, CA.
NIH 10588, nor-Binaltorphimine dihydrochloride, nor-BNI
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change mg/kg)
1) TF - Inactive at 1.0, 10.0 and
2) TF vs. M - Inactive at 1.0,
3) PPQ - Inactive at 1.0, 10.0
30 .0
10.0 and 30.0
and 30.0
Reported previously - NIDA
Res. Monog. 105, 1991.
Special pA2 determination in TF test
nor BNI is a highly selective kappa antagonist with a s.c. peak effect at 2 h (Takemori, et.
al., JPET, 246, 1988). It was tested versus one of the most potent kappa agonists known
(NIH 10672) or [5R-( ]-N-[7-(1-pyrrolidinyl)]-1-oxaspiro[4,5][dec-8-y1]-4-
benzofuracetamide·HCl. The apparent pA2 and slope function (see fig.) indicates that the
drug acts competitively with kappa agonists. Since the drug shows mu antagonist effects
in the monkey, additional pA2 studies involving morphine are indicated.
MONKEY DATA-   Reported previously - op cit.
(SDS)
In the SDS test, nor -BNI exacerbated withdrawal at 2 and 8 mg/kg. The drug has mu-
antagonist properties in rhesus monkeys.
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
NIH 10661 6-O-ß-D-Glucopyranosylmorphine (Morphine-6-glucuronide)
MOUSE DATA-ED50 OR
AD50 (95% C.L.) or %
change (mg/kg)
1) TF - 0.7 (0.3 - 1.5)
2) TF vs. M. - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.4 (0.2 - 0.6)
4 ) HP - 0.8 (0.3 - 2.3)
MONKEY DATA
S D S
Dose-dependent suppression of withdrawal signs was observed. Jaw sag and scratching
were also noted at the high dose. In 2 monkeys receiving the highest dose, morphine was
not required until 8 h had elapsed. Thus, the drug had a long duration of action and acted
promptly. Potency is estimated as equivalent to that of morphine.
NIH 10566 VERSUS NIH 10672 IN TAILFLICK (2hrs)
NIH 10588, nor-Binaltorphimine dihydrochloride, nor-BNI (cont.)
Apparent pA2 (Schild)
1 1 9
NIH 10661 6-O-B-D-Glucopyranosylmorphine (Morphine-6-glucuronide) (cont.)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
NIH10662 6-O-ß-D-Glucopyranosylcodeine (Codeine-6-glucuronide)
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1 ) TF - Inactive at 3.0 and 10.0,
16% at 30.0
2) TF vs. M - 11% at 1.0, Inactive
at 10.0 and 30.0
3) PPQ-5% at 1.0, 11% at 10.0
and 23% at 30.0
4) HP - 0% at 1.0 and 10.0, 13%
at 30.0
MONKEY DATA
(SDS)
NIH 10662 neither substituted completely for morphine nor exacerbated withdrawal in
abruptly withdrawn monkeys. The partial suppression may be related to the reduced
incidence of wet-dog shakes, coughing, vomiting, and retching and higher than usual
vehicle scores.
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NIH 10662 6-O-ß-D-Glucopyranosylcodeine (Codeine-6-glucuronide) (cont.)
NIH 10665 Etonitazene methanesulfonate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.005 (0.002-0.011)
2) TF vs. M-Inactive at 1.0, 10.0
and 30.0
3) PPQ - 0.0017 (0.0005-0.005)
4) HP - 0.003 (0.001 - 0.009)
Reported previously - NIDA Res.
Monog. 119, 1992.
Special Test: Naloxone vs ED80 of NM 10665 in Tail-Flick and PPQ Assays
1)
2)
Naloxone AD50 = 0.3 (0.2 - 0.5) in Tail-Flick Test
Naloxone AD50 = 0.9 (0.4 - 2.5) in PPQ Test
MONKEY DATA
(SDS)
See NIDA Res. Monog. 119, 1992.
NIH 10665 Etonitazene methanesulfonate (cont.)
1 2 1
NIH 10665 Etonitazene methanesulfonate (cont.)
Substituted completely for morphine in abruptly withdrawn animals. Potency estimate
1500 x morphine.
Apparent pA2 Determination Because the AD50 vs morphine in the TF and PPQ tests
suggested kappa properties, this test was conducted. The apparent pA2 calculated for
NIH 10665 indicates that this drug is a mu agonist and that it interacts competivively with
naloxone.
NALOXONE VERSUS NIH 10665 IN TAIL-FLICK
Apparent pA2 (Schild)
NIH 10678 (-)-1-(4)(Chlorophenyl)-N,N-dimethyl-1-ethyl-4-phenylbut-3-en-1-
ylamine hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 13.7 (4.9 - 37.8)
a
2) TF vs. M - Inactive at 1.0, 10.0 and
30 .0 a
3) PPQ - 0.9 (0.2 - 3.6)a
4) HP - 11.5 (4.4 - 30.2)a
aVechicle - 6% Tween 80 in water
1 2 2
NIH 10678 (-)-1-(4-Chlorophenyl)-N,N-dimethyl-1-ethyl-4-phenylbut-3-en-1-
ylamine hydrochloride (cont.)
MONKEY DATA
A .  ( S D S )
NIH 10678 substituted completely for morphine. Potency estimate was l/3 - l/2 that of
morphine.
B .  ( P P D )
According to the observations noted below and summarized in the accompanying table,
NIH 10678 probably has a mu-kappa opiate-dependence liability.
Overt signs typically associated with the administration of an opioid substance were seen
after all injections of NM 10678 s.c. In addition, naloxone precipitated withdrawal in all
the subjects receiving this compound. NIH 10678 produces physical dependence at
pharmacologically active doses.
General Comment: NIH 10678 appears to be a typical mu agonist.
B. PPD) According to the observations noted below and summarized in the
accompanying table, NIH 10678 probably has a mu-kappa opiate-dependence
liability.
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PRIMARY PHYSICAL DEPENDENCE STUDY WITH NIH 10678 IN RHESUS MONKEYS
DOSE (MG/KG)DAY COMMENTS
1 - 2
3
4 - 14
2.5a
7.5a
10.0
Three male and 1 female rheus monkeys (Macuca mulatta) in the weight range of 3.6 - 4.1
kg at the start of the study served as subjects. The dose schedule is indicated below.
Aqueous solutions (containing 1% Tween 80) of the test substance were given in a volume
of 1/4 ml/kg S.C. The signs designated as body and jaw sag, chewing, eyelid ptosis,
flushed face, restlessness, scratching and slowing were routinely scored during a 15 min
period, 1/2 hr after the drug was given.
15 10.0a
Precipitated Withdrawal (Day 15)
All animals were injected with 0.25 mg/kg S.C. of naloxone.HC1. Withdrawal signs
designated as vocalization, restlessness, coughing, lying on side or abdomen, vocalizes
when abdomen palpated and rigid abdominal muscles were noted. Most of these signs
lasted for approximately 45. min.
aFour injections daily at 12:00 Noon, 6:00 p.m., 12:00 Midnight and 6:00 a.m.
bOne injection at 6:00 am.
NIH 10688 1-Trimethyl-4-(3-thienyl)-4-piperidinemethanol hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1)  TF - Inactive 1.0, 10.0 and 30.0
2)  TF vs. M - Inactive at 1.0, 10.0 and
30.0
3)  PPQ - 5.4 (2.1 - 14.1)
4)  HP - Inactive at 1.0, 10.0 and 30.0
Reported previously. NIDA Res. Monog.
132, 1993.
MONKEY DATA-Reported previously. NIDA Res. Monog. 132, 1993
A. (SDS) At 4, 16 and 24 mg/kg NIH 10688 neither substituted for morphine nor
exacerbated withdrawal.
B. (PPD) New data.
According to the observations noted below and summarized in the accompanying table,
NIH 10688 probably has a mu-kappa opiate-dependence liability.
1 2 5
Table. Primary Physical Dependence Study (PPD) with NM 10688 in Rhesus Monkeys
DAY DOSE (mg/kg) COMMENTS
2 One female and 3 male rhesus monkeys (M. mulatta) (4/7 - 6.9 kg) served as subjects. Aqueous solutions
4 of test substances were administered S.C. in a volume of 0.25 ml/kg. Signs designated as ataxia, body sag,
8 eyelid ptosis, slowing, scratching and wide-eyed were scored during a 15-m observation period starting
12 0.5 h after drug was given. This observation schedule was continued throughout the 34-day study.
6
8
10
12
12
2-4
5
6-8
9-12
13
14
15
1 6
17-18
19-21
22-25
12
14
15
7.5 & 1526
27
Dose was reduced to 6 mg/kg because of convulsions in 1 animal.
Precipitated Withdrawal (Day 16)
All animals were injected with 0.25 mg/kg S.C. of naloxone.HCl. Mu opiate withdrawal signs designated
as lying on side or abdomen, fighting, avoids contact, vocalizes, crawling and rolling, restlessness,
tremors, wet-dog shakes, yawning, retching, genital stimulation, vocalizes when abdomen palpated, and
rigid abdominal muscles were noted. Other overt signs, not associated with mu-opiate withdrawal,
designated as ataxia, chewing, tongue movements, dystonia, searching, stretching, rocking back and forth,
aggression, piloerection and scratching were noted.
Same signs described after acute administration above.
One monkey convulsed on day 23. Myoclonic convulsions, slowing, fell from perch.
Two monkeys received 7.5 mg/kg and two received 15 mg/kg.
Precipitated Withdrawal (Day 27)
All animals received 0.25 mg/kg of naloxone. The following mu opioid withdrawal signs were. noted:
lying on side, fighting, vocalization, restlessness, tremors, retching, vomiting, vocalizes when abdomen
palpated, rigid abdominal muscles, yawning and genital stimulation. Other overt signs, not associated with
mu-opioid withdrawal, designated as walking backwards, piloerection, and chewing were noted. One
monkey had trouble finding its home cage. All monkeys seemed to move faster. All seemed to be aroused,
all stopped scratching.
DAY
27-31
32-34
Table. Primary Physical Dependence Study (PPD) with NM 10688 in Rhesus Monkeys
DOSE (mg/kg) COMMENTS
12 Abrupt Withdrawal (Day 34)
15
All animals were abruptly withdrawn from drug and 16 h later opioid signs designated as yawning, lying
on side or abdomen, fighting, avoids contact, vocalizes, restlessness, tremors, wet-dog shakes, retching,
genital stimulation, vocalizes when abdomen palpated and rigid abdominal muscles were noted. Other
overt signs, not associated with mu-opioid withdrawal were : body jerks, jaw movements, chewing,
drowsiness, and scratching. The withdrawal syndrome peaked 15 hours after last injection and had
completely abated 5 hr later.
Comment: NIH 10688 definitely produces physical dependence in rhesus monkeys. However, although
the withdrawal syndrome can be said to be associated with the mu opioid system, other systems are
involved, possibly the kappa and/or dopaminergic system. Body weights remained relatively constant
throughout the study.
NIH 10688 1-Trimethyl-4-(3-thienyl)-4-pipetidinemethanol hydrochloride (cont.)
RAT INFUSION  - Reported previously. NIDA Res. Monog. 132, 1993.
A. (SM) Did not substitute for morphine but some suppression of behavioral
withdrawal signs were apparent.
B. (PPD) Some evidence of mu opioid-like physical dependence.
Comment: This is an unusual compound. Although most of the results of the acute
experiments are not remarkable, chronic studies in rats and monkeys indicate a mu and
kappa opioid-like physical-dependence liability. The dopaminergic (D ) system may also
be involved.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
NM 10697 (-)-5-9 -Dimethyl-2’-hydroxy-2- n-octyl-6,7-benzomorphan
hydrochloride
MONKEY DATA
(SDS)
As illustrated in the accompanying graph, NIH 10697 did not substitute for morphine at
doses of 4 and 16 mg/kg. The drug may have exacerbated withdrawal. All drugs used in
the treatment regimens were dissolved in 25% aqueous hydroxypropyl-ß-cyclodextrin.
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF- 10.0 (4.3 - 23.2)a,b
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a,b
3) PPQ - 0.5 (0.2 - 1.5)a,c
4) HP - 5.4 (3.4 - 8.6)a,d
Vehicle - 50% DMSO in water
Vehicle - inactive
Vehicle - 47% inhibition
Vehicle - 25% inhibition
See previously reported NIDA REs.
Monog. 132, 1993
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NM 10697 (-)-5-9 -Dimethyl-2’-hydroxy-2- n -octyl-6,7-benzomorphan
hydrochloride (cont.)
Summary
Depending on the species, the drug shows opioid agonist or possible antagonist
properties.
NIH 10698 (+)-5,9 -Dimethyl-2’-hydroxy-2- n-octyl-6,7-benzomorphan
hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0 and
10.0,14% at 30.0a,b
TF vs. M - Inactive at 1.0, 10.0
and 30.0a
2)
3)
4)
PPQ - 7.8 (1.2 - 49.5)a,b
HP - 11.1 (3.1 - 40.3)a,c
aVehicle - 40% DMSO in water
 bVehicle - inactive
 cVehicle - 25% activity
Reported previously. See NIDA Res.
Monog. 132, 1993.
1 2 9
NIH 10698 (+)-5,9 -Dimethyl-2’-hydroxy-2-n-octyl-6,7-benzomorphan
hydrochloride  (cont.)
MONKEY DATA
(SDS)
At doses of 4 and 16 mg/kg, NM 10698 neither substituted for morphine nor exacerbated
withdrawal. The results are shown in the accompanying illustration. Vehicle consisted of
25% hydroxypropyl-ß-cyclodextrin in water.
Summary
Compared with the (-)-isomer (see NIH 10697), the (+)-isomer is less potent in the PPQ
ane HP antinociceptive tests and is inactive in the monkey SDS.
1 3 0
NIH 10707 (±)-3-[N-Methyl-N-(3,4-dichlorophenylacetamido)]-1-methylpiperidine
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
30 .0 a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 5.6 (1.6 - 19.6)a
4) HP - 25% at 1.0, 0% at 10.0
and 25% at 30.0a
 avehicle-H3 PO4 + water
MONKEY DATA
(SDS)
At doses of 2.5 and 10.0 mg/kg, no substitution for morphine or exacerbation of
withdrawal was observed (see fig. NIH 10707 SDS). An increased incidence of retching
was noted at the high dose. Vehicle was one drop of H3PO4 plus water.
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NIH 10707 (±)-3-[N-Methyl-N-(3,4-dichlorophenylacetamido)]-1-methylpiperidine
(cont.)
SUMMARY
NIH 10707 displays antinociceptive activity in the PPQ test and questionable
activity in the HP. In the dose range studied, no remarkable activity was observed
in the monkey.
NIH 10711 4,6-Di-(3-chlorophenyl)-3,7-diazabicyclo[3.3.1]non-an-9-one 1,5-
dicarboxylic acid dimethyl ester
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1)
2)
3)
TF - Inactive at 1.0 and 10.0,
12% at 30.0 a
TF vs. M - Inactive at 1.0, 10.0
and 30.0a
PPQ - 7% at 1.0, 31% at 10.0
and 10% at 30.0. Vehicle -
17% ac t iv i ty a
HP - Inactive at 1.0. 10.0 and
3 0 . 0 a
aVehicle - 0.5% gum tragacanth
in H2O. Drug not soluble in
DMSO or dil HCl.
4)
MONKEY DATA
SDS
As shown in the graph, NIH 10711 dose-dependently attenuated withdrawal but did not
substitute completely for morphine. At the high dose, two important withdrawal signs,
designated rigid abdomen and vocalization associated with palpation were suppressed
beginning one h after drug was given. However, retching, wet-dog shakes and
restlessness were not affected during the entire 2.5 h observation period.
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NIH 10711 4,6-Di-(3-chlorophenyl)-3,7-diazabicyclo[3.3.1]non-an-9-one 1,5-
dicarboxylic acid dimethyl ester (cont.)
Summary
NIH 10711 attenuates withdrawal in monkeys but delayed effects or delayed absorption
may preclude the full expression of activity Lack of antinociceptive activity in mice may
involve similar pharmacokinetic considerations.
1 3 3
NIH 10714 3,7-Dimethyl-4,6-di-(3-methylphenyl)-3,7-diazabicyclo[3.3.l]nonan-9-
one 1.5-dicarboxylic acid dimethyl ester
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0, and
30.0 a
2) TF vs. M - Inactive at 1.0, 10.0
3)  PPQ - 30% at 1.0, 11% at 3.0,
41% at 10.0 and 46% at 30.0a
4) HP - 0% at 1.0, 13% at 10.0 and
30.0 a
aSuspended in 5% gum tragacanth in
water. Would not dissolve in dil acid
or DMSO.
and 30.0a
NIH 10715 3,7-Dimethyl-4,6-di-(3-nitrophenyl)-3,7-diazaibicyclo[3.3.l]nonan-
9-one 1,5-dicarboxylic acid dimethyl ester
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0, 13%
and 30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - Inactive at 1.0 and 10.0,
and 18% at 30.0a
4) HP -25% at 1.0, 13% at 10.0 and
25% at 30.0a,b
aSuspended in 5% gum tragacanth
in water. Would not dissolve in dil
acid or DMSO.
bVehicle 13% activity.
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NIH 10716 1,5-Dimethyl-4,6-diphenyl)-3,7-diazabicyclo[3.3.1]nonan-9-one 1,5-
dicarboxylic acid dimethyl ester
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and 30.0a
2) TF vs. M - Inactive at 1.0, 10.0 and
30.0 a
3)  PPQ - Inactive at 1.0, 10.0 and 30.0a
4)  HP - Inactive at 1.0, 10.0 and 30.0a
aVehicle 0.5% gum tragacanth in
baqueous solution.
MONKEY DATA
(Preliminary SDS)
At 15-m intervals, doses of 0.8, 1.6, 3.2 and 6.4, respectively (cumulative dose of 12.0
mg/kg) of NIH 10716 neither attenuated, suppressed, nor exacerbated withdrawal.
Vehicle was 30% Tween 80 in water.
Summary
This compound does not have significant biological activity in our tests. Solubility may
be a factor.
NIH 10718 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenyl-2-furamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1)  TF - 7 x 10-4 (3.7 x 10” - 1.5 x 10-
3 ) a
2) TF vs. M - Inactive at 1.0, 10.0 and
30.0 a , b
3)  PPQ - 3.9 x 10-4 (1.6 x 10-4 - 9.4 x
1 0 - 4 ) a
4) HP - 4 x 10-4-4 (1.7 x 10” - 1.0 x 10-
3 ) a , b
aVehicle 10% DMSO in water
bStraub tail starting at 0.01 mg/kg
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NIH 10718 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl-N-
phenyl-2-furamide hydrochloride (cont.)
Special Test: Naloxone AD50 vs ED80 of NM 10718 in TF = 7.5 x 10-3 (2.0 x 10-3
2.5 x 10-2)
Special Test: Naloxone AD50 vs ED80 of morphine TF - 0.007 (0.002 - 0.025)
MONKEY DATA
(SDS)
Complete substitution for morphine was observed with this drug. The onset of action
was rapid and of at least of 2.5-h duration. Potency estimate is 3000 x that of the
reference standard, morphine. At the high dose, the behavioral signs ataxia, body and
jaw sag, slowing and drowsiness were observed. These signs are also seen when
excessive does of morphine are used to terminate withdrawal in morphine-dependent
monkeys.
Summary
Mu-opioid properties predominate in this compound.
1 3 6
NIH 10720 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl-N-
phenyl-2-thiophenecarboxamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.004 (0.002-0.01)a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a,b
3) PPQ - 0.003 (0.001 - 0.006)a
4) HP - 0.002 (0.0005 - 0.005)a
aTwo drops of H3PO4 and water.
bOne of 6 died at 30.0 mg/kg.
Special Test: Naloxone AD50 vs ED80 of NIH 10720 in TF = 0.007 (0.003 - 0.02)
MONKEY DATA
(SDS)
As shown in the accompanying figure, NIH 10720 dose-dependently substituted
completely for morphine. In addition, at the high dose, the signs designated jaw sag,
rubbing face, scratching and eyelid ptosis were seen. Onset of action was prompt.
Offset was about 2.5 h. Potency estimate is 1000 x morphine.
Summary
The data suggest that NIH 10720 is a potent mu agonist.
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NIH 10740 (±)-cis-N-[3-Methyl-1(2-iminohydroxy-2-phenylethyl)-4-piperidinyl]-N-
phenylpropanamide (more polar isomer)
MOUSE DATA ED50 OR AD 50
(95% C.L.) or % change (mg/kg)
1)  TF- 0.9 (0.3 - 2.4)a
2) TF vs. M  Inactive at 1.0, 10.0 and
30.0a
3)  PPQ - 0.8 (0.2 - 2.6)a,b
4)  HP - 1.8 (1.1 - 2.9)a
aVehicle - 30% DMSO, H3PO4 and water
bVehicle showed 20% activity in this test
MONKEY DATA
(SDS)
This compound dose-dependently substituted completely for morphine. The drug is
estimated to be equipotent with morphine. Onset and offset of action are also similar.
Vehicle was 20% Tween 80, phosphoric acid and water.
Summary
Strong mu-opioid properties are associated with this compound.
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NIH 10741 (ßS ,3R ,4S) - (+ ) - cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-
pipetidinyl[-N-phenylpropanamide hydrochloride or (BS,3R,4S)-(+)-cis-ß-Hydroxy-3-
methylfentanyl hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) T F - 2 x 1 0 - 4 ( 1 x 1 0 - 4 - 3 x 1 0 - 4 )
2) TF vs. M - Inactive at 1.0. 10.0
3) PPQ - 9 x 10-5 (3 x 10-5 - 2 x 10-4 and 30.0a)
4) HP - 1 x 10-4 (5 x 10-5 - 2 x 10-4)
aOne mouse found dead 1 hr after drug.
All mice lost righting reflexes at 1.0 and
3.0. All mice were immobile but
responded to touch at 1.0 and 3.0.
Special Test: Naloxone AD50 vs ED80 of NIH 10741 in TF = 8.3 x 10-3 (4 x 10-3 - 1.7
x 10-2)
MONKEY DATA
SDS
This compound substituted completely for morphine. Onset of action was rapid and
offset of action was about 90 m. Peak effect estimated to occur at 60 m. NIH 10741 is
20,000 to 50,000 times more potent than morphine.
Summary
This is an extremely potent mu agonist.
1 3 9
NIH 10742 (ßR,3S,4R)-(-)- cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl
4-piperidinyl]-N-phenylpropanamide  hydrochloride or (ßR,3S,4R)-(+)-c i s- ß -
Hydroxy-3-methylfentanyl hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.06 (0.03 - 0.11)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 0.03 (0.01 - 0.07)
4) HP - 0.08 (0.003 - 0.02)a
aLoss of righting reflex at 30.0
bStraub tail and increased locomotor
activity beginning at 0.2 mg/kg
Special Test: Naloxone AD50 vs ED80 of NIH 10742 in TF = 0.03 (0.01 - 0.09)
MONKEY DATA
S D S
NIH 10742 produced a dose-related reduction in withdrawal signs (see fig.). In addition,
the monkeys receiving the high dose did not require the usual injection of morphine at
noon. This compound acted promptly, had a longer duration of action and is estimated to
be 30 x more. potent than morphine.
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NIH 10742 (ßR,3S,4R)-(-)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyl]-N-phenylpropanamide hydrochloride or (BR,3S,4R)-(+)-c i s- ß -
Hydroxy-3-methylfentanyl hydrochloride (cont.)
Summary All the data indicated that NIH 10742 had opioid properties and that the mu
component was well represented. The drug may have a longer duration of action
compared with the reference compound morphine.
NM 10743 (BR,3R,4S)-(-)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyl[-N-phenylpropanamide oxalate or (BR,3R,4S)-(-)-c i s-ß-Hydroxy-3-
methylfentanyl oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 8.0 x 10-4 (3.0 x 10-4 - 2.0
x 10-3)
TF vs. M - Inactive at 1.0, 10.0
and 30.0
PPQ - 1.2 x 10-4 (2.1 x 10-5 -
6.5 x 10 )
HP - 1.3 x 10-3 (4.0 x 10-4 - 4.6
x 10-
3)a
2)
3)
4)
aStraub tail and increased locomotor
activity beginning at 0.1 mg/kg.
Special Test:  Naloxone AD50 vs ED80 of NIH 10743 in TF = 3.5 x 10-2 (1.0 x 10-2 -
1.1 x 10-1)
MONKEY DATA
As illustrated in the fig., NIH 10743 SDS, this compound substituted completely for
morphine at 0.002 mg/kg. Furthermore, t he action was dose-related. NIH 10743 acted
promptly; its duration of action was longer than that of morphine and the potency estimate
is approximately 1500 x morphine.
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NIH 10743 (ßR,3R,4S)-(-)-cis-N-[1-(2(B)-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyl[-N-phenylpropanamide oxalate or (ßR,3R,4S)-(-)-cis-ß-Hydroxy-3-
methylfentanyl oxalate (cont.)
Summary
NIH 10743 behaved as if it were a typical, very potent, mu opioid agonist.
NIH 10744 (ßS,3R,4S)-(+)- cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyl[-N-phenylpropanamide  oxalate or ßS,3R,4S)-(+)-c i s-ß-Hydroxy-3-
methylfentanyl oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 13.0 (5.6 - 30.6)
TF vs. M - Inactive at 1.0, 10.02 ) 
and 30.0
3) PPQ - 0.6 (0.2 - 2.1)
4) HP - 2.1 (0.6 - 7.8)
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NIH 10744 (ßS,3R,4S)-(+)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyl[-N-phenylpropanamide oxalate or ßS,3R,4S)-(+)-cis-ß-Hydroxy-3-
methylfentanyl oxalate (cont.)
MONKEY DATA
SDS
In the dose range of 0.6 - 12.0 mg/kg, NIH 10744 did not substitute for morphine. In
fact, it appeared to exacerbate withdrawal in a dose-related manner at the three lower
doses. However, at the highest dose, the drug’s effects were like those of the vehicle.
The data are illustrated in the drug’s figure designated NIH 10744 SDS. In addition,
salivation was noted at the highest dose in two monkeys.
Summary
NIH 10744 was active in the mouse antinociceptive assays. The activity could reflect mu
and/or kappa opioid activity. However, in the monkey. the drug had a biphasic effect
(behaved as a weak mu antagonist at the low dose but had no effect at the high dose).
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NIH 10745 (±)-cis-N-[1-(2-Amino-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide dihydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.6 (0.3 - 1.4)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ -0.09 (0.03 - 0.20)
4) HP - 0.7 (0.3 - 1.3)
Special Test:  Naloxone AD50 vs ED80 of NIH 10745 in TF = 0.03 (0.008 - 0.1)
MONKEY DATA
As shown in the accompanying illustration, NIH 10745 substituted completely for
morphine. The action was prompt and dose-related. The drug appeared to be
approximately 4-6 x more potent than morphine. Duration of action was similar to that of
the reference control.
Summary
This compound showed a profile of activity like that of a mu opioid agonist.
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NM 10748 (+)-N-(4-Fluorobenzyl)-3-hydroxymorphinan oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and 30.0a
2) TF vs M - Inactive at 1.0, 10.0 and
30.0a
3) PPQ - 12.0 (5.9 - 33.7)a
4) HP - Inactive  at 1.0, 10.0 and 30.0a
aVehicle-5% Tween 80 in water
MONKEY DATA
(SDS)
NIH 10748 neither substituted for morphine nor exacerbated withdrawal at doses of 4 and
16 mg/kg. One monkey at the high dose retched and vomited often. Vehicle was 25%
hydroxypropyl-B-cyclodextrin in water.
Some weak activity in the PPQ test and possible weak mu antgonist properties are
associated with NIH 10748.
Summary
145
NIH 10750 (-)-5,9 -Dimethyl-2’-hydroxy-2-(4-niuobenzyl)-6,7-benzomorphan
oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
14% at 30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0 a
3) PPQ - 6% at 1.0, 13% at 10.0
and 63% at 30.0a
4) HP-0% at 1.0, 13% at 10.0 and
30 .0 a
aVehicle - 5% Tween 80 aqueous
suspension
MONKEY DATA
(SDS)
Analysis of variance (Kruskal-Wallis test) of the data at 120 m revealed significant
differences among the treatment regimens (see fig NIH 10750-SDS). Post hoc
comparisons between the individual treatment regimens and vehicle controls indicated that
only the morphine control data were significantly different from those of vehicle controls.
It was concluded that NIH 10750 neither suppressed nor exacerbated withdrawal.
Vehicle was 25% hydroxypropyl-ß-Cyclodextrin in water.
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NIH 10750 (-)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan
oxalate (cont.)
Summary
Except for some  weak antinociceptive activity in the PPQ test, NIH 10750’s actions were
not remarkable. The drug is virtually free of in vivo  mu or kappa opioid activity.
NIH 10751 (+)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan
oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
30 .0 a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0 a
3)  PPQ - 11% at 1.0, 8% at 10.0 and
14% at 30.0a
4)  HP - Inactive at 1.0, and 10.0,
13% at 30.0
aVehicle - 5% Tween 80 aqueous
suspension
MONKEY DATA
(SDS)
As shown in the accompanying fig. (NIH 10751-SDS), this compound neither
suppressed nor exacerbated withdrawal at doses of 4 and 16 mg/kg in maximally-
morphine-dependent rhesus monkeys. Vehicle was 25% hydroxypropyl-ß-cyclodextrin
in water.
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NIH10751 (+)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan
oxalate (cont.)
Summary
The results suggested that the compound had no apparent mu or kappa opioid activity or
that solubility may be a problem.
NIH 10752 (-)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan
oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0 and 10.0a  and
15% at 30.0
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0 a
3) PPQ - 6% at 1.0, 17% at 10.0 and
49% at 30.0a
4) HP - Inactive at 1.0, and 10.0,
15% at 30.0
Vehicle - 5% Tween 80 aqueous
suspension
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NIH 10752 (-)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan
oxalate (cont.)
MONKEY DATA
(SDS)
This compound neither exacerbated nor suppressed withdrawal at 4 and 16 mg/kg in
abruptly withdrawn morphine-dependent monkeys (see fig. NIH 10752-SDS). Vehicle
was 25% hydroxypropyl-ß-cyclodextrin in water.
any, mu or kappa opioid activity.
Summary
The drug had some weak antinociceptive activity in the PPQ test. Lack of activity in the
TF, TF vs M, HP tests and in morphine-dependent monkeys suggested that it had little, if
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NIH 10753 Morphine sulfate pentahydrate
30.0
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1)  TF - 0.7 (0.4 - 1.5)
2) TF vs. M - Inactive at 1.0, 10.0 and
3) PPQ - 0.4 (0.2 - 0.8)
4) HP - 3.1 (1.5 - 6.4)
MONKEY DATA
(SDS)
NM 10753 substituted completely and dose-dependently for morphine. The drug acted
promptly and its duration of action was at least 2.5 h. The drug is about as potent as
morphine.
Summary
This drug displays a profile of activity which suggests a strong mu-opioid component. It
should be noted that NIH 10753 was submitted as an unknown and was tested “blind”.
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NIH 10754 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidnyl]-N(3-
pyridinyl)propanamide dihydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.001 (0.0005 - 0.003)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 4.0 x 10-4 (2x 10-4 x 1 x
10 -3)
4) HP - 0.004 (0.001 - 0.01)b
MONKEY DATA
SDS
NM 10754 dose-dependently substituted for morphine. However, although onset of
action was rapid, duration of action was about 90 m. Potency is estimated as 2000 x
morphine.
Summary
NIH 10754 is a potent mu opioid agonist.
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MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.12 (0.07 - 0.20)
2)  TF vs. M - Inactive at 1.0, 10.0
and 30.0
3)  PPO  - 0.07 (0.02 - 0.21)
4) HP - 0.16 (0.08 - 0.33)
NIH 10755 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(1-
piperidinyl)propanamide dihydrochloride
Special Test: Naloxone antagonism of NIH 10755 (ED80) in TF, AD50 = 0.04 (0.02 -
0.10).
MONKEY DATA
S D S
As shown in the accompanying graph, NIH 10755 dose dependently substituted
completely for morphine. The drug is approximately 10 x more potent than the reference
compound morphine Onset of action was prompt. Offset was at least as long as that of
morphine or at least 2.5 h.
Summary
The data indicate that NIH 10755 is a potent mu opioid agonist.
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10756 (±)-cis-N-[1-(2( trans-1-Hydroxy)indanyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.14 (0.06 - 0.32)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 0.03 (0.01 - 0.07)
4) HP - 0.18 (0.07 - 0.48)
Special Test: Naloxone antagonism of NIH 10756 (ED80) in TF, AD50 = 0.11 (0.05 -
0.26)
NIH 10756 substituted completely for morphine (see graph). The potency estimate was 6
x morphine. The drug acted promptly. However, its duration of action was less than
that of morphine.
Summary
This profile of activity suggests that 10756 is a potent mu agonist.
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MONKEY DATA
SDS
NIH 10757 (±)-cis-N-[1-(2-(trans-3-Hydroxy-1,2,3,4-tetrahydro)naphthyl)-3-
methyl-4-piperidinyl]-N-phenylpropanamide hydrochloride
One mouse died at 30.0.
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1 ) TF - 3.6 x 10-3 (1.3 x 10-3 - 9.9 x
1 0 - 3 )
2 ) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 1.3 x 10-3 (6 x 10-4 - 2.9 x
1 0 - 2 )
4 ) HP - 6.5 x 10
-3 (4.0 x 10-3 - 1.1 x
1 0 - 2 ) a
Special Test:  Naloxone antagonism of NIH 10757 (ED80) in TF, AD50 = 0.03 (0.01 -
0.07)
MONKEY DATA
(SDS)
As shown in the fig., this drug substituted completely for morphine. The drug is
estimated to be 300 x more potent than morphine. Jaw and body sag and scratching were
noted at the higher dose indicating that this dose was higher than that required to
substitute for morphine. Onset of action was prompt and duration of action was at least at
long as that of the reference standard.
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NIH 10757 (±)-cis-N-[1-(2-(trans-3-Hydroxy-1,2,3,4-tetrahydro)naphthyl)-3-
methyl-4-piperidinyl]-N-phenylpropanamide hydrochloride (cont.)
Summary
The evidence indicates that NIH 10757 is a potent mu agonist.
NIH 10759 Ethylnarceine·HCl (6[[6-[2-Diethylamino)ethyl]-4-methoxy-1,3-
benzodioxol-5-yl]acetyl]-2,3dimethoxybenzoic acid
1) TF - Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 67% at 1.0, 11% at 10.0
and 60% at 30.0
4) HP - Inactive at 1.0, 10.0 and
30.0
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
MONKEY DATA
SDS
In the dose range of 2.0 - 24.0 mg/kg, NM 10759 did not substitute for morphine. The
drug augmented the number of withdrawal signs at the two higher doses. Specifically,
the frequency of signs designated wet-dog shakes, vocalizes when abdomen palpated and
rigid abdominal muscles was increased.
1 5 5
NIH 10759 Ethylnarceine·HCl (6-[[6-[2-Diethylamino)ethyl]-4-methoxy-1,3-
benzodioxol-5-yl]acetyl]-2,3-dimethoxybenzoic acid (cont.)
Summary
This compound appeared to be free of significant mu agonist properties. The
augmentation of withdrawal signs at higher doses could reflect some weak mu antagonist
effects.
NIH 10760 Narceine (6-[[6-[2-Diethylamino)ethyl]-4-methoxy-1,3-
benzodioxol-5-yl]acetyl]-2,3-dimethoxybenzoic acid
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3)  PPQ - 6% at 1.0, 11% at
10.0 and 60% at 30.0
4) HP - Inactive at 1.0, 10.0
and 30.0
MONKEY DATA
SDS
As shown in the figure designated NIH 10759 SDS, this compound neither substituted
for morphine nor exacerbated. withdrawal in the dose range of 2.0 - 12.0 mg/kg.
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NIH 10760 Narceine (6-[[6-[2-Diethylamino)ethyl]-4-methoxy-1,3-
benzodioxol-5-yl]acetyl]-2,3-dimethoxybenzoic acid (cont.)
Summary
NIH 10760  did not produce actions suggestive of opioid-like activity.
NIH 10761 (±)-cis-N-[1-(2-Hydroxy)-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(2-
fluorophenyl)propanamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 4.2 x 10-4 (2.1 x 10-4 - 8.3 -
10 - 4)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 1.3 x 10-4 (5 x 10-5 - 3x10-
4 )
4) HP - 3.9 x 10-4 (1.9 x 10-4 - 8.2 x
10-4)
Special Test: Naloxone antagonism of NIH 10761 (ED80) in TF, AD50 = 0.04 (0.01 -
0.10)
As shown in the accompanying fig., NM 10761 substituted completely for morphine. At
the high dose, body and jaw sag, ataxia, eyelid ptosis, and scratching were noted. This
indicates that this dose was more than required for substiution. Potency is estimated at
6000 x morphine. Onset and offset of action were similar to those of morphine.
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MONKEY DATA
S D S
NIH 10761 (±)-cis-N-[1-(2-Hyroxy)-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(2-
fluorophenyl)propanamide hydrochloride (cont)
Summary
This compound has very potent mu opioid agonist properties.
NIH 10762 (±)-cis-N-[3-Methyl-1-[2-oxo-2-(2-thienyl)ethyl]-4-piperidinyl]-N-
phenylpropanamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 0.03 (0.01 - 0.07)
2) TF vs. M - Inactive at 1.0. 10.0
3) PPQ - 0.016 (0.006 - 0.045)
4) HP - 0.24 (0.12 - 0.50)
and 30.0
Special Test: Naloxone antagonism of NM 10762 (ED80) in TF, AD50 = 0.03 (0.01 -
0.07;
NIH 10762 (±)-cis-N-[3-Methyl-1-[2-oxo-2-(2-thienyl)ethyl]-4-piperidinyl]-N-
phenylpropanamide hydrochloride (cont.)
MONKEY DATA
(SDS)
NIH 10762 dose-dependently substituted completely for morphine. Potency estimate is
60 x morphine. Onset and offset of action were similar to morphine.
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NIH 10762 (±)-cis-N-[3-Methyl-1-[2-oxo-2-(2-thienyl)ethyl]-4-piperidinyl]-N-
phenylpropanamide hydrochloride (cont.)
Summary
This compound shares many pharmacological effects associated with mu opioid agonists.
NIH 10763 (±)-cis-N-[1-[2-Hydroxy-2-(2-thienyI)ethyl]-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride
MOUSE DATA ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF -  9.6x10-4 (4.7x10-4 - 2x10-3)
2) TF vs. M - Inactive at 1.0, 10.0 and
30.0
3) PPQ -1.1x10-4 (5x10-5 - 3x10-4)
4) HP - 1.7x10-3 (6.2x10-4  - 4.5x10-3)
Special Test: Naloxone vs NIH 10763 ED80 in TF: AD50 = 0.16 (0.08 - 0.32)
MONKEY DATA
(SDS)
NIH 10763 produced a dose-related reduction in withdrawal signs in abruptly with&awn
monkeys (see fig). In addition, the drug substituted completely for morphine. Onset and
offset of actions were similar to those of the morphine control. Potency estimate is 1500
x morphine.
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NIH 10763 (±)-cis-N-[1-[2-Hydroxy-2-(2-thienyl)ethyl]-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride (cont.)
Summary
This compound is a potent mu agonist.
NIH 10765 (±)-cis-N-[1-(2-Hydroxy-1-phenylethyl)-3-methyl-4-piperidinel]-N- 
phenylpropanamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 3.0 (1.3 - 7.2)
2) TF vs M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 0.1 (0.03 - 0.6)
4) HP - 3.4 (1.1 - 10.4)
MONKEY DATA
(SDS)
As shown in the fig., NIH 10765 dose-dependentIy substituted completely for morphine.
The drug behaved like the reference compound, morphine, regarding onset and offset of
action. Potency estimate - 1.5 x morphine.
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NIH 10765 (±)-cis-N-[1-(2-Hydroxy-1-phenylethyl)-3-methyl-4-piperidine1]-N-
phenylpropanamide hydrochloride (cont.)
Summary
This drug appears to be morphine-like regarding profile of activity.
N I H  1 0 7 6 6 8-[4-[4-(1,2-BenzoisothiazoI-3-yl)-1-piperazinyl]butyl]-8-
azaspiro(4.5)decane-7,9-dione hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
I) TF- 11% at 1.0, 22% at 10.0 and
0% at 30.0a
2) TF vs M - Inactive at 1.0, 10.0 and
30.0
3) PPQ - 0.07 (0.03 - 0.15)
4) HP - 5.3 (1.9 - 15.1)ª
aAt 30.0 mg/kg, the mice showed
splayed legs, eyelid ptosis and
reduced spontaneous activity.
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NIH 10766 8-[4-[4-(l,2-BenzoisothiazoI-3-yl)-1-piperazinyl]butyl]-8-
azaspiro(4.5)decane-7,9-dione hydrochloride (cont.)
MONKEY DATA
(SDS)
This compound attenuated, but did not completely suppress withdrawal at doses of 0.25
and 1.0 mg/kg (see fig). It reduced the incidence of the signs designated retching,
vomiting and fighting. Although the animals at the high dose also had relaxed abdominal
muscles and did not vocalize when their abdomens were palpated, many of the vehicle
controls also did the same. Therefore, no definite statement can be made with regard to
the abdominal responses. However, at the high dose other overt signs were noted such
as sagging, slowing, ataxia, eyelid ptosis, and cataleptic behavior.
Summary
The compound has biological activity. The data preclude a definite statement regarding
mu and/or kappa-like properties.
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NIH 10768 (-)-2-Decyl-5,9 -Dimethyl-2'-hydroxy-6,7-benzomorphan
hydrobromide
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
3 0 . 0 a , b
2) TF vs M - Inactive at 1.0, 10.0
and 30.0a,b
3) PPQ - 0% at 0.3, 31% at 1.0,
14% at 10.0 and 29% at 30.0a,b
4) HP - Inactive at 1.0, 10.0 and
30.0 a,b
aVehicle propylene glycol and
Tween 80
beyelid ptosis
MONKEY DATA
Preliminary Study
(SDS)
A .
After at a cumulative dose of 7.0 mg/kg (1.0, 2.0 and 4.0 mg/kg each at 15 m
intervals respectively), the monkey retched and vomited vigorously. Regular dose
of morphine (3 mg/kg) was given to terminate withdrawal. Onset of action for
morphine seemed delayed. Vehicle was 25% hydroxypropyl-ß-cyclodextrin in
water.
Monkey
(SDS)
NIH 10768 did not substitute for morphine at doses of 2.5 and 10.0 mg/kg (see
fig). At the highest dose, the drug may have exacerbated withdrawal. Vehicle was
25% hydroxypropyl-ß-cyclodextrin in water.
B.
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NIH 10768 (-)-2-Decyl-5,9 -Dimethyl-2'-hydroxy-6,7-benzomorphan
hydrobromide (cont.)
Summary
In morphine-dependent monkeys, 10768 may have mu antagonist properties.
NIH 10769 (+)-2-Decyl-5,9 -Dimethyl-2'-hydroxy-6,7-benzomorphan
hydrobromide
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 16% at 1.0, 11% at 10.0 and
7% at 30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 0% at 1.0, 14% at 10.0 and
17% at 30.0a
4) HP - 0% at 1.0 and 30.0 and 13%
at 10.0
a)  Vehicle - Propylene glycol, Tween
80 and water.
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NIH 10769 (+)-2-Decyl-5,9 -Dimethyl-2'-hydroxy-6,7-benzomorphan
hydrobromide (cont.)
MONKEY DATA
(SDS)
As shown in the accompanying figure, doses of 4 and 16 mg/kg of NIH 10769 neither
substituted for morphine nor exacerbated withdrawal. One monkey at the high dose was
ataxic and slow. Vehicle was 25% hydroxypropyl-ß-cyclodextrin.
Summary
At the doses tested, NIH 10769 lacked antinociceptive and mu or kappa opioid properties.
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NIH 10770 (-)-N-(4-Fluorobenzyl)-3-hydroxymorphinan oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0. 10.0
and  30.0a
3) PPQ - 14% at 1.0, 26% at 10.0
and 49% at 30.0a
4) HP - 13% at 1.0, 13% at 10.0
and 25% at 30.0a
aVehicle - Tween 80, propylene
glycol and water
Summary
The drug has very weak antinociceptive properties in the PPQ and HP tests.
NIH 10771 (-)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 9% at 1.0, 14% at 10.0 and
15% at 30.0
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 14% at 1.0, 14% at 10.0
and 23% at 30.0
4) HP - Inactive at 1.0 and 10.0,
13% at 30.0
aTween 80, propylene glycol and
water
Summary
The compound displays very weak, if any, aminociceptive activity.
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NIH 10772 (+)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan
oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and 10.0a
2) TF vs. M - Inactive at 1.0, 10.0 and
30.0 a
3) PPQ - 0% at 1.0, 14% at 10.0 and
23% at 30.0a
4) HP - Inactive at 10.0 and at 30.0a
13% at 1.0
a) Vehicle - Propylene glycol, Tween
80 and water.
MONKEY DATA
(SDS)
Although the data illusrated in the figure (NIH 10772-SDS) suggested that this
compound had exacerbated withdrawal, the results reflected a statistical anomaly. For the
first time in 20 years, all the vehicle controls did not vocalize when their abdominal
muscles were palpated. Also, all had relaxed abdominal muscles. The result was low
withdrawal scores for the controls. However, the monkeys displayed all the other
withdrawal signs. It is concluded that NIH 10772 neither exacerbated nor suppressed
withdrawal. Vehicle was 25% hydroxypropyl-ß-cyclodextrin  in water.
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NIH 10772 (+)-5,9 -Dimethyl-2'-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan
oxalate (cont.)
Summary
Summary
Except for some weak activity in the PPQ test, NIH 10772 lacked significant mu or kappa
opioid activity.
NIH 10778 4-Bromo-5-(3-hydroxyphenyl)-2-methylmorphan hydrobromide
MOUSE DATA-ED50 OR AD50
95% C.L.) or % change (mg/kg)
1) TF - inactive at 1.0, 10.0 and 30.0a
2 ) TF vs. M - Inactive at 1.0, 10.0 and
30 .0 a
3 ) PPQ - 14% at 1.0, 9% at 10.0 and
11% at 30.0a
4) HP - Inactive at 1.0, 10.0 and 
30.0a
aVehicle 5% Tween 80 in water
Summary NIH 10778 is probably devoid of aminociceptive and mu antagonist activity.
NIH 10779 2,3-Dimethyl-5-(3-hydroxyphenyl)morphan  hydrobromide
MMOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1 ) TF - 1.3 (0.5 - 3.2)
2) TF vs M - Inactive at 1.0, 10.0 and
30.0
3) PPQ - 0.3 (0.1 - 0.6)
4) HP - 4.8 (1.9 - 12.4)
This compound displays an antinociceptive profile of activity not unlike that of morphine.
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NIH 10780 (-)-N-Benzyl-3-hydroxymorphinan hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and 30.0a
2) TF vs M - Inactive at 1.0, 10.0 and
30.0 a
3) PPQ - 6% at 1.0 and 10.0, 14% at
30.0
4) HP - Inactive at 1.0, 10.0 and 30.0a
Summary
NIH 10780 does not show significant antinociceptive or mu antagonist properties.
NIH 10781 (-)-3-Hydroxy-N-(4-methoxylbenzyl)morphinan hydrobromide
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 13% at 1.0, 57% at 10.0
and 46% at 30.0a
4) HP - Inactive at 10.0 and 30.0
25% at 10.0
aVehicle 10% Tween 80 in water
Summary
Some weak antinociceptive activity may be associated with NIH 10781. In addition, it
lacks mu antagonist properties.
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NIH 10783 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-
methyl-2-pyridinyl)propanamide oxalate
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1 ) TF - 0.002 (0.001 - 0.007)
2)  TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3 )  PPQ - 0.0003 (0.0001 - 0.0006)
4)  HP - 0.009 (0.005 - 0.015)
a) Straub tail at 1.0 Loss of righting
reflex at 6.0 and 2 of 6 mice
died at 10.0.
Special Test: Naloxone AD50 vs NIH 10783 ED80 in TF = 0.04 (0.04 - 0.1)
MONKEY DATA
(SDS)
NIH 10783 dose-dependently suppressed withdrawal. (see fig. NIH 10783-SDS).
Onset of action was rapid and offset was longer than that of morphine at the highest dose,
i.e., 0.0005 mg/kg, the monkeys did not require the usual noontime injection of
morphine. Potency estimate is 12,000 X morphine.
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NIH 10783 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-
methyl-2-pyridinyl)propanamide  oxalate (cont.)
Summary
The profile of activity suggested that this drug has potent mu agonist properties and that
the duration of action is longer than that of morphine.
NIH 10799 Dynorphin (2-17) Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-
Try-Asp-Asn-Gly
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF-a
2)  TF vs M -a
3) PPQ-a
4) HP-a
aNot   tested
MONKEY DATA
(SDS)
Previous studies in this laboratory demonstrated that dynorphin-(1-13) or Dyn-(1-13) as
well as Dyn-(1-10), but not Dyn-(1-8) Dyn-(1-6) and -endorphin, suppressed
withdrawal behavior in maximally dependent rhesus monkeys (Aceto et al., Eur. J.
Pharmacol. 83, 1982 and Aceto et al., Fed. Proc. 42, 1983). In order to extend these
findings and to determine whether or not deletion of the tyrosine (tyr)-residue was
essential for suppression of withdrawal in our animal model, the present studies were
initiated. As shown in the fig below, an intravenous dose of 10 µM of Dyn-(2-17)
suppressed withdrawal behavior.
Summary
These results confirm that the tyr-residue is not critical for activity in the Dyn
series(Takemori and Lee, personal communication) and are in accord with previous
observations that short peptide fragments such as Dyn-(1-6) and Dyn-(1-8) are inactive or
less potent. They also suggest potential clinical uses for this and other active Dyn
peptides in the pharmacotherapy of pain, and tolerence to and dependence on opioids.
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NIH 10799 Dynorphin (2-17) Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-
Try-Asp-Asn-Gly (cont.)
NIH 10800 Pro-Leu-Gly-Amide (MIF)
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1)  TF-
2) TFvsM-
3) PPQ-
4 )  H P  -
A number of studies have shown that melanotropin release-inhibiting factor (MIF)
prevented the development of tolerance to the analgesic, cataleptic, hypothermic and/or
hyperthermic actions of morphine, buprenorphine,. and ß-endorphin (Bhargava and
Ramarao, Peptides, 10, 767, 1989); Bhargava, NIDA Res. Monog. 70, 337, 1986.
However, two other laboratories could not confirm these effects on tolerance to
morphine-induced antinociception. Mucha and Kalant, J. Pharm. Pharmacol., 31 , 572,
1989 and McLaughlin, et al., Behavioral Neuroscience, 103, 447, 1989.
Because of the possible implications regarding MIF in the pharmacotherapy of opioid
abuse, we decided to study the peptide in 2 animal models of morphine tolerance and
dependence. Supplies for the rat study were generously supplied by Dr. Bhargava, at the
University of Illinois in Chicago. For the monkey study, the drug was purchased from
Sigma Chemical Company, Lot #80H0319.
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NIH 10800 Pro-Leu-Gly-Amide (MIF) (cont.)
A.  Rat Continuous Infusion Study (PPD)
The results of the effects of MIF on morphine-induced changes in body weight during the
development of tolerance and physical dependence and during abrupt withdrawal of
morphine are illustrated in the accompanying figures. Experimental details and overt
behavioral observations noted during abrupt withdrawal are provided in the table. It is
apparent that the daily administration of either 0.25 or 1.0 mg/kg of MIF S.C. during the
continuous i.p. administration of morphine for 4 days did not significantly influence the
development of tolerance to or dependence on morphine.
B. Monkey Data
PPD Study: Nine experimentally naive rhesus monkeys of both sexes, in the
weight range of 2.3 - 3.1 kg served as subjects. They were randomly assigned to receive
either saline and morphine or MIF at (1.0 or 4.0 mg/kg) and morphine. Each animal was
injected S.C. every 6 h with 3 mg/kg of morphine sulfate. In addition, at 10 A.M. each
animal received an injection of the assigned dose of saline or MIF. Two hours after the
noon injection of morphine, they were scored for the presence or absence of the signs
designated scratching, jaw and body sag, slowing and eyelid ptosis during a 15-m
observation period. On day 14, each animal was given 0.25 mg/kg s.c. of
naloxone·HCl. The animals were scored for any and all withdrawal signs noted. They
were designated: lying on side or abdomen, fighting, avoids contact, vocalizes, crawling,
restlessness, drowsy, tremors, retching, vomiting, coughing, rigid abdominal muscles,
vocalization when abdomen palpated, masturbation, and yawning. For full details consult
Aceto et al (Pharmacology 15, 1, 1977).
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NIH 10800 Pro-Leu-Gly-Amide (MIF) (cont.)
Table. Effects of Pro-Leu-Gly amide, (MIF), on the Development of Physical
Dependence in the Bat Continously Infused with Morphine for 4 Days and
then Abruptly Withdrawn
Treatment regimens (4Days) Hr Off Drugs
Figure
symbols 2 4 4 8 72
Significant Differences in Behavioral Scoresa
96
1. Vehicle + Vehicle c n s c c n s c
2. Vehicle + Morphine b n s b b n s b
3. MIF + Morphine b n s b n s b n s b
4. MIF + Morphine b n s b n s
b n s b
aBehavior score: hypersensitivity, squeaking, aggression, wet-dog shakes, rubbing and
chewing
bOne-tailed test (Mann-Whitney U-test), p < 0.05 compared to vehicle controls, ns - not
significant
cOne-tailed test (Mann-Whitney U-test), p < 0.05 compared to morphine controls, ns -
not significant
dVehicle was water. Days 1-4: 0.1 ml/l00 g body weight s.c., one injection/24 hr and 8
ml i.p./24 h; N=4
eVehicle s.c., injection as above. Morphine sulfate i.p. 50 mg/kg on day 1; 100 mg/kg
on day 2; 200 mg/kg on days 3 thru 4; N=6
fMIF s.c injection/24 hr; 0.25 mg/kg on days 1 thru 4 and morphine sulfate i.p. as
above; N=5
gMIF s.c. one injection/24 hr. 1.0 mg/kg on days 1 thru 4 morphine sulfate i.p/ as above;
N=5
1 7 4
NIH 10800 Pro-Leu-Gly-Amide (MIF) (cont.)
Effect of NIH 10800 (MIF) on the Development of Tolerence
to Morphine In Rhesus Monkeys
As shown in the fig. (Effects of MIF or Saline on Tolerance to Morphine), the results of
the saline-treated and MIF-treated animals are indistinguishable. By day 9, tolerance to
morphine was evident. Had tolerance not developed in the MIF-treated monkeys, they
would have continued to show the overt signs initially seen in naive subjects first
challenged with morphine.
Regarding physical dependence, MIF did not prevent the development of physical
dependence on morphine. Naloxone precipitated withdrawal and as illustrated in the fig.
(Naloxone challenge of morphine-dependent monkeys treated daily with MIF).
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NIH 10800 Pro-Leu-Gly-Amide (MIF)  (cont.)
Naloxone Challenge of Morphine-Dependent Rhesus Monkeys
Treated with NIH 10800 (MIF)
Summary Results in rats and monkeys indicate that MIF does not influence the course of
the development of tolerance to and/or physical dependence on morphine.
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BIOLOGICAL EVALUATION OF COMPOUNDS FOR THEIR
PHYSICAL DEPENDENCE POTENTIAL AND ABUSE LIABILITY.
XVII. DRUG EVALUATION COMMITTEE OF THE COLLEGE
ON PROBLEMS OF DRUG DEPENDENCE, INC. (1993)
A. E. Jacobson
PURPOSES OF THE DRUG EVALUATION COMMlTTEE
The Drug Evaluation Committee (DEC) of the CPDD (Dr. T. Cicero, Chairman) is
charged with the responsibility of determining the physical dependence potential
and abuse liability of potential analgesics, stimulants and depressants, and with
associated methodological research. The drugs are obtained from investigators
in universities, industrial groups, and the public sector. The testing function is
carried out under the auspices of the CPDD as a public service and has provided
information to pharmaceutical industry and governmental agencies for the
appropriate scheduling of a drug with the potential for abuse. The information
which DEC provides to university researchers, who frequently work under a NIDA
grant, is useful for determining the desirability of structural modification of a drug
and the DEC biological data are often needed for publication of their work in
medicinal chemistry journals.
THE DRUG EVALUATION COMMITTEE’S PARTICIPATION IN THE MAIN
FUNCTIONS OF CPDD
The dissemination of information on the physical dependence potential and
abuse liability of drugs for the public welfare continues to serve one of the major
purposes of the CPDD, as it has since the establishment of CPDD as a
Committee of the National Academy of Sciences, National Research Council.
The data obtained by the DEC have been requested this past year by U.S.
governmental agencies, such as NIDA, the Drug Enforcement Agency (DEA),
and the Food and Drug Administration (FDA). Examples of our continued
cooperation with governmental agencies are as follows.
1) We were asked this year to examine a drug seized by the DEA, and its
structural relative. These compounds (see NIH 10759 and 10760, in table 9)
were not found to have opioid-like effects.
2) Data recently obtained on LAAM (levo-alpha-acetylmethadol) by the DEC were
provided to the FDA in response to the request of one of their officials. These
data were apparently required as part of the comprehensive information
necessary for a scheduling decision on LAAM.
3) Some of our older data were also utilized by the FDA. In 1982 the analgesic
testing groups reported on a drug which was recently found to be a minor
contaminant in a commercially marketed product. These data were used to allow
retention of the commercial product on the market. Toxicological studies on the
contaminant will be requested from the supplier by the FDA.
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4) Evaluation of NIH 10710 (table 8) and 10766 (table 9) by the analgesic testing
groups, was requested by the NIDA Medications Development group. The testing
of NIH 10710 by the stimulant/depressant groups was reported last year (as
CPDD 0037, Woolverton et al. 1993).
5) Lastly, the stimulant/depressant groups evaluated two compounds at the
request of NIDA, CPDD 0039 and 0040. The World Health Organization (WHO)
asked NIDA to provide data on the latter compound, Mesocarb (CPDD 0040,
table 10).
Thus, the DEC in this past year has provided data for NIDA, the FDA and DEA,
and the WHO. The CPDD has then, through the DEC. fulfilled one of its main
functions, providing essential dependence potential and abuse liability information
on drugs with the potential for abuse to governmental agencies, pharmaceutical
industry, and university researchers.
PUBLICATION OF DATA
The CPDD’s evaluation of drugs began around 1951 and the data gathered on
these drugs have been published since 1979 in a NIDA Monograph “Problems of
Drug Dependence”. The published data have always been archival, in the sense
that they were declared to be reference material. In 1977 and 1978, the testing
data were published by CPDD as part of the proceedings of the annual scientific
meeting. From 1951 to 1976, however, the reports were published by the
National Academy of Sciences. In those volumes the proceedings of the CPDD
meeting were not archival and were not meant to be used as reference material,
but rather to record research in progress. The drug testing results, however,
were available for quotation. Thus, for more than 40 years, the results obtained
from drug testing have been part of the open literature. Unfortunately the
volumes published by the National Academy of Sciences are out of print and
have been unavailable to all but the few individuals who have maintained a
private library of such work. Fortunately, most of these data have now been
included in a computerized database by the NIDA Medications Development
group, and this database can be accessed and utilized by researchers.
GROUPS REPRESENTED IN THE DEC AND THEIR FUNDING
The testing function has evolved over the past 40 years. At this time two
university groups, one at the Medical College of Virginia (MCV) of Virginia
Commonwealth University (headed by Drs. M. Aceto and L. Harris) and the other
at the University of Michigan (UM) Medical School (led by Dr. J. Woods), are
involved with testing potential analgesics, and three groups, one at each of the
above mentioned medical schools (Dr. G. Patrick at MCV, and G. Winger at UM)
and the third at the University of Chicago Medical School, have been involved
with work on stimulants and depressants. Dr. W. Woolverton, who is in charge of
the latter group, will continue the work in the future at the University of Mississippi
Medical Center. The stimulant/depressant work by the consortium of university
groups is carried out through a NIDA grant to Washington University under the
direction of Dr. T. Cicero, the Chairman of the Drug Evaluation Committee. The
analgesic work at the Medical College of Virginia is carried out under a contract
with NIDA, and the work at the University of Michigan Medical School is pursued
with a NIDA grant. Each of these groups receives a supplemental grant from the
CPDD for their research. There are eight members of the Drug Evaluation
Committee, one from each of the five testing groups, Dr. Cicero, myself as
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Biological Coordinator, and Dr. Steve Holtzman, who is also a member of the
Board of the CPDD. Three representatives from NIDA also attended the annual
meeting of the Drug Evaluation Committee.
PROCEDURES FOR EVALUATION OF DRUGS
The analgesic testing program employs some or all of the following assays:
1) Antinociceptive and narcotic antagonist assessment in the mouse.
2) Substitution for morphine and primary physical dependence by rat infusion.
3) Single dose suppression and, if warranted, precipitated withdrawal, as well as
primary physical dependence studies in the rhesus monkey.
4) Opioid receptor binding.
5) Electrical stimulation of the mouse vas deferens.
6) Self-administration in the rhesus monkey.
7) Drug discrimination in the rhesus monkey.
8) Analgesic studies in the rhesus monkey.
9) Respiratory function studies in the rhesus monkey.
The stimulant and depressant groups use the following methodology:
1) Inverted screen test and spontaneous locomotor activity, in mice.
2) Physical dependence potential by substitution in pentobarbital-dependent rats
using continuous intraperitoneal infusion.
3) Primary physical dependence determination in rats, by infusion.
4) Self-administration studies in rhesus monkeys.
5) Drug discrimination studies in rhesus monkeys.
A complete description of each of the tests on potential analgesics can be
obtained from the reports from the Medical College of Virginia (Aceto et al. 1994)
and the Universitv of Michigan (Woods et al. 1994). The procedures used for the
evaluation of stimulants and depressants are described in the group report which
will be written this year by Dr. Graham Patrick (Patrick et al. 1994). All of these
testing procedures were summarized in a previous report (Jacobson 1993).
STATISTICS
About 62 compounds were evaluated as potential analgesics this year at either or
both the Medical College of Virginia and the University of Michigan. Several
others were explored as basic research topics (Aceto et al. 1994) and do not
appear in the tables of this report. For example, researchers at the Medical
College of Virginia investigated the effects of various dynorphins (2-17, 1-13, and
a three amino acid peptide MIF), as well as (-)-nicotine). Of the compounds
which were sent for testing, 5% came from industrial sources (domestic and
foreign), 48% came from university groups (domestic and foreign), 14% were
sent by government agencies, and the remaining 32% came from a non-profit
institution. Except for the diminution of requests for examination of drugs from
industrial sources, a downward trend observed over the last decade, and the
large number from a single group, neither the sources of the drugs nor their
number were particularly unusual.
SURVEY OF EVALUATED COMPOUNDS
1) Analgesics
In order to more easily discern the biological effect of structural changes in a basic
molecular structure, the examined drugs were grouped in structural classes in the
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following 10 tables. More comprehensive data on the individual drugs can be
obtained from the reports of the members of the DEC (Aceto et al. 1994, Woods et
al. 1994).
Two 4,5-epoxymorphinans and two phenylmorphans are shown in table 1, and
eight morphinans, divided between the (+)- and the (-)-enantiomeric series are
listed in table 2. Table 3 displays eight N-substituted benzomorphans, also divided
between the (+)- and the (-)-enantiomeric series. Three arylpiperidines are shown
in table 4, and 18 compounds related to fentanyl are listed in tables 5-7. The
remaining two tables consider the miscellaneous compounds.
Remarkable differences in the activity of enantiomers can be seen among the
fentanyl compounds. For example, there is about a 16,000-fold difference in the
tail flick assay between the enantiomeric NIH 10743 and 10744 (table 5). They are
10,000-fold different in the vas deferens preparation and 10744 was noted to
exhibit only partial agonist properties. NIH 10744 does not substitute for morphine
in the SDS assay in monkeys. Similarly, the enantiomers NIH 10741 and 10742 in
table 5 show even more extreme differences in the vas deferens preparation
(4,000,000-fold different), and appear to be 10,000 to 20,000-fold different in the
SDS assay. One of these fentanyl compounds, NIH 10741, was found to be
20,000 to 50,000 times more potent than morphine in the SDS assay. The potency
of the other fentanyl compounds ranged from morphine-like to 12,000 times more
potent than morphine in that assay. The extremely potent drugs are likely to be
interesting research tools, especially if they are found to be opioid receptor subtype
selective.
An additional compound of interest is NIH 10678 (table 8) which appears to have a
novel profile of action, dissimilar to other opioid agonists and partial agonists.
Structurally, as a two-dimensional drawing, the compound does not appear to have
much resemblance to the usual opioid types.
2) Stimulants and Depressants
The number and origin of stimulants or depressants were not unusual this year.
The NIDA grant for this work is mostly utilized for basic research by the individual
investigators. Four compounds were released for publication this year. That
number of compounds is around the maximum which we are able to examine with
current available resources. Two new compounds were received for evaluation
(5/1/92 to 4/30/92).
This Monograph contains the detailed report (Patrick et al. 1994) on the four
compounds re leased for  publ icat ion.  These are CPDD 0027 (cis-4-
phosphomethyl)-2-piperidinecarboxylic acid), 0035 (1.3.4.16b-tetrahydro-2-
methyl-2 H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4] benzodiazepine-16-carboxylic
acid methyl ester hydrochloride), 0039 (Aminorex hydrochloride [4,5-dihydro-5-
phenyl-2-oxazolamine hydrochloride]), and 0040 (Mesocarb [3-(1-methyl-2-
phenylethyl ) -N-(phenylaminocarbonyl)sydnone imine]) .  The lat ter  two
compounds were submitted by NIDA. The molecular structures of these four
compounds and the summarization of the data collected on them by the
Stimulant/Depressant testing groups in the Drug Evaluation Committee are
shown in table 10.
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ABBREVIATIONS USED IN TABLES 1 - 9
Rounded numbers are used in the tables; M = morphine. For precise values and
details of the procedures see Aceto et al. 1994 and Woods et al. 1994.
For “E” notation: 1E-3 = 1 x 10-3 or 0.001 M (1 µ), 1E-6 = 1 µM, 1E-9 = 1 nM,
1E-12 = 1 pM (picomole), and 1E-15 = 1 fM (femtomole).
1 ) MOUSE E50/AD50: Antinociceptive Assays (SC injection)
Confidence limits are listed in the MCV report (Aceto et al. 1994).
HP = hot plate (morphine ED50 = 0.8 (0.3-1 .8))
PPQ = phenylquinone (morphine ED50 = 0.23 (0.20-0.25))
TF = tail-flick (morphine ED50 = 5.8 (5.7-5.9))
TFA = tail-flick antagonism vs. morphine (naltrexone AD50 = 0.007 (0.002-
0.02); naloxone AD50 = 0.035 (0.01-0.093)).
I = inactive, without a reasonable dose-response relationship, or
insufficiently active for statistical analysis.
2) IN VITRO (Data from UM, Woods et al. 1994)
RBH = binding affinity in rat cerebrum membranes (displacement of 0.5 nM
[3H]etorphine) in the presence of 150mM NaCl (morphine EC50 = 23.6).
NE = no effect.
NOTE: Contemporary EC50 data cannot be directly compared with
those from some previous reports (Jacobson 1985, and
preceding years) which were obtained under “-NaCI” (without
NaCI) conditions.
VD = electrically stimulated mouse vas deferens EC50 values, rounded to
one significant figure. Partial agonist indicated by % inhibition of twitch in
parenthesis; [A] = antagonism by naltrexone.
SE = slight effect on twitch.
NE = No significant agonist or antagonist effect.
ANT = Antagonist activity. Selective antagonist activity at µ
and/or receptors is noted in parentheses. The
antagonist effect may or may not be competitive.
Compounds which suppress the twitch and are not antagonized by
naltrexone or other narcotic antagonists are said to be non-opioid agonists
(e.g., clonidine, a non-opioid agonist, can suppress the twitch but is not
antagonized by naltrexone). Compounds which bind with reasonable affinity
in the RBH assay and do not suppress the twitch in the VD may have narcotic
antagonist properties. The opioid receptor at which the drug exerts its
antagonist effect is determined by testing various concentrations of the drug
to induce a blockade (antagonism) of the suppression of the twitch in the VD
preparation caused by sufentanil (µ), DSLET or U50,488 (for these
data see Woods et al. 1994).
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3) IN VIVO: in the rhesus monkey (from MCV, Aceto et al. 1994; prior to 1988 from
MCV or UM).
SDS = single-dose-suppression
NS = no suppression
CS = complete suppression
PS = partial suppression
(Parenthesized numbers = dose range studied, in mg/kg)
Other Studies (noted in the footnotes to the tables)
A) In Rat:
RI = rat continuous infusion (data from MCV)
1) SM = substitution for morphine
NS = no substitution for morphine
CS = complete substitution
PS = partial substitution
2) PPD = primary physical dependence
B) In Rhesus Monkey:
1) PPt-W = studies in non-withdrawn monkeys (data from MCV)
PW = precipitated-withdrawal at dose levels, in mg/kg, indicated
in parentheses &/or comparison with naloxone [N].
SP = slight precipitation
NP = no precipitation
2) ND = studies using non-dependent monkeys (data from MCV)
M-like = morphine-like effect.
3) PPD = primary physical dependence (data from MCV)
4) SA or SI = self-administration or self-injection (data from UM)
NE = no effect
High = codeine-like
IN = intermediate between saline and codeine
SE = slight effect
5) DD = drug discrimination (data from UM)
NE = no effect
CS = complete substitution
6) MA = monkey analgesia (data from UM)
7) RF = respiratory function (data from UM)
C) In Vitro (data from UM)
BIND - binding affinity using monkey brain cortex membranes
(selectivity for µ, and opioid receptors using [3H]-sufentanil,
[3H]-DPDPE and [3H]-U69,593, respectively).
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Previous Reports
Previous work on a compound is noted using the year listed in the monograph title
(e.g., work cited as “1992” indicates that the work was included in “Problems of
Drug Dependence 1992”, which was published in 1993). Note that the
monograph’s publication date may be one year after the titled year of the
monograph. Complete details of the original work on a compound can be found in
the Annual Report of either Aceto et al. or Woods et al.
TABLE 1. 4,5-EPOXYMORPHINANS AND 5-PHENYLMORPHANSa
a) See text for explanation of column headings and abbreviations.
b) Selective µ-agonist.
c) Prompt action, long duration.
d) W eak -agonist.
e) Does not completely substitute for M or exacerbate withdrawal.
f ) µ- and -agonist.
g) Prompt action, 2.5 hr. duration.
h) Weak, non-selective antagonist, no agonist activity.
i ) Low potency u-partial agonist.
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TABLE 2. MORPHINANSa
a) See text for explanation of column headings and abbreviations.
b) Low potency -antagonist activity (and some -antagonist activity).
c ) No agonist activity, very weak -antagonist with limited selectivity.
d) Partial agonist, weak non-selective antagonist.
e) Weak non-selective antagonist.
f ) Very weak partial agonist only slightly antagonized by naltrexone,
very weak non-selective antagonist.
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TABLE 3. 6, 7-BENZOMORPHANSa
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1993.
c) Non-typical µ- and -agonist, weak µ-antagonist.
d) May exacerbate withdrawal, possible -agonist properties.
e) Weak µ- and -antagonist.
f) Partial agonist, weak non-selective µ- and -antagonist
g) Weak non-competitive -antagonist with limited selectivity.
h) Weak low efficacy partial agonist, antagonized by naloxone at lower
concentrations; non-opioid action at higher concentrations.
i ) May exacerbate withdrawal at 10 mg/kg.
j ) Low efficacy partial agonist or non-opioid.
k) Weak non-selective antagonist.
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TABLE 4.  ARYLPlPERlDlNESa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPQ TF TFA RBH VD SDS
10688 I b 5 . 4 b I b I b 1 0 . 3 µ M b S E b , c PS(4,24)b , d , e , f
10738 - - - - 3 .4µM A N T g -
10739 - - - - 1.3µM A N T h -
10795 - - - - 5 0 7 n M A N T I -
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1992.
c ) Unusual partial agonist with doubtful opioid action.
d) RI( SM: NS, but behavioral suppression; and PPD: PS): Doubtful µ-like
dependence potential
DD - agonist effects (>5.6 mg/kg), no µ agonist or antagonist activity;
MA - 100% effect (10 mg/kg, 50°, attenuated by quadazocine);
RF - decreased function (attenuated by quadazocine);
SA - limited reinforcing capacity.
f ) New data - PPD (monkeys) - produced physical dependence, probably
µ-related and, possibly, and/or dopaminergic.
g) Low potency - and -antagonist; not simple competitive-type.
h) Low potency, mostly -antagonist (some k-antagonism); not competitive.
i ) Weak, partial agonist, non-opioid; weak non-selective antagonist.
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TABLE 5. FENTANYL-LIKE COMPOUNDSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP P P Q T F T F A RBH V D S D S
10740 1.8 0.8 0.9 I 3 µM 2  µM(47)[A]b CS(0.3-3.6)
10741 0.0001 9 E - 5 2E-4c I 5.9 nM 5 6 f M [ A ]
d C S
(1.5E-4-3E-5)e
10742 0.08 0.03 0.06c I 102 nM 1.4uM[A]
f CS[30 x M]
10743 0.0013 1.2E-4 8E-4c I 6.8 nM 9 6 f M [ A ] g CS[1500 x M]
10744 2 . 1 0.6 13.0 I 380 nM 1nM(28)[A]h NS(0.6,12)i
10745 0.7 0.09 0 . 6 c I 410 nM 7.6 nM[A] CS[4-6 x M]
a ) See text for explanation of column headings and abbreviations.
b ) No significant agonist or antagonist activity.
c ) Naloxone (AD50) vs ED80 of 10741=0.008, of 10742 and 10745=0.03, of
10743=0.035.
d) Biphasic (also, 4 nM[A]).
e) 20,000-50,000 x M.
f ) Biphasic.
g ) Biphasic (also, 6.7E-9[A]).
h) Weak partial µ-agonist, and weak µ-antagonist.
i ) Biphasic (weak antagonist at lower doses; no effect at highest dose).
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TABLE 6. FENTANYL-LIKE COMPOUNDS (CONTINUED)a
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPQ T F TFA RBH VD SDS
10754 0.004 4E-4 0.001 I 28.4 nM 32 nM[A]b CS[2000 x M]
10755 0.16 0.07 0.12c I 377 nM 90 nM(85)[A] CS[10 x M]
10756 0.18 0.03 0.14c I 1037 nM 310nM(91)[A]d CS[6 x M]
10757 0.006 1E-3 3.6E-3 I 48.2 nM Agoniste CS[300 x M]
10761 4E-4 1E-4 4E-4 c I 1.02 nM 33 nMf CS[6000 x M]
10762 0.24 0.02 0.03c I - - CS[60 x M]
a) See text for explanation of column headings and abbreviations.
b) Actions at µ- and opioid receptors.
c) Naloxone (AD50) vs ED80 of 10755=0.04, of 10756=0.11, of 10761=0.04,
and of 10762=0.03.
d) Partial agonist, u-selective.
e) Fairly potent, multiphasic action.
f) Only slightly antagonized by µ-, or k-antagonists; possible -agonist
and µ-antagonist activity.
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TABLE 7. FENTANYL-LIKE COMPOUNDS (CONTINUED)a
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPQ TF TFA RBH VD SDS
10763 2E-3 1E-4 1E-3 b I 5.6 nM 113 nM
c CS
[1500 x M]
10765 3 . 4 0.1 3.0 I - - CS[1.5 x M]
10732; 0 . 6
d
0 . 3 d 0 . 7
d
I d 3 µMd 15.7 µMd,e CS[12 x M]
d
10774 5.3 µM 1.6 µM(85)[A]f
10731; 4E-3d 1E-3d 3E-3d I d 7.3 nMd 300nM[NA] d , g CS[750 x M]
d
10776 2.8 nM 3 n M [ A ] h
10783 9E-3 3E-4 2E-3 I 19 nM 7 nM [A]
i CS
[12,000xM]
10784 - - - - 6.5 nM 7.6 nM[A]i -
a) See text for explanation of column headings and abbreviations.
b) Naloxone (AD50) vs ED80 = 0.02.
c) Slight antagonism by µ- and k-antagonists.
d) Published in 1992.
e) Slight shift by µ- and antagonists; actions possibly non-opioid.
f ) µ-selective agonist.
g) Non-opioid action.
h) Potent agonist primarily at and, possibly, p-receptors.
i) Potent µ-agonist.
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TABLE 8. MISCELLANEOUSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPQ TF TFA R B H V D SDS
10678 - 0.9 13.7 I 216 nMb 734 nM(90)[A] CS[0.5 x M]c
10707 I 5.6 I I >6 µM N E NS(2.5,10)
10708 - - - - >6 µM 58 nM(22) -
10710 I I I I - - NS(2 ,8) d , e
10711 I f I f I
f I 5.6 µM 1.7µM[A]g PS(2,10)
10712 - - - - >6 µM 9 1  µ M [ A ] h -
10714 I I I I >6 µM ANT i -
10715 I I I I >6 µM 10 nM(33) -
10716 I I I I >6 µM ANT j NS(1.8-6.4)
a) See text for explanation of column headings and abbreviations.
b) BIND: µ=40 nM =727 nM, k=86 nM.
c) PPD : produced physical dependence. Study terminated because of skin
ulcers; DD: No discriminative effect; RF: non-opioid, similar to competitive
NMDA antagonists and ketamine-like drugs; MA: inactive, but augments
effect of  µ- or k-agonists; SA: Maintained rates of responding slightly
below alfentanil at one dose only.
d ) May exacerbate withdrawal.
e) PPt-W: NP(3,12); RI (PPD): low or no physical dependence.
f ) Delayed effects or delayed absorption due to vehicle (gum tragacanth).
g) Unusual agonist with µ-, -,and -effects.
h) -, or µ- agonist actions.
i ) µ - , -antagonist at high concentrations.
j ) Competitive µ-antagonist.
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TABLE 9. MISCELLANEOUS (CONTINUED)a
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPQ T F TFA RBH V D SDS
10759 I I I I >6 µM NE NS(2-24)b
10760 I I I I >6 µM 3.9 nM(41)c NS(2-12)d
10766 5.3 0.07 I I >6 µMc 4.1 µM
c PS(0.25,1.0)
a) See text for explanation of column headings and abbreviations.
b) SA: Reinforcing properties (like alfentanil) in only one out of four
c) Non-opioid or partial low efficacy agonist, u-selective.
d ) SA: No reinforcing properties.
monkeys.
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TABLE 10. EVALUATION OF STIMULANT/DEPRESSANT DRUGS
CPDD# SLAa I S b PD-Sc PD-PPDd S A e D D f
0027 D E P R E S S . g DEPRESS. N O h MILD i NO j NO k
0035 D E P R E S S . I DEPRESS. I N O m - NO N O n
0039 STIMULANT N O o Y E S p - YES
q YES r
0040 STIMULANT NO _ t - YESu YES r
a) Spontaneous locomotor activity (mouse).
b) Inverted screen assay (mouse).
c ) Physical dependence - substitution for pentobarbital (rat infusion).
d ) Physical dependence - primary (rat infusion).
e ) Self-administration (monkey).
f ) Drug discrimination (intragastric administration, monkey).
g) Depression: ED50= 3 mg/kg (5 to 8 x more potent than pentobarbital).
h) Did not substitute for pentobarbital to prevent weight loss on withdrawal.
i ) Mild abstinence on abrupt withdrawal; unlike pentobarbital or
benzodiazepines.
j ) Reinforcing effects in one out of three monkeys; ataxic at 1.O mg/kg/inj.
k) Does not share discriminative stimulus effects with c/-amphetamine or
pentobarbital after intravenous, intramuscular, or intragastric administration.
I ) Slightly more potent than pentobarbital.
m) Lack of suppression may be due low doses necessitated by drug insolubility.
n) Does not share discriminative stimulus effects with &amphetamine or
pentobarbital.
o ) Impairment observed at highest dose (20 mg/kg) due to toxicity.
p) Exacerbation of withdrawal in pentobarbital-treated rats; potency and
duration of action greater than cocaine in cocaine-infused rats.
q) Variability within animals.
r ) Discriminative stimulus effects similar to &amphetamine, but not to
pentobarbital.
s) Stimulant efficacy and potency slightly greater than cocaine.
t ) Insufficient solubility for assay.
u) Reinforcing effects; limited by solubility of compound.
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EVALUATION OF NEW COMPOUNDS FOR OPIOID ACTIVITY
ANNUAL REPORT (1993)
J. H. Woods, C. P. France, F. Medzihradsky, C. B. Smith and G. D. Winger
This report contains information on opioid abuse liability evaluations on compounds that have
been submitted to the Drug Evaluation Committee of the College and released for publication
by the submitters. The information obtained can involve both in vitro evaluation in opioid
binding assays and smooth muscle (largely, mouse vas deferens) preparations. In addition, the
compounds may be evaluated for discriminative and reinforcing effects. Analgesic and
respiratory function assays are also possible. These behavioral assessments are conducted in
rhesus monkeys. Each of these assays is described below. Usually when limited information
is provided ( e.g., in vitro assessment only), it is because the sample provided by the submitter
was insufficient to carry out further evaluation.
The evaluation of new compounds by the programs at the University of Michigan and the
Medical College of Virginia is coordinated by Dr. Arthur E. Jacobson, Laboratory of Medicinal
Chemistry, NIDDK, National Institutes of Health, Bethesda, MD. The drugs, which come
originally from pharmaceutical companies, universities, government laboratories, and
international organizations are submitted to Dr. Jacobson.
At the UM and MCV laboratories, drug samples arrive from Dr. Jacobson with only the
following information: (1) an identifying NIH number, (2) molecular weight, (3) solubility
information and (4) a recommended starting dose. After the evaluation is complete and the
report submitted to Dr. Jacobson, the submitter is requested to release the chemical structure to
include with the evaluation data in the ANNUAL REPORT. The submitter has up to three years
before release of the structure is required. When the structure is released all of the data on the
compound are reported to the Drug Evaluation Committee.
DRUG DISCRIMINATION IN RHESUS MONKEYS
We currently use three groups of monkeys to test the discriminative stimulus effects of submitted
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drugs: one of these groups discriminates the administration of the agonist ethylketazocine
(EKC); a second group discriminates the µ agonist alfentanil; a third group is treated daily with
morphine and discriminates the opioid antagonist naltrexone.
The procedures used with the EKC-trained monkeys have been described by Bertalmio et al.
(1982). The monkeys are removed from their home cages each day and seated in primate
restraining chairs. These chairs are placed in isolation chambers equipped with two response
levers, several stimulus lights and a cup to receive Noyes, banana-flavored pellets. These
monkeys are required to make 100 consecutive responses on the correct one of the two levers
and receive ten 300-mg food pellets. The right lever is correct if they were given a
subcutaneous injection of 0.0032 mg/kg EKC immediately prior to the start of the cycle. The
left lever is designated correct if they were given a sham injection before the start of the cycle.
Bach cycle lasts 15-min and consists of an initial 10-min black out period followed by a period
of as long as 5 min, during which a blue light is illuminated in the chamber and the monkey can
respond for food. If the food pellets are delivered before the 5 min period is completed, the
lights are extinguished for the remainder of this time. Typically, a daily session consists of
several 15 min cycles. During a training session, if EKC is given, it is given on the penultimate
cycle of that session. Responding on the drug-appropriate lever is reinforced during that cycle
and on the subsequent, final cycle of the day. These last two cycles may be preceded by from
zero to four sham cycles on a training day. A training session of six sham cycles is also
scheduled from time to time.
With this type of multiple, discrete-cycle training, the animals can be tested with a cumulative
dosing procedure. On a test session, the first cycle is preceded by an injection of saline, and
prior to subsequent cycles, increasing, cumulative doses of the test drug are administered. One
hundred consecutive responses on either lever are reinforced throughout the test session. The
test drug is administered in increasing doses until the monkey either responds on the drug-
appropriate lever, the response rate falls to less than half of the saline-control rate, or six cycles
are given. In the latter situation, it is assumed that the selected dose range is too low, and the
test is continued at higher doses on the next test session. Bach test session is preceded and
followed by a training session. The criterion for satisfactory performance must be met on each
training session that is followed by a test session. This criterion is that at least 90% of the
responses during each cycle of a training session must be on the injection-appropriate lever,
either sham or EKC.
The procedure for the alfentanil-trained monkeys is similar, but not identical. These animals
are also trained and tested in a discrete, multiple-cycle procedure. The main difference between
the alfentanil procedure and the EKC procedure is that the alfentanil monkeys are required to
make 20 rather than 100 responses, and they receive a single pellet for correct responses. They
can receive as many as 10 pellets during the 5-min, food-availability period of each cycle, but
each pellet is delivered after 20 responses. Because in this procedure, monkeys can switch
from one lever to another following the delivery of food, an additional criterion is added for
satisfactory performance. In addition to making 90% or more of their responses on the correct
lever, the monkeys must make fewer than 20 responses on the incorrect lever prior to delivery
of the first food pellet of each cycle. Tests of the discriminative stimulus effects of submitted
drugs in the alfentanil-trained monkeys are also done using a cumulative dosing procedure with
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dosing criteria identical to those used in the EKC-trained monkeys.
The procedure for studying discriminative stimulus effects in morphine-treated monkeys has been
described previously (France and Woods, 1989). Daily comprised of a 10-min time out during
which lever presses have no programmed consequence and a 5-min response period during which
green stimulus lights are illuminated and signal the activation of a schedule of stimulus-shock
termination. sessions consist of between two and six discrete, 15-min cycles with each cycle,
Under these experimental conditions electric shock is scheduled to be delivered to the subject’s
feet every 15 seconds; monkeys can terminate the lights and postpone scheduled shocks for 30
seconds by pressing five times consecutively (i .e ., fixed-ratio 5) the lever appropriate for the
solution administered during the first minute of the time out (left lever, saline; right lever,
naltrexone). Monkeys receive an injection of saline (0.1 ml/kg) or drug (0.01 mg/kg naltrexone)
during the first minute of each time out. On drug training days a single injection of naltrexone
is administered during one time out and for that cycle and all subsequent cycles on that day only
responding on the right lever postpones shocks. A variable number of saline cycles (O-5)
precede the naltrexone cycle and on some days saline is administered during the time out of all
cycles. Under these conditions monkeys switch their response choice from the saline lever to
the naltrexone lever with complete generalization occurring in all three subjects at a dose of 0.01
mg/kg. Responding on the naltrexone lever is accompanied by other behavioral effects
indicative of opioid withdrawal (e.g., irritability, miosis, salivation). Moreover, when saline
is substituted for the daily injection of 3.2 mg/kg of morphine monkeys respond predominantly
on the naltrexone lever and show directly observable signs of withdrawal; the discriminative
stimulus and other effects produced by morphine abstinence are reversed by some opioid agonists
(e.g., alfentanil; France and Woods, 1989; France et al., 1990).
For test sessions increasing doses of drug are administered during the first minute of consecutive
time outs and five consecutive responses on either lever postpone shocks. In monkeys that
receive 3.2 mg/kg of morphine 3 hours earlier, increasing doses of a test compound are
administered up to doses that produce an average of at least 80% responding on the naltrexone
lever or to doses that disrupt responding and result in the delivery of electric shock. Drugs that
do not substitute for naltrexone (i .e ., precipitate withdrawal) are also studied’ for their ability to
reverse responding on the naltrexone lever in morphine-abstinent (i.e., withdrawn) subjects.
Test compounds are studied using a cumulative-dosing procedure in morphine-abstinent monkeys
up to doses that reverse completely responding on the naltrexone lever (< 20%) or to doses that
disrupt responding. Some compounds that substitute for naltrexone also are studied for their
capacity to prevent the effects of cumulative doses of opioid agonists. Monkeys that receive
saline three hours earlier, rather than the daily injection of morphine, receive saline (control)
or a single injection of test compound during the first cycle and increasing doses of agonist
(alfentanil or morphine) during subsequent cycles. Agonists are administered up to doses that
produce a switch from the naltrexone lever to the saline lever or to doses that disrupt responding
and result in the delivery of electric shock.
DEPENDENCE EVALUATION IN RHESUS MONKEYS
Details of these techniques have been presented in the ANNUAL REPORT to the Committee
in 1963 (Minutes of the 25th Meeting) by Deneau and Seevers (1963) and by Villarreal (1973).
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ANALGESIA IN RHESUS MONKEYS
The tail withdrawal procedure used to study analgesic effects of test compounds in rhesus
monkeys has been described previously (Dykstra and Woods, 1986). Monkeys are restrained
loosely at the neck and arms while seated in Plexiglas primate chairs. For tests of tail
withdrawal latency, the lower 10-12 cm of the shaved tail is immersed in a thermos containing
water at 40°, 50°, or 55° C and the latency until the tail is withdrawn from the thermos is
recorded for each monkey at each temperature. When the tail is not withdrawn within 20
seconds (cut-off latency) the experimenter removes the thermos and a latency of 20 seconds is
recorded. Experimental sessions begin with several exposures to 40° C water. Four or five
monkeys are tested consecutively and the time between tail immersions for individual monkeys
is 5 minutes. Generally, 40° C water does not produce tail withdrawal in rhesus monkeys
(Dykstra and Woods, 1986); however, if a monkey fails to keep its tail in 40° C water for 20
seconds on at least 3 of 4 immersions, that animal is not tested further for that particular session.
In a subsequent pre-test component, tails are immersed in 40°, 50°, and 55° C water. The
order in which the three temperatures are presented is varied among subjects. If the latencies
for tail withdrawal in the pre-test component are at or near 20 seconds for 40° C water and less
than 5 seconds for 55° C water, monkeys receive the test compound. The test is identical to
the pretest, except that monkeys receive s.c. injections of drug 10 minutes prior to tail
immersion. The time between immersions for individual subjects is 5 minutes or less and the
order in which temperatures are presented varies among subjects and across cycles. The
interinjection interval typically is 30 minutes and between four and six doses are studied in a
single experiment using the cumulative dosing procedure. For some studies a single dose of an
opioid antagonist is administered prior to the test compound and for other studies a single dose
of test compound is administered prior to increasing doses of a µ (e.g., alfentanil) or ( e .g . ,
U-50,488) opioid agonist.
RESPIRATORY FUNCTION STUDIES IN RHESUS MONKEYS
The effects of test compounds on ventilatory function are studied in rhesus monkeys breathing
air or 5% CO2 in air (France and Woods, 1990; Howell et al., 1988). Monkeys are restrained
at the neck and waist while seated in a Plexiglas primate chair. Normal air or 5% CO2 in air
is delivered at a rate of 10 l/min into a sealed helmet placed over the subject’s head. Changes
in pressure within the helmet are measured and recorded by a transducer and a microprocessor,
and are transformed according to known standards to frequency of respiration (f) in
breaths/minute and to tidal volume (VT) in ml/inspiration. Data are recorded continuously
during 23-minute exposures to air alternating with 7-minute exposures to CO2 The last 3
minutes of exposure to CO2 are used for data analyses and are compared to the last 3 minutes
of exposure to air only. Increasing doses of drug are administered during the first minute of
consecutive time outs so that the interinjection interval is 30 minutes. For some studies a single
injection of an opioid antagonist is administered prior to increasing doses of a test compound and
for other studies a single injection of test compound is administered prior to cumulative doses
of a standard compound (e.g., alfentanil).
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SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug to maintain responding in monkeys
trained to self-inject codeine. Bach of at least three monkeys is studied with saline as a negative
control and a number of doses of the test compound until a maximum rate of responding was
obtained or until, in the absence of evidence of a reinforcing effect, observable changes in
behavior are produced by the compound.
The schedule of intravenous drug delivery is a fixed-ratio 30; when a light above a lever is
illuminated, the 30th response produce an intravenous drug injection accompanied by another
light that is illuminated during drug delivery. After each injection, a 45 sec timeout period
occurred. A component of the session ended after 20 injections had been received or 25 min
had passed, whichever occurred first. Different doses of the drug was available during each of
four components of a session. Other procedural details are given in Winger et al. (1989).
DISPLACEMENT OF RADIOLABELED LIGAND BINDING
Details of the binding assay based on the displacement of 3H-etorphine in rat brain membranes
have been described previously (Medzihradsky et al., 1984). Briefly, aliquots of a membrane
preparation from rat cerebrum are incubated with 3H-etorphine in the presence of 150 mM NaCl,
and in the presence of different concentrations of the drug under investigation. Specific, i.e.,
opioid-receptor-related interaction of 3H-etorphine is determined as the difference in binding
obtained in the absence and presence of an appropriate excess of unlabeled etorphine. The
potency of the drugs in displacing the specific binding of 3H-etorphine is determined from log-
probit plots of the data. See Table I for representative results with different opioids.
To enhance the characterization of novel opioids, we are also investigating their selectivity in
binding to µ-, , and -opioid receptors in membranes from monkey brain cortex. Thus, we
are now providing EC50 values of the tested compounds in displacing the following radiolabeled
opioid ligands:
etorphine (nonselective, reflects opioid character),
sufentanil or Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO); (µ selective),
[D-Pen2-D-Pen5]enkephalin (DPDPE; selective),
U-69,593 ( selective).
Using the receptor-specific assays, we have described the selectivity of various established
opioids in brain membranes of different species (Clark et al., 1988). The selection of monkey
brain as the tissue for the selective binding assays strengthens the correlation between this in
vitro assessment and the behavioral evaluation of the tested compounds. In the ANNUAL
REPORT, the results of the selective binding assays are listed under “Binding in monkey brain
cortex”. See Table II for representative results with different opioids in rat and monkey brain.
Based on ligand binding, a method was recently developed for the determination of lipophilicity
of opioids (Medzihradsky et al., 1992). The procedure offers the routine determination of the
octanol-water partition coefficients, requires submilligram amounts of the compounds, and yields
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accuracy that is comparable to other, less sensitive and more cumbersome methods of
quantitation. Considering the significance of lipophilicity in the function of opioids, the
lipid/water partition coefficient should be a valuable biochemical determinant in the preclinical
evaluation of opioids (Medzihradsky, 1987).
TABLE I
EC50's of representative opioids for displacement of 0.5 nM 
3H-etorphine from rat brain
membrane, and inhibition of the twitch of the mouse vas deferens preparation.
Compound BINDING* MVD
EC50 (nM)
DPDPE - - -
U50,488 - - -
Fentanyl
DAMGO
Etorphine
(-)Cyclazocine
Naltrexone - - -
Bremazocine
UM 1071R** - - -
Sufentanil
(-)SKF l0047 - - -
Ethylketazocine
Ketazocine
Morphine
DSLET
Dextrorphan
36.2
23.9
0.37
0.53
0.63
1.42
1.55
1.60
3.93
6.60
14.1
23.6
43.0
<6000
5.52
6.29
37.1
81.3
0.0068
11.9
0.29
4.43
11.6
1.18
3 9 5
1.71
1010
* In the presence of 150 mM NaCl.
**1R-5R-9R-2”R-5,9dimethyl-2’-hydroxy-2-tetrahydrofurfuryl-6obenzomorphanhydrochloride
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TABLE II
Inhibition of radiolabeled sufentanil, DPDPE and U69, 593 binding in rat and monkey brain. In membranes from
rat cerebrum and monkey brain cortex, the inhibition of specific equilibrium binding of 0.5 nM [3H]sufentil, 1.5
nM [³H]DPDPE and 1.5 nM [3H]U69, 593 by five different concentrations of the listed compounds was investigated
in the presence. of 150 mM NaC1 (modified from Clark et al., 1988).
EC50 (nM)
Compound [³H]Sufentanil [³H] DPDPE [³H]U69,593
Rat Cerebrum
DAMGO
Sufentanil
Morphine
ß-FNA
ß-CNA
Naloxone
Etorphine
Buprenorphine
Bremazocine
Superfit
DSLET*
ICI-174,864
DPDPE
U50,488
U69,593
13.2
1.25
31.4
6.99
1.29
6.37
0.60
1.07
1.79
576
121
58900
7720
7230
690
45.0
422
43.9
7.48
14.3
1.13
1.12
1.12
16.5
1 . 0 5
59.0
6.44
13100
1340038000
Monkey cortex
Sufentanil 1.18 81.1 >lOOOO
DPDPE 18900 4.21 > l O O O
U69,593 10700 17000 8.41
*(D-Ser2,Leu5)enkephalin-Thr6
Within our goal to enhance the molecular characterization of novel opioids (Medzihradsky, 1987)
we have established functional assays for assessing receptor-effector interactions, reflecting
receptor coupling to regulatory G protein and adenylate cyclase, respectively. The methods are
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based on the stimulation of brain GTPase and inhibition of adenylate cyclase by opioid agonists,
processes blocked by antagonists (Clark and Medzihradsky, 1987; Carter and Medzihradsky,
1992). We are presently evaluating the quantitative responses of partial and irreversible agonists
in these assays.
ISOLATED, ELECTRICALLY-STlMULATED MOUSE VAS DEFERENS PREPARATION
The development of new, highly selective antagonists such as the reversible K receptor antagonist
norbinaltorphimine (Smith et al., 1989) and the competitive receptor antagonist ICI-174864
have made possible the evaluation of selectivity of opioid agonists and antagonists by use of the
mouse vas deferens preparation. Male, albino ICR mice, weighing between 25 and 30 g, are
used. The mice are decapitated, the Vasa deferentia removed, and 1.5 cm segments are
suspended in organ baths which contain 30 ml of a modified Kreb’s physiological buffer. The
buffer contains the following (mM): NaC1, 118; KC1, 4.75; CaCl2 2.54; MgSO4, 1.19;
KH2 ,PO4 , 1.19; glucose, 11; NaHCO3 , 25; pargyline HCl, 0.3; and disodium edetate, 0.03. The
buffer is saturated with 95% O2 - 5% CO2 and kept at 37° C. The segments are attached to
strain gauge transducers and suspended between two platinum electrodes. After a 30-min
equilibration period, the segments are stimulated once every 10 sec with pairs of pulses of 2
msec duration, 1 msec apart and at supramaximal voltage. See Table III for potencies of
representative agonists
The following antagonists are studied: naltrexone HC1, ICI-1 74864 [N,N-diallyl-Tyr-Aib-Aib-
Phe-Leu-OH] and norbinaltorphimine. The antagonists are added to the organ baths 15 minutes
before the determination of cumulative concentration-effect relationships for the various agonists.
See Table III for the potencies of different competitive antagonists studied in relation to
prototypic agonists. EC50’s are calculated by probit analysis, and pA2 values are determined to
assess relative potencies of antagonists.
All drugs which are submitted for evaluation are studied in the following manner: 1) the
submitted drug is tested on the vas deferens preparation in the absence and in the presence of
a concentration of naltrexone sufficient to block µ, a n d receptors. 2) If the submitted drug
inhibits the twitch and its actions are blocked by naltrexone, it is evaluated further in the absence
and presence of ICI-174864 and norbinaltorphimine used in concentrations at which these
antagonists are selective for and receptors, respectively. 3) If the submitted drug is a partial
agonist or devoid of agonistic activity at opioid receptors, it is evaluated further as an antagonist
against the following agonists: sufentanil
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TABLE III
Potencies of antagonists assessed in the mouse vas deferens
pA2 values* determined with three agonists
Sufentanil (µ) U50,488 ( ) DSLET )
Antagonist
Naltrexone 8.76 7.74 7.41
Naloxone 7.99 6.90 7.35
Cyprodime* 7.41 6.15 5 . 9 8
Nalbuphine 7.23 6.31 5 . 7 6
Naltrindole 7.71 7.38 9.44
ICI-174,864 <5.00 <5.00 7.90
*The pA2 value is the negative logarithm of the molar concentration of antagonist necessary to shift the agonist
concentration-effect curve to the right by a factor of 2-fold.
(µ selective), DSLET ( selective) and U50,488 (k selective). If the submitted drug has
antagonistic activity against any or all of the receptor-selective agonists or upon any of the other
preparations used in the Drug Evaluation Unit, the type of antagonism (competitive,
noncompetitive, irreversible) is determined. For further details of the procedure and for a
description of experiments in which ß-funaltrexamine was used see Smith (1986). Drugs studied
in the preparation prior to 1987 were evaluated with the protocol reported in the 1985 Annual
Report.
2 0 4
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan during the past year, and
the individual tests which were performed are shown in Table IV. Also shown are dates of
Reports to the Biological Coordinator, Dr. A.E. Jacobson, in which results are reported.
TABLE IV
SUMMARY OF TESTS PERFORMED
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Table IV (continued)
* Date  report was submitted to CPDD Biological Coordinator.  MBC  = Monkey Brain Cortex
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N I H  1 0 6 6 1 6-O-ß-D-Glucopyranosylmorphine
DISPLACEMENT OF
[3H]ETORPHINE BINDING
EC50 of 40.4 nM in the presence of 150 mM
NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10661 was studied upon the isolated, electrically stimulated mouse vas deferens preparation
in concentrations which ranged from 10-9 M to 3 x 10-5 M. Concentrations between 10--8 M and
3 x 105 M caused an inhibition of the twitch. The EC50 for NIH 10661 was 1.67 x 10
-7 M ±
0.26, and the maximum response was a 100% inhibition of the twitch (n= 11). Naltrexone
caused a (21.7-fold) shift to the right in the concentration-effect curve. In the presence of
naltrexone, 107 M, the EC for NIH 10661 was 3.62 x 10-6 M ± 0.29, and the maximum
response was a 98.5 ± 1.5% inhibition of the twitch (n=3). Neither ICI-174,864 (a
antagonist) nor nor-binaltorphimine (a k antagonist) significantly shifted the NIH 10661
concentration-effect curve. In the presence of ICI-174,864, 10-7 M, the EC50 for NIH 10661 was
4.59 x l0-7 M ± 2.45, and the maximum response was a 99.6 ± 0.4% inhibition of the twitch
(n=5). In the presence of nor- binaltorphimine, 10-8 M, the EC50 for NIH 10661 was 3.05 x
1O-7 M ± 1.15, and the maximum response was a 100% inhibition of the twitch (n=3).
SUMMARY
The in vitro preparations indicate significant morphine-like potency. NIH 10661 is selectively
antagonized by compounds active at the µ receptor.
* * *
NIH 10662 6-O-ß-D-Glucopyranosylcodeine
DISPLACEMENT OF
[3H]ETORPHINE BINDING
EC50 of 6377 nM in the presence of 150
mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10662 was studied upon the isolated, electrically stimulated mouse vas deferens preparation
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NIH 10662 (continued)
in concentrations which ranged from 10-6 M to 3 x 10-4 M. Concentrations between 3 x 10-6 and
3 x 10-4 M caused an inhibition of the twitch. The EC50 for NIH 10662 was 1.23 x 10
-5 M ±
0.25, and the maximum response was a 80.6 ± 9.4% inhibition of the twitch (n=9).
Naltrexone and nor-binaltorphimine, but not ICI-174864, blocked the inhibitory actions of NIH
10662. In the presence of naltrexone, 10-7 M, the EC50 for NIH 10662 was 9.21 x 10
-5 M ±
1.81 (a 7.5-fold shift), and the maximum response was 70.4 ± 8.8% inhibition of the twitch
(n=3). In the presence of nor-binaltorphimine (an antagonist selective for k receptors), 10-8 M,
the EC50 for NIH 10662 was 8.61 x 10
-6 M ± 7.25, but the maximum response was a 28.9 ±
13.6% inhibition of the twitch (n=3). In the presence of ICI-174864 (an antagonist selective
for receptors), 10-7 M, the EC50 for NIH 10662 was 8.86 x 10-7 M ±. 4.06, and the maximum
response was 53.2 ± 13.3%% inhibition of the twitch (n=3).
SUMMARY
NIH 10662 was a very low potency compound in both preparations. It was a agonist in the
vas deferens.
* * *
NIH 10678 (-)-1-(4-Chlorophenyl)-N,N-dimethyl-1-ethyl-4-phenylbut-3-en-1ylamine
hydrochloride
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of 216 nM in the presence of 150 mM NaCl.
MONKEY BRAIN CORTEX BINDING
This finding was obtained in displacing the specific equilibrium binding of (a) 0.5 nM
[³H]DAG0 (µ-selective assay), (b) 1.5 nM [3H]DPDPE ( specific assay), and in 1.5 nM
[³H]U69,593 (k-selective assay) in membranes from monkey brain cortex suspended in 50 mM
Tris.HCl buffer pH 7.4) containing 150 mM NaC1. EC50 ’s (nM) are as follows:
(a) µ-receptor 39.6 nM
(b)
( c )
-receptor 727.0 nM
-receptor 86.2 nM
MOUSE VAS DEFERENS PREPARATION
NIH 10678 was studied upon the isolated, electrically stimulated mouse vas deferens preparation
in concentrations which ranged from 10-8 M to 3 x l0-5 M. Concentrations between 10-7 M and
3 x 10-5 caused an inhibition of the twitch. The EC50 for NIH 10678 was 7.34 x 10
-7 ± 0.58,
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NIH 10678 (continued)
and the maximum response was a 90.3 ± 1.9% inhibition of the twitch (n=9). Naltrexone
caused a marked decrease in the magnitude of the maximum response to NIH 10678 without
changing the EC50 . In the presence of naltrexone, 10
-7 M, the EC50 for NIH 10678 was 6.57 x
l0-7 M ± 0.46, and the maximum response was a 27.7 ± 7.8% inhibition of the twitch. ICI
174864 (a antagonist) did not shift the NIH 10678 concentration-effect curve. In the presence
of ICI 174864, 10-7 M, the EC for NIH 10678 was 6.62 x 10 M ± 2.00, and the maximum
response was a 90.6 ±. 4.4% inhibition of the twitch (n=3). Nor-binaltorphimine (a k antago-
nist) caused a slight decrease in the maximum response to NIH 10678. In the presence of nor-
binaltorphimine, 10-8 M, the EC50 for NIH 10678 was 7.83 x 10
-7 M ± 1.13, and the maximum
response was a 75.7 ± 4.2% inhibition of the twitch.
DISCRIMINATIVE STIMULUS, ANALGESIC AND RESPIRATORY FUNCTION
STUDIES IN RHESUS MONKEYS.
NIH 10678 was studied in rhesus monkeys for its discriminative stimulus effects, analgesic
effects, and effects on respiratory function. In monkeys discriminating between saline and
0.0056 mg/kg of the opioid µ agonist alfentanil, NIH 10678 did not substitute completely for
alfentanil up to a dose of 3.2 mg/kg. Only on one occasion did subjects respond on the
alfentanil-associated lever after receiving 3.2 mg/kg of NIH 10678. This discriminative stimulus
effect of NIH 10678 was not clearly antagonized by pretreatment with 0.1 mg/kg of the opioid
antagonist quadazocine. The limited solubility of NIH 10678 precludes a complete evaluation
of this apparent discriminative stimulus effect.
Up to the largest dose that could be administered (3.2 mg/kg), NIH 10678 failed to substitute
for ethylketocyclazocine in normal monkeys and failed to substitute for naltrexone in morphine-
treated (3.2 mg/kg/day) monkeys discriminating between 0.032 mg/kg of naltrexone and saline.
When saline is substituted for the daily injection of morphine in monkeys discriminating between
naltrexone and saline, subjects respond on the naltrexone lever; this naltrexone-appropriate
responding is reversed by morphine-like opioids (e.g., alfentanil) and appears to be related to
opioid withdrawal. Up to a dose of 3.2 mg/kg, NIH 10678 failed to reverse naltrexone-lever
responding in morphine-withdrawn monkeys. Thus, NIH 10678 does not appear to have either
µ, k, nor µ antagonist discriminative stimulus effects in rhesus monkeys. NIH 10678 had little
or no effect on rates of lever pressing.
NIH 10678 was studied for its effects on the latency of monkeys to remove their tails from
warm water. Up to a dose of 3.2 mg/kg, NIH 10678 had no effect on tail withdrawal latency
from 50 or 55° C. water. When administered as a pretreatment to a dose-effect determination
for alfentanil or the k agonist U-50,488, NIH 10678 appeared to augment the analgesic effects
of each agonist as reflected by shifts to the left in the alfentanil and U-50,488 dose-effect curves.
The effects of NIH 10678 on respiratory function were studied in a monkey breathing air or 5 %
CO2 in air. Up to a dose of 0.32 mg/kg, NIH 10678 produced a slight increase in ventilatory
frequency (f) and a slight decrease (< 30%) in ventilatory volume (VT) resulting in little change
in minute volume. Doses larger than 0.32 mg/kg decreased Vr further but did not increase f,
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NIH 10678 (continued)
producing a net decrease in minute volume. The pattern and magnitude of effects observed with
NIH 10678 in studies of respiratory function (decreases in VT and increases in f) are similar to
results obtained in this procedure with nonopioids, including ketamine-like compounds and
competitive NMDA antagonists.
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10678 were evaluated in three monkeys experienced in
responding and receiving intravenous infusions of alfentanil. The program was one in which
four doses of alfentanil were available during each 130 min session. Each dose was available
for 25 min or 20 injections and was separated from other dose-availability periods by a 10 min
blackout. The schedule of drug delivery was a fixed ratio 30, timeout 45 sec. NIH 10678 was
substituted in single test sessions; each test session was separated by at least three sessions in
which either alfentanil or saline was delivered contingently on lever press responses.
Doses from 0.0001 to 1.0 mg/kg/inj NIH 10678 were evaluated. NIH 10678 at 0.3 mg/kg/inj
maintained rates of responding that were slightly below those maintained by the maximum rate-
maintaining dose of alfentanil. No other dose maintained response rates above those maintained
by saline.
SUMMARY
The in vitro data suggest significant opioid activity. The binding data show moderate affinities
at µ and binding sites. There was some evidence for a partial agonist effect in the vas deferens
that was sensitive to naltrexone antagonist -- also suggesting µ receptor activity.
The in vivo evidence, however, is not compelling for narcotic agonist or partial agonist actions.
NIH 10678 failed to produce any discriminative effect indicative of or µ activity. It had no
activity as an analgesic when given alone, but augmented and µ analgesic-induced effects. The
compound had modest respiratory depressant effects that, while they resembled excitatory amino
acid antagonists (as noted above), did not show the analgesia found with this class of compound.
Finally, NIH 10678 was self-injected, a result associated with µ agonists and partial agonists and
a variety of nonopioids in this procedure. Thus, NIH 10678 had a novel profile of action.
We have no compounds that have been assessed in humans with which we can make direct
comparisons. NIH 10678 is likely, therefore, to produce a set of effects in humans that may be
different than µ or agonists or partial agonists at these receptors.
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NIH 10707 (±)-3-[N-Methyl-N-(3,4-dichlorophenylacetamido)]-N’-methylpiperidine
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50  of >6,000 nM (7% inhibition at 6 µM) in the
presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10707 was devoid of agonist activity on the isolated, electrically stimulated mouse vas
deferens preparation. This drug, in concentrations up to and including 30 µM, did not block the
agonist actions of sufentanil(µ), DSLET ( ) r U50,488 (K). Thus, NIH 10707 does not have
opioid activity on the mouse vas deferens preparation.
S U M M A R Y
NIH 10707 had no significant opioid activity in either preparation.
* * *
NIH 10708 1-(3,4-Dichlorophenylacetyl)-3-(1-pyrrolidinyl)piperidine.oxalate
DISPLACEMENT OF SPECIFIC
[³]ETORPHINE BINDING
EC50 of >6,000 nM (7.4% inhibition at 6 µM) in
presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%)
Control 58.0 ± 32.9 21.9 ± 1.2 3
Naltrexone (100 nM) 20.0 ± 3.1 17.4 ± 1.7 0 . 3 3
SUMMARY
NIH 10708 had no significant opioid activity in either preparation
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NIH 10711 4,6-Di-(3-chlorophenyl)-3,7-dimenthyl-3,7-diazabicyclo[3.3.1]nonan-9-one
1,5-dicarboxylic acid
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 5.56 µM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum Response (%) Shift (x-fold) n
Control 1.65 ± 0.25 97.8 ± 1.6 9
Naltrexone (100 nM) 10.28 ± 10.12 14.9 ± 4.2 6.2 3
ICI-174864 (100 nM) 5.33 ± 2.29 93.3 ± 6.7 3.2 3
Nor-BNI (10 nM) 5.39 ± 2.25 91.3 ± 5.9 3 . 3 3
SUMMARY
NIH 10711 was not potent in either assay. It had interesting properties in the vas deferens
preparation. Its actions were unusual in that, at nearly every concentration between 10 nM and
100 µM, it produced an inhibition of the twitch followed almost immediately by an increase in
the magnitude of the twitch. For the purpose of this analysis the response was taken as the
greatest inhibition that occurred after administration of each concentration of drug. Naltrexone
virtually abolished inhibitory responses to NIH 107 11, but did not affect the increases in twitch
magnitude. ICI 174-864, a selective opioid receptor antagonist, and nor-binaltorphimine, a
-selective  opioid receptor antagonist, both shifted the NIH 10711 concentration-effect curve to
the right. Thus, NIH 10711 would seem to be an unusual agonist that has actions at µ, and
opioid receptors.
* * *
NIH 10712 4,6-Di-(3-hydroxyphenyl)-3,7-dimethyl-3,7-dimethyl-3,7-diazabicyclo[3.3.1]
nonan-9-one 1,5-dicarboxylic acid dimethyl ester
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (39% inhibition at 6 µM) in
the presence of 150 mM NaCl.
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NIH 10712 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum Shift n
Response (%)
Control 0.98 ± 0.01 81.1 ± 3.6 9
Naltrexone (100 nM) 98.0 ± 58.2 100 99.8 3
Nor-BNI (0.1 nM) 1.01 ± 0.21 41.7 ± 4.2 1.0 3
ICI 174854 (100 nM) 1.02 ± 0.05 79.8 ± 3.6 1.0 3
S U M M A R Y
NIH 10712 was not potent in either preparation. The concentration-effect curve produced by
NIH 10712 in the mouse vas deferens was shifted to the right by naltrexone and was completely
blocked by 10 nM nor-BNI (data not shown). We interpret this pattern of response in the vas
deferens as a agonist action, although a mixed µ- agonist action cannot be ruled out.
NIH 10714 3,7-Dimethyl-4,6-di-(3-methylphenyl)-3,7-diazabicyclo[3.3.1]nonan-9-one1,5
dicarboxylic acid dimethyl ether
DISPLACEMENT OF SPECIFIC
[³H] ETORPHINE BINDING
EC50 of >6000 nM (12% AT 6 µm) in presence of 
150mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist p A 2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil 5.84 1.13 ± 0.17 5.88 ± 0.38 6
DSLET 5.50 1.09 ± 0.21 5.50 ± 0.37 6
U50,488 6
Note: Solubility - 3 mM in DMSO. Lack of solubility may affect the reliability
of the determined pA2 values.
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NIH 10714 (continued)
S U M M A R Y
NIH 10714 was not potent in either assay. At high concentrations, it acted as an antagonist in
the vas deferens against two of the three agonists. NIH 10714, 10 µM, did not block the action
of U50,488. It is not likely to have significant opioid activity at low doses in vivo.
* * *
NIH 10715 3,7-Dimethyl-4,6-di(3-nitrophenyl)-3,7-diazabicyclo[3.3.1[nonan-9-one
1,5-dicarboxylic acid
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (10% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%)
Control 11.1 ± 3.2 32.8 ± 7.1 3
Naltrexone (100 nM) 7.8 ± 3.7 18.6 ± 1.0 0 .7 3
SUMMARY
NIH 10715 was without significant opioid activity in either preparation.
* * *
NIH 10716 3,7-Dimenthyl-4,6-diphenyl-3,7-diazabicycle[3.3.1]nonan-9-one 1,5-
dicarboxylic acid dimethyl ester
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (14% inhibition at 6 µM in
the presence of 150 mM NaCl.
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NIH 10716 (continued)
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 ± S.E.M. Slope ± S.E.M. n
Sufentanil (µ) 8.54 ± 0.33 0.99 ± 0.17 6
U50,488 ( ) 6.40 ± 0.45 1.10 ± 0.20 6
DSLET ( ) 5.84 ± 0.37 1.11 ± 0.14 6
SUMMARY
NIH 10716 was a competitive antagonist in the vas deferens with significant selectivity for the
µ agonist, sufentanil. It failed to have significant affinity for the etorphine binding site. This
is an anomaly.
* * *
NIH 10735 (+)-N-Benzyl-3-hydroxymorphinan hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (32% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10735 was studied on the isolated, electrically stimulated mouse vas deferens preparation
in concentrations which ranged from 1 nM to 30 µM. Concentrations up to 1 µM had no
appreciable effect on this preparation. At concentrations of 3 µM and 10 µM, NIH 10735
markedly increased the magnitude of the twitch. This response was not altered in the presence
of 100 nM naltrexone. When tested as an antagonist NIH 10735 (10 µM) did not block the
inhibitory actions of sufentanil, a µ opioid receptor agonist. NIH 10735 caused a 3.9-fold shift
to the right in the concentration effect curve for DSLET, a opioid receptor agonist, and a 14.6-
fold shift to the right in the concentration-effect curve for U50,488, a k opioid receptor agonist.
Because of the low potency of this drug, pA2 values were not determined.
NOTE: NIH 10735 was studied in the vas deferens at 3 mM
in 19% ethanol.
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NIH 10735 (continued)
SUMMARY
NIH 10735 was not potent in either preparation. In the vas deferens it was devoid of opioid
agonist activity, but appeared to be antagonist of very low potency, with some selectivity for
receptors.
* * *
NIH 10738 4-(3-Hydroxyphenyl)-4-ketoethyl-1-(4-nitrobenzyl)piperidinleydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 3.4 µM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA 2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) <5 .5 3
DSLET 6.18 1.3 ± 0.04 6.38 ± 0.44 6
U50,488 5.96 1.73 ± 0.42 6.29 ± 0.64 6
SUMMARY
NIH 10738 was of low potency in both preparations. In the vas deferens preparation it was
devoid of opioid agonist activity. Concentrations of 10 and 30 µM markedly increased the
magnitude of the twitch, an action that was not blocked by 100 nM naltrexone. NIH 10738 was
an antagonist of low potency on this preparation. It was equipotent as an antagonist at and
opioid receptors. At a concentration of 10 µM, the compound caused a 9.02-fold shift in the
sufentanil concentration-effect curve. Because of its low potency and direct actions on the
smooth muscle preparation, pA2, values could not be calculated for its antagonist activity at µ
opioid receptors. The high slopes of the Schild plots suggest that the antagonism produced by
NIH 10738 is not a simple competitive type of antagonism.
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NIH 10739 1-(4-Fluorobenzyl)-4-(3-hydroxybenzyl)-4-ketoethyl-piperidine
hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC5o of 1330 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2(Constrained ± S.E. n
Sufentanil (µ) <5 .0 4
DSLET 6.37 1.66 ± 0.16 6.94 ± 0.59 6
U50,488 5.71 1.82 ± 0.52 5.88 ± 0.69 6
SUMMARY
NIH 10739 was not very potent in either preparation. It was devoid of opioid agonist activity
on the isolated, electrically stimulated mouse vas deferens preparation. Concentrations of 10 and
30 µM markedly increased the magnitude of the twitch, an action which was not blocked by 100
nM naltrexone. NIH 10739 was an antagonist of low potency on this preparation. It was ten
times more potent as an antagonist at opioid receptors than at k opioid receptors. Although
NIH 10739 did not shift the sufentanil concentration-effect curve to the right, it significantly
decreased the maximum inhibitory action of sufentanil. NIH 10739, at a concentration of 10
µM, reduced the maximum response to sufentanil to 43.1% of control values. The high slopes
of the Schild plots and the changes in the maximum responses to sufentanil suggest that the
antagonist produced by NIH 10739 is not competitive.
* * *
N I H  1 0 7 4 0 (±)-cis-N-[3-Methyl-l-(2-iminohydroxy-2-phenylethyl)-4-piperidinyl]-N-
phenylpropanamide (more polar isomer)
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 3000 nM in the presence of 150 mM NaCl.
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NIH 10740 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum Response (%) Shift (x-fold) n
Control 2.08 ± 0.96 47.1 ± 7.3 8
Naltrexone (100 nM) 0.004 ± 0.001 14.6 ± 14.6 0.0 4
ICI-174,864 (100 nM) 0.58 ± 0.18 24.3 ± 24.3 0.3 4
Nor-BNI (10 nM) 0.31 ± 0.05 46.1 ± 8.6 0.2 3
SUMMARY
NIH 10740 was equally potent in the two preparations. In the mouse vas deferens preparation,
NIH 10740 was of low potency and efficacy. Not all preparations responded to this drug.
Naltrexone, nor-binaltorphimine (a -selective opioid receptor antagonist) and ICI 174,864 (a
-selective opioid receptor antagonist) had no consistent effects on responses this drug. NIH
10740, in a concentration of 1 µM, did not alter responses to sufentanil (µ-selective agonist),
DSLET ( selective agonist), or U-50,488 ( -selective agonist). Thus, NIH 10740 was devoid
of significant opioid activity in the mouse vas deferens preparation.
* * *
NIH 10741 (ßS-3R,4S)-(+)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride (or (ßS,3R,4S )-(+)-cis-ß-Hydroxy-3-methylfentanyl
hydrochloride)
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC,, of 5.9 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Higher Affinity Inhibitory Actions
Condition EC50 (femtoM) Maximum Response (%) Shift (x-fold) n
Control 55.9 ± 22.6 100 9
Naltrexone (100 nM) cannot be calculated no response 3
ICI-174,864 (100 nM) 70.9 ± 31.2 100 1.3 3
Nor-BNI (10 nM) 76.3 ± 31.2 100 1.4 3
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NIH 10741 (continued)
Lower Affinity Inhibitory Actions
Condition EC50 (mM) Maximum Response (%) Shift (x-fold) n
Control 4.3 ± 22.6 100 9
Naltrexone (100 nM) 21.1 ± 8.0 100 4 .9 3
ICI-174,864 (100 nM) 16.9 ± 11.0 100 3 .9 3
Nor-BNI (10 nM) 2.2 ± 0.6 100 0.5 3
NIH 10741 was an agonist on the mouse vas deferens preparation. It produced an inhibitory
action that is associated with a biphasic concentration-effect curve. It was extremely potent with
concentrations as low as 3 femtomolar (3 x 1015 M) causing an inhibition of the twitch.
Naltrexone completely blocked the high affinity actions of NIH 10741. The other antagonists
did not alter appreciably the actions of NIH 10741. Both naltrexone and ICI-174864, a
receptor antagonist, shifted the concentration-effect curve associated with the lower affinity
actions of NIH 10741 to the right. Because of the complexity of the actions of this drug, caution
should be used in interpreting these results.
SUMMARY
NIH 10741 was quite potent in both assays.
NIH 10742 (ßR,3S,4R)-(-)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamidehydroChloride(or( ßR,3S,4R)-(-)-cis-ß -Hydroxy-3-methylfentanyl
hydrochloride)
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50  of 1023 nM in presence of 150 mM NaCl.
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NIH 10742 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 140.0 ± 65.9 97.5 ± 1.8 9
Naltrexone (100 nM) 342.2 ± 70.4 98.1 ± 1.9 2.4 3
ICI-174,864 (100 nM) 151.5 ± 68.2 100 1.1 3
Nor-BNI (10 nM) 57.3 ± 29.3 85.4 ± 7.8 0.4 3
Agonist pA 2 Slope ± S.D. pA2 (Constrained ± S.E. n
Sufentanil (µ) 6.10 1.42 ± 0.67 6.35 6
DSLET 5.79 1.50 ± 0.14 6.10 ± 0.67 6
U50,488 5.99 2.92 ± 0.91 6.93 ± 1.35 6
SUMMARY
NIH 10742 was less potent than morphine in both assays. On the mouse vas deferens
preparation, it produced an inhibitory action that is associated with a biphasic concentration-
effect curve. It was fairly potent with concentrations as low as 0.03 nanomolar causing an
inhibition of the twitch. both phases of the NIH 10742 concentration-effect curve were
antagonized by naltrexone and the first phase of the curve was antagonized by both
norbinaltorphimine, a receptor-selective antagonist, and by ICI-174864, a receptor
antagonist. It was possible to calculate EC50’s for the second (lower affinity) phase of the
concentration-effect curve although these might be somewhat inaccurate because of the complex
nature of the control curve. Only naltrexone antagonized the lower affinity actions of NIH
10742.
* * *
NIH 10743 (ßR,3R,4S)-(-)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide oxalate (or (ßR,3R,4S )-(-)-cis-ß-Hydroxy-3-methylfentanyl oxalate)
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 6.8 nM in the presence of 150 mM NaCl.
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NIH 10743 (continued)
MOUSE VAS DEFERENS PREPARATION
Higher Affinity Inhibitory Actions
Condition EC50 (femtoM) Maximum Response (%) Shift (x-fold) n
Control 96.4 ± 39.1 53.3 ± 4.3 9
Naltrexone (100 nM) 785.6 ± 378.4 35.4 ± 0.9 8.1 3
ICI-174,864 (100 nM) 194.5 ± 67.5 31.0 ± 2.7 2.0 3
Nor-BNI (10 nM) 510.4 ± 104.2 35.8 ± 0.3 5.3 3
Lower Affinity Inhibitory Actions
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 6.7 ± 2.8 100 9
Naltrexone (10 nM) 74.5 ± 44.0 100 11.1 3
ICI-174,864 (100 nM) 4.8 ± 2.2 100 0.7 3
Nor-BNI (10 nM) 6.0 ± 2.3 100 0.9 3
NIH 10743 was very similar to NIH 10741 in its actions and in its affinity for opioid receptors.
It produced an inhibitory action that is associated with a biphasic concentration-effect curve.
It was extremely potent with concentrations as low as 3 femtomolar causing an inhibition of the
twitch. This higher affinity action is blocked to some extent by all three receptor-selective
antagonists, although naltrexone is much more effective than either ICI-174864 or
norbinaltorphimine. The lower affinity actions of NIH 10743 were blocked only by naltrexone,
which suggested that this drug was acting at µ opioid receptors. Because of the complexity of
the actions of this drug, caution should be exerted in interpreting these results.
SUMMARY
NIH 10743 was a potent opioid in both assays.
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N I H  1 0 7 4 4 (ßS,3S,4R)-(+)-cis-N-[1-(2(ß)Hydroxy-2-phenylethyl)-3-methyl-4-
piperidinyl]N-phenylpropanamide oxalate
(or (ßS,3S,4R )(+)-cis-ß-Hydroxy-3-methylfentanyl oxalate)
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 380 nM in presence of 150 mM
NaC1.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 1.24 ± 0.24 28.1 ± 4.6 9
Naltrexone (100 nM) 6.4 ± 2.8 19.0 ± 0.7 5.1 3
ICI-174865 (100 nM) 2.4 ± 0.6 21.1 ± 5.5 2.0 3
Nor-BNI (10 nM) 4.5 ± 0.7 13.9 ± 2.6 3 .7 3
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 6.70 0.93 6.62 ± 0.31 3
SUMMARY
NIH 10744 was less potent in the binding than in the vas deferens preparation. In the latter, it
acted as a weak partial agonist with selectivity for µ opioid receptors. It also was a weak
antagonist at µ opioid receptors. It did not block actions of DSLET or U50,488 in
concentrations up to 3 µM.
* * *
NIH 10745 (± ) -c i s-N-[1-(2-Amino-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide dihydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHlNE BINDING
EC50 of 410 nM in the presence of 150 mM NaCl.
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NIH 10745 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 76.4 ± 13.5 100 10
Naltrexone (100 nM) 53921.0 ± 5008.2 100 705.8 4
ICI-174865 (100 nM) 55.4 ± 9.1 100 0.7 3
Nor-BNI (10 nM) 118.8 ± 0.0 100 1.6 3
SUMMARY
NIH 10745 had moderate potency in displacing etorphine, and exerted µ-opioid actions in the
vas deferens preparation.
* * *
NIH 10748 (+)-N-(4-Fluorobenzyl)-3-hydroxymorphinan oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (29% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10748 was studied on the isolated, electrically stimulated mouse vas deferens preparation
in concentrations which ranged from 1 nM to 100 µM. Concentrations up to 1 µM had no
appreciable effect on this preparation. Concentrations of 3 µM and greater caused marked
increases in the magnitude of the twitch. At a concentration of 300 µM, the twitch was
suppressed completely, an effect not blocked by 100 µM of naltrexone. When tested as an
antagonist at concentrations up to 30 µM, NIH 10748 did not block the inhibitory actions of
sufentanil, a µ opioid receptor-selective agonist, DSLET, a opioid receptor agonist, or to
U50,488, a opioid receptor agonist. Thus, NIH 10748 is devoid of significant opioid agonist
activity on the mouse vas deferent preparation.
SUMMARY
NIH 10748 was without significant opioid effects in either preparation.
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N I H  1 0 7 4 9
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50  of >6,000 nM (16% inhibition at 6 µM) in the
presence of 150 mM NaCl.
(+)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate
DISPLACEMENT OF SPECIFIC
[³H]ETORPHlNE BINDING‘
EC50 of >6000 nM (29% inhibition at 6µM) in
presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10749 could not be studied because it was insoluble in the mouse vas deferens physiological
buffer solution. It was soluble in 48% ethanol at 3 mM, but precipitated when added to Krebs
buffer.
SUMMARY
NIH 10749 was without activity in the binding assay.
* * *
N I H  1 0 7 5 0 (-)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan  oxolate
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 1.84 ± 0.94 37.0 ± 5.1 9
Naltrexone (100 nM) 6.30 ± 4.98 14.1 ± 2.3 3.4 3
ICI-174865 (100 nM) 2.36 ± 0.70 31.3 ± 5.9 1.3 3
Nor-BNI(10 nM) 1.47 ± 0.45 20.1 ± 3.4 0.8 3
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NIH 10750 (continued)
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 5.76 1.35 5.84 ± 0.46 3
DSLET <5.00 3
U50,488 5.70 0.74 5.63 ± 0.25 3
Note: Solubilized at 3mM in 48% ethanol.
SUMMARY
NIH 10750 had no significant activity in the binding assay. In the mouse vas deferens
preparation, it acted as a partial agonist that was antagonized by naltrexone. It was also a very
weak, nonselective antagonist at µ and receptors.
* * *
NIH 10751 (+)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzo-morphan oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of > 6000 nM (32 % at 6 µM) in the presence
of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA 2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) <5 .0 3
DSLET 5.15 1.54 5.23 ± 0.54 3
U50,488 6.86 0.51 6.19 ± 0.19 3
SUMMARY
NIH 10751 had no significant activity in the binding assay. It was likewise devoid of opioid
agonist activity in the mouse vas deferens in concentrations that ranged from 10 nM to 100 µM,
at which concentration it increased the magnitude of the twitch. It was a very weak antagonist
with some limited selectivity for the opioid receptor. The antagonism did not appear to be
competitive based upon the slopes of the Schild plots. In concentrations up to 10 µM it did not
antagonize the actions of sufentanil, a µ agonist.
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NIH 10752 (-)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan
oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (27% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Repeated attempts to dissolve NIH 10752 and to keep in solution when added to physiological
solution were unsuccessful. Therefore, EC50 values could not be determined.
SUMMARY
NIH 10752 had no significant activity in the binding assay. Data on its effects in the mouse vas
deferens could not be acquired due to solubility problems.
* * *
N I H  1 0 7 5 3 Morphine sulfate pentahydrate
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of 74.5 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 543.9 ± 38.0 89.4 ± 5.0 11
Naltrexone (100 nM) 1185.0 ± 2669.9 100 20.6 5
ICI-174,864 (100 nM) 965.7 ± 279.5 96.0 ± 4.0 1.8 3
Nor-BNI (10 nM) 1.3716.3 ± 150.6 42.2 3
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NIH 10753 (continued)
SUMMARY
NIH 10753 was slightly more potent in the binding assay than the vas deferens. In the mouse
vas deferens preparation, it acted as an agonist. Naltrexone and nor-binaltorphimine (a -
selective opioid receptor antagonist) antagonized the inhibitory actions of NIH 10753. The
antagonism produced by nor-binaltorphimine was unsurmountable. ICI-174,864 (a -selective
opioid receptor antagonist) did not shift the NIH 10753 concentration-effect curve. Thus, in the
vas deferens, NIH 10753 would seem to be an agonist with actions at µ and K opioid receptors.
* * *
NIH 10754 (±)-cis-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(3-
pyridinyl)propanamide dihydrochloride
DISPLACEMENT OF SPECIFIC
[³H] ETORPHINE BINDING
EC50 of 28.4 nM in the presence of 150 mM  NaC1
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 32.1 ± 13.45 100 10
Naltrexone (100 nM) 1431.5 ± 519.3 97.9 ± 2.1 44.6 3
ICI-174,864 (100 nM) 436.6 ± 274.9 100 13.6 4
Nor-BNI (10 nM) 6.97 ± 1.39 100 0.2 3
SUMMARY
NIH 10754 was equally potent in the two preparations. In the mouse vas deferens preparation,
NIH 10754 acted as an agonist. Naltrexone and ICI 174,864 (a selective opioid receptor
antagonist) antagonized the inhibitory actions of NIH 10754. Nor-binaltorphimine, a -selective
opioid receptor antagonist, did not shift the NIH 10754 concentration-effect curve to the right.
Thus, NIH 10754 would seem to be an agonist that has actions at µ and opioid receptors.
2 2 7
NIH 10755 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(1-
piperidinyl)propanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of 377 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 89.9 ± 14.1 85.1 ± 5.3 9
Naltrexone (100 nM) 2678.1 ± 2648.7 24.4 ± 8.4 29.8 3
ICI-174,864 (100 nM) 122.6 ± 27.9 87.0 ± 6.6 1.4 3
Nor-BNI (10 nM) 62.3 ± 32.1 89.5 ± 10.5 0.7 3
SUMMARY
NIH 10755 was slightly more potent in the vas deferens preparation than in the binding assay.
It inhibited the electrically-induced twitch by only 90%; its inhibitory effects were antagonized
only by naltrexone, suggesting that its inhibitory effect was completely through the µ receptor.
* * *
N I H  1 0 7 5 6 (±)-cis-N-[1-(2-trans-l-Hydroxy)indanyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 1037 nM in the presence of 150 mM NaCl.
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NIH 10756 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 309.5 ± 41.7 91.0 ± 3.7 9
Naltrexone (100 nM) NC NC 3
ICI-174,864 (100 nM) 443.9 ± 87.4 83.8 ± 7.6 1.4 3
Nor-BNI (10 nM) 315.0 ± 25.3 92.0 ± 2.9 1.0 3
SUMMARY
NIH 10756 was slightly more potent in the vas deferens than in the binding assay. On the
mouse vas deferens preparation NIH 10756 inhibited the electrically induced twitch by 90%.
It was markedly antagonized by naltrexone. EC50s could not be determined since, at a
concentration of 30 µM and in the presence of 100 nM naltrexone, the response to this drug was
negligible; and at a concentration of 100 µ, NIH 10756 completely suppressed the twitch by a
nonopioid action. Neither ICI-174864 -selective opioid antagonist) nor U-50,488 ( -selective
opioid antagonist) significantly altered responses to this drug. Thus, NIH 10756 would appear
to be a partial agonist selective for µ opioid receptors.
* * *
N I H  1 0 7 5 7 (±)-cis-N-[1-(2-(trans-3-Hydroxy-1,2,3,4-tetrahydro)-naphthyl)-3-methyl-
4-piperidinyl]-N-phenylpropanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of 48.2 nM in the presence of 150 mM NaCl.
MOUSE VAS  DEFERENS  PREPARATION
NIH 10757 was studied on the isolated, electrically stimulated mouse vas deferens preparation
in concentrations that ranged from 0.1 nM to 1 µM. Because of the multiphasic nature of the
concentration-effect curves, determination of EC50’s was not feasible. NIH 10757 is a fairly
potent agonist on the mouse vas deferens preparation. Its actions are antagonized by naltrexone
and nor-binaltorphimine, but apparently potentiated by ICI 174,864. These results indicate that
NIH 10757 acts at opioid receptors, but a definitive classification of the type of receptor(s) that
are stimulated is not possible.
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NIH 10757 (continued)
SUMMARY
NIH 10757 had complex actions in the vas deferens, and it was comparable to morphine in
potency in the binding assay.
N I H  1 0 7 5 9 Ethylnarceine.HCl (6-[[6-[2-Diethylamino)ethyl]-4-methoxy-1,3-
benzodioxol-5-yl]acetyl]-2,3-dimethoxybenzoic acid
MOUSE VAS DEFERENS PREPARATION
NIH 10759 was studied on the isolated, electrically stimulated mouse vas deferens preparation
in concentrations which ranged from 1 nM to 100 µM. Concentrations up to 1 µM had no
appreciable effect on this preparation. Concentrations of 3 µM and greater caused marked
increases in the magnitude of the twitch. At a concentration of 300 µM, the twitch was
suppressed completely, an effect not blocked by 100 nM naltrexone. When tested as an
antagonist (at concentrations up to 30 µM) NIH 10759 did not block the inhibitory actions of
sufentanil, a µ opioid receptor selective agonist, DSLET, a opioid receptor agonist or
U50,488, a K receptor selective agonist. Thus, in the vas deferens preparation, NIH 10759 was
devoid of significant opioid agonist or antagonist activity.
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10759 were evaluated in four monkeys experienced in responding
and receiving intravenous infusions of alfentanil. Doses of from 0.00001 to 3.34 mg/kg/inj
were evaluated. One monkey showed high rates of responding maintained by NIH 10759. In
this monkey, rates of responding maintained by the maximally effective dose of NIH 10759
(0.32 mg/kg/inj) were as high as those maintained by the maximally effective dose of alfentanil
(0.0003 mg/kg/inj). The other three monkeys did not demonstrate a reinforcing effect of 10759.
Rates of responding maintained by the drug in these monkeys was usually as low as rates
maintained by saline in this situation.
SUMMARY
NIH 10759 had insignificant opioid activity in both the in vitro and in vivo assays.
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NIH 10760 Narceine (6-[[6-[2-Dimethylamino)ethyl]-4-methoxy-1,3-benzodioxol-5-
yl]acetyl]-2,3-dimethoxybenzoic  acid)
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of > 6,000 nM (2.4 % inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 385.2 ± 108.0 40.5 ± 3.0 9
Naltrexone (100 nM) 821.6 ± 395.8 32.0 ± 8.7 2.1 3
ICI-174,864 (100 nM) 383.5 ± 112.4 29.2 ± 4.4 1.0 3
Nor-BNI (10 nM) 215.8 ± 141.9 39.7 ± 8.1 0.6 3
When evaluated as an antagonist at a concentration of 10 µM, NIH 10760 did
not modify responses to sufentanil (µ agonist), DSLET agonist) or U50,488
agonist).
SELF-ADMINISTRATION IN RHESUS MONKEYS
Doses of 0.0001 to 0.3 mg/kg/inj NIH 10760 were evaluated in four monkeys experienced in
responding and receiving intravenous infusions of alfentanil. NIH 10760 maintained rates of
responding that were well below rates maintained by 0.001 mg/kg/inj alfentanil in all three
monkeys. Only one monkey maintained any rates above 0.5 responses per second, the criterion
rate when saline is substituted in the procedure.
SUMMARY
NIH 10760 had insignificant opioid activity in the binding assay. In the mouse vas deferens
preparation, it appeared to be either a non-opioid compound or a partial agonist of very low
efficacy with selectivity for µ opioid receptors. NIH 10760 failed to maintain significant self-
administration responding.
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NIH 10761 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]N-(2-
fluorophenyl)propanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 1.02 nM in the presence of 150 mM NaC1.
MOUSE VAS DEFERENS PREPARATION
Condition EC5 0  (nM) Maximum Shift (x-fold) n
Response (%)
Control 32.5 ± 9.1 98.8 ± 0.7 9
Naltrexone (100 nM) 49.2 ± 1.9 100 1.5 3
ICI-174,864 (100 nM) 67.2 ± 12.6 2.197.3 ± 2.7 3
Nor-BNI (10 nM) 61.0 ± 2.3 100 1.9 3
SUMMARY
NIH 10761 acted as an agonist on the mouse vas deferens preparation. Its actions were slightly
antagonized by naltrexone, ICI-174864 -selective), and nor-binaltorphimine ( -selective). NIH
10761, at a concentration of 10 nM, caused a 3.1-fold shift to the right in the sufentanil
concentration-effect curve and a decrease (31.2%) in the maximum response to this p-receptor-
selective agonist. NIH 10761 did not antagonize the actions of U50,488 ( -selective agonist) or
DSLET ( selective agonist). Thus, in this assay, NIH 10761 had agonistic effects most
consistent with an action at opioid receptors and an antagonistic action at µ opioid receptors.
NIH 10761 was a potent compound in both preparations. It is unusual that a compound potent
in the binding assay and exerts inhibitory actions in the vas deferens is also insensitive to the
antagonists we employ.
2 3 2
N I H  1 0 7 6 3 (±)-cis-N-[1-[2-Hydroxy-2-(2-thienyl)ethyl]-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 5.64 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 113.0 ± 17.7 99.1 ± 0.5 9
Naltrexone (100 nM) 390.0 ± 133.0 100 3.5 3
ICI-174,864 (100 nM) 197.5 ± 59.4 100 1.7 3
Nor-BNI (10 nM) 268.8 ± 146.6 100 2.4 3
SUMMARY
NIH 10763 was an agonist of relatively low potency on the mouse vas deferens preparation. Its
actions were antagonized slightly by naltrexone and nor-binaltorphimine ( -selective antagonist),
but not by IC-174864 selective antagonist). NIH 10763, in a concentration of 100 nM, did
not antagonize the actions of U50,488 ( -Selective agonist), sufentanil (µ-selective agonist) or
DSLET ( selective agonist). Thus, NIH 10763 acted as an agonist in the mouse vas deferens
prepartion but was devoid of antagonist activity. It was more potent in the binding assay than
in the mouse vas deferens preparation.
N I H  1 0 7 6 6
* * *
8-[4-[4-(1,2-Benzoisothiazol-3-yl)-1-piperazinyl]butyl]-8-
azaspiro(4.5)decane-7,9-dione hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of > 6,000 nM (28.2% inhibition at 6 µM) in
the presence of 150 mM NaCl.
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NIH 10766 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum Response (%) Shift (x-fold) n
Control 4.10 ± 0.21 100 9
Naltrexone (100 nM) 5.08 ± 0.72 100 1.2 3
ICI-174,864 (100 nM) 5.69 ± 0.69 100 1 .4 3
Nor-BNI (10 nM) 4.71 ± 0.35 100 1.1 3
SUMMARY
NIH 10766 was not potent in either preparation. It is unlikely to have significant opioid actions.
* * *
N I H  1 0 7 6 8 (-)-2-Decyl-5,9 -Dimethyl-2’-hydroxy-6,7-benzomorphan hydrobromide
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (43% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10768 had complex actions on the mouse vas deferens preparation. Low concentrations
caused an inhibition of the twitch that was antagonized by naltrexone and nor-binaltorphimine,
suggesting an action at either µ or receptors, or both. Higher concentrations of NIH 10768
caused a further inhibition of the twitch, an action that was not modified by any of the
antagonists.
SUMMARY
NIH 10768 was active in the binding assay only a high concentrations. It had weak effects of
both opioid and non-opioid character in the vas deferens preparation.
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NIH 10769 (+)-2-Decyl-5,9 -Dimethyl-2’-hydroxy-6,7-benzomorphanhydrobromide
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC5 0  of >6,000 nM (26% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC5 0  (nM) Maximum Shift (x-fold) n
Response (%)
Control 13.0 ± 5.6 20.4 ± 2.2 9
Naltrexone (100 nM) 35.5 ± 11.7 14.5 ± 1.8 2.7 3
ICI-174,864 (100 nM) 9.8 ± 4.5 18.1 ± 5.7 0.9 3
Nor-BNI (10 nM) 11.5 ± 3.3 14.9 ± 1.2 0.9 3
SUMMARY
NIH 10769 had insignificant potency in the binding assay. It was either a nonopioid compound
or a partial agonist of very low efficacy on the mouse vas deferens preparation with selectivity
for µ opioid receptors. Concentrations above 0.3 µM increased the magnitude of the twitch.
When evaluated as an antagonist at a concentration of 3 µM, NIH 10769 did not modify
responses to sufentanil (a µ receptor agonist), DSLET (a receptor agonist), or U50,488 (a
receptor agonist).
* * *
NIH 10770 (-)-N-(4-Fluorobenzyl)-3-hydroxymorphinan  oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 1269 nM in the presence of 150 mM NaCl.
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NIH 10770 (continued)
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) < 5 . 0 3
DSLET 5.80 0.57 5.68 ± 0.21 3
U50,488 6.15 1.31 6.36 ± 0.45 3
SUMMARY
NIH 10770 was of low potency in both preparations. In the vas deferens preparation it was
devoid of opioid agonist activity in concentrations that ranged from 10 nM to 100 µM at which
concentration it increased the magnitude of the twitch. NIH 10770 was a very weak antagonist
with some limited selectivity for opioid receptors. In concentrations up to 10 µM, it did not
antagonize the actions of sufentanil, a µ agonist.
NIH 10771
* * *
(-)-3-Hydroxy-N-(4-nitrobenzyl)morphinan   oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 2175 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 7.0 ± 1.6 20.5 ± 2.4 9
Naltrexone (100 nM) 3.4 ± 1.0 14.7 ± 3.1 0.5 3
ICI-174864 (100 nM) 20.2 ± 7.9 11.8 ± 2.3 2.9 3
Nor-BNI (10 nM) 12.7 ± 0.5 9.5 ± 1.1 1 .8 3
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 6.47 0.83 6.40 ± 0.30 3
DSLET 6.21 0.65 6.21 ± 0.23 3
U50,488 6.19 1.56 6.29 ± 0.54 3
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NIH 10771 (continued)
SUMMARY
NIH 10771 had very low potency in the binding assay. In the mouse vas deferens preparation
it acted as a partial agonist and weak, non-selective antagonist. Although naltrexone did not
shift the NIH 10771 concentration-effect curve to the right, it did decrease the maximum
response. The other two antagonists shifted the NIH 10771 concentration-effect curve to the
right and decreased the maximum response.
* * *
NIH 10772 (+)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan
oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHlNE BINDING
EC50 of >6,000 nM (35% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 6.13 0.82 6.02 ± 0.28 3
DSLET 5.47 1.04 5.49 ± 0.35 3
U50,488 5.80 1.61 5.98 ± 0.57 3
SUMMARY
NIH 10772 had no significant activity in the binding assay. In the mouse vas deferens
preparation it acted as a weak, nonselective antagonist.
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NIH 10774 (±)-cis-N-[1-2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-
morpholinyl)propanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 5300 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC5 0  (µM) Maximum Response (%) Shift (x-fold) n
Control 1.57 ± 0.29 85.1 ± 3.6 9
Naltrexone (100 nM) 12.91 ± 3.14 27.8 ± 7.9 8.2 3
ICI-174,864 (100 nM) 2.36 ± 2.29 55.1 ± 1.9 1.5 3
Nor-BNI (10 nM) 0.92 ± 0.06 79.0 ± 3.9 0.6 3
SUMMARY
NIH 10774 had low potency in both assays. In the vas deferens, naltrexone virtually abolished
inhibitory responses to NIH 10774. ICI-174,864 (a -selective antagonist), caused a slight shift
to the right in the NIH 10774 concentration-effect curve and reduced the maximum response.
Nor-binaltorphimine (a -selective antagonist) neither shifted the concentration-effect curve nor
significantly altered the maximum response. When evaluated as an antagonist at a concentration
of 1 µM, NIH 10744 did not modify responses to sufentanil (µ-selective agonist), DSLET (
selective agonist) or U50,488 ( -selective agonist). Thus, in the vas deferens, NIH 10744 would
seem to be an agonist with actions primarily at µ opioid receptors.
* * *
NIH 10776 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenyl-
3-thiophenecarboxamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 2.83 nM in the presence of 150 mM NaCl.
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NIH 10776 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 3.42 ± 1.55 100 9
Naltrexone (100 nM) 100.1 ± 12.8 100 29.2 3
ICI-174.864 (100 nM) 17.8 ± 6.7 100 5.2 3
Nor-BNI (10 nM) 2.14 ± 0.56 100 0 . 6 3
SUMMARY
NIH 10776 had significant opioid activity in the binding assay. It acted as a potent agonist on
the mouse vas deferens preparation. Both naltrexone and ICI 174,864 ( antagonist) caused
shifts to the right in the NIH 10776 concentration-effect curve. Nor-binaltorphimine (
antagonist) neither shifted the NIH 10776 concentration-effect curve, nor significantly altered
the maximum response. Thus, NIH 10776 would seem to be an agonist with actions at opioid
receptors -- although an action at µ opioid receptors is also possible. We are currently
examining NIH 10776 in binding experiments with receptor-selective ligands.
Note: NIH 10776 was done as a blind control to NIH 10731. Following are the
evaluation results from NIH 10731, reported in 1992.
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 7.3 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
C o n d i t i o n EC50 (nM) Maximum Response (%) Shift (x-fold) n
C on t ro l 2 5 9 . 2  ±  8 2 . 7 67.5 + 3.3 9
Naltrexone (100 nM) 117 .3  ±  8 .9 98.4 ± 1.6 0 . 5 3
ICI-174864 (100 nM) 460 .0  ±  76 .4 36.9 ± 1.3 1 . 8 3
Nor-BNI (10 nM) 318 .2  ±  125 .1 51.4 ± 9.9 1 . 2 3
239
N I H  1 0 7 7 8 4-Bromo-5-(3-hydroxyphenyl)-2-methylmorphan hydrobromide
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 753 nM in the presence of 150mM NaCl
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil 6.26 0.64 5.82 ± 0.23 3
DSLET 5.83 1.09 5.90 ± 0.37 3
U50,488 5.49 1 .17 5.57 ± 0.39 3
SUMMARY
NIH 10778 was of low potency in both preparations. In the vas deferens preparation it acted
as a weak, non-selective antagonist.
* * *
NIH 10779 2,3-Dimethyl-5-(3-hydroxyphenyl)morphan  hydrobromide
DISPLACEMENT OF SPECIFIC
[³H]ETORPHINE BINDING
EC50 of 592 nM in the presence of 150mM NaC1
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum response (%) Shift (x-fold) n
Control 15.8 ± 9.8 81.1 ± 7.8 9
Naltrexone (100 nM) 79.7 ± 36.6 75.0 ± 25.0 5.0 3
ICI-174,864 (100) nM) 23.8 ± 18.2 80.8 ± 19.2 1.5 3
Nor-BNI (10 nM) 1.72 ± 1.0 39.6 ± 8.0 0.1 3
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NIH 10779 (continued)
SUMMARY
NIH 10779 had low potency in both assays. It was a partial agonist of low potency on the
mouse vas deferens preparation with selectivity for µ opioid receptors. When evaluated as an
antagonist at a concentration of 1 µM, NIH 10779 did not modify responses to sufentanil, a µ
opioid receptor selective agonist, DSLET, a opioid-receptor selective agonist, or U50,488, a
opioid-receptor agonist.
* * *
N I H  1 0 7 8 0 (-)-N-Benzyl-3-hydroxymorphinan hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 260 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D.
Sufentanil 6.04 0.77
DSLET 6.17 0.52
U50,488 6.49 1.98
pA2 (Constrained) ± S.E. n
6.03 ± 0.26 3
6.10 ± 019 3
6.46 ± 0.78 3
SUMMARY
NIH 10780 was of low potency in both preparations. In the vas deferens preparation it acted
as a weak, non-selective antagonist.
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NIH 10781 (-)-3-Hydroxy-N-(4-methoxybenzyl)morphinan hydrobromide
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (43% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 5.29 ± 0.91 18.3 ± 3.2 9
Naltrexone (100 nM) 11.9 ± 1.4 18.9 ± 2.4 2.3 3
Agonist pA2 Slope ± S.E. pA2 (Constrained) ± S.E. n
Sufentanil 5.66 1.51 5.68 ± 0.37 3
DSLET 5.69 0.94 5.68 ± 0.16 4
U50,488 5.89 2.13 6.33 ± 0.84 3
SUMMARY
NIH 10781 had insignificant affinity for the etorphine binding site. It was a very weak partial
agonist that was only slightly antagonized by naltrexone on the isolated, electrically stimulated
mouse vas deferens preparation. It was also a very weak, nonselective antagonist. The
antagonistic actions at µ and receptors were probably not competitive as indicated by the slopes
of the Schild plots.
* * *
NIH 10783 (+)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-
methyl-2-pyridinyl)propanamide oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 19.1 nM in the presence of 150 mM NaCl.
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NIH 10783 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 7.15 ± 2.12 100 3
Naltrexone (100 nM) 632.7 ± 151.5 100 88.5 3
ICI-174,864 (100 nM) 32.4 ± 27.0 98.6 ± 1.4 4.5 3
Nor-BNI (10 nM) 2.30 ± 0.12 98.6 ± 1.4 0.3 3
SUMMARY
NIH 10783 had opioid activity in the binding assay. In the mouse vas deferens preparation, it
acted as a potent agonist relatively selective for µ opioid receptors.
NIH 10784
*  *  *
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(3-
fluorophenyl)propanamide hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 6.5 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 7.61 ± 0.26 99.8 ± 0.2 9
Naltrexone (100 nM) 1016.1 ± 208.2 100 133.6 3
ICI-174,864 (100 nM) 126.3 ± 37.4 98.7 ± 1.3 16.6 3
Nor-BNI (10 nM) 109.6 ± 47.8 97.2 ± 1.4 14.4 3
SUMMARY
NIH 10784 had opioid activity in both assays. It was a potent agonist relatively selective for
µ opioid receptors on the isolated, electrically-stimulated mouse vas deferens preparation.
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NIH 10794 Amitriptylene hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (2.4% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Response (%) Shift (x-fold) n
Control 3.03 ± 1.56 39.4 ± 8.0 3
Naltrexone (100 nM) 17.4 ± 7.0 40.9 ± 3.1 5.7 3
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 5.38 1.71 5.38 ± 0.63 3
SUMMARY
NIH 10794 had no significant activity in the binding assay. In the mouse vas deferens
preparation it acted as a mixed agonist-antagonist relatively selective for µ opioid receptors. It
had low efficacy as an agonist and low potency as an antagonist. Concentration of NIH 10794
above 3 µM markedly increased the magnitude of the twitch. Because of this action and its low
potency as an antagonist, pA2 values could only be determined when sufentanil was used as an
agonist.
NIH 10795 4-(3-Hydroxyphenyl-4-(1-oxopropyl)-1-(2-methyl-2-butenyl)piperidine
hydrochloride
or (N-3,3-Dimethylallyl)-N-norketobemidone hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 507 nM in the presence of 150 mM NaCl.
2 4 4
NIH 10795 (continued)
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) 6.58 1.47 6.84 ± 0.52 3
DSLET 6.06 1.58 6.39 ± 0.56 3
SUMMARY
NIH 10795 had low potency, opioid activity in the binding assay. In the mouse vas deferens
preparation NIH 10795 produced a slight inhibition of the twitch (26.1% maximum) that was
not modified by 100 nM naltrexone. NIH 10795 was a weak, nonselective antagonist on the
isolated, electrically-stimulated mouse vas deferens preparation. It caused a 23.4-fold shift to
the right in the U50,488 concentration-effect curve at a concentration of 30 µM, but pA2 values
were not determined because lower concentrations did not shift the U5O,488 concentration-effect
curve. Note that the slopes of the Schild plots are considerably greater than 1.0.
NIH 10796
* * *
(+)-N-(2-Methylpropenyl)-3-hydroxymorphinan hydrobromide
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of >6,000 nM (7.2% inhibition at 6 µM) in
the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Agonist pA2 Slope ± S.D. pA2 (Constrained) ± S.E. n
Sufentanil (µ) <5.00 3
DSLET <5.00 3
U50,488 5.45 1.56 5.68 ± 0.57 3
SUMMARY
NIH 10796 had very low potency in both preparations. In the vas deferens preparation it was
devoid of agonist activity in concentrations that ranged from 10 nM to 100 µM; at the 100 µM
concentration, it increased the magnitude of the twitch. It was a very weak antagonist with some
selectivity for opioid receptors. In concentrations up to 10 µM it did not antagonize the
actions of sufentanil or DSLET.
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PROGRESS REPORT FROM THE TESTING PROGRAM FOR
STIMULANT AND DEPRESSANT DRUGS (1993)
G. A. Patrick, L. S. Harris, W. L. Woolverton, M. A. Nader,
G. Winger and J. H. Woods
The research group involved in the evaluation of stimulant and depressant compounds has
been in existence for approximately ten years. The group includes laboratories at Virginia
Commonwealth University (Patrick, Harris), the University of Chicago (Wootverton,
Nader), the University of Michigan (Winger, Woods) and NIH (Jacobson). The group is
part of the Drug Evaluation Committee, chaired by Ted Cicero, of the College on Problems
of Drug Dependence (CPDD) and is supported by both CPDD and NIDA. One of the
purposes of the group is to evaluate new compounds, generally classified as either stimulants
or depressants, for their abuse liability and potential to produce dependence. Compounds
are received, coded and distributed by Dr. Jacobson for blind testing in the various
laboratories. They are evaluated for discriminative stimulus effects (UC), reinforcing effects
(UM), and capacity to produce physical dependence (VCU). This report includes the results
of evaluation of the following compounds: CPDD-0027 ([cis-4-phosphomethyl]-2-
piperidinecarboxylic acid); CPDD-0035 (1.3.4.16b-tetrahydro-2-methyl-2H,10H-
indolo[2,1-c]pyrazino[1,2a][1,4]benzodiazepine-16-carboxylic acid methyl ester
hydrochloride or CGS-15044A); CPDD-0039 (aminorex hydrochloride); and CPDD-0040
(mesocarb).
METHODS
Reinforcing Effects in Rhesus Monkeys
The reinforcing effects of test compounds were evaluated in a substitution self-administration
procedure with methohexital serving as the baseline drug. Rhesus monkeys were surgically
prepared with indwelling silicone rubber catheters using 10mg/kg i.m. ketamine and 2.0
mg/kg i.m. xylazine as aesthetics. Catheters were implanted in jugular (internal or
external), femoral or brachial veins as necessary. The catheter passed subcutaneously from
the site of the incision to the mid-scapular region, where it exited the monkey and continued,
through a hollow restraining arm, to the outside rear of the cage.
The restraint and catheter protection device has been described in detail by Deneau et al.
(1969). Monkeys were individually housed in stainless steel cages, measuring 83.3 X 76.2
X 91.4 cm deep. Each monkey wore a tubular stainless steel harness that protected the exit
site of the catheter and allowed relatively unrestricted movements within the cage. A Teflon
cloth jacket (Alice King Chatharn Medical Arts, Los Angeles, CA) provided further
protection for animals who tended to locate and pull their catheters. The harness was
connected to a flexible spring arm that carried the catheter to the back of the cage where it
joined tubing passing through a roller infusion pump (Watson and Marlow Co., Model
MHRK 55, Falmouth, UK).
A 15.4 cm square stimulus panel was located on the side of each cage, approximately 10 cm
from the front and 19 cm from the bottom of the cage. Across the top of the stimulus panel,
2.5 cm apart, were three circles, 2.5 cm in diameter, covered with translucent plastic and
capable of being illuminated from behind by 5 W colored bulbs. The two side lights could
be illuminated ted and the center light green. Below each of the two red stimulus lights was
a response lever (Model 121-07; BRS-LVE, Beltsville, MD) capable of being operated bv
10-15 gm of force. Experimental control was provided by an IBM PS/2 computer
programmed with Med-PC (Med-Associates, Fairfield, VT) software and located in an
adjoining room.
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Monkeys were adapted to restraining arms for a week or more, then an intravenous catheter
was implanted and the animals were given the opportunity to respond to receive drug.
Evaluation of drugs with depressant properties was carried out in monkeys trained to self-
administer sodium methohexital. For these monkeys, at the beginning of each session, a red
light was illuminated over one of two levers in each monkey’s cage and 10 responses (fixed-
ratio 10; FR10) on that lever resulted in a 5-second infusion of 0.1 mg/kg sodium
methohexital, followed by a 10-second time-out during which all stimulus lights were
extinguished and responding had no programmed consequence. During an infusion, the red
lever light was extinguished and the center green light illuminated for the duration of the
infusion. Experimental sessions were limited to 210 min or until a maximum of 200
injections were delivered. No monkey ever received 200 injections of methohexital. Two
sessions were scheduled each day, separated by at least four hours. On approximately half
of the baseline sessions, the monkeys were exposed to response-contingent saline. When
them was a clear and consistent differential response between saline and methohexital, a dose
of the test compound was substituted for one session. All conditions were similar to training
sessions except the maximum number of injections of the test compound was limited to
150/session. Each dose was tested twice in each monkey.
CPDD-0027,0035 and 0039 were dissolved in distilled water; CPDD-0040 was dissolved in
a vehicle of equal parts Emulphor EL-620 and ethanol (each < 10 % of total volume) diluted
with distilled water.
Discriminative Stimulus Effects in Rhesus Monkeys
The subjects were two female and five male rhesus monkeys weighing between 6.5 and 12.1
kg. All monkeys had extensive experience with the present drug discrimination procedure.
They were housed individually in stainless steel cages in which water was continuously
available. They were fed 100 to 150 g of monkey chow after each session and were given a
chewable vitamin tablet 3 days/week. During experimental sessions each monkey was
seated in a Plas-Lab restraining chair and placed in a wooden cubicle (175 cm high X 85 cm
wide X 65 cm deep) containing two response levers mounted 100 cm above the floor. A 40
W white house light was mounted on the ceiling. The monkey’s feet were placed into shoes,
the bottoms of which were fitted with brass plates which could deliver electric shocks.
Programming and recording of experimental events were accomplished by an Aim 65
microprocessor located in an adjacent room.
The monkeys had been trained previously to discriminate d-amphetamine (AMPH: 7737,
7739.8515) or pentobarbital (PB: 8106, 8236, 7976, 8814) from saline in a two-lever,
discrete-trial shock avoidance procedure similar to the one descibed by Holtzrnan (1982).
One hour after an intragastric infusion (via nasogastric tube) of the training drug (0.56 or
1.0 mg/kg AMPH or 10 mg/kg PB) or saline, the houselights and lever lights were
illuminated (trial) and responding on one lever (designated the correct lever) avoided electric
shock and extinguished the lights. Responding on the incorrect lever started a 2-
second change-over delay during which correct lever responding had no consequence. If a
correct lever response was not made within 5 seconds of onset of the lights, an electric shock
(250 msec duration, 7mA intensity) was delivered; if a correct response was made within 2
sec after the first shock (escape), the trial was terminated, otherwise., a second shock
automatically ended a trial. Two consecutive trials with escape failure automatically ended
the session. Trials were separated by a 30-sec TO. The session lasted 30 trials or 20 min,
whichever came first The correct lever was determined by the infusion that was
administered  before the session. For three monkeys, the right lever was correct after drug
infusion and the left lever was correct after saline infusions. This condition was reversed for
the other four monkeys.
Monkeys were considered to be stable in the discrimination when more than 90% of the trials
were completed on the correct lever on at least seven out of eight consecutive sessions. At
this point, testing was begun with the training drugs and the test drugs. Two
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5-day sequences alternated drug, vehicle and test sessions so that the first test session was
preceded by two training sessions, one with saline and one with drug pretreatment and the
second test session of the sequence was preceded by either vehicle or drug pretreatment. In
the event that the criterion for stimulus control was not met during the training sessions, the
training sequence was continued. During test sessions, both levers were operational, i.e.,
shock could be avoided by responding on either lever.
Saline, at least three doses of the training drug, and three doses of each test drug, in addition
to the test drug vehicle, were evaluated under the test conditions for each monkey. The
percentage of trials that were completed on the drug lever is presented for each test session.
In addition, the average time between the onset of a trial and a lever press (average latency)
was calculated for each test session. Because these test compounds were evaluated blind
without any dose-response information, initial test doses were done in an ascending or&r
from 0.1 mg/kg to doses that either significantly increased latency to respond or resulted in at
least 90% drug-appropriate responding. Out of concern for the monkeys, doses greater than
30 mg/kg were not tested. If a dose substituted for a training drug, that dose and doses
higher and lower were tested again, in a random order.
PB and the test drugs were prepared immediately before testing, while a stock solution of
AMPH was prepared each week. PB (40 mg/ml) and AMPH (5 mg/ml) were dissolved in
saline. CPDD-0027, 0035,  and 0039 were dissolved in water. CPDD-40 was dissolved in
ethanol (10%), propylene glycol (40%) in saline.
Physical Dependence Studies in Rats and Potency Estimation in Mice
Male Sprague-Dawley rats (Harlan Labs, Dublin, VA) initially weighing 200-225 g were
individually housed in stainless steel cages with food and water freely available. They were
used in the chronic infusion and substitution experiments. CF-1 mice (Harlan Labs, Dublin,
VA) weighing 25 to 35 g were housed in plastic cages with food and water ad lib. The mice
were used in initial studies for potency estimation. All animals were acclimated to the animal
facility for several days prior to use in any study.
Rats were surgically prepared with an intraperitoneal cannula (PE90 tubing) while under
methoxyflurane anesthesia Acclimation to the infusion system occurred for three days
during which the rats were infused with 0.9% saline. This was followed by the continuous
infusion of either saline (control) or pentobarbital sodium for 12 consecutive days using an
escalating dosing schedule (Yutrzenka et al., 1985). At the end of the infusion period most
rats were receiving pentobarbital at a dose of 850-900 mg/kg-24 hr. Body weight was
monitored daily during the drug infusion period.
Following the final day of pentobarbital infusion, a 24-hour substitution period commenced
during which pentobarbital-dependent rats were infused with either saline, vehicle, or test
drug. This was followed by a 24-hour drug withdrawal period during which all rats
received saline.
Every two hours for the first 12 hours and again at 24 hours of each period, rats were
assigned a withdrawal score based on the degree of expression of several behavioral
responses and signs. In addition, body weight was determined at 0.8 and 24 hours of each
period. Scores were assigned by two observers who were blind to the drug treatment.
Investigators were blind to the identity of the compounds until all data were collected and
analyzed (Yutrzenka et al., 1989).
In the primary physical dependence study with CPDD-0027, rata were infused with a
solution of the test drug continually for 12 days, using an escalating dosage schedule.
Following cessation of the drug infusion, saline was substituted for 48 hours, and overt
behavioral signs of withdrawal and changes in body weight were measured as described
above.
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Preliminary studies to ascertain potency of the test compounds were conducted in mice.
Drug-treated mice were assayed using the inverted screen test (Coughenour et al., 1977) and
alteration of spontaneous locomotor activity. At least three doses of each drug, with at least
six mice per dose, were used to determine dose-response curves. Vehicle-treated mice
served as controls and were assayed concurrently with drug-treated mice.
The inverted screen test was conducted at 20, 30, 60, and 120 min following drug
administration. The ED-50 dose, which was determined to be the dose at which one-half of
the treated mice failed to right themselves within the 60-second time period, was computed
for each time period where appropriate. Spontaneous locomotor activity was determined
using a single beam photocell (Autotron, Inc., Danville, IL,) which bisected a plastic cage
containing two mice (CPDD-0027, 0035 and 0039) or using a 16-beam infrared photocell
(Omnitech, Columbus, OH) which transected a plastic cage containing one mouse (CPDD-
0040). Movement of the mice disrupted the beam(s) and a “count" of activity was recorded.
Following drug administration, activity was recorded at 5-15 min, 35-50 min, 65-95 min,
and 125-185 min. The ED-50 dose for a depressant drug was determined to be that dose
which reduced spontaneous locomotor activity to one-half that recorded for concurrently
tested vehicle-treated control mice. For stimulant drugs, activity at a given dose was
expressed as “percent of control activity”. Potency estimates of each test drug were
determined at time of peak activity and when, in addition, the vehicle effect was no longer
evident.
Pentobarbital sodium was dissolved in distilled water made isotonic with sodium chloride.
CPDD-0027 and 0039 were dissolved in distilled water. CPDD-0035 was dissolved in
propylene glycol (40%) and ethanol (10%) in distilled water, and 0040 was dissolved in
Emulphor EL-620 (10%) and ethanol (10%) in distilled water.
Withdrawal scores for each treatment group were compared to the control by use of the
Mann-Whitney U-test. Alterations in body weight were tested for significance by use of the
t-test. ED-50 values and 95% confidence intervals in the inverted screen test and locomotor
activity measure were also determined when appropriate by the method of Litchfield and
Wilcoxon (1949).
RESULTS
CPDD-0027
(cis-4-phosphomethyl)-2-piperidinecarboxylic acid
Self-administration Studies in Rhesus Monkeys
The reinforcing effects of doses of 0.1 through 1.0 mg/kg/injection of compound 0027 were
evaluated in three rhesus monkeys. All doses maintained fairly low drug intake (number of
injections) relative to the number of injections of methohexital taken. However, number of
injections taken of CPDD-0027 tended to increase as the dose of drug increased (see Figure
1). Larger doses could not be evaluated due to solubility problems. At the largest dose
tested (1.0 mg/kg/inj) the number of injections taken of 0027 was above those maintained by
saline in one of two monkeys. The third monkey was not evaluated at this dose. Two of the
three monkeys showed direct effects of the drug administration after the session. One
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showed ketamine-like effects (e.g. salivation, apparent anesthesia with eyes open). The
other showed decreased rates of methohexital-maintained responding of the subsequent
session.
Figure 1. Self-administration of CPDD-0027 by rhesus monkeys. The points shown at METH are the
average number of injections taken of 0.1 mg/kg/inj sodium methohexital on the sessions just preceding
each substitution of CPDD-0027. These data are shown for the individual monkeys as indicated by the
legend. Similar data are shown for saline availability over the point indicated by SAL. Data shown for
CPDD-0027 are averaged across at least two observations for each monkey.
Drug Discrimination Studies in Rhesus Monkeys
When given i.g., CPDD-0027 occasioned only saline-appropriate responding in all monkeys
tested in doses from 0.1 to 30 mg/kg. There were no systematic effects of i.g. 0027 on
response latency. Parenteral administration of CPDD-0027 occasioned primarily saline-lever
responding in all monkeys, although some PB-appropriate responding was observed (see
Table 1). One PB-trained monkey (8106) made 100% drug-lever responding following 10
mg/kg (i.v.) CPDD-0027; however, when this dose was retested, only saline-lever
responding resulted; and a higher dose eliminated responding. Parenteral administration of
CPDD-0027 also increased latency to respond relative to saline controls and changes in overt
behavior were noticed (e.g., two monkeys would not leave their home cages at the start of
the session). These results demonstrate that CPDD-0027, administered intragastrically or
parenterally, does not have discriminative stimulus effects similar to those of PB or AMPH
in rhesus monkeys. Table 1
Effects of parenteral administration of CPDD 0027 in
PB- or AMPH-trained monkeys
Subject Training Drug Saline 1.0 3.0 5.6 10 17 30
Pentobarbital-trained
8236 100/0.37 0/0.1 0/0.1 1.7/0.03 31.5/0.27
7976 100/0.99 0/0.02 0/0.50 0/0.07 38/0.83*
8106 100/0.20 0/0.1 0/0.07 50.3/0.0 * *
8814 92/0.53 0/0.40 0/0.47 0/0.17 15.5/0.99*
d-Amphetamine-trained
7739 100/0.96 0/0.60 0/0.72 0/0.57 0.0/0.72 * * *
8515 100/0.25 0/0.1 33.5/0.05 6.7/0.10 0/0.13 0/0.63
7737 93.5/0.95 0/0.33 0/0.57 0/0.69 6.5/0.67 0/0.47 ***
Rhesus monkeys were trained to discriminate either 10 mg/kg (i.g.) pentobarbital or 0.56-1.0 mg/kg (i.g.) d-amphetamine from saline in
a discrete-trials avoidance/escape paradigm. Data presented represent the percent drug-appropriate responding/average response latency
(sec). Generally, CPDD 0027 was administered intravenously 60 minutes prior to testing, except for 7739 who received CPDD 0027
intramuscularly 4 hrs prior to testing.  Except where noted, 30 trials were completed.
* shocks were received and less than 30 trials were completed
** no responses made during the session
*** drug was administered but monkey could not be placed in the chair.
252
Potency Estimation in Mice
CPDD-0027 produced a dose-related depression of activity most evident from 35 to 95 min
after treatment (see Table 2), with an ED-50 of approximately 3 mg/kg (making it about 8
times as potent as pentobarbital). This effect gradually abated between 2 and 3 hours after
treatment. Performance on the inverted screen task was affected from 20 to 120 min post-
treatment, with an ED-50 of approximately 5 mg/kg. This effect was largely dissipated by
4 hours after drug administration.
Table 2. Effects of CPDD Compound #0027 on Spontaneous Locomotor Activity
Time after treatment (min)
Dose (mg/kg) 5-15 35-50 65-95 125-185
1.25 9 9 a 9 9 5 8 7 7
2.5 7 9 5 0 7 0 248
5 58 1 7 2 0 4 7
10 55 8 1 8 105
aValue expressed as percent of control activity of concomitantly tested,
vehicle-treated mice.
*************************************
Physical Dependence Studies in Rats
Substitution and Withdrawal in Pentobarbital-dependent Rats
On the basis of the potency estimates gleaned from the study of acute effects on performance
in the inverted screen task and on locomotor activity, doses of CPDD-0027, equal to one-
fifth (180 mg/kg-24 hr) and one-tenth (90 mg/kg-24 hr) of the final dosage of PB, were
infused into rats that had been chronically infused with PB.
Substitution of CPDD-0027 significantly affected the overt behavioral signs of withdrawal
from PB only at 8, 10 and 24 hours into withdrawal (see Figure 2a). When 0027 was
discontinued and saline was substituted, there was no significant elevation of signs
suggestive of withdrawal from the compound (Figure 2b). These results suggest that
CPDD-0027 substitutes only mildly for PB in dependent animals.
Figure 2a. Meann withdrawal score of control rats and PB-dependent rats during substitution of CPDD-0027
or vehicle. CPDD-0027 was infused in doses of 90 and 180 mg/kg-24 hr. (n=3 to 6)
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Figure 2b: Withdrawal Scores on Substltutlon of Saline(S) and CPDD#0027
Figure 2b. Mean withdrawal score of control and P-Bdependent rats during substitution of saline (24 to 48 hr
into withdrawal, the “Withdrawal Phase”). (n=3 to 6)
Changes in body weights of animals during substitution of CPDD-0027 and during
withdrawal were more conclusive. As shown in Figure 3, rats receiving CPDD-0027
suffered an even greater loss of weight than vehicle-substituted rats, and the pattern of
changes in weight was the same for vehicle- and 0027-substituted animals. Some of the rats
receiving CPDD-0027 appeared sedated during the substitution phase of the experiment, but
the sedation did not appear to be sufficient to suppress feeding.
Figure 3: Changes In Body Weight with Substitution of Saline(S) and CPDD#0027
Figure 3. Change in body weight of control and PB-dependent rats during substitution of vehicle or CPDD-
0027 (0 to 24 hr. substitution phase) and substitution of saline (24 to 48 hr, withdrawal phase). CPDD-0027
was infused in doses of 90 and 180 mg/kg-24 hr. (n=3 to 6)
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Primary Physical Dependence Liability in Rats
During infusion of CPDD-0027 the rats became quite sedated and hypoactive with
diminished muscle tone. One rat died of apparent overdose on the eleventh day of infusion.
During the course of infusion, rats gained little or no weight, in contrast to the frequent 20 to
30 % weight gain seen in rats infused with PB for the same period. Dosage began at 20
mg/kg-24 hr on the first day of infusion and concluded at 200 mg/kg-24 hr for most rats on
the twelfth day of infusion.
When saline was substituted for CPDD-0027, there was little observance of overt signs of
abstinence, particularly for the first 12 hours (see Figures 4a & 4b). During the 24 to 36
hour period, there was a mild but significant elevation in signs, approximating those seen in
PB-abstinent rata during the same period. Changes in body weight during substitution of
saline did not reflect a barbiturate-like withdrawal pattern (see Figure 5). In fact, rather than
exhibiting the weight loss that is characteristic of barbiturate abstinence, the CPDD-0027-
withdrawn rats gamed weight relative to saline-infused control animals.
FIGURE 4A: WITHDRAWAL SCORES ON SUBSTITUTION OF SALINE(S) AND CPDD #0027
FIGURE 4B: WITHDRAWAL SCORES ON SUBSTITUTION OF SALINE(S) AND CPDD#0027
Figures 4a & 4b. Mean withdrawal scores of control rats, PB-dependent rats, and CPDD 0027-infused rats
during substitution of saline (0 to 48 hr). CPDD 0027 was infused in a final dose of 200 mg/kg-24 hr. (n=4
to 6)
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FIGURE 5: CHANGE IN BODY WEIGHT WITH SUBSTITUTION OF SALINE IN RATS INFUSED WITH PB OR CPDD #0027
Figure 5. Change in body weight of control rats, PB-dependent rats, and CPDD 0027-infused rats during
substitution of saline (0 to 48 hr). (n = 4 to 6)
CPDD-0035
1,3,4,16b-Tetrahydro-2-methyl-2H,10H-indolo(2,l-c)pyrazino(1,2-a)
(1,4)benzodiazepine-16-carboxylic acid methyl ester hydrochloride or CGS-
15044A
Self-administration Studies in Rhesus Monkeys
CPDD-0035 did not maintain self-administration in any of the three rhesus monkeys
evaluated. Doses of from 0.001 to 0.1 mg/kg/inj maintained injection levels similar to those
maintained by saline.
Drug Discrimination Studies in Rhesus Monkeys
Administration of CPDD-0035 occasioned primarily saline-appropriate responding in all
monkeys. With the exception of monkey 7737, doses of 0035 up to 30 mg/kg i.g. did not
substantially affect average response latency or overall activity of the monkey in the
homecage. Monkey 7737 would not leave his homecage 55 min after receiving 30 mg/kg of
CPDD-0035.
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Potency Estimation in Mice
CPDD-0035 produced a dose-related depression of spontaneous locomotor activity up to 60
min after treatment, with an ED-50 at the 5 to 15 min interval of 11.3 mg/kg (3.9 - 32.3
mg/kg, 95% confidence limits) and an ED-50 at the 35 to 50 min interval of 13.3 mg/kg (5.6
-31.4). The effect abated rather dramatically over the next 2 hours.
Performance on the inverted screen task was affected rather erratically, with a dose-
responsive effect observed only at the earliest time of measurement (20 min). The ED-50 at
that time was 25.2 mg/kg (0.75 - 840). This effect was dissipated largely by 30 to 60 min
after drug administration, with only occasional animals affected at 60 min and later.
These data suggest that CPDD-0035 is only slightly more potent than PB in these tests of
depression, being roughly equipotent in the inverted screen test and less than twice as potent
in the suppression of locomotor activity.
Physical Dependence (Substitution) Study in PB-dependent Rats
CPDD-0035 was infused into PB-dependent rats at doses of 100 and 200 mg/kg-24 hr (n =
3 to 7 per group). These doses are substantially below equipotency with the final dose of
PB received, but the limited solubility of the drug precluded administration of higher doses.
When CPDD-0035 was substituted for PB, there was no significant effect on overt signs of
abstinence. Likewise, when the compound was discontinued and saline was substituted for
it, there was no significant increase in signs of abstinence.
Changes in body weight during withdrawal also failed to show suppression of abstinence by
CPDD-0035. The pattern of weight loss was similar in the drug-substituted and vehicle-
substituted groups of rats.
CPDD-0039
Aminorcx hydrochloride (4,5-Dihydro-5-phenyl-2-oxazolamine hydrochloride)
Self-administration Studies in Rhesus Monkeys
Monkeys allowed to self-administer compound 0039 in doses of from 0.001 to 0.1
mg/kg/inj self-administered nearly as many injections of this drug as they did of the baseline
dose of methohexital. Maximum number of injections were taken at a dose of 0.03
mg/kg/inj (see Figure 6).
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Figure 6. Self-administration of CPDD-0039 by rhesus monkeys. The points shown at METH are the
average number of injections taken of 0.1 ms/kg/inj sodium methohexital on the sessions just preceding each
substitution of CPDD-0039. These averages are shown for the individual monkeys as indicated by the
legend. Similar data are shown for saline availability over the point indicated by SAL. Data shown for
CPDD-0039 are averaged across at least two observations for each monkey.
Drug Discrimination Studies in Rhesus Monkeys
CPDD-0039 produced a dose-related increase in drug-lever responding in all three AMPH-
trained monkeys. Full substitution for AMPH was found with at least one dose in all three
monkeys (see Figure 7a). Latency to respond was not systematically affected (Figure 7b).
Fig. 7a
Fig. 7b
Figure. 7. (a) Discriminative stimulus effects of CPDD-0039 in rhesus monkeys trained to discriminate
amphetamine from saline. Each point represents the percentage of trials in a test session that were completed
on the drug lever. Generally, each point is the mean of two determinations and this is always the case for
points that are above 80%. (b) Latency to respond in the same trials.
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Potency Estimation in Mice
CPDD-0039 caused a mild increase in locomotor activity at 0.625 mg/kg, and the stimulant
effect became significant at 1.25 mg/kg. Stimulation was dose-related between 1.25 and 20
mg/kg, but not markedly so (see Table 3). The highest dose tested (20 mg/kg) exhibited
significant toxicity in that it was the only dose that caused impairment of performance in the
inverted screen test (from 58% impairment at 20 min post-treatment declining to 20%
impairment at 120 min). That dose was lethal in one of six mice.
Table 3: Effects of CPDD Compound #0039 on Spontaneous Lacomotor Activity
Time after injection (min)
Dose of #39 5-15 35-50 65-95 125-185
0.625 149a 124 196 234
1.25 180 238 488 82
2.50 270 183 674 152
5.00 244 379 180 176
10.00 303 460 1074
20.00 95 132 562 3010
a Values are expressed as the percentage of activity of concomitantly tested
vehicle-treated control mice.
Physical Dependence (Substitution) Studies in Chronically-infused Rats
PDD-0039 was infused i.p. in doses of 40 and 80 mg/kg-day for 24 hr into rats that had
been infused with pentobarbital (PB) for 12 days. There were 4 to 6 rats in each treatment
group.
When CPDD-0039 was infused into PB-dependent rats, the overt signs of withdrawal were
markedly increased (see Figure 8). In addition, tremor was noted in many of the rats
receiving the compound. The exacerbation of withdrawal symptomatology was dose-
related, and the elevation of signs persisted for 24 hr following cessation of the higher dose.
The weight loss associated with barbiturate abstinence was also significantly increased by
substitution of compound 0039 (Figure 9), although there was no difference in the degree of
effect between the two doses.
Figure 8. Mean withdrawal scores of control rats and PB-dependent rats during substitution of CPDD-0039
or vehicle (Day 13, Substitution) and during substitution of saline (Day 14, Withdrawal) (n=4 to 6)
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CHANGES IN BODY WEIGHT WITH SUBSTITUTION OF SALINE
AND CPDD #0039 IN PENTOBARBITAL-INFUSED RATS
Figure 9. Change in body weight of control rats and PB-dependent rats during substitution of CPDD-0039 or
vehicle (0 to 24 hr, Substitution) and during substitution of saline (24 to 48 hr, Withdrawal) (n = 4 to 6)
CPDD-0040
Mesocarb (3-[1-methyl-2-phenethyl]-N-[phenylaminocarbonyl]sydnone imine)
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Self-administration Studies in Rhesus Monkeys
CPDD-0040 produced a dose-related increase in rates of drug-maintained responding over a
dose range of 0.003 to 0.03 mg/kg/inj (see Figure 10). At a larger dose of 0.1 mg/kg/inj,
rates of responding were somewhat decreased. A reinforcing effect of 0040 was observed in
each of the three monkeys in which it was evaluated.
Figure 10. Self-administration of CPDD-0040 by rhesus monkeys. The points shown at METH are the
average number of injections taken of 0.1 mg/kg/inj sodium methohexital on the sessions just preceding each
substitution of CPDD-0040. These averages are shown for the individual monkeys as indicated by the
legend. Similar data are shown for saline availability over the point indicated by SAL. Data shown for
CPDD-0040 are averaged across at least two observations for each monkey.
Drug Discrimination Studies in Rhesus Monkeys
CPDD-0040 did not occasion pentobarbital-lever responding in any monkey tested up to
doses of 1.0 mg/kg. Compound 0040 did produce a dose-related increase in AMPH-lever
responding in AMPH-trained monkeys. Full substitution for AMPH was found with at least
one dose in all monkeys (see Figure 11). Latency to respond was not systematically
affected.
Figure 11. Discriminative stimulus effects of CPDD-0040 in rhesus monkeys trained to discriminate
amphetamine (AMPH) from saline. Each point represents the percentage of trials in a test session that were
completed on the drug lever. Generally, each point is the mean of two detcrminations and this is always the
case for points that are above 80%.
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Potency Estimation in Mice
CPDD-0040 caused a mild increase in activity at 1.25 mg/kg, and the effect became
significant at 2.5 mg/kg. The stimulant effect was dose-related, although the increase in
activity with each increment in dosage was rather mild (see Table 4). No dose tested
exhibited significant toxicity nor caused impairment of performance in the inverted screen
test. Inability to solubilize the compound sufficiently has precluded evaluation of
dependence liability.
Table 4: Effects of CPDD Compound #0040 on Spontaneous Locomotor Activity
Dose of #40 5-15
Time after injection (min)
35-50 65-95 12.5-185
(mg/kg)
1.25 160 222 142 184
2.50 110 210 227 425
5.0 137 255 298 424
10.0 280 407 385 745
20.0 192 316 431 1020
a Values are expressed as the percentage of activity of concomitantly tested vehicle-treated
control mice.
CONCLUSIONS
CPDD-0027, an NMDA antagonist, did not have reinforcing effects in rhesus monkeys, and
it possessed only mild pentobarbital-like discriminative stimulus effects in the same species.
In mice and rats. it produces definite sedative effects. CPDD-0027 produced occasional mild
suppression of overt behavioral signs of withdrawal in pentobarbital-dependent rats, and
mild behavioral signs were exhibited when rats were withdrawn from it after chronic
infusion. However: it did not suppress the weight loss associated with barbiturate
withdrawal, nor did rats withdrawn from it lose weight but rather gained weight. Although
this compound does exhibit behavioral effects typical of CNS depressant drugs, it appears
unlikely to possess barbiturate-like abuse liability or the potential-to produce physical-
dependence characteristic of the barbiturates or benzodiazepines.
CPDD-0035 exhibited neither reinforcing properties nor barbiturate-discriminative stimulus
properties in rhesus monkeys. In mice it produced short-lived depressant effects. At doses
that could be solubilized, this compound did not affect the course of withdrawal in
pentobarbital-dependent rats. Therefore, this compound seems unlikely to possess
significant potential for abuse or for promoting physical dependence.
CPDD-0039 (Aminorex) exhibited marked reinforcing properties in rhesus monkeys. It also
produced dose-related drug discrimination in amphetamine-trained monkeys, fully
substituting for amphetamine at some dosage in all animals tested. The compound produced
acute stimulant effects in mice, and it exacerbated withdrawal when infused into
pentobarbital-dependent rats. These results indicate that CPDD-0039 should have
reinforcing effects and abuse liability similar to amphetamine and other potent psychomotor
stimulants.
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CPDD-0040 (Mesocarb) produced reinforcing effects in self-administration studies in rhesus
monkeys. Similarly, it produced amphetamine-like discriminative stimulus effects, although
it was less potent than CPDD-0039 in this regard. It also produced acute stimulant effects in
mice. This compound, like aminorex, appears to have reinforcing properties and abuse
liability resembling the psychomotor stimulants.
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T.J. Crowely, 5-10
8-[4-[4-(1,2-Benzoisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro(4.5)decane-7,9-dione
hydrochloride (NIH 10766)
analgesia in mice. 161
biological evaluation of physical-dependence potential and abuse liability, 193
displacement of radiolabeled opioid binding, 233
inhibition of electrically stimulated mouse vas deferens, 234
physical dependence evaluation in rhesus monkeys, 162
(-)-N-Benzyl-3-hvdroxymorphinan hvdrochloride NIH 10780)
analgesia in mice, 169
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid bindine, 241
inhibition of electrically stimulated mouse vas deferens, 241
(+)-N-Benzyl-3-hydroxymorphinan hydrochloride (NIH 10735)
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 215
inhibition of electrically stimulated mouse vas deferens, 215
nor-Binaltorphimine dihydrochloride (NIH 10588, nor-BNI)
analgesia in mice, 118
physical dependence evaluation in rhesus monkeys, 118
Bremazocine
displacement of radiolabeled opioid binding, 201-202
4-Bromo-5-(3-hydroxyphenyl)-2-methylmorphan hydrobromide (NIH 10778)
2 6 4
analgesia in mice, 168
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 240
inhibition of electrically stimulated mouse vas deferens, 240
Buprenorphine
displacement of radiolabeled opioid binding, 202
Cannabinoids
identification of endogenous cannabinoid ligands, 58
neurochemical tools, 95
receptor binding activity of neuromodulator-like ligands, 57
receptor-mediated G-protein coupled activities, 56
pharmacological profile of anandamide, 59-60
tolerance studies with the mouse vas deferens, 55
(-)-1-(4-Chlorophenyl)-N,N-dimethyl-1-ethyl-4-phenylbut-3-en-1-ylamine hydrochloride
(NIH 10678)
analgesia in mice, 122
analgesia in rhesus monkeys, 209
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 208
drug discrimination in rhesus monkeys, 209
inhibition of electrically stimulated mouse vas deferens, 208-209
physical dependence evaluation in rhesus monkeys, 123-124
respiratory function studies in rhesus monkeys, 209
self-administration by monkeys, 210
ß-CNA
displacement of radiolabeled opioid binding, 202
Cocaine
cardiovascular effects in animals, 79
cardiovascular effects in humans, 81
effects on vagal tone in humans, 82
measures of reinforcement and ‘craving’ using a multiple schedule in rat, 101
modulation of the immune system communication, 90
peripheral mechanisms in cardiovascular effects, 80
pharmacological mechanisms in cardiovascular effects, 80
potential pharmacotheraperies on behavior maintained by cocaine, 101
self-administration, implications for discovery of pharmacotheraperies, 100
sensitization and tolerance, 71
structure-activity relationship study, 96
teratogenicity of exposure, 52-53
Codeine-6-glucuronide (NIH 10662, 6-O-ß-D-glucopyranosylcodeine)
analgesia in mice, 120
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207-208
physical dependence evaluation in rhesus monkeys, 120
Codeine phosphate
analgesia in mice, 105
CPDD 0027 (c i s-4-Phosphomethyl)-2-piperidinecarboxylic acid)
biological evalation of physical-dependence potential and abuse liability, 194
drug discrimination in rhesus monkeys, 252
physical dependence studies in rats, 253-254
potency estimation in mice, 253
primary physical dependence liability in rats, 254-256
self-administration in rhesus monkeys, 251-252
CPDD 0035 (1,3,4,16b-Tetrahydro-2-methyl-2H,10H-indolo(2,l-c)pyrazino(1,2-
a)(1,4)benzodiazepine-16-carboxylic acid methyl ester hydrochloride or CGS-15044A)
2 6 5
biological evaluation of physical-dependence potential and abuse liability, 194
drug discrimination in rhesus monkeys, 256
physical dependence studies in rats, 257
potency estimation in mice, 257
self-administration in rhesus monkeys, 256
CPDD 0039 (Aminorex hydrochloride or 4,5-dihydro-5-phenyl-2-oxazolamine
hydrochloride)
biological evaluation of physical-dependence potential and abuse liability, 194
drug discrimination in rhesus monkeys, 258
physical dependence studies in rats, 259-260
potency estimation in mice, 259
self-administration in rhesus monkeys, 257
CPDD 0040 (Mesocarb or 3-[1-methyl-2-phenethyl]-N-[phenylaminocarbonyl]sydnone
i m i n e )
biological evaluation of physical-dependence potential and abuse liability, 194
drug discrimination in rhesus monkeys, 261
potency estimation in mice, 262
self-administration in rhesus monkeys, 261
Cyclazocine
analgesia in mice, 105
displacement of radiolabeled opioid binding, 201
Cyprodime
inhibition of electrically stimulated mouse vas deferens, 204
trans-3,4-Dimethyl-4-arylpiperidines
selective opioid antagonists and therapeutic agents, 95
DAMGO
displacement of radiolabeled opioid binding, 201-202
(-)-2-Decyl-5,9 -Dimethyl-2’-hydroxy-6,7-benzomorphan hydrobromide (NIH 10768)
analgesia in mice, 163
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding, 234
inhibition of electrically stimulated mouse vas deferens, 234
physical dependence evaluation in rhesus monkeys, 163-164
(+)-2-Decyl-5,9 -Dimethyl-2’-hydroxy-6,7-benzomorphan hydrobromide (NIH 10769)
analgesia in mice, 164
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding, 235
inhibition of electrically stimulated mouse vas deferens, 235
physical dependence evaluation in rhesus monkeys, 165
Dextrorphan
displacement of radiolabeled opioid binding, 201
1-(3,4-Dichlorophenylacetyl)-3-(1-pyrrolidinyl)piperidine oxalate (NIH 10708)
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 211
inhibition of electrically stimulated mouse vas deferens, 211
4,6-Di-(3-chlorophenyl)-3,7-dimethyl-3,7-diazabicyclo[3.3.1]nonan-9-one 1,5-
dicarboxylic acid (NIH 10711)
4,6-Di-(3-hydroxyphenyl)-3,7-dimethyl-3,7-dimethyl-3,7-diazabicyclo[3.3.1] nonan-9-one
1,5-dicarboxylic acid dimethyl ester (NIH 10712)
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 212
inhibition of electrically stimulated mouse vas deferens. 213
3,7-Dimethyl-4,6-di-(3-methylphenyl)-3,7-diazabicyclo[3.3.1]nonan-9-one 1,5-
dicarboxylic acid dimethyl ester (NIH 10714)
analgesia in mice, 134
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 213
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inhibition of electrically stimulated mouse vas deferens, 213
3,7-Dimethyl-4,6-di-(3-nitrophenyl)-3.7-diazabicyclo[3.3.1]nonan-9-one 1,5-dicarboxylic
acid dimethyl ester (NIH 10715)
analgesia in mice, 134
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 214
inhibition of electrically stimulated mouse vas deferens, 214
3,7-Dimethyl-4,6-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one 1,5-dicarboxylic acid
dimethyl ester (NIH 10716)
analgesia in mice, 135
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 214
inhibition of electrically stimulated mouse vas deferens, 215
physical dependence evaluation in rhesus monkeys, 135
(+)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan oxalate (NIH 10751)
analgesia in mice, 147
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding, 225
physical dependence evaluation in rhesus monkeys, 147-148
inhibition of electrically stimulated mouse vas deferens, 225
(-)-5,9 -Dimethyl-2-(4-fluorobenzyl)-2’-hydroxy-6,7-benzomorphan oxalate (NIH 10752)
analgesia in mice, 148
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding. 226
inhibition of electrically stimulated mouse vas deferens, 226
physical dependence evaluation in rhesus monkeys, 149
(-)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomomorphan oxalate (NIH 10750)
analgesia in mice, 146
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding, 224
inhibition of electrically stimulated mouse vas deferens, 224-225
physical dependence evaluation in rhesus monkeys, 146-147
(+)-5,9 -Dimethyl-2’-hydroxy-2-(4-nitrobenzyl)-6,7-benzomorphan  oxalate (NIH 10772)
analgesia in mice, 167
biological evaluation of physical-dependence potential and abuse liability, 187
displacement of radiolabeled opioid binding, 237
inhibition of electrically stimulated mouse vas deferens, 237
physical dependence evaluation in rhesus monkeys, 167
(-)-5-9 -Dimethyl-2’-hydroxy-2- n-octyl-6,7-benzomorphan hydrochloride (NIH 10697)
analgesia in mice, 128
biological evaluation of physical-dependence potential and abuse liability, 187
physical dependence evaluation in rhesus monkeys, 128-129
inhibition of electrically stimulated mouse vas deferens,
(+)-5,9 -Dimethyl-2’-hydroxy-2- n-octyl-6,7-benzomorphan hydrochloride (NIH 10698)
analgesia in mice, 129
biological evaluation of physical-dependence potential and abuse liability, 187
physical dependence evaluation in rhesus monkeys, 130
2,3-Dimethyl-5-(3-hydroxyphenyl)morphan hydrobromide (NIH 10779)
analgesia in mice, 168
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 240
inhibition of electrically stimulated mouse vas deferens, 240
DPDPE
displacement of radiolabeled opioid binding, 201-202
Drug Abuse Research Accomplishments
Richard A. Millstein, 11-22
Drug abuse treatment
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innovative approaches, 61-64
Drug abusing parolees
outcomes of experimental intervention, 86
Drug research
policy implications, 84-88
Drug self-administration
interrelationships between self-administration and drug discrimination, 99
contextual determinants of self-administration in monkeys, 100
Drug treatment
national study of quality standards and assessment, 87
DSLET
displacement of radiolabeled opioid binding, 201-202
Dynorphin 1-13 (NIH 10303)
analgesia in mice, 116
behavioral effects in morphine-dependent and non-tolerant monkeys, 117
physical dependence evaluation in rhesus monkeys, 116
Dynorphin 2-17 (Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Try-Asp-Asn-Gly,
NIH 10799)
analgesia in mice, 171
physical dependence evaluation in rhesus monkeys, 171-172
Ethylketazocine
displacement of radiolabeled opioid binding, 201
Ethylnarceine hydrochloride (6-[[6-[2-Diethylamino)ethy1]-4-methoxy-1,3-benzodioxol-5-
yl]acetyl]-2,3-dimethoxybenzoic acid, NIH 10759)
analgesia in mice, 155
biological evaluation of physical-dependence potential and abuse liability, 193
displacement of radiolabeled opioid binding, 230
inhibition of electrically stimulated mouse vas deferens, 230
physical dependence evaluation in rhesus monkeys. 155
Self-administration by monkeys, 230
Etonitazene methanesulfonate (NIH 10665)
analgesia in mice, 121
physical dependence evaluation in rhesus monkeys, 121
Etorphine
displacement of radiolabeled opioid binding, 201-202
Excitatory amino acids
role in the actions of abused drugs, 65-68
Fentanyl
displacement of radiolabeled opioid binding, 201
1-(4-Fluorobenzyl)-4-(3-hydroxybenzyl)-4-ketoethyl-piperidine hydrochloride (NIH
10739)
biological evaluation of physical-dependence potential and abuse liability, 188
displacement of radiolabeled opioid binding, 217
inhibition of electrically stimulated mouse vas deferens, 217
(-)-N-(4-Fluorobenzyl)-3-hydroxymorphinan oxalate (NIH 10770)
analgesia in mice, 166
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 235
inhibition of electrically stimulated mouse vas deferens, 236
(+)-N-(4-Fluorobenzyl)-3-hydroxymorphinan oxalate (NIH 10748)
analgesia in mice, 145
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 223
inhibition of electrically stimulated mouse vas deferens, 223
physical dependence evaluation in rhesus monkeys, 145
ß-FNA
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displacement of radiolabeled opioid binding, 202
Freedman, Daniel X.
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6-O-ß-D-Glucopyranosylcodeine (NIH 10662, codeine-6-glucuronide)
analgesia in mice, 120
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207-208
physical dependence evaluation in rhesus monkeys, 120
6-O-ß-D-Glucopyranosylmorphine (NIH 10661, morphine-6-glucuronide)
analgesia in mice. 119
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207
physical dependence evaluation in rhesus monkeys, 119
Hallucinogenic agents
classical hallucinogens, 94
trans-3,4-dimethyl-4-arylpiperidines as selective opioid antagonists, 95
Heroin
self-administration, implications for discovery of pharmacotheraperies, 100
HIV transmission models
CD4 differences between infected IDU’s and non-IDU’s, 92
epidemiologic tools for evaluating consequences of partner notification, 85
( ± ) -c i s-N-[1-(2- t r a n s-1-Hydroxy)indanyl)-3-methyl-4-piperidinyl] N-phenylpropanamide
hydrochloride (NIH 10756)
analgesia in mice, 153
biological evaluation of physical-dependence potential and abuse liability, 190
displacement of radiolabeled opioid binding, 228
inhibition of electrically stimulated mouse vas deferens, 228
physical dependence evaluation in rhesus monkeys, 153
(-)-3-Hydroxy-N-(4-methoxybenzyl)morphinan hydrobromide (NIH 10781)
analgesia in mice, 169
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 242
inhibition of electrically stimulated mouse vas deferens, 242
(+)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate (NIH 10749)
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 224
inhibition of electrically stimulated mouse vas deferens, 224
(-)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate (NIH 10771)
analgesia in mice, 166
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 236
inhibition of electrically stimulated mouse vas deferens, 236
(±)-cis -N-[1-(2-Hydroxy-1-phenylethyl)-3-methyl-4-piperidine 1]-N-phenylpropanamide
hydrochloride (NIH 10765)
analgesia in mice, 160
biological evaluation of physical-dependence potential and abuse liability, 191
physical dependence evaluation in rhesus monkeys, 160-161
( ± ) - cis -N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(2-
fluorophenyl)propanamide hydrochloride (NIH 10761)
analgesia in mice, 157
biological evaluation of physical-dependence potential and abuse liability, 190
displacement of radiolabeled opioid binding, 232
inhibition of electrically stimulated mouse vas deferens, 232
physical dependence evaluation in rhesus monkeys, 157-158
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(± ) -cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(3-
fluorophenyl)propanamide hydrochloride (NIH 10784)
biological evaluation of physical-dependence potential and abuse liability, 191
displacement of radiolabeled opioid binding, 243
inhibition of electrically stimulated mouse vas deferens, 243
(±) -cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-methyl-2-
pyridinyl)propanamide oxalate (NIH 10783)
analgesia in mice, 170
biological evaluation of physical-dependence potential and abuse liability, 191
displacement of radiolabeled opioid binding, 242
inhibition of electrically stimulated mouse vas deferens, 243
physical dependence evaluation in rhesus monkeys, 170
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenyl-2-furamide
hydrochloride (NIH 10718)
analgesia in mice, 135
physical dependence evaluation in rhesus monkeys, 136
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(4-
morpholinyl)propanamide hydrochloride (NIH 10774)
biological evaluation of physical-dependence potential and abuse liability, 191
displacement of radiolabeled opioid binding, 238
inhibition of electrically stimulated mouse vas deferens, 238
ßS-3R,4S)-(+)- cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride, or (ßS,3R,4S)-(+)-cis-ß-hydroxy-3-methylfentanyl
hvdrochloride (NIH 10741)
analgesia in mice, 139
biological evaluation of physical-dependence potential and abuse liability, 189
displacement of radiolabeled opioid binding, 218
physical dependence evaluation in rhesus monkeys, 139
inhibition of electrically stimulated mouse vas deferens, 218-219
ßR,3S,4R)-(-)- cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-
phenylpropanamide hydrochloride, or (ßR,3S,4R)-(-)-cis-ß-hydroxy-3-methylfentanyl
hydrochloride (NIH 10742)
analgesia in mice, 140
biological evaluation of physical-dependence potential and abuse liability, 189
displacement of radiolabeled opioid binding, 219
inhibition of electrically stimulated mouse vas deferens, 219
physical dependence evaluation in rhesus monkeys, 140-141
ßR,3R,4S)-(-)-cis-N-[1-(2(ß)-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl[-N-
phenylpropanamide oxalate, or (ßR,3R,4S)-(-)-c i s-ß-hydroxy-3-methylfentanyl oxalate
(NIH 10743)
analgesia in mice, 141
biological evaluation of physical-dependence potential and abuse liability, 189
displacement of radiolabeled opioid binding, 220
inhibition of electrically stimulated mouse vas deferens, 220
physical dependence evaluation in rhesus monkeys, 141-142
ßS,3R,4S)-(+)- c i s-N-[1-(2(ß)-Hdroxy-2-phenylethl)-3-methyl-4-piperidinyl[-N-
phenylpropanamide oxalate, or ßS,3R,4S)-(+)-cis-ß-hydroxy-3-methylfentanyl oxalate
(NIH 10744)
analgesia in mice, 142
biological evaluation of physical-dependence potential and abuse liability, 189
displacement of radiolabeled opioid binding, 222
inhibition of electrically stimulated mouse vas deferens, 222
physical dependence evaluation in rhesus monkeys, 143
( ± ) -c i s-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-penyl-2-
thiophenecarboxamide hydrochloride (NIH 10720)
analgesia in mice, 137
drug discrimination in rhesus monkeys, 137
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(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenyl-3-
thiophenecarboxamide hydrochloride (NIH 10776)
biological evaluation of physical-dependence potential and abuse liability, 191
displacement of radiolabeled opioid binding, 238-239
inhibition of electrically stimulated mouse vas deferens, 239
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(1-
piperidinyl)propanamide hydrochloride (NIH 10755)
analgesia in mice, 152
biological evaluation of physical-dependence potential and abuse liability. 190
displacement of radiolabeled opioid binding, 228
physical dependence evaluation in rhesus monkeys, 152
inhibition of electrically stimulated mouse vas deferens, 228
(±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-(3-
pyridinyl)propanamide dihydrochloride (NIH 10754)
analgesia in mice, 151
biological evaluation of physical-dependence potential and abuse liability, 190
displacement of radiolabeled opioid binding, 227
physical dependence evaluation in rhesus monkeys, 151
inhibition of electrically stimulated mouse vas deferens, 227
4-(3-Hydroxyphenyl)-4-ketoethyl-1-(4-nitrobenzyl)piperidine hydrochloride (NIH 10738)
biological evaluation of physical-dependence potential and abuse liability, 188
displacement of radiolabeled opioid binding, 216
inhibition of electrically stimulated mouse vas deferens, 216
4-(3-Hydroxyphenyl-4-(1-oxopropyl)-1-(2-methyl-2-butenyil)piperidine hydrochloride, or
N-3,3-dimethylallyl)-N-norketobemidone hydrochloride (NIH 10795)
biological evaluation of physical-dependence potential and abuse liability, 188
displacement of radiolabeled opioid binding, 244
inhibition of electrically stimulated mouse vas deferens, 245
(±)-cis-N-[1-(2-(trans-3-Hydroxy-1,2,3,4-tetrahydro)-naphthyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide hydrochloride (NIH 10757)
analgesia in mice, 154
biological evaluation of physical-dependence potential and abuse liability, 190
displacement of radiolabeled opioid binding, 229
inhibition of electrically stimulated mouse vas deferens, 229
physical dependence evaluation in rhesus monkeys, 154
(±)-cis-N-[1-[2-Hydroxy-2-(2-thienyl)ethyl]-3-methyl-4-piperidinyl]-N-phenylpropanamide
hydrochloride (NIH 10763)
analgesia in mice, 159
biological evaluation of physical-dependence potential and abuse liability, 191
displacement of radiolabeled opioid binding, 233
inhibition of electrically stimulated mouse vas deferens, 233
ICI-174,874
physical dependence evaluation in rhesus monkeys, 159-160
displacement of radiolabeled opioid binding, 202
inhibition of electrically stimulated mouse vas deferens, 204
Intravenous drug users
CD4 differences between HIV infected IDU’s and non-IDU’s, 92
Ketazocine
displacement of radiolabeled opioid binding, 201
Linking research and service delivery,
Mary A. Jansen, 23-26
Marijuana
immunomodulators, 90
Martin, William R.
in memoriam, 1-2
Meperidine hydrochloride
analgesia in mice, 105
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Mesocarb (3-[1-methyl-2-phenethyl]-N-[phenylaminocarbonyl]sydnone imine, CPDD
0040)
biological evaluation of physical-dependence potential and abuse liability, 194
drug discrimination in rhesus monkeys, 261
potency estimation in mice, 262
self-administration in rhesus monkeys, 261
(±)-3-[N-Methyl-N-(3,4-dichlorophenylacetamido)]-N’-methylpiperidine (NIH 10707)
analgesia in mice, 131
biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 211
inhibition of electrically stimulated mouse vas deferens, 211
physical dependence evaluation in rhesus monkeys, 131-132
(±)-cis-N-[3-Methyl-1-(2-iminohydroxy-2-phenylethyl)-4-piperidinyl]-N-
phenylpropanamide (more polar isomer) (NIH 10740)
analgesia in mice, 138
biological evaluation of physical-dependence potential and abuse liability, 189
displacement of radiolabeled opioid binding, 217
physical dependence evaluation in rhesus monkeys, 138
respiratory function studies in rhesus monkeys,
inhibition of electrically stimulated mouse vas deferens, 218
(±)-c i s-N-[3-Methyl-1-[2-oxo-2-(2-thienyl)ethyl]-4-piperidinyl-N-phenylpropanamide
hydrochloride (NIH 10762)
analgesia in mice, 158
biological evaluation of physical-dependence potential and abuse liability, 190
physical dependence evaluation in rhesus monkeys, 158-159
(+)-N-(2-Methylpropenyl)-3-hydroxymorphinan hydrobromide (NIH 10796)
biological evaluation of physical-dependence potential and abuse liability, 186
displacement of radiolabeled opioid binding, 245
inhibition of electrically stimulated mouse vas deferens, 245
MIF (Pro-Leu-Gly-Amide, NIH 10800)
analgesia in mice, 172
physical dependence evaluation in rats. 173-174
physical dependence evaluation in rhesus monkeys, 173-176
Morphine
analgesia in mice, 105
displacement of radiolabeled opioid binding, 201-202
modulation of the immune system communication, 90
Morphine sulfate pentahydrate (NIH 10753)
analgesia in mice, 150
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 226
inhibition of electrically stimulated mouse vas deferens, 226
physical dependence evaluation in rhesus monkeys, 150
Morphine-6-glucuronide (6-O-ß-D-glucopyranosylmorphine, NIH 10661)
analgesia in mice, 119
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207
physical dependence evaluation in rhesus monkeys, 119
Nalbuphine
inhibition of electrically stimulated mouse vas deferens, 204
Nalorphine hydrochloride
analgesia in mice, 105
Naloxone hydrochloride
analgesia in mice, 105
displacement of radiolabeled opioid binding, 202
inhibition of electrically stimulated mouse vas deferens, 204
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Naltrexone hydrochloride (NIH 9930)
analgesia in mice, 105, 114
displacement of radiolabeled opioid binding, 201
inhibition of electrically stimulated mouse vas deferens, 204
physical dependence evaluation in rhesus monkeys, 114
Naltrindole
inhibition of electrically stimulated mouse vas deferens, 204
Narceine (6-[[6-[2-Dimethylamino)ethyl]-4-methoxy-1,3-benzodioxol-5-yl]acetyl]-2,3-
dimethoxybenzoic acid, NIH 10760)
analgesia in mice, 156
biological evaluation of physical-dependence potential and abuse liability, 193
displacement of radiolabeled opioid binding, 231
inhibition of electrically stimulated mouse vas deferens, 231
physical dependence evaluation in rhesus monkeys, 156
self-administration by monkeys, 231
Nathan B. Eddy Award
introduction of recipient, 27-29
lecture by L.N. Robins, 30-45
(-)-(S)-Nicotine di -l -tartrate (NIH 9733)
analgesia in mice, 110
physical dependence evaluation in rhesus monkeys, 110
NIH 9733 [(-)-(S)-Nicotine di- l -tartrate]
analgesia in mice, 110
physical dependence evaluation in rhesus monkeys, 110
NIH 9752 [(-)-Quadazocine, Win 44441-3]
analgesia in mice, 112
physical dependence evaluation in rhesus monkeys, 112
NIH 9930 (Naltrexone hydrochloride)
analgesia in mice, 114
physical dependence evaluation in rhesus monkeys, 114
NIH 10303 [Dynorphin 1-13 (porcine), Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
Leu-Lys]
analgesia in mice, 116
behavioral effects in morphine-dependent and non-tolerant monkeys, 117
physical dependence evaluation in rhesus monkeys, 116
NIH 10588 (nor-Binaltorphimine dihydrochloride,n o r -BNI)
analgesia in mice, 118
physical dependence evaluation in rhesus monkeys, 118
NIH 10661 (6-O-ß-D-Glucopyranosylmorphine, morphine-6-glucuronide)
analgesia in mice, 119
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207
physical dependence evaluation in rhesus monkeys, 119
NIH 10662 (6-O-ß-D-Glucopyranosylcodeine, codeine-6-glucuronide)
analgesia in mice, 120
biological evaluation of physical-dependence potential and abuse liability, 185
displacement of radiolabeled opioid binding, 207
inhibition of electrically stimulated mouse vas deferens, 207-208
physical dependence evaluation in rhesus monkeys, 120
NIH 10665 (Etonitazene methanesulfonate)
analgesia in mice, 121
physical dependence evaluation in rhesus monkeys, 121
NIH 10678 [(-)-1-(4-Chlorophenyl)-N,N-dimethyl-1-ethyl-4-phenylbut-3-en-1-ylamine
hydrochloride]
analgesia in mice, 122
analgesia in rhesus monkeys, 209
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biological evaluation of physical-dependence potential and abuse liability, 192
displacement of radiolabeled opioid binding, 208
drug discrimination in rhesus monkeys, 209
inhibition of electrically stimulated mouse vas deferens, 208-209
physical dependence evaluation in rhesus monkeys, 123-124
respiratory function studies in rhesus monkeys, 209
self-administration by monkeys, 210
NIH 10688 ( ,1-Trimethyl-4-(3-thienyl)-4-piperidinemethanol hydrochloride)
analgesia in mice, 125
biological evaluation of physical-dependence potential and abuse liability, 188
physical dependence evaluation in rats, 128
physical dependence evaluation in rhesus monkeys, 125-127
NIH 10697 [(-)-5-9 -Dimethyl-2’-hydroxy-2- n-octyl-6,7-benzomorphan hydrochloride]
analgesia in mice, 128
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